{ "Akums_Drugs_and_Pharmaceuticals_Limited_merged.pdf": {
        "filename": "Akums_Drugs_and_Pharmaceuticals_Limited_merged.pdf",
        "tables": [
            {
                "page_number": 1,
                "table_data": [
                    {
                        "REGISTERED\nOFFICE": "304, Mohan Place, LSC\nSaraswati Vihar, Delhi\n110 034, India",
                        "Col1": null,
                        "CORPORATE\nOFFICE": "Akums House, Plot No.\n131 to 133, Block C,\nMangolpuri Industrial.\nArea Phase-1, Delhi 110\n083, India",
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": "Dharamvir Malik\nCompany Secretary and\nCompliance Officer",
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": "Email: cs@akums.net\nTelephone: + 91 11\n6904 1000",
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": "www.akums.in"
                    },
                    {
                        "REGISTERED\nOFFICE": "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER\nTRUST",
                        "Col1": null,
                        "CORPORATE\nOFFICE": null,
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "DETAILS OF THE OFFER TO THE PUBLIC",
                        "Col1": null,
                        "CORPORATE\nOFFICE": null,
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "TYPE",
                        "Col1": "FRESH ISSUE\nSIZE",
                        "CORPORATE\nOFFICE": null,
                        "Col3": "OFFER FOR\nSALE SIZE",
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": "TOTAL\nOFFER SIZE",
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": "ELIGIBILITY AND RESERVATION",
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "Fresh Issue and\nOffer for Sale",
                        "Col1": "Fresh issue of up to\n[\u25cf] Equity Shares\naggregating up to \u20b9\n6,800 million",
                        "CORPORATE\nOFFICE": null,
                        "Col3": "Offer for Sale of up\nto 18,598,365\nEquity Shares\naggregating up to \u20b9\n[\u25cf] million",
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": "Up to [\u25cf] Equity\nShares\naggregating up to\n\u20b9 [\u25cf] million",
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": "The Offer is being made in accordance with\nRegulation 6(2) of the Securities and\nExchange Board of India (Issue of Capital\nand Disclosure Requirements) Regulations,\n2018, as amended (\u201cSEBI ICDR\nRegulations\u201d). For further details, see\n\u201cOther Regulatory and Statutory\nDisclosures \u2013 Eligibility for the Offer\u201d on\npage 392. For details in relation to share\nreservation among QIBs, NIBs, RIBs and\nEligible Employees, see \u201cOffer Structure\u201d\non page 411.",
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "DETAILS OF THE OFFER FOR SALE",
                        "Col1": null,
                        "CORPORATE\nOFFICE": null,
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "NAME OF THE\nSELLING\nSHAREHOLDER",
                        "Col1": null,
                        "CORPORATE\nOFFICE": "TYPE",
                        "Col3": null,
                        "Col4": "NUMBER OF EQUITY SHARES\nOFFERED",
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": "WEIGHTED AVERAGE COST\nOF ACQUISITION (IN \u20b9 PER\nEQUITY SHARE)*#",
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "Sanjeev Jain",
                        "Col1": null,
                        "CORPORATE\nOFFICE": "Promoter Selling\nShareholder",
                        "Col3": null,
                        "Col4": "Up to 2,145,965 Equity Shares\naggregating up to \u20b9 [\u25cf] million",
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": "0.15",
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "Sandeep Jain",
                        "Col1": null,
                        "CORPORATE\nOFFICE": "Promoter Selling\nShareholder",
                        "Col3": null,
                        "Col4": "Up to 2,145,965 Equity Shares\naggregating up to \u20b9 [\u25cf] million",
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": "0.14",
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "Ruby QC Investment\nHoldings Pte. Ltd.",
                        "Col1": null,
                        "CORPORATE\nOFFICE": "Investor Selling\nShareholder",
                        "Col3": null,
                        "Col4": "Up to 14,306,435 Equity Shares\naggregating up to \u20b9 [\u25cf] million",
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": "231.64",
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "* As certified by T A M S & CO LLP, Chartered Accountants by way of their certificate dated 10, 2024.\n# Includes 33,000 Equity Shares held jointly by Sanjeev Jain with Arushi Jain, 5,500 Equity Shares held jointly by Sandeep\nJain with Kanishk Jain and 5,500 Equity Shares held joint by Sandeep Jain with Manan Jain",
                        "Col1": null,
                        "CORPORATE\nOFFICE": null,
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "RISKS IN RELATION TO THE FIRST OFFER",
                        "Col1": null,
                        "CORPORATE\nOFFICE": null,
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "This being the first public issue of Equity Shares of our Company, there has been no formal market for the Equity Shares. The\nface value of each Equity Share is \u20b9 2. The Floor Price, Cap Price and Offer Price determined by our Company, in consultation\nwith the Book Running Lead Managers, in accordance with the SEBI ICDR Regulations), and on the basis of the assessment\nof market demand for the Equity Shares by way of the Book Building Process as stated in \u201cBasis for Offer Price\u201d on page 106\nshould not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance\ncan be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares\nwill be traded after listing.",
                        "Col1": null,
                        "CORPORATE\nOFFICE": null,
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "GENERAL RISK",
                        "Col1": null,
                        "CORPORATE\nOFFICE": null,
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the\nOffer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors\ncarefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own\nexamination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been\nrecommended, nor approved by the Securities and Exchange Board of India (\u201cSEBI\u201d), nor does SEBI guarantee the accuracy\nor adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the Bidders is invited to \u201cRisk Factors\u201d\non page 27.",
                        "Col1": null,
                        "CORPORATE\nOFFICE": null,
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": null
                    },
                    {
                        "REGISTERED\nOFFICE": "COMPANY AND SELLING SHAREHOLDERS\u2019 ABSOLUTE RESPONSIBILITY",
                        "Col1": null,
                        "CORPORATE\nOFFICE": null,
                        "Col3": null,
                        "Col4": null,
                        "CONTACT PERSON": null,
                        "Col6": null,
                        "EMAIL AND\nTELEPHONE": null,
                        "Col8": null,
                        "Col9": null,
                        "WEBSITE": null
                    }
                ],
                "rows": 16,
                "cols": 11
            },
            {
                "page_number": 2,
                "table_data": [
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Red Herring\nProspectus contains all information with regard to our Company and the Offer which is material in the context of the Offer,\nthat the information contained in this Draft Red Herring Prospectus is true and correct in all material aspects and is not\nmisleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no\nother facts, the omission of which makes this Draft Red Herring Prospectus as a whole or any of such information or the\nexpression of any such opinions or intentions misleading in any material respect. Each of the Selling Shareholders, severally\nand not jointly, accepts responsibility for and confirms the statements expressly and specifically made by them in this Draft\nRed Herring Prospectus to the extent of information specifically pertaining to them and their respective portion of the Offered\nShares and assumes responsibility that such statements are true and correct in all material respects and not misleading in any\nmaterial respect. Each of the Selling Shareholders, severally and not jointly, assumes no responsibility, for any other statement\nin this Draft Red Herring Prospectus, including, inter alia, any of the statements made by or relating to our Company or any\nother Selling Shareholder or any other persons(s).",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "LISTING",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "The Equity Shares that will be offered through the Red Herring Prospectus are proposed to be listed on the BSE Limited\n(\u201cBSE\u201d) and National Stock Exchange of India Limited (\u201cNSE\u201d). For the purposes of the Offer, [\u25cf] is the Designated Stock\nExchange.",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "BOOK RUNNING LEAD MANAGERS",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "Names and Logos of the Book\nRunning Lead Managers",
                        "Col1": null,
                        "Col2": "Contact Person",
                        "Col3": null,
                        "Col4": null,
                        "Col5": "E-mail and Telephone",
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "ICICI Securities Limited",
                        "Col1": null,
                        "Col2": "Namrata Ravasia / Harsh Thakkar",
                        "Col3": null,
                        "Col4": null,
                        "Col5": "E-mail: akums.ipo@icicisecurities.com\nTel: +91 22 6807 7100",
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "Axis Capital Limited",
                        "Col1": null,
                        "Col2": "Akash Aggarwal / Jigar Jain",
                        "Col3": null,
                        "Col4": null,
                        "Col5": "E-mail: akums.ipo@axiscap.in\nTel: +91 22 4325 2183",
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "Citigroup Global Markets India\nPrivate Limited",
                        "Col1": null,
                        "Col2": "Abhishek Mawandiya",
                        "Col3": null,
                        "Col4": null,
                        "Col5": "E-mail: akums.ipo@citi.com\nTel: +91 22 6175 9999",
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "Ambit Private Limited",
                        "Col1": null,
                        "Col2": "Siddhesh Deshmukh",
                        "Col3": null,
                        "Col4": null,
                        "Col5": "E-mail: akums.ipo@ambit.co\nTel: +91 22 6623 3030",
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "REGISTRAR TO THE OFFER",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "Name of the Registrar",
                        "Col1": null,
                        "Col2": null,
                        "Col3": "Contact Person",
                        "Col4": null,
                        "Col5": null,
                        "Col6": "E-mail and Telephone",
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "Link Intime India Private Limited",
                        "Col1": null,
                        "Col2": null,
                        "Col3": "Shanti Gopalkrishnan",
                        "Col4": null,
                        "Col5": null,
                        "Col6": "E-mail:\nakumsdrugs.ipo@linkintime.co.in\nTel: +91 810 811 4949",
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "BID/ OFFER PERIOD",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null
                    },
                    {
                        "(Please scan this QR code to view the DRHP) 100% Book Built Offer": "ANCHOR INVESTOR\nBID/ OFFER PERIOD\nOPENS AND CLOSES\nON*",
                        "Col1": "[\u25cf]*",
                        "Col2": null,
                        "Col3": "BID/\nOFFER\nOPENS ON",
                        "Col4": "[\u25cf]",
                        "Col5": null,
                        "Col6": "BID/ OFFER\nCLOSES ON**",
                        "Col7": "[\u25cf]***"
                    }
                ],
                "rows": 14,
                "cols": 8
            },
            {
                "page_number": 3,
                "table_data": [
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "INITIAL PUBLIC OFFER OF UP TO [\u25cf] EQUITY SHARES OF FACE VALUE OF \u20b9 2 EACH (\u201cEQUITY SHARES\u201d) OF AKUMS DRUGS AND PHARMACEUTICALS LIMITED (\u201cCOMPANY\u201d OR \u201cISSUER\u201d)\nFOR CASH AT A PRICE OF \u20b9 [\u25cf] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF \u20b9 [\u25cf] PER EQUITY SHARE) (\u201cOFFER PRICE\u201d) AGGREGATING UP TO \u20b9 [\u25cf] MILLION COMPRISING A\nFRESH ISSUE OF UP TO [\u25cf] EQUITY SHARES AGGREGATING UP TO \u20b9 6,800 MILLION BY OUR COMPANY (\u201cFRESH ISSUE\u201d) AND AN OFFER FOR SALE OF UP TO 18,598,365 EQUITY SHARES\nAGGREGATING UP TO \u20b9 [\u25cf] MILLION (\u201cOFFERED SHARES\u201d) BY THE SELLING SHAREHOLDERS, COMPRISING UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO \u20b9 [\u25cf] MILLION BY\nSANJEEV JAIN, UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO \u20b9 [\u25cf] MILLION BY SANDEEP JAIN (TOGETHER THE \u201cPROMOTER SELLING SHAREHOLDERS\u201d) AND UP TO 14,306,435\nEQUITY SHARES AGGREGATING UP TO \u20b9 [\u25cf] MILLION BY RUBY QC INVESTMENT HOLDINGS PTE. LTD. (THE \u201cINVESTOR SELLING SHAREHOLDER\u201d) (THE PROMOTER SELLING\nSHAREHOLDERS AND THE INVESTOR SELLING SHAREHOLDER, COLLECTIVELY REFERRED TO AS THE \u201cSELLING SHAREHOLDERS\u201d) (\u201cOFFER FOR SALE\u201d, TOGETHER WITH THE FRESH\nISSUE, THE \u201cOFFER\u201d).\nTHIS OFFER INCLUDES A RESERVATION OF UP TO [\u25cf] EQUITY SHARES AGGREGATING UP TO \u20b9[\u25cf] MILLION FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE \u201cEMPLOYEE\nRESERVATION PORTION\u201d). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE \u201cNET OFFER\u201d. THE OFFER AND THE NET OFFER WILL\nCONSTITUTE [\u25cf]% AND [\u25cf]% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL, RESPECTIVELY.\nOUR COMPANY, IN CONSULTATION WITH THE BRLMs, MAY CONSIDER A PRIVATE PLACEMENT OF UP TO 20% OF THE FRESH ISSUE OR SUCH OTHER AMOUNT AS MAY BE ALLOWED\nUNDER APPLICABLE LAW FOR CASH CONSIDERATION AGGREGATING UP TO \u20b9 1,360 MILLION, PRIOR TO FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO\nPLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMs. IF THE PRE-IPO PLACEMENT IS UNDERTAKEN, THE\nMINIMUM OFFER SIZE (COMPRISING THE FRESH ISSUE SO REDUCED BY THE AMOUNT RAISED FROM THE PRE-IPO PLACEMENT, AND THE OFFER FOR SALE) SHALL CONSTITUTE AT\nLEAST 10% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.\nTHE FACE VALUE OF EQUITY SHARES IS \u20b9 2 EACH. THE OFFER PRICE IS [\u25cf] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE\nDECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS AND WILL BE ADVERTISED IN ALL EDITIONS OF [\u25cf], AN ENGLISH NATIONAL DAILY\nNEWSPAPER AND ALL EDITIONS OF [\u25cf], A HINDI NATIONAL DAILY NEWSPAPER (HINDI ALSO BEING THE REGIONAL LANGUAGE OF DELHI, WHERE OUR REGISTERED OFFICE IS\nLOCATED), EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ OFFER OPENING DATE AND SHALL BE MADE AVAILABLE TO BSE AND NSE (TOGETHER\nWITH BSE, THE \u201cSTOCK EXCHANGES\u201d) FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES.",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "In case of any revision to the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days following such revision of the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force\nmajeure, banking strike or similar circumstances, our Company, in consultation with the Book Running Lead Managers, for reasons to be recorded in writing, may extend the Bid/ Offer Period for a minimum of three Working Days, subject to the Bid/\nOffer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the\nchange on the respective websites of the Book Running Lead Managers and at the terminals of the Syndicate Members and by intimation to Self-Certified Syndicate Banks (\u201cSCSBs\u201d), other Designated Intermediaries and the Sponsor Banks, as applicable.",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the SCRR read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than\n75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (\u201cQIBs\u201d) (\u201cQIB Portion\u201d), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from\ndomestic Mutual Funds at or above the Anchor Investor Allocation Price (\u201cAnchor Investor Portion\u201d), in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance\nEquity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a\nproportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the\nbalance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not more than 15% of the Net Offer shall be available for allocation to Non-Institutional\nBidders out of which (a) one third of such portion shall be reserved for applicants with application size of more than \u20b9200,000 and up to \u20b91,000,000; and (b) two third of such portion shall be reserved for applicants with application size of more than\n\u20b91,000,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not more than 10% of the Net Offer shall be available for allocation to Retail\nIndividual Bidders, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the\nEmployee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (\u201cASBA\u201d) process by providing\ndetails of their respective ASBA accounts and UPI ID (in case of UPI Bidders) (as defined hereinafter), in which case the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (\u201cSCSBs\u201d) or under the UPI Mechanism, as\napplicable to participate in the Issue. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see \u201cOffer Procedure\u201d on page 415.",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "RISKS IN RELATION TO THE FIRST OFFER",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "This being the first public issue of Equity Shares of our Company, there has been no formal market for the Equity Shares. The face value of each Equity Share is \u20b9 2. The Floor Price, Cap Price and Offer Price (determined by our Company, in consultation\nwith the Book Running Lead Managers, in accordance with the SEBI ICDR Regulations), and on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process as stated in \u201cBasis for Offer Price\u201d on page 106\nshould not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares\nwill be traded after listing.",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "GENERAL RISK",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their investment. Bidders are advised to read the risk factors carefully before\ntaking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor\napproved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Red Herring Prospectus. Specific attention of the Bidders is invited to \u201cRisk Factors\u201d on page 27.",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "ISSUER\u2019S AND THE SELLING SHAREHOLDERS\u2019 ABSOLUTE RESPONSIBILITY",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Draft Red Herring Prospectus contains all information with regard to our Company and the Offer, which is material in the context of the Offer, that the\ninformation contained in this Draft Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the\nomission of which makes this Draft Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect. Each of the Selling Shareholders, severally and not jointly, accepts\nresponsibility for and confirms only the statements expressly and specifically made by them in this Draft Red Herring Prospectus to the extent of information specifically pertaining to them and their respective portion of the Offered Shares and assumes\nresponsibility that such statements are true and correct in all material respects and not misleading in any material respect. Each of the Selling Shareholders, severally and not jointly, assumes no responsibility, for any other statement in this Draft Red\nHerring Prospectus, including, inter alia, any of the statements made by or relating to our Company or any other Selling Shareholder or any other persons(s).",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "LISTING",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "The Equity Shares that will be offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges. Our Company has received \u2018in-principle\u2019 approvals from BSE and NSE for the listing of the Equity Shares pursuant to their\nletters dated [\u25cf] and [\u25cf], respectively. For the purposes of the Offer, the Designated Stock Exchange shall be [\u25cf]. A signed copy of the Red Herring Prospectus and the Prospectus shall be delivered to the RoC for filing. For details of the material contracts\nand documents that will be available for inspection from the date of the Red Herring Prospectus up to the Bid/ Offer Closing Date, see \u201cMaterial Contracts and Documents for Inspection\u201d on page 449.",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "BOOK RUNNING LEAD MANAGERS",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": "REGISTRAR TO THE OFFER"
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "",
                        "Col1": "",
                        "Col2": "",
                        "Col3": "",
                        "Col4": ""
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "ICICI Securities Limited\nICICI Venture House\nAppasaheb Marathe Marg\nPrabhadevi\nMumbai 400 025\nMaharashtra, India\nTel: +91 22 6807 7100\nE-mail: akums.ipo@icicisecurities.com\nInvestor grievance e-mail:\ncustomercare@icicisecurities.com\nWebsite: www.icicisecurities.com\nContact Person: Namrata Ravasia / Harsh\nThakkar\nSEBI Registration No.: INM000011179",
                        "Col1": "Axis Capital Limited\n1st Floor, Axis House\nC-2 Wadia International Centre\nPandurang Budhkar Marg\nWorli, Mumbai 400 025\nMaharashtra, India\nTel: +91 22 4325 2183\nE-mail: akums.ipo@axiscap.in\nInvestor grievance e-mail:\ncomplaints@axiscap.in\nWebsite: www.axiscapital.co.in\nContact Person: Akash Aggarwal / Jigar Jain\nSEBI Registration No.: INM000012029",
                        "Col2": "Citigroup Global Markets India Private\nLimited\n1202, 12th Floor\nFirst International Financial Centre\nG-Block, Bandra Kurla Complex\nBandra (East), Mumbai \u2013 400 098\nMaharashtra, India\nTel: +91 22 6175 9999\nE-mail: akums.ipo@citi.com\nWebsite:\nwww.online.citibank.co.in/rhtm/citigroupglobal\nscreen1.htm\nInvestor Grievance ID:\ninvestors.cgmib@citi.com\nContact Person: Abhishek Mawandiya\nSEBI Registration Number: INM000010718",
                        "Col3": "Ambit Private Limited\nAmbit House, 449, Senapati Bapat Marg\nLower Parel, Mumbai 400 013\nMaharashtra, India\nTel: + 91 22 6623 3030\nE-mail: akums.ipo@ambit.co\nInvestor Grievance E-mail:\ncustomerservicemb@ambit.co\nWebsite: www.ambit.co\nContact person: Siddhesh Deshmukh\nSEBI registration number: INM000010585",
                        "Col4": "Link Intime India Private Limited\nC-101, 1st Floor\n247 Park\nLal Bahadur Shastri Marg\nVikhroli (West)\nMumbai 400 083\nMaharashtra, India\nTel: +91 810 811 4949\nE-mail: akumsdrugs.ipo@linkintime.co.in\nWebsite: www.linkintime.co.in\nInvestor Grievance ID:\nakumsdrugs.ipo@linkintime.co.in\nContact Person: Shanti Gopalkrishnan\nSEBI Registration Number: INR000004058"
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "BID/ OFFER PROGRAMME",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "BID/ OFFER OPENS ON*",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": "[\u25cf]"
                    },
                    {
                        "THE PROMOTERS OF OUR COMPANY ARE SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST": "BID/ OFFER CLOSES ON**",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": "[\u25cf]***"
                    }
                ],
                "rows": 17,
                "cols": 5
            },
            {
                "page_number": 6,
                "table_data": [
                    {
                        "Term": "\u201cour Company\u201d/ \u201cthe Company\u201d,\n\u201cthe Issuer\u201d",
                        "Description": "Akums Drugs and Pharmaceuticals Limited, a public limited company incorporated under the\nCompanies Act, 1956 with its registered office at 304, Mohan Place, LSC Saraswati Vihar, Delhi \u2013 110\n034, India and corporate office at Akums House, Plot No. 131 to 133, Block C, Mangolpuri, Industrial\nArea, Phase 1, Delhi \u2013 110 083, India"
                    },
                    {
                        "Term": "\u201cwe\u201d/ \u201cus\u201d / \u201cour\u201d / \u201cGroup\u201d",
                        "Description": "Unless the context otherwise indicates or implies, refers to our Company together with our Subsidiaries\nand an erstwhile associate, on a consolidated basis as at and during the relevant period/ Fiscal Year"
                    }
                ],
                "rows": 2,
                "cols": 2
            },
            {
                "page_number": 6,
                "table_data": [
                    {
                        "Term": "AHCL",
                        "Description": "Akums Healthcare Limited"
                    },
                    {
                        "Term": "AHL",
                        "Description": "Akumentis Healthcare Limited"
                    },
                    {
                        "Term": "ALL",
                        "Description": "Akums Lifesciences Limited"
                    },
                    {
                        "Term": "\u201cArticles of Association\u201d, \u201cAoA\u201d\nor \u201cArticles\u201d",
                        "Description": "Articles of association of our Company, as amended from time to time"
                    },
                    {
                        "Term": "Audit Committee",
                        "Description": "The audit committee of our Board, as described in \u201cOur Management - Committees of the Board \u2013\nAudit Committee\u201d on page 225"
                    },
                    {
                        "Term": "\u201cBoard\u201d or \u201cBoard of Directors\u201d",
                        "Description": "The board of directors of our Company, as described in \u201cOur Management\u201d beginning on page 219"
                    },
                    {
                        "Term": "Chief Financial Officer",
                        "Description": "Sumeet Sood, the chief financial officer of our Company"
                    },
                    {
                        "Term": "Committee(s)",
                        "Description": "Duly constituted committee(s) of our Board"
                    },
                    {
                        "Term": "Company Secretary and\nCompliance Officer",
                        "Description": "Dharamvir Malik, the company secretary and compliance officer of our Company"
                    },
                    {
                        "Term": "Corporate Office",
                        "Description": "Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area, Phase1, Delhi - 110 083,\nIndia"
                    },
                    {
                        "Term": "Corporate Social Responsibility\nCommittee",
                        "Description": "The corporate social responsibility committee of our Board, as described in \u201cOur Management -\nCommittees of the Board \u2013 Corporate Social Responsibility Committee\u201d on page 230"
                    },
                    {
                        "Term": "Director(s)",
                        "Description": "The directors on our Board. For details see, \u201cOur Management\u201d on page 219"
                    },
                    {
                        "Term": "ESOP 2022",
                        "Description": "Akums Employee Stock Scheme 2022"
                    },
                    {
                        "Term": "ESOP Trust",
                        "Description": "Akums Employees Benefit Trust"
                    },
                    {
                        "Term": "Equity Shares",
                        "Description": "Equity shares of face value of \u20b9 2 each of our Company"
                    },
                    {
                        "Term": "Executive Director(s)/ Whole-time\nDirector(s)",
                        "Description": "Executive director(s) of our Company. For further details of our Executive Directors, see \u201cOur\nManagement\u201d on page 219"
                    },
                    {
                        "Term": "F&S",
                        "Description": "Frost & Sullivan (India) Private Limited"
                    },
                    {
                        "Term": "\u201cF&S Report\u201d or \u201cIndustry Report\u201d",
                        "Description": "The report titled \u201cIndependent Market Research on the Overview of the Global and Indian Contract"
                    }
                ],
                "rows": 18,
                "cols": 2
            },
            {
                "page_number": 7,
                "table_data": [
                    {
                        "Term": "",
                        "Description": "Development & Manufacturing Organization Industry\u201d dated February 8, 2024, prepared and issued\nby F&S, which has been commissioned by and paid for by our Company exclusively for the purposes\nof the Offer, pursuant to engagement letter dated October 7, 2023"
                    },
                    {
                        "Term": "\u201cIndependent Chartered\nAccountant\u201d or \u201cICA\u201d",
                        "Description": "T A M S & CO LLP, Chartered Accountants"
                    },
                    {
                        "Term": "Independent Directors",
                        "Description": "The independent directors of our Company, appointed as per the Companies Act, 2013 and the SEBI\nListing Regulations. For further details of our Independent Directors, see \u201cOur Management\u201d on page\n219"
                    },
                    {
                        "Term": "\u201cKey Managerial Personnel\u201d or\n\u201cKMP\u201d",
                        "Description": "The key managerial personnel of our Company in terms of Regulation 2(1)(bb) of the SEBI ICDR\nRegulations, as described in \u201cOur Management\u201d beginning on page 219"
                    },
                    {
                        "Term": "Materiality Policy",
                        "Description": "The policy adopted by our Board on January 17, 2024 for identification of group companies, material\noutstanding litigation, and outstanding dues to material creditors, in accordance with the disclosure\nrequirements under the SEBI ICDR Regulations"
                    },
                    {
                        "Term": "Material Subsidiaries",
                        "Description": "Collectively, AHL, ALL*, MLPL, MNL, PCHL, in terms of Regulation 16 of SEBI Listing\nRegulations.\nSolely for the purposes of disclosures in \u201cGovernment and Other Approvals\u201d section, such subsidiaries\nof our Company have been identified as material subsidiaries which are material in terms of (i) the\ndefinition of \u2018material subsidiary\u2019 stipulated under Regulation 16(1)(c) of the SEBI Listing\nRegulations, and (ii) the requirements specified under paragraph 11 (Financial Statements), I(A)(ii)(b)\nof Schedule VI of the SEBI ICDR Regulations.\n*ALL has been merged with PCHL with effect from April 1, 2022."
                    },
                    {
                        "Term": "\u201cMemorandum of Association\u201d or\n\u201cMoA\u201d",
                        "Description": "The memorandum of association of our Company, as amended from time to time"
                    },
                    {
                        "Term": "MLPL",
                        "Description": "Malik Lifesciences Private Limited"
                    },
                    {
                        "Term": "MNL",
                        "Description": "Maxcure Nutravedics Limited"
                    },
                    {
                        "Term": "NHL",
                        "Description": "Nicholas Healthcare Limited"
                    },
                    {
                        "Term": "\u201cNomination and Remuneration\nCommittee\u201d or \u201cNRC Committee\u201d",
                        "Description": "The nomination and remuneration committee of our Board, as described in \u201cOur Management -\nCommittees of the Board - Nomination and Remuneration Committee\u201d on page 227"
                    },
                    {
                        "Term": "Non-Executive Director(s)",
                        "Description": "Non-executive director(s) of our Company. For further details of our Non-executive Directors, see\n\u201cOur Management\u201d on page 219"
                    },
                    {
                        "Term": "PCHL",
                        "Description": "Pure and Cure Healthcare Private Limited"
                    },
                    {
                        "Term": "PPL",
                        "Description": "Plenteous Pharmaceuticals Limited"
                    },
                    {
                        "Term": "Promoters",
                        "Description": "Sanjeev Jain, Sandeep Jain and Akums Master Trust"
                    },
                    {
                        "Term": "Promoter Group",
                        "Description": "Individuals and entities constituting the promoter group of our Company in terms of Regulation\n2(1)(pp) of the SEBI ICDR Regulations, as described in \u201cOur Promoters and Promoter Group\u201d on\npage 237"
                    },
                    {
                        "Term": "Promoter Trust",
                        "Description": "Akums Master Trust"
                    },
                    {
                        "Term": "Registered Office",
                        "Description": "304, Mohan Place, LSC Saraswati Vihar, Delhi \u2013 110 034, India"
                    },
                    {
                        "Term": "\u201cRegistrar of Companies\u201d or\n\u201cRoC\u201d",
                        "Description": "The Registrar of Companies, Delhi and Haryana at New Delhi"
                    },
                    {
                        "Term": "Restated Consolidated Financial\nInformation",
                        "Description": "Restated consolidated financial information of our Company, our Subsidiaries and our erstwhile\nassociate as at and for the six months period ended September 30, 2023 and September 30, 2022 and\nfor the years ended March 31, 2023, March 31, 2022 and March 31, 2021 comprising the restated\nconsolidated statement of assets and liabilities as at September 30, 2023 and September 30, 2022 and\nas at March 31, 2023, March 31, 2022 and March 31, 2021, the restated consolidated statement of profit\nand loss (including other comprehensive income), the restated consolidated statement of changes in\nequity, the restated consolidated statement of cash flow, for the six months period ended September\n30, 2023 and September 30, 2022 and each for the years ended March 31, 2023, March 31, 2022 and\nMarch 31, 2021, the notes, comprising material accounting policies and other explanatory information,\nprepared as per the requirement of Section 26 of Part I of Chapter III of the Companies Act, 2013,\nSEBI ICDR Regulations, as amended and the Guidance Note on \u2018Reports in Company Prospectuses\n(Revised 2019)\u2019 issued by the Institute of Chartered Accountants of India, as amended from time to\ntime, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements)\nRegulations, 2018, as amended to date; and the Guidance Note on Reports in Company Prospectuses\n(Revised 2019) issued by the Institute of Chartered Accountants of India, as amended from time to\ntime."
                    },
                    {
                        "Term": "Risk Management Committee",
                        "Description": "The risk management committee as described in \u201cOur Management - Committees of the Board \u2013 Risk\nManagement Committee\u201d on page 229"
                    },
                    {
                        "Term": "Shareholder(s)",
                        "Description": "The shareholder(s) of our Company from time to time"
                    }
                ],
                "rows": 22,
                "cols": 2
            },
            {
                "page_number": 8,
                "table_data": [
                    {
                        "Term": "Stakeholders\u2019 Relationship\nCommittee",
                        "Description": "The stakeholders\u2019 relationship committee as described in \u201cOur Management - Committees of the\nBoard \u2013 Stakeholders\u2019 Relationship Committee\u201d on page 229"
                    },
                    {
                        "Term": "\u201cStatutory Auditors\u201d or \u201cAuditors\u201d",
                        "Description": "Walker Chandiok & Co LLP, Chartered Accountants, the statutory auditors of our Company"
                    },
                    {
                        "Term": "SHA",
                        "Description": "Shareholders\u2019 agreement dated October 3, 2019 entered into by and among our Company, Sandeep\nJain, Sanjeev Jain, and Ruby QC Investment Holdings Pte. Ltd. read with the Waiver cum Amendment\nAgreement dated February 9, 2024 to the SHA, entered into by and among our Company, Sandeep\nJain, Sanjeev Jain, and Ruby QC Investment Holdings Pte. Ltd."
                    },
                    {
                        "Term": "SHA Parties",
                        "Description": "Our Company, Sandeep Jain, Sanjeev Jain, and Ruby QC Investment Holdings Pte. Ltd."
                    },
                    {
                        "Term": "\u201cSenior Management Personnel\u201d\nor \u201cSMP\u201d",
                        "Description": "The senior management personnel of our Company in terms of Regulation 2(1)(bbbb) of the SEBI\nICDR Regulations, as disclosed in \u201cOur Management\u201d beginning on page 219"
                    },
                    {
                        "Term": "SPL",
                        "Description": "Sarvagunaushdhi Private Limited"
                    },
                    {
                        "Term": "SSPA",
                        "Description": "Share Subscription and Purchase Agreement dated October 3, 2019 entered into by and among our\nCompany, Sandeep Jain, Sanjeev Jain, and Ruby QC Investment Holdings Pte. Ltd."
                    },
                    {
                        "Term": "\u201cSubsidiary\u201d or \u201cour Subsidiary\u201d\nor \u201cSubsidiaries\u201d",
                        "Description": "The subsidiaries of our Company are as disclosed in \u201cHistory and Certain Corporate Matters \u2013 Our\nSubsidiaries\u201d on page 208.\nIn addition to the above, Upadhrish Reserchem LLP is accounted for as a subsidiary in accordance with\nInd AS 110 in the Restated Consolidated Financial Information included in this Draft Red Herring\nProspectus. Since this entity is a limited liability partnership firm, it is not a \u201csubsidiary\u201d as defined\nunder the Companies Act, 2013."
                    }
                ],
                "rows": 8,
                "cols": 2
            },
            {
                "page_number": 8,
                "table_data": [
                    {
                        "Term": "Acknowledgement Slip",
                        "Description": "The slip or document issued by the relevant Designated Intermediary(ies) to a Bidder as proof of\nregistration of the Bid cum Application Form"
                    },
                    {
                        "Term": "\u201cAllot\u201d or \u201cAllotment\u201d or\n\u201cAllotted\u201d",
                        "Description": "Unless the context otherwise requires, allotment (in case of the Fresh Issue) or transfer (in case of the\nOffered Shares pursuant to the Offer for Sale), of the Equity Shares pursuant to the Offer to the\nsuccessful Bidders"
                    },
                    {
                        "Term": "Allotment Advice",
                        "Description": "Note or advice or intimation of Allotment sent to all the Bidders who have Bid in the Offer after the\nBasis of Allotment has been approved by the Designated Stock Exchange"
                    },
                    {
                        "Term": "Allottee",
                        "Description": "A successful Bidder to whom the Equity Shares are Allotted"
                    },
                    {
                        "Term": "Ambit",
                        "Description": "Ambit Private Limited"
                    },
                    {
                        "Term": "Anchor Investor",
                        "Description": "A QIB, applying under the Anchor Investor Portion in accordance with the requirements specified in\nthe SEBI ICDR Regulations and the Red Herring Prospectus and who has Bid for an amount of at least\n\u20b9 100 million"
                    },
                    {
                        "Term": "Anchor Investor Allocation Price",
                        "Description": "The price at which Equity Shares will be allocated to the Anchor Investors in terms of the Red Herring\nProspectus and the Prospectus, which will be decided by our Company, in consultation with the Book\nRunning Lead Managers"
                    },
                    {
                        "Term": "Anchor Investor Application Form",
                        "Description": "The application form used by an Anchor Investor to make a Bid in the Anchor Investor Portion in\naccordance with the requirements specified under the SEBI ICDR Regulations and which will be\nconsidered as an application for Allotment in terms of the Red Herring Prospectus and the Prospectus"
                    },
                    {
                        "Term": "\u201cAnchor Investor Bid/Offer\nPeriod\u201d",
                        "Description": "One Working Day prior to the Bid/ Offer Opening Date, on which Bids by Anchor Investors shall be\nsubmitted, prior to and after which the Book Running Lead Managers will not accept any Bids from\nAnchor Investors, and allocation to Anchor Investors shall be completed"
                    },
                    {
                        "Term": "Anchor Investor Offer Price",
                        "Description": "The final price at which the Equity Shares will be Allotted to the Anchor Investors in terms of the Red\nHerring Prospectus and the Prospectus, which price will be equal to or higher than the Offer Price but\nnot higher than the Cap Price.\nThe Anchor Investor Offer Price will be decided by our Company in consultation with the Book\nRunning Lead Managers, in terms of the Red Herring Prospectus and the Prospectus"
                    },
                    {
                        "Term": "Anchor Investor Pay-in Date",
                        "Description": "With respect to Anchor Investor(s), the Anchor Investor Bid/ Offer Period, and in the event the Anchor\nInvestor Allocation Price is lower than the Anchor Investor Offer Price, not later than two Working\nDays after the Bid/ Offer Closing Date"
                    },
                    {
                        "Term": "Anchor Investor Portion",
                        "Description": "Up to 60% of the QIB Portion which may be allocated by our Company, in consultation with the Book\nRunning Lead Managers, to the Anchor Investors on a discretionary basis in accordance with the SEBI\nICDR Regulations.\nOne-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds only, subject to\nvalid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation\nPrice, in accordance with the SEBI ICDR Regulations."
                    }
                ],
                "rows": 12,
                "cols": 2
            },
            {
                "page_number": 9,
                "table_data": [
                    {
                        "Term": "Application Supported by Blocked\nAmount or ASBA",
                        "Description": "An application, whether physical or electronic, used by ASBA Bidders, to make a Bid and authorising\nan SCSB to block the Bid Amount in the ASBA Account and will include amounts blocked by the\nSCSB upon acceptance of UPI Mandate Request by the UPI Bidders using the UPI Mechanism"
                    },
                    {
                        "Term": "ASBA Account",
                        "Description": "A bank account maintained by ASBA Bidders with an SCSB and specified in the ASBA Form\nsubmitted by such ASBA Bidder in which funds will be blocked by such SCSB to the extent of the\namount specified in the ASBA Form submitted by such ASBA Bidder and includes a bank account\nmaintained by a UPI Bidder linked to a UPI ID, which will be blocked by the SCSB upon acceptance\nof the UPI Mandate Request in relation to a Bid by a UPI Bidder Bidding through the UPI Mechanism"
                    },
                    {
                        "Term": "\u201cASBA Bidders\u201d or \u201cASBA\nBidder\u201d",
                        "Description": "All Bidders except Anchor Investors"
                    },
                    {
                        "Term": "ASBA Form",
                        "Description": "An application form, whether physical or electronic, used by ASBA Bidders to submit Bids, which will\nbe considered as the application for Allotment in terms of the Red Herring Prospectus and the\nProspectus"
                    },
                    {
                        "Term": "Axis",
                        "Description": "Axis Capital Limited"
                    },
                    {
                        "Term": "Banker(s) to the Offer",
                        "Description": "Collectively, the Escrow Collection Bank, Refund Bank, Public Offer Account Bank and Sponsor\nBanks, as the case maybe"
                    },
                    {
                        "Term": "Basis of Allotment",
                        "Description": "The basis on which Equity Shares will be Allotted to successful Bidders under the Offer. For further\ndetails, see \u201cOffer Procedure\u201d on page 415"
                    },
                    {
                        "Term": "Bid",
                        "Description": "An indication to make an offer during the Bid/ Offer Period by an ASBA Bidder pursuant to submission\nof the ASBA Form, or during the Anchor Investor Bid/ Offer Period by an Anchor Investor, pursuant\nto submission of the Anchor Investor Application Form, to subscribe to or purchase the Equity Shares\nat a price within the Price Band, including all revisions and modifications thereto as permitted under\nthe SEBI ICDR Regulations and in terms of the Red Herring Prospectus and the Bid cum Application\nForm. The term \u201cBidding\u201d shall be construed accordingly"
                    },
                    {
                        "Term": "Bid Amount",
                        "Description": "The highest value of optional Bids indicated in the Bid cum Application Form and payable by the\nBidder or blocked in the ASBA Account of the ASBA Bidders, as the case may be, upon submission\nof the Bid.\nThe maximum Bid Amount under the Employee Reservation Portion by an Eligible Employee shall\nnot exceed \u20b9 500,000. However, the initial Allotment to an Eligible Employee in the Employee\nReservation Portion shall not exceed \u20b9 200,000. Only in the event of under-subscription in the\nEmployee Reservation Portion, the unsubscribed portion will be available for allocation and Allotment,\nproportionately to all Eligible Employees who have Bid in excess of \u20b9 200,000, subject to the maximum\nvalue of Allotment made to such Eligible Employee not exceeding \u20b9 500,000.\nHowever, RIBs can apply at the Cut-off Price and the Bid amount shall be Cap Price, multiplied by the\nnumber of Equity Shares Bid for by such RIBs mentioned in the Bid cum Application Form."
                    },
                    {
                        "Term": "Bid cum Application Form",
                        "Description": "Anchor Investor Application Form or the ASBA Form, as the context requires"
                    },
                    {
                        "Term": "Bid Lot",
                        "Description": "[\u25cf] Equity Shares and in multiples of [\u25cf] Equity Shares thereafter"
                    },
                    {
                        "Term": "Bid/ Offer Closing Date",
                        "Description": "Except in relation to any Bids received from the Anchor Investors, the date after which the Designated\nIntermediaries will not accept any Bids, which shall be published in all editions of [\u25cf], an English\nnational daily newspaper, all editions of [\u25cf] and a Hindi national daily newspaper (Hindi also being\nthe regional language of Delhi, where our Registered Office is located), each with wide circulation.\nOur Company, in consultation with the Book Running Lead Managers, may consider closing the Bid/\nOffer Period for QIBs one Working Day prior to the Bid/ Offer Closing Date in accordance with the\nSEBI ICDR Regulations. In case of any revision, the revised Bid/ Offer Closing Date shall be notified\non the websites of the Book Running Lead Managers and at the terminals of the Syndicate Members\nand communicated to the Designated Intermediaries and the Sponsor Banks, and shall also be notified\nin an advertisement in the same newspapers in which the Bid/ Offer Opening Date will be published"
                    },
                    {
                        "Term": "Bid/ Offer Period",
                        "Description": "Except in relation to Anchor Investors, the period between the Bid/ Offer Opening Date and the Bid/\nOffer Closing Date, inclusive of both days, during which Bidders can submit their Bids, including any\nrevisions thereof, in accordance with the SEBI ICDR Regulations, provided that such period shall be\nkept open for a minimum of three Working Days.\nOur Company, in consultation with the Book Running Lead Managers, may consider closing the Bid/\nOffer Period for QIBs one Working Day prior to the Bid/ Offer Closing Date in accordance with the\nSEBI ICDR Regulations"
                    },
                    {
                        "Term": "\u201cBidder\u201d or \u201cApplicant\u201d",
                        "Description": "Any prospective investor who makes a Bid pursuant to the terms of the Red Herring Prospectus and\nthe Bid cum Application Form and unless otherwise stated or implied, which includes an ASBA Bidder\nand an Anchor Investor"
                    },
                    {
                        "Term": "Bidding Centres",
                        "Description": "The centres at which the Designated Intermediaries shall accept the Bid cum Application Forms, being\nthe Designated Branches for SCSBs, Specified Locations for the Syndicate, Broker Centres for\nRegistered Brokers, Designated RTA Locations for RTAs and Designated CDP Locations for CDPs"
                    },
                    {
                        "Term": "Book Building Process",
                        "Description": "Book building process, as provided in Part A of Schedule XIII of the SEBI ICDR Regulations, in terms\nof which the Offer is being made"
                    }
                ],
                "rows": 16,
                "cols": 2
            },
            {
                "page_number": 10,
                "table_data": [
                    {
                        "Term": "\u201cBook Running Lead Managers\u201d\nor \u201cBRLMs\u201d",
                        "Description": "The book running lead managers to the Offer, namely, I-Sec, Axis, Citi and Ambit"
                    },
                    {
                        "Term": "Broker Centres",
                        "Description": "The broker centres notified by the Stock Exchanges where ASBA Bidders can submit the ASBA Forms\nto a Registered Broker.\nThe details of such Broker Centres, along with the names and the contact details of the Registered\nBrokers are available on the respective websites of the Stock Exchanges (www.bseindia.com and\nwww.nseindia.com)"
                    },
                    {
                        "Term": "\u201cConfirmation of Allocation Note\u201d\nor \u201cCAN\u201d",
                        "Description": "A notice or intimation of allocation of the Equity Shares sent to Anchor Investors, who have been\nallocated Equity Shares, after the Anchor Investor Bid/ Offer Period"
                    },
                    {
                        "Term": "Cap Price",
                        "Description": "The higher end of the Price Band, subject to any revisions thereto, above which the Offer Price and\nAnchor Investor Offer Price will not be finalised and above which no Bids will be accepted. The Cap\nPrice shall be at least 105% of the Floor Price"
                    },
                    {
                        "Term": "Cash Escrow and Sponsor Banks\nAgreement",
                        "Description": "The cash escrow and sponsor banks agreement to be entered into between and amongst our Company,\nthe Selling Shareholders, the Book Running Lead Managers, the Registrar to the Offer, the Banker(s)\nto the Offer and the Syndicate Members for, inter alia, collection of the Bid Amounts from the Anchor\nInvestors, transfer of funds to the Public Offer Account and where applicable, refunds of the amounts\ncollected from the Anchor Investors, on the terms and conditions thereof, in accordance with the UPI\nCirculars"
                    },
                    {
                        "Term": "Citi",
                        "Description": "Citigroup Global Markets India Private Limited"
                    },
                    {
                        "Term": "Client ID",
                        "Description": "The client identification number maintained with one of the Depositories in relation to dematerialized\naccount"
                    },
                    {
                        "Term": "\u201cCollecting Depository\nParticipant\u201d or \u201cCDP\u201d",
                        "Description": "A depository participant as defined under the Depositories Act, 1996, registered with SEBI and who is\neligible to procure Bids from relevant Bidders at the Designated CDP Locations in terms of SEBI\ncircular number CIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 as per the list available\non the respective websites of the Stock Exchanges, as updated from time to time"
                    },
                    {
                        "Term": "Cut-off Price",
                        "Description": "The Offer Price finalised by our Company, in consultation with the Book Running Lead Managers\nwhich shall be any price within the Price Band\nOnly RIBs in the Retail Portion and Eligible Employees (subject to the Bid Amount being \u20b9200,000)\nare entitled to Bid at the Cut-off Price. QIBs (including the Anchor Investors) and Non-Institutional\nBidders are not entitled to Bid at the Cut-off Price"
                    },
                    {
                        "Term": "Demographic Details",
                        "Description": "The demographic details of the Bidders including the Bidders\u2019 address, name of the Bidders\u2019 father or\nhusband, investor status, occupation, bank account details, PAN and UPI ID, where applicable"
                    },
                    {
                        "Term": "Designated Branches",
                        "Description": "Such branches of the SCSBs which shall collect the ASBA Forms from relevant Bidders, a list of which\nis available on the website of SEBI at\nhttps://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 or at such\nother website as may be prescribed by SEBI from time to time"
                    },
                    {
                        "Term": "Designated CDP Locations",
                        "Description": "Such locations of the CDPs where relevant ASBA Bidders can submit the ASBA Forms.\nThe details of such Designated CDP Locations, along with names and contact details of the CDPs\neligible to accept ASBA Forms are available on the websites of the Stock Exchanges\n(www.bseindia.com and www.nseindia.com), as updated from time to time"
                    },
                    {
                        "Term": "Designated Date",
                        "Description": "The date on which the Escrow Collection Bank(s) transfer funds from the Escrow Account to the Public\nOffer Account or the Refund Account, as the case may be, and the instructions are issued to the SCSBs\n(in case of UPI Bidders using UPI Mechanism, instruction issued through the Sponsor Bank(s)) for the\ntransfer of amounts blocked by the SCSBs in the ASBA Accounts to the Public Offer Account, in terms\nof the Red Herring Prospectus and the Prospectus, following which the Equity Shares will be Allotted\nin the Offer"
                    },
                    {
                        "Term": "Designated Intermediary(ies)",
                        "Description": "Collectively, the members of the Syndicate, sub-syndicate or agents, SCSBs (other than in relation to\nRIBs using the UPI Mechanism), Registered Brokers, CDPs and RTAs, who are authorised to collect\nBid cum Application Forms from the relevant Bidders, in relation to the Offer.\nIn relation to ASBA Forms submitted by RIBs and HNIs bidding with an application size of \u20b9 0.50\nmillion (not using UPI Mechanism) by authorising an SCSB to block the Bid Amount in the ASBA\nAccount, Designated Intermediaries shall mean SCSBs.\nIn relation to ASBA Forms submitted by UPI Bidders where the Bid Amount will be blocked upon\nacceptance of UPI Mandate Request by such UPI Bidder using the UPI Mechanism, Designated\nIntermediaries shall mean Syndicate, sub-syndicate/agents, Registered Brokers, CDPs, and RTAs.\nIn relation to ASBA Forms submitted by QIBs and Non-Institutional Bidders (not using the UPI\nMechanism), Designated Intermediaries shall mean Syndicate, sub-syndicate/ agents, SCSBs,\nRegistered Brokers, the CDPs and RTAs"
                    },
                    {
                        "Term": "Designated RTA Locations",
                        "Description": "Such locations of the RTAs where relevant ASBA Bidders can submit the ASBA Forms to RTAs."
                    }
                ],
                "rows": 15,
                "cols": 2
            },
            {
                "page_number": 11,
                "table_data": [
                    {
                        "Term": "",
                        "Description": "The details of such Designated RTA Locations, along with names and contact details of the RTAs\neligible to accept ASBA Forms are available on the websites of the Stock Exchanges\n(www.bseindia.com and www.nseindia.com)"
                    },
                    {
                        "Term": "Designated Stock Exchange",
                        "Description": "[\u25cf]"
                    },
                    {
                        "Term": "\u201cDraft Red Herring Prospectus\u201d or\n\u201cDRHP\u201d",
                        "Description": "This draft red herring prospectus dated February 10, 2024 issued in accordance with the SEBI ICDR\nRegulations, which does not contain complete particulars of the price at which the Equity Shares will\nbe Allotted and the size of the Offer, including any addenda or corrigenda thereto"
                    },
                    {
                        "Term": "Eligible Employees",
                        "Description": "Permanent employees, working in India or outside India (excluding such employees who are not\neligible to invest in the Offer under applicable laws), of our Company or our Subsidiaries; or a Director\nof our Company, whether whole-time or not, as on the date of the filing of the Red Herring Prospectus\nwith the RoC and on date of submission of the Bid cum Application Form, but not including (i)\nPromoters; (ii) persons belonging to the Promoter Group; or (iii) Directors who either themselves or\nthrough their relatives or through any body corporate, directly or indirectly, hold more than 10% of the\noutstanding Equity Shares of our Company.\nThe maximum Bid Amount under the Employee Reservation Portion by an Eligible Employee shall\nnot exceed \u20b9500,000. However, the initial Allotment to an Eligible Employee in the Employee\nReservation Portion shall not exceed \u20b9200,000. Only in the event of under-subscription in the\nEmployee Reservation Portion, the unsubscribed portion will be available for allocation and Allotment,\nproportionately to all Eligible Employees who have Bid in excess of \u20b9200,000, subject to the maximum\nvalue of Allotment made to such Eligible Employee not exceeding \u20b9500,000"
                    },
                    {
                        "Term": "Employee Reservation Portion",
                        "Description": "The portion of the Offer being up to [\u25cf] Equity Shares aggregating \u20b9 [\u25cf] million which shall not exceed\n5% of the post-Offer Equity Share capital of our Company, available for allocation to Eligible\nEmployees, on a proportionate basis"
                    },
                    {
                        "Term": "Eligible FPI(s)",
                        "Description": "FPI(s) from such jurisdictions outside India where it is not unlawful to make an offer/ invitation under\nthe Offer and in relation to whom the Bid cum Application Form and the Red Herring Prospectus\nconstitutes an invitation to subscribe to the Equity Shares"
                    },
                    {
                        "Term": "Eligible NRI(s)",
                        "Description": "NRI(s) eligible to invest under Schedule 3 and Schedule 4 of the FEMA NDI Rules, from jurisdictions\noutside India where it is not unlawful to make an offer or invitation under the Offer and in relation to\nwhom the Bid cum Application Form and the Red Herring Prospectus will constitute an invitation to\nsubscribe to or purchase the Equity Shares"
                    },
                    {
                        "Term": "Escrow Account(s)",
                        "Description": "The \u2018no-lien\u2019 and \u2018non-interest bearing\u2019 account(s) to be opened with the Escrow Collection Bank and\nin whose favour the Bidders (excluding the ASBA Bidders) will transfer money through direct\ncredit/NEFT/RTGS/NACH in respect of the Bid Amount when submitting a Bid"
                    },
                    {
                        "Term": "Escrow Collection Bank(s)",
                        "Description": "Bank(s), which are clearing members and registered with SEBI as a banker to an issue under the SEBI\nBTI Regulations and with whom the Escrow Account(s) will be opened, in this case being, [\u25cf]"
                    },
                    {
                        "Term": "\u201cFirst Bidder\u201d or \u201cSole Bidder\u201d",
                        "Description": "The Bidder whose name shall be mentioned in the Bid cum Application Form or the Revision Form\nand in case of joint Bids, whose name also appears as the first holder of the beneficiary account held\nin joint names"
                    },
                    {
                        "Term": "Floor Price",
                        "Description": "The lower end of the Price Band, subject to any revision thereto, not being less than the face value of\nthe Equity Shares, at or above which the Offer Price and the Anchor Investor Offer Price will be\nfinalised and below which no Bids will be accepted"
                    },
                    {
                        "Term": "Fraudulent Borrower",
                        "Description": "A company or person, as the case may be, categorised as a fraudulent borrower by any bank or financial\ninstitution (as defined under the Companies Act, 2013) or consortium thereof, in accordance with the\nguidelines on fraudulent borrowers issued by the RBI"
                    },
                    {
                        "Term": "Fresh Issue",
                        "Description": "Fresh issue of up to [\u25cf] Equity Shares aggregating up to \u20b9 6,800 million by our Company.\nOur Company, in consultation with the BRLMs, may consider a private placement of up to 20% of the\nFresh Issue or such other amount as may be allowed under applicable law for cash consideration\naggregating up to \u20b9 1,360 million, prior to filing of the Red Herring Prospectus with the RoC. The Pre-\nIPO Placement, if undertaken, will be at a price to be decided by our Company, in consultation with\nthe BRLMs. If the Pre-IPO Placement is undertaken, the minimum Offer size (comprising the Fresh\nIssue so reduced by the amount raised from the Pre-IPO Placement, and the Offer for Sale) shall\nconstitute at least 10% of the post-Offer paid-up Equity Share capital of our Company"
                    },
                    {
                        "Term": "General Information Document or\nGID",
                        "Description": "The General Information Document for investing in public issues, prepared and issued in accordance\nwith the SEBI circular (SEBI/HO/CFD/DIL1/CIR/P/2020/37) dated March 17, 2020, suitably modified\nand updated pursuant to, among others, the SEBI circular (SEBI/HO/CFD/DIL2/CIR/P/2020/50) dated\nMarch 30, 2020"
                    },
                    {
                        "Term": "Gross Proceeds",
                        "Description": "The gross proceeds of the Fresh Issue that will be available to our Company"
                    },
                    {
                        "Term": "\u201cInvestor\u201d or \u201cInvestor Selling\nShareholder\u201d",
                        "Description": "Ruby QC Investment Holdings Pte. Ltd."
                    },
                    {
                        "Term": "I-Sec",
                        "Description": "ICICI Securities Limited"
                    },
                    {
                        "Term": "Monitoring Agency",
                        "Description": "[\u25cf]"
                    }
                ],
                "rows": 18,
                "cols": 2
            },
            {
                "page_number": 12,
                "table_data": [
                    {
                        "Term": "Monitoring Agency Agreement",
                        "Description": "The agreement to be entered into between and amongst our Company and the Monitoring Agency"
                    },
                    {
                        "Term": "Mutual Fund Portion",
                        "Description": "Up to 5% of the Net QIB Portion or [\u25cf] Equity Shares which shall be available for allocation to Mutual\nFunds only on a proportionate basis, subject to valid Bids being received at or above the Offer Price"
                    },
                    {
                        "Term": "Net Offer",
                        "Description": "The Offer, less the Employee Reservation Portion"
                    },
                    {
                        "Term": "Net Proceeds",
                        "Description": "Gross Proceeds less our Company\u2019s share of the Offer expenses. For further details, see \u201cObjects of the\nOffer\u201d on page 89"
                    },
                    {
                        "Term": "Net QIB Portion",
                        "Description": "The QIB Portion less the number of Equity Shares Allotted to the Anchor Investors"
                    },
                    {
                        "Term": "\u201cNon-Institutional Bidders\u201d or\n\u201cNIBs\u201d",
                        "Description": "All Bidders that are not QIBs or RIBs and who have Bid for Equity Shares, for an amount of more than\n\u20b9 200,000 (but not including NRIs other than Eligible NRIs)"
                    },
                    {
                        "Term": "Non-Institutional Portion",
                        "Description": "The portion of the Offer being not more than 15% of the Net Offer comprising [\u25cf] Equity Shares which\nshall be available for allocation to Non-Institutional Bidders, subject to valid Bids being received at or\nabove the Offer Price, in the following manner:\n(a) one third of the portion available to non-institutional investors shall be reserved for applicants with\napplication size of more than \u20b9 200,000 and up to \u20b9 1.00 million;\n(b) two third of the portion available to non-institutional investors shall be reserved for applicants with\napplication size of more than \u20b9 1.00 million:\nProvided that the unsubscribed portion in either of the sub-categories specified in clauses (a) or (b),\nmay be allocated to applicants in the other sub-category of non-institutional investors"
                    },
                    {
                        "Term": "Offer",
                        "Description": "The initial public offer of up to [\u25cf] Equity Shares of face value of \u20b9 2 each for cash at a price of \u20b9 [\u25cf]\neach (including a share premium of \u20b9 [\u25cf] per Equity Share), aggregating up to \u20b9 [\u25cf] million, comprising\nthe Net Offer and the Employee Reservation Portion"
                    },
                    {
                        "Term": "Offer Agreement",
                        "Description": "The offer agreement dated February 10, 2024 entered into between and amongst our Company, the\nSelling Shareholders, and the Book Running Lead Managers, pursuant to which certain arrangements\nare agreed to in relation to the Offer"
                    },
                    {
                        "Term": "Offer for Sale",
                        "Description": "Offer for Sale of up to 18,598,365 Equity Shares aggregating up to \u20b9 [\u25cf] million by the Selling\nShareholders"
                    },
                    {
                        "Term": "Offer Price",
                        "Description": "The final price at which Equity Shares will be Allotted to ASBA Bidders in terms of the Red Herring\nProspectus and the Prospectus. Equity Shares will be Allotted to Anchor Investors at the Anchor\nInvestor Offer Price, in terms of the Red Herring Prospectus.\nThe Offer Price will be decided by our Company, in consultation with the Book Running Lead\nManagers, on the Pricing Date in accordance with the Book Building Process and the Red Herring\nProspectus"
                    },
                    {
                        "Term": "Offer Proceeds",
                        "Description": "The proceeds of the Fresh Issue which shall be available to our Company and the proceeds of the Offer\nfor Sale (net of their proportion of Offer-related expenses and the relevant taxes thereon) which shall\nbe available to the Selling Shareholders. For further details on the use of Offer Proceeds from the Fresh\nIssue, see \u201cObjects of the Offer\u201d on page 89"
                    },
                    {
                        "Term": "Offered Shares",
                        "Description": "Up to 18,598,365 Equity Shares aggregating up to \u20b9 [\u25cf] million offered by the Selling Shareholders in\nthe Offer for Sale"
                    },
                    {
                        "Term": "Pre-IPO Placement",
                        "Description": "The private placement of up to 20% of the Fresh Issue or such other amount as may be allowed under\napplicable law for cash consideration aggregating up to \u20b9 1,360 million, which may be undertaken by\nour Company, in consultation with the BRLMs, to be completed prior to filing of the Red Herring\nProspectus with the RoC. The Pre-IPO Placement, if undertaken, will be at a price to be decided by our\nCompany, in consultation with the BRLMs.\nIn the event such private placement is completed, the relevant details will be included in the Red\nHerring Prospectus.\nIf the Pre-IPO Placement is undertaken, the minimum Offer size (comprising the Fresh Issue so reduced\nby the amount raised from the Pre-IPO Placement, and the Offer for Sale) shall constitute at least 10%\nof the post-Offer paid-up Equity Share capital of our Company"
                    },
                    {
                        "Term": "Price Band",
                        "Description": "The price band of a minimum price of \u20b9 [\u25cf] per Equity Share (Floor Price) and the maximum price of\n\u20b9 [\u25cf] per Equity Share (Cap Price) including revisions thereof.\nThe Price Band and the minimum Bid Lot for the Offer will be decided by our Company, in consultation\nwith the Book Running Lead Managers and will be advertised in all editions of [\u25cf], an English national\ndaily newspaper, all editions of [\u25cf] and a Hindi national daily newspaper (Hindi also being the regional\nlanguage of Delhi, where our Registered Office is located), each with wide circulation, at least two\nWorking Days prior to the Bid/ Offer Opening Date and shall be available to the Stock Exchanges for\nthe purpose of uploading on their respective websites"
                    },
                    {
                        "Term": "Pricing Date",
                        "Description": "The date on which our Company, in consultation with the Book Running Lead Managers, will finalise\nthe Offer Price"
                    },
                    {
                        "Term": "Promoter Selling Shareholders",
                        "Description": "Sanjeev Jain and Sandeep Jain"
                    }
                ],
                "rows": 17,
                "cols": 2
            },
            {
                "page_number": 13,
                "table_data": [
                    {
                        "Term": "Prospectus",
                        "Description": "The prospectus to be filed with the RoC on or after the Pricing Date in accordance with Section 26 of\nthe Companies Act, 2013 and the SEBI ICDR Regulations containing, inter alia, the Offer Price that is\ndetermined at the end of the Book Building Process, the size of the Offer and certain other information\nincluding any addenda or corrigenda thereto"
                    },
                    {
                        "Term": "Public Offer Account",
                        "Description": "The \u2018no-lien\u2019 and \u2018non-interest bearing\u2019 account to be opened, in accordance with Section 40(3) of the\nCompanies Act, 2013 with the Public Offer Account Bank to receive monies from the Escrow Account\nand the ASBA Accounts on the Designated Date"
                    },
                    {
                        "Term": "Public Offer Account Bank(s)",
                        "Description": "Bank(s) which are a clearing member and registered with SEBI as a banker to an issue, and with whom\nthe Public Offer Account for collection of Bid Amounts from Escrow Accounts and ASBA Accounts\nwill be opened, in this case being [\u25cf]"
                    },
                    {
                        "Term": "QIB Portion",
                        "Description": "The portion of the Offer (including the Anchor Investor Portion) being not less than 75% of the Net\nOffer consisting of [\u25cf] Equity Shares which shall be available for allocation to QIBs (including Anchor\nInvestors), subject to valid Bids being received at or above the Offer Price or Anchor Investor Offer\nPrice (for Anchor Investors)"
                    },
                    {
                        "Term": "\u201cQIBs\u201d or \u201cQIB Bidders\u201d or\n\u201cQualified Institutional Buyers\u201d",
                        "Description": "Qualified institutional buyers as defined under Regulation 2(1)(ss) of the SEBI ICDR Regulations"
                    },
                    {
                        "Term": "\u201cRed Herring Prospectus\u201d or\n\u201cRHP\u201d",
                        "Description": "The red herring prospectus to be issued by our Company in accordance with Section 32 of the\nCompanies Act, and the provisions of the SEBI ICDR Regulations, which will not have complete\nparticulars of the price at which the Equity Shares will be offered and the size of the Offer, including\nany addenda or corrigenda thereto.\nThe Bid/ Offer Opening Date shall be at least three Working Days after the filing of the Red Herring\nProspectus with the RoC and will become the Prospectus upon filing with the RoC on or after the\nPricing Date"
                    },
                    {
                        "Term": "Refund Account(s)",
                        "Description": "The \u2018no-lien\u2019 and \u2018non-interest bearing\u2019 account opened with the Refund Bank, from which refunds, if\nany, of the whole or part, of the Bid Amount to the Anchor Investors shall be made"
                    },
                    {
                        "Term": "Refund Bank(s)",
                        "Description": "The Banker(s) to the Offer which are a clearing member and registered with SEBI as a banker to an\nissue, and with whom the Refund Account(s) will be opened and in this case being, [\u25cf]"
                    },
                    {
                        "Term": "Registered Brokers",
                        "Description": "The stock brokers registered under SEBI (Stock Brokers and Sub-Brokers) Regulations, 1992, as\namended with the stock exchanges having nationwide terminals, other than the members of the\nSyndicate and eligible to procure Bids from relevant Bidders in terms of SEBI circular number\nCIR/CFD/14/2012 dated October 4, 2012 issued by SEBI"
                    },
                    {
                        "Term": "Registrar Agreement",
                        "Description": "The registrar agreement dated February 9, 2024 entered into between and amongst our Company, the\nSelling Shareholders, and the Registrar to the Offer, in relation to the responsibilities and obligations\nof the Registrar to the Offer pertaining to the Offer"
                    },
                    {
                        "Term": "\u201cRegistrar to the Offer\u201d or\n\u201cRegistrar\u201d",
                        "Description": "Link Intime India Private Limited"
                    },
                    {
                        "Term": "\u201cRetail Individual Bidder(s)\u201d or\n\u201cRetail Individual Investor(s)\u201d or\n\u201cRII(s)\u201d or \u201cRIB(s)\u201d",
                        "Description": "Resident Indian individual Bidders, who have Bid for the Equity Shares for an amount not more than\n\u20b9 200,000 in any of the bidding options in the Offer (including HUFs applying through their Karta) and\nEligible NRIs"
                    },
                    {
                        "Term": "Retail Portion",
                        "Description": "Portion of the Offer being not more than 10% of the Net Offer consisting of [\u25cf] Equity Shares which\nshall be available for allocation to Retail Individual Bidders (subject to valid Bids being received at or\nabove the Offer Price)"
                    },
                    {
                        "Term": "Revision Form",
                        "Description": "The form used by Bidders to modify the quantity of the Equity Shares or the Bid Amount in any of\ntheir Bid cum Application Forms or any previous Revision Form(s), as applicable.\nQIB Bidders and Non-Institutional Bidders are not allowed to withdraw their Bid(s) or lower the size\nof their Bid(s) (in terms of quantity of Equity Shares or the Bid Amount) at any stage. Anchor Investors\nare not allowed to withdraw their Bids after the Anchor Investor Bidding Date. RIBs can revise their\nBids during the Bid/ Offer Period and withdraw their Bids until Bid/ Offer Closing Date"
                    },
                    {
                        "Term": "\u201cRTAs\u201d or \u201cRegistrar and Share\nTransfer Agents\u201d",
                        "Description": "The registrar and share transfer agents registered with SEBI and eligible to procure Bids from relevant\nBidders at the Designated RTA Locations in terms of SEBI circular number\nCIR/CFD/POLICYCELL/11/2015 dated November 10, 2015 issued by SEBI and available on the\nwebsites of the Stock Exchanges at www.nseindia.com and www.bseindia.com"
                    },
                    {
                        "Term": "SCORES",
                        "Description": "SEBI Complaints Redress System, a centralized web based complaints redressal system launched by\nSEBI"
                    },
                    {
                        "Term": "\u201cSelf Certified Syndicate Bank(s)\u201d\nor \u201cSCSB(s)\u201d",
                        "Description": "The banks registered with SEBI, offering services (i) in relation to ASBA (other than through UPI\nMechanism), a list of which is available on the website of SEBI at\nhttps://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 or\nhttps://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35, as\napplicable, or such other website as updated from time to time, and (ii) in relation to ASBA (through\nUPI Mechanism), a list of which is available on the website of SEBI at\nhttps://sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 or such other\nwebsite as may be prescribed by SEBI and updated from time to time."
                    }
                ],
                "rows": 17,
                "cols": 2
            },
            {
                "page_number": 14,
                "table_data": [
                    {
                        "Term": "",
                        "Description": "In relation to Bids (other than Bids by Anchor Investor) submitted to a member of the Syndicate, the\nlist of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive\ndeposits of Bid cum Application Forms from the members of the Syndicate is available on the website\nof the SEBI\n(https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35) and\nupdated from time to time. For more information on such branches collecting Bid cum Application\nForms from the Syndicate at Specified Locations, see the website of the SEBI at\nhttps://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 as updated\nfrom time to time.\nApplications through UPI in the Offer can be made only through the SCSBs mobile applications (apps)\nwhose name appears on the SEBI website. A list of SCSBs and mobile applications, which, are live for\napplying in public issues using UPI mechanism is provided as Annexure \u2018A\u2019 to the SEBI circular no.\nSEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019. The list is available on the website of SEBI\nat www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43 and updated\nfrom time to time and at such other websites as may be prescribed by SEBI from time to time"
                    },
                    {
                        "Term": "Selling Shareholders",
                        "Description": "Collectively, the Promoter Selling Shareholders and the Investor Selling Shareholder"
                    },
                    {
                        "Term": "Share Escrow Agent",
                        "Description": "The share escrow agent to be appointed pursuant to the Share Escrow Agreement, namely, [\u25cf]"
                    },
                    {
                        "Term": "Share Escrow Agreement",
                        "Description": "The share escrow agreement to be entered into between and amongst our Company, the Selling\nShareholders and the Share Escrow Agent in connection with the transfer of Equity Shares under the\nOffer for Sale by the Selling Shareholders and credit of such Equity Shares to the demat accounts of\nthe Allottees in accordance with the Basis of Allotment"
                    },
                    {
                        "Term": "Specified Locations",
                        "Description": "The Bidding centres where the Syndicate shall accept Bid cum Application Forms from relevant\nBidders, a list of which is available on the website of SEBI (www.sebi.gov.in), and updated from time\nto time"
                    },
                    {
                        "Term": "Sponsor Bank(s)",
                        "Description": "[\u25cf] and [\u25cf] being Bankers to the Offer registered with SEBI, appointed by our Company to act as\nconduits between the Stock Exchanges and NPCI in order to push the mandate collect requests and / or\npayment instructions of the UPI Bidders using the UPI Mechanism, in terms of the UPI Circulars"
                    },
                    {
                        "Term": "Syndicate Agreement",
                        "Description": "The syndicate agreement to be entered into between and amongst our Company, the Selling\nShareholders, the Registrar and the members of the Syndicate in relation to collection of Bid cum\nApplication Forms by the Syndicate"
                    },
                    {
                        "Term": "Syndicate Members",
                        "Description": "The intermediaries (other than the Book Running Lead Managers) registered with SEBI who are\npermitted to carry out activities as an underwriter, namely [\u25cf]"
                    },
                    {
                        "Term": "Sub-Syndicate Members",
                        "Description": "The sub-syndicate members, if any, appointed by the Book Running Lead Managers and the Syndicate\nMembers, to collect ASBA Forms and Revision Forms"
                    },
                    {
                        "Term": "\u201cSyndicate\u201d or \u201cmembers of the\nSyndicate\u201d",
                        "Description": "Together, collectively, the Book Running Lead Managers and the Syndicate Members"
                    },
                    {
                        "Term": "Underwriters",
                        "Description": "[\u25cf]"
                    },
                    {
                        "Term": "Underwriting Agreement",
                        "Description": "The underwriting agreement to be entered into between and amongst our Company, the Selling\nShareholders, and the Underwriters, on or after the Pricing Date, but prior to filing the Prospectus with\nthe RoC"
                    },
                    {
                        "Term": "UPI",
                        "Description": "Unified payments interface which is an instant payment mechanism, developed by NPCI"
                    },
                    {
                        "Term": "UPI Bidders",
                        "Description": "Collectively, individual investors applying as (i) RIBs in the Retail Portion, and (ii) Non-Institutional\nBidders with an application size of up to \u20b9 0.50 million in the Non-Institutional Portion, and Bidding\nunder the UPI Mechanism through ASBA Form(s) submitted with Syndicate Members, Registered\nBrokers, Collecting Depository Participants and Registrar and Share Transfer Agents.\nPursuant to Circular no. SEBI/HO/CFD/DIL2/P/CIR/P/2022/45 dated April 5, 2022 issued by SEBI,\nall individual investors applying in public issues where the application amount is up to \u20b9 500,000 using\nUPI Mechanism, shall provide their UPI ID in the bid-cum-application form submitted with: (i) a\nsyndicate member, (ii) a stock broker registered with a recognized stock exchange (whose name is\nmentioned on the website of the stock exchange as eligible for such activity), (iii) a depository\nparticipant (whose name is mentioned on the website of the stock exchange as eligible for such\nactivity), and (iv) a registrar to an issue and share transfer agent (whose name is mentioned on the\nwebsite of the stock exchange as eligible for such activity)"
                    },
                    {
                        "Term": "UPI Circulars",
                        "Description": "SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, SEBI circular no.\nSEBI/HO/CFD/DIL2/CIR/P/2019/50 dated April 3, 2019, SEBI circular no.\nSEBI/HO/CFD/DIL2/CIR/P/2019/76 dated June 28, 2019, SEBI circular no.\nSEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019 SEBI circular no.\nSEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 8, 2019, SEBI circular no.\nSEBI/HO/CFD/DIL2/CIR/P/2020/50 dated March 30, 2020, SEBI circular no.\nSEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, SEBI circular no.\nSEBI/HO/CFD/DIL1/CIR/P/2021/47 dated March 31, 2021, SEBI circular no.\nSEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, SEBI circular no.\nSEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, read along with SEBI RTA Master"
                    }
                ],
                "rows": 15,
                "cols": 2
            },
            {
                "page_number": 15,
                "table_data": [
                    {
                        "Term": "",
                        "Description": "Circular, SEBI circular no. CFD/DIL2/CIR/P/2018/22 dated February 15, 2018, SEBI circular no.\nSEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022, SEBI circular no.\nSEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, SEBI circular no.\nSEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022, SEBI master circular with circular no.\nSEBI/HO/MIRSD/POD-1/P/CIR/2023/70 dated May 17, 2023 (to the extent that such circulars pertain\nto the UPI Mechanism), SEBI master circular with circular no. SEBI/HO/CFD/PoD-\n2/P/CIR/2023/00094 dated June 21, 2023, SEBI circular no. SEBI/HO/CFD/TPD1/CIR/P/2023/140\ndated August 9, 2023, and any subsequent circulars or notifications issued by SEBI in this regard, along\nwith the circulars issued by the Stock Exchanges in this regard, including the circular issued by the\nNSE having reference no. 25/2022 dated August 3, 2022, and the circular issued by BSE having\nreference no. 20220803-40 dated August 3, 2022 and any subsequent circulars or notifications issued\nby SEBI in this regard"
                    },
                    {
                        "Term": "UPI ID",
                        "Description": "ID created on the UPI for single-window mobile payment system developed by the NPCI"
                    },
                    {
                        "Term": "UPI Mandate Request",
                        "Description": "A request (intimating the UPI Bidder by way of a notification on the UPI application and by way of a\nSMS for directing the UPI Bidder to such UPI mobile application) to the UPI Bidder initiated by the\nSponsor Banks to authorise blocking of funds on the UPI application equivalent to Bid Amount and\nsubsequent debit of funds in case of Allotment"
                    },
                    {
                        "Term": "UPI Mechanism",
                        "Description": "Process for applications by UPI Bidders submitted with intermediaries with UPI as mode of payment,\nin terms of the UPI Circulars"
                    },
                    {
                        "Term": "UPI PIN",
                        "Description": "A password to authenticate a UPI transaction"
                    },
                    {
                        "Term": "Working Day",
                        "Description": "All days on which commercial banks in Mumbai are open for business, provided however, for the\npurpose of announcement of the Price Band and the Bid/ Offer Period, \u201cWorking Day\u201d shall mean all\ndays, excluding all Saturdays, Sundays and public holidays on which commercial banks in Mumbai,\nIndia are open for business and the time period between the Bid/ Offer Closing Date and listing of the\nEquity Shares on the Stock Exchanges, \u201cWorking Day\u201d shall mean all trading days of the Stock\nExchanges excluding Sundays and bank holidays in India in accordance with circulars issued by SEBI"
                    }
                ],
                "rows": 6,
                "cols": 2
            },
            {
                "page_number": 15,
                "table_data": [
                    {
                        "Term": "AB-PMJAY",
                        "Description": "Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana"
                    },
                    {
                        "Term": "ADC",
                        "Description": "Antibody Drug Conjugate"
                    },
                    {
                        "Term": "ANDA",
                        "Description": "Abbreviated New Drug Application"
                    },
                    {
                        "Term": "APAC",
                        "Description": "Asia Pacific"
                    },
                    {
                        "Term": "API",
                        "Description": "Active Pharmaceutical Ingredient"
                    },
                    {
                        "Term": "ASEAN",
                        "Description": "Association of Southeast Asian Nations"
                    },
                    {
                        "Term": "AT&M",
                        "Description": "Alimentary Tract and Metabolism"
                    },
                    {
                        "Term": "BER",
                        "Description": "Business Environment Rankings"
                    },
                    {
                        "Term": "BLA",
                        "Description": "Biologics License Application"
                    },
                    {
                        "Term": "BRICS",
                        "Description": "Brazil, Russia, India, China, and South Africa"
                    },
                    {
                        "Term": "CDMO",
                        "Description": "Contract Development and Manufacturing Organization"
                    },
                    {
                        "Term": "CDSCO",
                        "Description": "Central Drug Standard Control Organization"
                    },
                    {
                        "Term": "CHE",
                        "Description": "Current Healthcare Expenditure"
                    },
                    {
                        "Term": "CNS",
                        "Description": "Central Nervous System"
                    },
                    {
                        "Term": "CRAMS",
                        "Description": "Contract Research and Manufacturing Services"
                    },
                    {
                        "Term": "CRO",
                        "Description": "Contract Research Organization"
                    },
                    {
                        "Term": "CVS",
                        "Description": "Cardiovascular"
                    },
                    {
                        "Term": "EIU",
                        "Description": "Economist Intelligence Unit"
                    },
                    {
                        "Term": "EMA",
                        "Description": "European Medicine Agency"
                    },
                    {
                        "Term": "ESG",
                        "Description": "Environmental, Social, and Governance"
                    },
                    {
                        "Term": "EU GMP",
                        "Description": "European Union Good Manufacturing Practice"
                    },
                    {
                        "Term": "FDA",
                        "Description": "Food and Drug Administration"
                    },
                    {
                        "Term": "GATT",
                        "Description": "General Agreement on Trade and Tariffs in 1995 and becoming fully"
                    },
                    {
                        "Term": "GDP",
                        "Description": "Gross Domestic Product"
                    },
                    {
                        "Term": "GDUFA",
                        "Description": "Generic Drug User Fee Amendments"
                    },
                    {
                        "Term": "GI",
                        "Description": "Gastro-intestinal"
                    }
                ],
                "rows": 26,
                "cols": 2
            },
            {
                "page_number": 16,
                "table_data": [
                    {
                        "Term": "GMP",
                        "Description": "Good Manufacturing Process"
                    },
                    {
                        "Term": "GU",
                        "Description": "Genitourinary"
                    },
                    {
                        "Term": "HPAPI",
                        "Description": "Highly Potent Active Pharmaceutical Ingredient"
                    },
                    {
                        "Term": "IPFC",
                        "Description": "Investment Promotion & Facilitation Centre"
                    },
                    {
                        "Term": "IPM",
                        "Description": "India Pharma Market"
                    },
                    {
                        "Term": "ISO",
                        "Description": "International Standardization Organization"
                    },
                    {
                        "Term": "KSM",
                        "Description": "Key Starting Materials"
                    },
                    {
                        "Term": "MNC",
                        "Description": "Multinational Company"
                    },
                    {
                        "Term": "NDA",
                        "Description": "New Drug Application"
                    },
                    {
                        "Term": "NDDS",
                        "Description": "New Drug Delivery Systems"
                    },
                    {
                        "Term": "NME",
                        "Description": "New Molecular Entity"
                    },
                    {
                        "Term": "NMP",
                        "Description": "National Master Plan"
                    },
                    {
                        "Term": "NPPA",
                        "Description": "National Pharmaceutical Pricing Authority"
                    },
                    {
                        "Term": "NSIPI",
                        "Description": "NCAER-State Investment Potential Index"
                    },
                    {
                        "Term": "OAI",
                        "Description": "Official Action Indicated"
                    },
                    {
                        "Term": "OOP",
                        "Description": "Out of Pocket"
                    },
                    {
                        "Term": "OTC",
                        "Description": "Over the Counter"
                    },
                    {
                        "Term": "PLI",
                        "Description": "Production-Linked Incentive"
                    },
                    {
                        "Term": "PMBJP",
                        "Description": "Pradhan Mantri Bhartiya Janaushadi Pariyojana"
                    },
                    {
                        "Term": "PQR",
                        "Description": "Product Quality Review"
                    },
                    {
                        "Term": "PQS",
                        "Description": "Pharmaceutical Quality System"
                    },
                    {
                        "Term": "QRM",
                        "Description": "Quality Risk Management"
                    },
                    {
                        "Term": "R&D",
                        "Description": "Research and Development"
                    },
                    {
                        "Term": "RNA",
                        "Description": "Ribonucleic Acid"
                    },
                    {
                        "Term": "RoW",
                        "Description": "Rest of the World"
                    },
                    {
                        "Term": "SAI",
                        "Description": "Systemic Anti-Infectives"
                    },
                    {
                        "Term": "SFDA",
                        "Description": "Saudi Food and Drug Authority"
                    },
                    {
                        "Term": "STEM",
                        "Description": "Science, Technology, Engineering, and Mathematics"
                    },
                    {
                        "Term": "TAM",
                        "Description": "Total Addressable Market"
                    },
                    {
                        "Term": "TRIPS",
                        "Description": "Trade-Related Intellectual Property Rights"
                    },
                    {
                        "Term": "US NSF",
                        "Description": "United States National Sanitation Foundation International"
                    },
                    {
                        "Term": "WHO",
                        "Description": "World Health Organization"
                    },
                    {
                        "Term": "WHO GMP",
                        "Description": "World Health Organization Good Manufacturing Practice"
                    }
                ],
                "rows": 33,
                "cols": 2
            },
            {
                "page_number": 16,
                "table_data": [
                    {
                        "Term": "\u201c\u20b9\u201d, \u201cRs.\u201d, \u201cRupees\u201d or \u201cINR\u201d",
                        "Description": "Indian Rupees"
                    },
                    {
                        "Term": "AIFs",
                        "Description": "Alternative Investments Funds, as defined in, and registered under the SEBI AIF Regulations"
                    },
                    {
                        "Term": "AGM",
                        "Description": "Annual general meeting"
                    },
                    {
                        "Term": "BSE",
                        "Description": "BSE Limited"
                    },
                    {
                        "Term": "Category I AIF",
                        "Description": "AIFs who are registered as \u201cCategory I Alternative Investment Funds\u201d under the SEBI AIF\nRegulations"
                    },
                    {
                        "Term": "Category II AIF",
                        "Description": "AIFs who are registered as \u201cCategory II Alternative Investment Funds\u201d under the SEBI AIF\nRegulations"
                    },
                    {
                        "Term": "Category III AIF",
                        "Description": "AIFs who are registered as \u201cCategory III Alternative Investment Funds\u201d under the SEBI AIF\nRegulations"
                    },
                    {
                        "Term": "Category I FPIs",
                        "Description": "FPIs who are registered as \u201cCategory I Foreign Portfolio Investors\u201d under the SEBI FPI Regulations"
                    },
                    {
                        "Term": "Category II FPIs",
                        "Description": "FPIs who are registered as \u201cCategory II foreign portfolio investors\u201d under the SEBI FPI Regulations"
                    },
                    {
                        "Term": "CAGR",
                        "Description": "Compound annual growth rate"
                    }
                ],
                "rows": 10,
                "cols": 2
            },
            {
                "page_number": 17,
                "table_data": [
                    {
                        "Term": "CBDT",
                        "Description": "Central Board of Direct Taxes"
                    },
                    {
                        "Term": "CDSL",
                        "Description": "Central Depository Services (India) Limited"
                    },
                    {
                        "Term": "CIN",
                        "Description": "Corporate Identity Number"
                    },
                    {
                        "Term": "\u201cCompanies Act\u201d or \u201cCompanies\nAct, 2013\u201d",
                        "Description": "Companies Act, 2013, as amended, along with the relevant rules made thereunder"
                    },
                    {
                        "Term": "Consolidated FDI Policy",
                        "Description": "Consolidated Foreign Direct Investment Policy notified by the DPIIT by way of circular bearing\nnumber DPIIT file number 5(2)/2020-FDI Policy dated October 15, 2020 effective from October 15,\n2020"
                    },
                    {
                        "Term": "Depositories",
                        "Description": "NSDL and CDSL"
                    },
                    {
                        "Term": "Depositories Act",
                        "Description": "The Depositories Act, 1996, as amended"
                    },
                    {
                        "Term": "DGFT",
                        "Description": "Directorate General of Foreign Trade, Ministry of Commerce and Industry, Government of India"
                    },
                    {
                        "Term": "DIN",
                        "Description": "Director Identification Number"
                    },
                    {
                        "Term": "DPIIT",
                        "Description": "Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry,\nGovernment of India"
                    },
                    {
                        "Term": "DP ID",
                        "Description": "Depository Participant\u2019s Identification"
                    },
                    {
                        "Term": "DP or Depository Participant",
                        "Description": "A depository participant as defined under the Depositories Act"
                    },
                    {
                        "Term": "EGM",
                        "Description": "Extraordinary general meeting"
                    },
                    {
                        "Term": "EPS",
                        "Description": "Earnings per share"
                    },
                    {
                        "Term": "FCNR",
                        "Description": "Foreign Currency Non-Resident"
                    },
                    {
                        "Term": "FDI",
                        "Description": "Foreign direct investment"
                    },
                    {
                        "Term": "FEMA",
                        "Description": "The Foreign Exchange Management Act, 1999, read with rules and regulations thereunder"
                    },
                    {
                        "Term": "\u201cFEMA Non-debt Instruments\nRules\u201d or \u201cFEMA NDI Rules\u201d",
                        "Description": "Foreign Exchange Management (Non-debt Instruments) Rules, 2019, as amended"
                    },
                    {
                        "Term": "FEMA Regulations",
                        "Description": "FEMA Non-debt Instruments Rules, the Foreign Exchange Management (Mode of Payment and\nReporting of Non debt Instruments) Regulations, 2019 and the Foreign Exchange Management (Debt\nInstruments) Regulations, 2019, as applicable"
                    },
                    {
                        "Term": "\u201cFinancial Year\u201d, \u201cFiscal\u201d or\n\u201cFiscal Year\u201d or \u201cFY\u201d",
                        "Description": "Unless stated otherwise, the period of 12 months ending March 31 of that particular year"
                    },
                    {
                        "Term": "FPI(s)",
                        "Description": "Foreign portfolio investors as defined under the SEBI FPI Regulations"
                    },
                    {
                        "Term": "Fugitive Economic Offender",
                        "Description": "An individual who is declared a fugitive economic offender under Section 12 of the Fugitive Economic\nOffenders Act, 2018, as amended"
                    },
                    {
                        "Term": "FVCI(s)",
                        "Description": "Foreign venture capital investors as defined and registered under the SEBI FVCI Regulations"
                    },
                    {
                        "Term": "GDP",
                        "Description": "Gross domestic product"
                    },
                    {
                        "Term": "\u201cGoI\u201d or \u201cGovernment\u201d or \u201cCentral\nGovernment\u201d",
                        "Description": "Government of India"
                    },
                    {
                        "Term": "GST",
                        "Description": "Goods and services tax"
                    },
                    {
                        "Term": "HUF",
                        "Description": "Hindu Undivided Family"
                    },
                    {
                        "Term": "IBC 2016",
                        "Description": "The Insolvency and Bankruptcy Code, 2016"
                    },
                    {
                        "Term": "ICAI",
                        "Description": "The Institute of Chartered Accountants of India"
                    },
                    {
                        "Term": "ICSI",
                        "Description": "The Institute of Company Secretaries of India"
                    },
                    {
                        "Term": "IFRS",
                        "Description": "International Financial Reporting Standards, as issued by the International Accounting Standards\nBoard"
                    },
                    {
                        "Term": "Ind AS 24",
                        "Description": "Indian Accounting Standard 24- Related Party Disclosures"
                    },
                    {
                        "Term": "Ind AS 34",
                        "Description": "Indian Accounting Standard 34 \u2013 Interim Financial reporting"
                    },
                    {
                        "Term": "Ind AS 37",
                        "Description": "Indian Accounting Standard 37- Provisions, Contingent Liabilities and Contingent Assets"
                    },
                    {
                        "Term": "\u201cInd AS\u201d or \u201cIndian Accounting\nStandards\u201d",
                        "Description": "Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 read with\nCompanies (Indian Accounting Standards) Rules, 2015, as amended and other relevant provisions of\nthe Companies Act, 2013"
                    },
                    {
                        "Term": "India",
                        "Description": "Republic of India"
                    },
                    {
                        "Term": "Indian GAAP/ IGAAP",
                        "Description": "Accounting Standards notified under Section 133 of the Companies Act, 2013, read together with Rule\n7 of the Companies (Accounts) Rules, 2014, as amended and Companies (Accounting Standards)\nAmendment Rules, 2016, as amended"
                    },
                    {
                        "Term": "IP",
                        "Description": "Intellectual property"
                    }
                ],
                "rows": 38,
                "cols": 2
            },
            {
                "page_number": 18,
                "table_data": [
                    {
                        "Term": "IPO",
                        "Description": "Initial public offering"
                    },
                    {
                        "Term": "IST",
                        "Description": "Indian Standard Time"
                    },
                    {
                        "Term": "IT",
                        "Description": "Information technology"
                    },
                    {
                        "Term": "IT Act",
                        "Description": "The Income-tax Act, 1961, as amended"
                    },
                    {
                        "Term": "KYC",
                        "Description": "Know your customer"
                    },
                    {
                        "Term": "MCA",
                        "Description": "Ministry of Corporate Affairs"
                    },
                    {
                        "Term": "MSMEs",
                        "Description": "Micro, Small, and Medium Enterprises"
                    },
                    {
                        "Term": "Mutual Funds",
                        "Description": "Mutual funds registered under the Securities and Exchange Board of India (Mutual Funds)\nRegulations, 1996, as amended"
                    },
                    {
                        "Term": "N.A.",
                        "Description": "Not applicable"
                    },
                    {
                        "Term": "NACH",
                        "Description": "National Automated Clearing House"
                    },
                    {
                        "Term": "\u201cNAV\u201d or \u201cNet Asset Value\u201d",
                        "Description": "Net asset value per share represents net worth at the end of the year/period (excluding non-controlling\ninterest) divided by the weighted average number of shares outstanding during the period/year post\nthe proposed issuance of equity shares against the outstanding options under ESOP scheme"
                    },
                    {
                        "Term": "NEFT",
                        "Description": "National Electronic Funds Transfer"
                    },
                    {
                        "Term": "Non-Resident",
                        "Description": "A person resident outside India, as defined under FEMA and includes NRIs, FPIs and FVCIs"
                    },
                    {
                        "Term": "NPCI",
                        "Description": "National Payments Corporation of India"
                    },
                    {
                        "Term": "NRI",
                        "Description": "Person resident outside India, who is a citizen of India or a person of Indian origin, and shall have the\nmeaning ascribed to such term in the Foreign Exchange Management (Deposit) Regulations, 2016, as\namended or an overseas citizen of India cardholder within the meaning of Section 7(A) of the\nCitizenship Act, 1955, as amended"
                    },
                    {
                        "Term": "NSDL",
                        "Description": "National Securities Depository Limited"
                    },
                    {
                        "Term": "NSE",
                        "Description": "National Stock Exchange of India Limited"
                    },
                    {
                        "Term": "OCB or Overseas Corporate Body",
                        "Description": "A company, partnership, society or other corporate body owned directly or indirectly to the extent of\nat least 60% by NRIs including overseas trusts, in which not less than 60% of beneficial interest is\nirrevocably held by NRIs directly or indirectly and which was in existence on October 3, 2003 and\nimmediately before such date had taken benefits under the general permission granted to OCBs under\nFEMA. OCBs are not allowed to invest in the Offer"
                    },
                    {
                        "Term": "p.a.",
                        "Description": "Per annum"
                    },
                    {
                        "Term": "PAN",
                        "Description": "Permanent Account Number"
                    },
                    {
                        "Term": "PAT",
                        "Description": "Profit after tax"
                    },
                    {
                        "Term": "PE",
                        "Description": "Private equity"
                    },
                    {
                        "Term": "P/E",
                        "Description": "Price/earnings"
                    },
                    {
                        "Term": "P/E Ratio",
                        "Description": "Price to Earnings ratio"
                    },
                    {
                        "Term": "RBI",
                        "Description": "The Reserve Bank of India"
                    },
                    {
                        "Term": "RBI Act",
                        "Description": "The Reserve Bank of India Act, 1934, as amended"
                    },
                    {
                        "Term": "Regulation S",
                        "Description": "Regulation S under the U.S. Securities Act"
                    },
                    {
                        "Term": "\u201cRoNW\u201d or \u201cReturn on Net Worth\u201d",
                        "Description": "Restated profit/(loss) attributable to equity holders of the parent (before other comprehensive income)\ndivided by total equity attributable to equity holders of the parent"
                    },
                    {
                        "Term": "RTGS",
                        "Description": "Real Time Gross Settlement"
                    },
                    {
                        "Term": "Rule 144A",
                        "Description": "Rule 144A under the U.S. Securities Act"
                    },
                    {
                        "Term": "SCRA",
                        "Description": "Securities Contracts (Regulation) Act, 1956, as amended"
                    },
                    {
                        "Term": "SCRR",
                        "Description": "Securities Contracts (Regulation) Rules, 1957, as amended"
                    },
                    {
                        "Term": "SEBI",
                        "Description": "Securities and Exchange Board of India constituted under the SEBI Act"
                    },
                    {
                        "Term": "SEBI Act",
                        "Description": "Securities and Exchange Board of India Act, 1992, as amended"
                    },
                    {
                        "Term": "SEBI AIF Regulations",
                        "Description": "Securities and Exchange Board of India (Alternative Investment Funds) Regulations, 2012, as\namended"
                    },
                    {
                        "Term": "SEBI BTI Regulations",
                        "Description": "Securities and Exchange Board of India (Bankers to an Offer) Regulations, 1994, as amended"
                    },
                    {
                        "Term": "SEBI FPI Regulations",
                        "Description": "Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2019, as amended"
                    },
                    {
                        "Term": "SEBI FVCI Regulations",
                        "Description": "Securities and Exchange Board of India (Foreign Venture Capital Investors) Regulations, 2000, as\namended"
                    },
                    {
                        "Term": "SEBI ICDR Master Circular",
                        "Description": "SEBI master circular bearing reference number SEBI/HO/CFD/PoD-2/P/CIR/2023/00094, dated June\n21, 2023"
                    }
                ],
                "rows": 39,
                "cols": 2
            },
            {
                "page_number": 19,
                "table_data": [
                    {
                        "Term": "SEBI ICDR Regulations",
                        "Description": "Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations,\n2018, as amended"
                    },
                    {
                        "Term": "SEBI Listing Regulations",
                        "Description": "Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements)\nRegulations, 2015, as amended"
                    },
                    {
                        "Term": "SEBI Merchant Bankers\nRegulations",
                        "Description": "Securities and Exchange Board of India (Merchant Bankers) Regulations, 1992, as amended"
                    },
                    {
                        "Term": "SEBI RTA Master Circular",
                        "Description": "SEBI master circular bearing number SEBI/HO/MIRSD/POD-1/P/CIR/2023/70 dated May 17, 2023"
                    },
                    {
                        "Term": "SEBI SBEB & SE Regulations",
                        "Description": "Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity)\nRegulations, 2021, as amended"
                    },
                    {
                        "Term": "SEBI VCF Regulations",
                        "Description": "Securities and Exchange Board of India (Venture Capital Fund) Regulations, 1996 as repealed\npursuant to the SEBI AIF Regulations"
                    },
                    {
                        "Term": "SME",
                        "Description": "Small and Medium Enterprises"
                    },
                    {
                        "Term": "Stamp Act",
                        "Description": "The Indian Stamp Act, 1899"
                    },
                    {
                        "Term": "State Government",
                        "Description": "The government of a state in India"
                    },
                    {
                        "Term": "Stock Exchanges",
                        "Description": "BSE and NSE"
                    },
                    {
                        "Term": "STT",
                        "Description": "Securities transaction tax"
                    },
                    {
                        "Term": "Systemically Important NBFC",
                        "Description": "Systemically important non-banking financial company as defined under Regulation 2(1)(iii) of the\nSEBI ICDR Regulations"
                    },
                    {
                        "Term": "Takeover Regulations",
                        "Description": "Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers)\nRegulations, 2011, as amended"
                    },
                    {
                        "Term": "TAN",
                        "Description": "Tax Deduction Account Number"
                    },
                    {
                        "Term": "U.K., UK",
                        "Description": "United Kingdom"
                    },
                    {
                        "Term": "\u201cU.S.A.\u201d, \u201cU.S.\u201d, \u201cUS\u201d or \u201cUnited\nStates of America\u201d",
                        "Description": "United States of America"
                    },
                    {
                        "Term": "U.S. GAAP",
                        "Description": "Generally Accepted Accounting Principles in the United States"
                    },
                    {
                        "Term": "U.S. SEC",
                        "Description": "Securities and Exchange Commission of the United States of America"
                    },
                    {
                        "Term": "U.S. Securities Act",
                        "Description": "United States Securities Act of 1933, as amended"
                    },
                    {
                        "Term": "USD or US$",
                        "Description": "United States Dollars"
                    },
                    {
                        "Term": "Wilful Defaulter",
                        "Description": "A company or person, as the case may be, categorised as a wilful defaulter by any bank or financial\ninstitution (as defined under the Companies Act, 2013) or consortium thereof, in accordance with the\nguidelines on wilful defaulters issued by the RBI"
                    },
                    {
                        "Term": "VCFs",
                        "Description": "Venture Capital Funds as defined in and registered with SEBI under the SEBI VCF Regulations"
                    }
                ],
                "rows": 22,
                "cols": 2
            },
            {
                "page_number": 21,
                "table_data": [
                    {
                        "Currency": null,
                        "Exchange rate as at": "September 30, 2023",
                        "Col2": "September 30, 2022",
                        "Col3": "March 31, 2023",
                        "Col4": "March 31, 2022",
                        "Col5": "March 31, 2021"
                    },
                    {
                        "Currency": "1 USD",
                        "Exchange rate as at": "83.06",
                        "Col2": "81.55",
                        "Col3": "82.22",
                        "Col4": "75.81",
                        "Col5": "73.50"
                    },
                    {
                        "Currency": "1 \u20ac",
                        "Exchange rate as at": "87.94",
                        "Col2": "80.11",
                        "Col3": "89.61",
                        "Col4": "84.66",
                        "Col5": "86.10"
                    },
                    {
                        "Currency": "1 \u00a3",
                        "Exchange rate as at": "101.67",
                        "Col2": "90.77",
                        "Col3": "101.87",
                        "Col4": "99.55",
                        "Col5": "100.95"
                    }
                ],
                "rows": 4,
                "cols": 6
            },
            {
                "page_number": 25,
                "table_data": [
                    {
                        "Offer *(1)(2)": "of which:",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9 [\u25cf] million": ""
                    },
                    {
                        "Offer *(1)(2)": "(i) Fresh Issue*(1)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9 [\u25cf] million": "Up to [\u25cf] Equity Shares aggregating up to \u20b9 6,800 million"
                    },
                    {
                        "Offer *(1)(2)": "(ii) Offer for Sale(2)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9 [\u25cf] million": "Up to 18,598,365 Equity Shares aggregating up to \u20b9 [\u25cf] million"
                    },
                    {
                        "Offer *(1)(2)": "which includes:",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9 [\u25cf] million": ""
                    },
                    {
                        "Offer *(1)(2)": "Employee Reservation Portion(3)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9 [\u25cf] million": "Up to [\u25cf] Equity Shares aggregating up to \u20b9 [\u25cf] million"
                    },
                    {
                        "Offer *(1)(2)": "Net Offer",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9 [\u25cf] million": "Up to [\u25cf] Equity Shares aggregating up to \u20b9 [\u25cf] million"
                    }
                ],
                "rows": 6,
                "cols": 2
            },
            {
                "page_number": 25,
                "table_data": [
                    {
                        "Name of the Selling Shareholder": "Promoter Selling Shareholders",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": null,
                        "Date of corporate authorisation/\nboard resolution": null,
                        "Date of consent letter": null
                    },
                    {
                        "Name of the Selling Shareholder": "Sanjeev Jain",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": "2,145,965",
                        "Date of corporate authorisation/\nboard resolution": "NA",
                        "Date of consent letter": "January 16, 2024"
                    },
                    {
                        "Name of the Selling Shareholder": "Sandeep Jain",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": "2,145,965",
                        "Date of corporate authorisation/\nboard resolution": "NA",
                        "Date of consent letter": "January 16, 2024"
                    },
                    {
                        "Name of the Selling Shareholder": "Investor Selling Shareholder",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": null,
                        "Date of corporate authorisation/\nboard resolution": null,
                        "Date of consent letter": null
                    },
                    {
                        "Name of the Selling Shareholder": "Ruby QC Investment Holdings Pte. Ltd.",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": "14,306,435",
                        "Date of corporate authorisation/\nboard resolution": "January 16, 2024",
                        "Date of consent letter": "January 16, 2024"
                    }
                ],
                "rows": 5,
                "cols": 4
            },
            {
                "page_number": 26,
                "table_data": [
                    {
                        "Objects": "Repayment/prepayment of all or certain borrowings of our Company and Subsidiaries",
                        "Estimated Amount*\n(in \u20b9 million)": "3,870.00"
                    },
                    {
                        "Objects": "Funding incremental working capital requirements of our Company",
                        "Estimated Amount*\n(in \u20b9 million)": "550.00"
                    },
                    {
                        "Objects": "Pursuing inorganic growth initiatives through acquisitions(1)",
                        "Estimated Amount*\n(in \u20b9 million)": "[\u25cf]"
                    },
                    {
                        "Objects": "General corporate purposes(1)",
                        "Estimated Amount*\n(in \u20b9 million)": "[\u25cf]"
                    },
                    {
                        "Objects": "Total(1)",
                        "Estimated Amount*\n(in \u20b9 million)": "[\u25cf]"
                    }
                ],
                "rows": 5,
                "cols": 2
            },
            {
                "page_number": 26,
                "table_data": [
                    {
                        "S.\nNo.": "Promoters",
                        "Name of the shareholder": null,
                        "Pre-Offer number\nof Equity Shares": null,
                        "Percentage of the\npre-Offer equity\nshare capital (%)": null,
                        "Post-Offer\nnumber of Equity\nShares*": null,
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": null
                    },
                    {
                        "S.\nNo.": "1.",
                        "Name of the shareholder": "Sanjeev Jain",
                        "Pre-Offer number\nof Equity Shares": "60,725,940\u03b2",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "42.45\u03b2",
                        "Post-Offer\nnumber of Equity\nShares*": "[\u25cf]",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "2.",
                        "Name of the shareholder": "Sandeep Jain",
                        "Pre-Offer number\nof Equity Shares": "60,739,690\u03b1",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "42.46\u03b1",
                        "Post-Offer\nnumber of Equity\nShares*": "[\u25cf]",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "3.",
                        "Name of the shareholder": "Akums Master Trust#",
                        "Pre-Offer number\nof Equity Shares": "-",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "-",
                        "Post-Offer\nnumber of Equity\nShares*": "[\u25cf]",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "Promoter Group",
                        "Name of the shareholder": null,
                        "Pre-Offer number\nof Equity Shares": null,
                        "Percentage of the\npre-Offer equity\nshare capital (%)": null,
                        "Post-Offer\nnumber of Equity\nShares*": null,
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": null
                    },
                    {
                        "S.\nNo.": "1.",
                        "Name of the shareholder": "Arushi Jain (jointly with\nSanjeev Jain)",
                        "Pre-Offer number\nof Equity Shares": "33,000",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "0.02",
                        "Post-Offer\nnumber of Equity\nShares*": "33,000",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "2.",
                        "Name of the shareholder": "Lata Jain",
                        "Pre-Offer number\nof Equity Shares": "13,750\u221e",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "0.01\u221e",
                        "Post-Offer\nnumber of Equity\nShares*": "13,750\u221e",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "3.",
                        "Name of the shareholder": "Umang Jain (jointly with Lata\nJain)",
                        "Pre-Offer number\nof Equity Shares": "5,500",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "Negligible",
                        "Post-Offer\nnumber of Equity\nShares*": "5,500",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "4.",
                        "Name of the shareholder": "Kanishk Jain (jointly with\nSandeep Jain)",
                        "Pre-Offer number\nof Equity Shares": "5,500",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "Negligible",
                        "Post-Offer\nnumber of Equity\nShares*": "5,500",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "5.",
                        "Name of the shareholder": "Manan Jain (jointly with\nSandeep Jain)",
                        "Pre-Offer number\nof Equity Shares": "5,500",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "Negligible",
                        "Post-Offer\nnumber of Equity\nShares*": "5,500",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    }
                ],
                "rows": 10,
                "cols": 6
            },
            {
                "page_number": 26,
                "table_data": [
                    {
                        "Sl.\nNo.": "Promoter Selling Shareholders",
                        "Name of the Selling\nShareholder": null,
                        "Pre-Offer number\nof Equity Shares": null,
                        "Percentage of the\npre-Offer equity\nshare capital (%)": null,
                        "Post-Offer number\nof Equity Shares*": "",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": ""
                    },
                    {
                        "Sl.\nNo.": "1.",
                        "Name of the Selling\nShareholder": "Sanjeev Jain",
                        "Pre-Offer number\nof Equity Shares": "60,725,940\u03b2",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "42.45 \u03b2",
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    },
                    {
                        "Sl.\nNo.": "2.",
                        "Name of the Selling\nShareholder": "Sandeep Jain",
                        "Pre-Offer number\nof Equity Shares": "60,739,690\u03b1",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "42.46 \u03b1",
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    },
                    {
                        "Sl.\nNo.": "Investor Selling Shareholder",
                        "Name of the Selling\nShareholder": null,
                        "Pre-Offer number\nof Equity Shares": null,
                        "Percentage of the\npre-Offer equity\nshare capital (%)": null,
                        "Post-Offer number\nof Equity Shares*": "",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": ""
                    },
                    {
                        "Sl.\nNo.": "3.",
                        "Name of the Selling\nShareholder": "Ruby QC Investment\nHoldings Pte. Ltd.",
                        "Pre-Offer number\nof Equity Shares": "21,584,970",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "15.09",
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the\npost-Offer Equity\nShare capital (%)": "[\u25cf]"
                    }
                ],
                "rows": 5,
                "cols": 6
            },
            {
                "page_number": 27,
                "table_data": [
                    {
                        "Particulars": "Equity Share capital",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "286.13",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "143.07",
                        "As at and for the\nyear ended\nMarch 31, 2023": "286.13",
                        "As at and for the\nyear ended\nMarch 31, 2022": "143.07",
                        "As at and for\nthe year ended\nMarch 31, 2021": "13.01"
                    },
                    {
                        "Particulars": "Net Worth",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "5,603.85",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "6,901.52",
                        "As at and for the\nyear ended\nMarch 31, 2023": "7,171.89",
                        "As at and for the\nyear ended\nMarch 31, 2022": "6,219.76",
                        "As at and for\nthe year ended\nMarch 31, 2021": "8,848.47"
                    },
                    {
                        "Particulars": "Revenue from operations",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "21,511.38",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "18,213.63",
                        "As at and for the\nyear ended\nMarch 31, 2023": "36,548.20",
                        "As at and for the\nyear ended\nMarch 31, 2022": "36,718.93",
                        "As at and for\nthe year ended\nMarch 31, 2021": "27,226.29"
                    },
                    {
                        "Particulars": "Profit/(Loss) for the period/year",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "(1,547.39)",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "690.85",
                        "As at and for the\nyear ended\nMarch 31, 2023": "978.17",
                        "As at and for the\nyear ended\nMarch 31, 2022": "(2,508.74)",
                        "As at and for\nthe year ended\nMarch 31, 2021": "1,234.35"
                    },
                    {
                        "Particulars": "Basic EPS (\u20b9)*",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "(10.93)",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "4.80",
                        "As at and for the\nyear ended\nMarch 31, 2023": "6.63",
                        "As at and for the\nyear ended\nMarch 31, 2022": "(17.65)",
                        "As at and for\nthe year ended\nMarch 31, 2021": "8.58"
                    },
                    {
                        "Particulars": "Diluted EPS (\u20b9)*",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "(10.93)",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "4.80",
                        "As at and for the\nyear ended\nMarch 31, 2023": "6.63",
                        "As at and for the\nyear ended\nMarch 31, 2022": "(17.65)",
                        "As at and for\nthe year ended\nMarch 31, 2021": "8.58"
                    },
                    {
                        "Particulars": "Net Asset Value per Equity Share (\u20b9)",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "39.17",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "48.24",
                        "As at and for the\nyear ended\nMarch 31, 2023": "50.13",
                        "As at and for the\nyear ended\nMarch 31, 2022": "43.48",
                        "As at and for\nthe year ended\nMarch 31, 2021": "61.85"
                    },
                    {
                        "Particulars": "Current borrowings (A)",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "6,067.55",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "5,863.20",
                        "As at and for the\nyear ended\nMarch 31, 2023": "4,214.77",
                        "As at and for the\nyear ended\nMarch 31, 2022": "3,446.20",
                        "As at and for\nthe year ended\nMarch 31, 2021": "959.03"
                    },
                    {
                        "Particulars": "Non-current borrowings (B)",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "1,009.96",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "1,369.32",
                        "As at and for the\nyear ended\nMarch 31, 2023": "1,154.96",
                        "As at and for the\nyear ended\nMarch 31, 2022": "133.33",
                        "As at and for\nthe year ended\nMarch 31, 2021": "11.61"
                    },
                    {
                        "Particulars": "Total borrowings (C=A + B)",
                        "For the six\nmonths period\nended\nSeptember 30,\n2023": "7,077.51",
                        "For the six\nmonths period\nended\nSeptember 30,\n2022": "7,232.52",
                        "As at and for the\nyear ended\nMarch 31, 2023": "5,369.73",
                        "As at and for the\nyear ended\nMarch 31, 2022": "3,579.53",
                        "As at and for\nthe year ended\nMarch 31, 2021": "970.64"
                    }
                ],
                "rows": 10,
                "cols": 6
            },
            {
                "page_number": 27,
                "table_data": [
                    {
                        "Name of Entity": "Company",
                        "Criminal\nproceedings": null,
                        "Tax proceedings": null,
                        "Statutory or\nregulatory\nproceedings": null,
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": null,
                        "Material civil\nlitigations": null,
                        "Aggregate\namount involved\n(\u20b9 in million)*": null
                    },
                    {
                        "Name of Entity": "By our Company",
                        "Criminal\nproceedings": "25",
                        "Tax proceedings": "Not applicable",
                        "Statutory or\nregulatory\nproceedings": "Not applicable",
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": "Not applicable",
                        "Material civil\nlitigations": "7",
                        "Aggregate\namount involved\n(\u20b9 in million)*": "267.33"
                    },
                    {
                        "Name of Entity": "Against our Company",
                        "Criminal\nproceedings": "Nil",
                        "Tax proceedings": "14",
                        "Statutory or\nregulatory\nproceedings": "35",
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": "Not applicable",
                        "Material civil\nlitigations": "1",
                        "Aggregate\namount involved\n(\u20b9 in million)*": "102.35"
                    },
                    {
                        "Name of Entity": "Directors",
                        "Criminal\nproceedings": null,
                        "Tax proceedings": null,
                        "Statutory or\nregulatory\nproceedings": null,
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": null,
                        "Material civil\nlitigations": null,
                        "Aggregate\namount involved\n(\u20b9 in million)*": null
                    },
                    {
                        "Name of Entity": "By the Directors",
                        "Criminal\nproceedings": "Nil",
                        "Tax proceedings": "Not applicable",
                        "Statutory or\nregulatory\nproceedings": "Not applicable",
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": "Not applicable",
                        "Material civil\nlitigations": "Nil",
                        "Aggregate\namount involved\n(\u20b9 in million)*": "Nil"
                    }
                ],
                "rows": 5,
                "cols": 7
            },
            {
                "page_number": 28,
                "table_data": [
                    {
                        "Name of Entity": "Against the Directors",
                        "Criminal\nproceedings": "Nil",
                        "Tax proceedings": "2",
                        "Statutory or\nregulatory\nproceedings": "8",
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": "Not applicable",
                        "Material civil\nlitigations": "Nil",
                        "Aggregate\namount involved\n(\u20b9 in million)*": "38.32"
                    },
                    {
                        "Name of Entity": "Promoters",
                        "Criminal\nproceedings": null,
                        "Tax proceedings": null,
                        "Statutory or\nregulatory\nproceedings": null,
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": null,
                        "Material civil\nlitigations": null,
                        "Aggregate\namount involved\n(\u20b9 in million)*": null
                    },
                    {
                        "Name of Entity": "By the Promoters",
                        "Criminal\nproceedings": "Nil",
                        "Tax proceedings": "Not applicable",
                        "Statutory or\nregulatory\nproceedings": "Not applicable",
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": "Not applicable",
                        "Material civil\nlitigations": "Nil",
                        "Aggregate\namount involved\n(\u20b9 in million)*": "Nil"
                    },
                    {
                        "Name of Entity": "Against the Promoters",
                        "Criminal\nproceedings": "Nil",
                        "Tax proceedings": "Nil",
                        "Statutory or\nregulatory\nproceedings": "6",
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": "Nil",
                        "Material civil\nlitigations": "Nil",
                        "Aggregate\namount involved\n(\u20b9 in million)*": "Nil"
                    },
                    {
                        "Name of Entity": "Subsidiaries",
                        "Criminal\nproceedings": null,
                        "Tax proceedings": null,
                        "Statutory or\nregulatory\nproceedings": null,
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": null,
                        "Material civil\nlitigations": null,
                        "Aggregate\namount involved\n(\u20b9 in million)*": null
                    },
                    {
                        "Name of Entity": "By the Subsidiaries",
                        "Criminal\nproceedings": "153",
                        "Tax proceedings": "Not applicable",
                        "Statutory or\nregulatory\nproceedings": "Not applicable",
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": "Not applicable",
                        "Material civil\nlitigations": "4",
                        "Aggregate\namount involved\n(\u20b9 in million)*": "177.74"
                    },
                    {
                        "Name of Entity": "Against the\nSubsidiaries",
                        "Criminal\nproceedings": "2",
                        "Tax proceedings": "19",
                        "Statutory or\nregulatory\nproceedings": "59",
                        "Disciplinary\nactions by the\nSEBI or Stock\nExchanges\nagainst our\nPromoters": "Not applicable",
                        "Material civil\nlitigations": "1",
                        "Aggregate\namount involved\n(\u20b9 in million)*": "1020.96"
                    }
                ],
                "rows": 7,
                "cols": 7
            },
            {
                "page_number": 28,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Particulars": "Income tax matters",
                        "As on September 30, 2023": "768.80",
                        "As on March 31, 2023": "768.80"
                    },
                    {
                        "S. No.": "2.",
                        "Particulars": "Product pricing related matters",
                        "As on September 30, 2023": "106.40",
                        "As on March 31, 2023": "44.26"
                    },
                    {
                        "S. No.": "3.",
                        "Particulars": "Others",
                        "As on September 30, 2023": "3.15",
                        "As on March 31, 2023": "2.35"
                    },
                    {
                        "S. No.": "",
                        "Particulars": "Total",
                        "As on September 30, 2023": "878.35",
                        "As on March 31, 2023": "815.41"
                    }
                ],
                "rows": 4,
                "cols": 4
            },
            {
                "page_number": 28,
                "table_data": [
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "D.C Jain",
                        "Nature of transaction/ Particulars": "Rent paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.28",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.28",
                        "Financial\nYear 2023": "0.56",
                        "Financial\nYear 2022": "0.56",
                        "Financial\nYear 2021": "0.56"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.01%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.01%",
                        "Financial\nYear 2023": "0.01%",
                        "Financial\nYear 2022": "0.01%",
                        "Financial\nYear 2021": "0.02%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Professional charges paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "3.25",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "2.73",
                        "Financial\nYear 2023": "5.49",
                        "Financial\nYear 2022": "5.49",
                        "Financial\nYear 2021": "5.40"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.13%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.11%",
                        "Financial\nYear 2023": "0.11%",
                        "Financial\nYear 2022": "0.13%",
                        "Financial\nYear 2021": "0.17%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Sandeep Jain",
                        "Nature of transaction/ Particulars": "Rent paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "12.13",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "12.64",
                        "Financial\nYear 2023": "25.43",
                        "Financial\nYear 2022": "24.41",
                        "Financial\nYear 2021": "23.87"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.48%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.49%",
                        "Financial\nYear 2023": "0.51%",
                        "Financial\nYear 2022": "0.59%",
                        "Financial\nYear 2021": "0.76%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "21.50",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "18.62",
                        "Financial\nYear 2023": "38.00",
                        "Financial\nYear 2022": "33.50",
                        "Financial\nYear 2021": "33.18"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.67%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.63%",
                        "Financial\nYear 2023": "0.64%",
                        "Financial\nYear 2022": "0.66%",
                        "Financial\nYear 2021": "0.78%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Sanjeev Jain",
                        "Nature of transaction/ Particulars": "Rent paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "11.88",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "12.10",
                        "Financial\nYear 2023": "24.27",
                        "Financial\nYear 2022": "23.05",
                        "Financial\nYear 2021": "22.93"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.47%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.47%",
                        "Financial\nYear 2023": "0.49%",
                        "Financial\nYear 2022": "0.55%",
                        "Financial\nYear 2021": "0.73%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "21.50",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "18.62",
                        "Financial\nYear 2023": "38.00",
                        "Financial\nYear 2022": "33.50",
                        "Financial\nYear 2021": "33.18"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.67%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.63%",
                        "Financial\nYear 2023": "0.64%",
                        "Financial\nYear 2022": "0.66%",
                        "Financial\nYear 2021": "0.78%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Lata Jain",
                        "Nature of transaction/ Particulars": "Rent paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.23",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.23",
                        "Financial\nYear 2023": "0.46",
                        "Financial\nYear 2022": "0.46",
                        "Financial\nYear 2021": "0.48"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.01%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.01%",
                        "Financial\nYear 2023": "0.01%",
                        "Financial\nYear 2022": "0.01%",
                        "Financial\nYear 2021": "0.02%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "2.27",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "2.27",
                        "Financial\nYear 2023": "4.60",
                        "Financial\nYear 2022": "4.38",
                        "Financial\nYear 2021": "-"
                    }
                ],
                "rows": 15,
                "cols": 7
            },
            {
                "page_number": 29,
                "table_data": [
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "",
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.07%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.08%",
                        "Financial\nYear 2023": "0.08%",
                        "Financial\nYear 2022": "0.09%",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Archana Jain",
                        "Nature of transaction/ Particulars": "Rent paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.34",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.34",
                        "Financial\nYear 2023": "0.67",
                        "Financial\nYear 2022": "0.67",
                        "Financial\nYear 2021": "0.67"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.01%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.01%",
                        "Financial\nYear 2023": "0.01%",
                        "Financial\nYear 2022": "0.02%",
                        "Financial\nYear 2021": "0.02%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "2.49",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "2.27",
                        "Financial\nYear 2023": "4.60",
                        "Financial\nYear 2022": "4.38",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.08%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.08%",
                        "Financial\nYear 2023": "0.08%",
                        "Financial\nYear 2022": "0.09%",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Akome Lifecare\nPrivate Limited",
                        "Nature of transaction/ Particulars": "Rent paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "34.93",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "34.84",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "1.37%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.70%",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Sales of goods and others",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.04",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of revenue from operations",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.00%",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Sales of property, plant and\nequipment",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.37",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "271.00",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of Sales of property, plant and\nequipment",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.15%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "64.30%",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Purchase of goods and others",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.65",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "1.86",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of cost of goods sold",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.01%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.01%",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Expenses incurred on behalf of\ngroup company",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "1.39",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.62",
                        "Financial\nYear 2023": "0.62",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.05%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.02%",
                        "Financial\nYear 2023": "0.01%",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Akums Foundation",
                        "Nature of transaction/ Particulars": "Corporate social responsibility",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "29.66",
                        "Financial\nYear 2023": "65.44",
                        "Financial\nYear 2022": "6.78",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "1.16%",
                        "Financial\nYear 2023": "1.32%",
                        "Financial\nYear 2022": "0.16%",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Sales of goods and others",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "3.94",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "61.08",
                        "Financial\nYear 2023": "61.18",
                        "Financial\nYear 2022": "0.89",
                        "Financial\nYear 2021": "0.01"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of revenue from operations",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.02%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.34%",
                        "Financial\nYear 2023": "0.17%",
                        "Financial\nYear 2022": "0.00%",
                        "Financial\nYear 2021": "0.00%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Akums Health and\nEducation Society",
                        "Nature of transaction/ Particulars": "Corporate social responsibility",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "4.00",
                        "Financial\nYear 2022": "10.52",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.08%",
                        "Financial\nYear 2022": "0.25%",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Sales of goods and others",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.02",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "3.95",
                        "Financial\nYear 2023": "3.96",
                        "Financial\nYear 2022": "3.83",
                        "Financial\nYear 2021": "0.24"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of revenue from operations",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.00%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.02%",
                        "Financial\nYear 2023": "0.01%",
                        "Financial\nYear 2022": "0.01%",
                        "Financial\nYear 2021": "0.00%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Basant Kumar Singh",
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "2.31",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "2.47",
                        "Financial\nYear 2023": "3.49",
                        "Financial\nYear 2022": "0.20",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.07%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.08%",
                        "Financial\nYear 2023": "0.06%",
                        "Financial\nYear 2022": "0.00%",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Deepak Haldankar",
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "9.65",
                        "Financial\nYear 2021": "2.06"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "0.19%",
                        "Financial\nYear 2021": "0.05%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Vinod Raheja",
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "14.14",
                        "Financial\nYear 2021": "7.99"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "0.28%",
                        "Financial\nYear 2021": "0.19%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Sumeet Sood",
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "9.61",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "6.17",
                        "Financial\nYear 2023": "13.23",
                        "Financial\nYear 2022": "1.66",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.30%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.21%",
                        "Financial\nYear 2023": "0.22%",
                        "Financial\nYear 2022": "0.03%",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Arushi Jain",
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "3.47",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "3.15",
                        "Financial\nYear 2023": "6.30",
                        "Financial\nYear 2022": "3.50",
                        "Financial\nYear 2021": "6.00"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.11%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.11%",
                        "Financial\nYear 2023": "0.11%",
                        "Financial\nYear 2022": "0.07%",
                        "Financial\nYear 2021": "0.14%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Director sitting fees",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "0.05",
                        "Financial\nYear 2021": "0.10"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "0.00%",
                        "Financial\nYear 2021": "0.00%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Kanishk Jain",
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "1.88",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "3.15",
                        "Financial\nYear 2023": "6.30",
                        "Financial\nYear 2022": "6.00",
                        "Financial\nYear 2021": "5.99"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.06%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.11%",
                        "Financial\nYear 2023": "0.11%",
                        "Financial\nYear 2022": "0.12%",
                        "Financial\nYear 2021": "0.14%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Director sitting fees",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "0.01"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "0.00%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Manan Jain",
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.15",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.00%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Dharamvir Malik",
                        "Nature of transaction/ Particulars": "Remuneration paid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "1.21",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "1.01",
                        "Financial\nYear 2023": "2.11",
                        "Financial\nYear 2022": "2.08",
                        "Financial\nYear 2021": "2.07"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of employee benefits expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.04%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.03%",
                        "Financial\nYear 2023": "0.04%",
                        "Financial\nYear 2022": "0.04%",
                        "Financial\nYear 2021": "0.05%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Director sitting fees",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.03",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.02",
                        "Financial\nYear 2023": "0.04",
                        "Financial\nYear 2022": "0.05",
                        "Financial\nYear 2021": "0.10"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.00%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.00%",
                        "Financial\nYear 2023": "0.00%",
                        "Financial\nYear 2022": "0.00%",
                        "Financial\nYear 2021": "0.00%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "AUSL Pharma",
                        "Nature of transaction/ Particulars": "Inter-corporate loan repaid",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "7.50",
                        "Financial\nYear 2023": "55.00",
                        "Financial\nYear 2022": "25.00",
                        "Financial\nYear 2021": "8.50"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Interest received",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "3.16",
                        "Financial\nYear 2023": "4.27",
                        "Financial\nYear 2022": "8.85",
                        "Financial\nYear 2021": "10.37"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Sales of goods and others",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "3.53",
                        "Financial\nYear 2023": "3.53",
                        "Financial\nYear 2022": "17.14",
                        "Financial\nYear 2021": "53.77"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of revenue from operations",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.02%",
                        "Financial\nYear 2023": "0.01%",
                        "Financial\nYear 2022": "0.05%",
                        "Financial\nYear 2021": "0.20%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Purchase of goods and others",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.04",
                        "Financial\nYear 2022": "18.89",
                        "Financial\nYear 2021": "34.14"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of cost of goods sold",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.00%",
                        "Financial\nYear 2022": "0.08%",
                        "Financial\nYear 2021": "0.20%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Expenses incurred on behalf of\nGroup Company",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.22",
                        "Financial\nYear 2023": "0.22",
                        "Financial\nYear 2022": "0.10",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.01%",
                        "Financial\nYear 2023": "0.00%",
                        "Financial\nYear 2022": "0.00%",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "Profit/ (loss) share from investment\nin partnership firm/ LLP",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "(1.70)",
                        "Financial\nYear 2023": "(2.03)",
                        "Financial\nYear 2022": "2.03",
                        "Financial\nYear 2021": "3.47"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of Profit/ (loss) share from\ninvestment in partnership firm/ LLP",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "100%",
                        "Financial\nYear 2023": "100%",
                        "Financial\nYear 2022": "100%",
                        "Financial\nYear 2021": "100%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Kewal Kundanlal\nHanda",
                        "Nature of transaction/ Particulars": "Director sitting fees",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.70",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.50",
                        "Financial\nYear 2023": "2.40",
                        "Financial\nYear 2022": "0.08",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.03%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.02%",
                        "Financial\nYear 2023": "0.05%",
                        "Financial\nYear 2022": "0.00%",
                        "Financial\nYear 2021": "-"
                    }
                ],
                "rows": 57,
                "cols": 7
            },
            {
                "page_number": 30,
                "table_data": [
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Nand Lal Kalra",
                        "Nature of transaction/ Particulars": "Director sitting fees",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.36",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.22",
                        "Financial\nYear 2023": "0.47",
                        "Financial\nYear 2022": "0.19",
                        "Financial\nYear 2021": "0.14"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.01%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.01%",
                        "Financial\nYear 2023": "0.01%",
                        "Financial\nYear 2022": "0.00%",
                        "Financial\nYear 2021": "0.00%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Neena Vivek",
                        "Nature of transaction/ Particulars": "Director sitting fees",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.03",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "0.18",
                        "Financial\nYear 2021": "0.12"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.00%",
                        "Financial\nYear 2023": "-",
                        "Financial\nYear 2022": "0.00%",
                        "Financial\nYear 2021": "0.00%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Matangi\nGowrishankar",
                        "Nature of transaction/ Particulars": "Director sitting fees",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.70",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.40",
                        "Financial\nYear 2023": "2.20",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.03%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "0.02%",
                        "Financial\nYear 2023": "0.04%",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Welcure\nPharmaceuticals\nPrivate Limited",
                        "Nature of transaction/ Particulars": "Royalty expense",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.06",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.12",
                        "Financial\nYear 2022": "0.12",
                        "Financial\nYear 2021": "0.12"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of other expenses",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "0.00%",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.00%",
                        "Financial\nYear 2022": "0.00%",
                        "Financial\nYear 2021": "0.00%"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": "Dhanwantri\nVedaresearch LLP",
                        "Nature of transaction/ Particulars": "Sale of non-current investments",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "0.16",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    },
                    {
                        "Related parties with\nwhom transactions\nhave taken place": null,
                        "Nature of transaction/ Particulars": "%age of Sale of non-current\ninvestments",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2023": "-",
                        "For six\nmonths\nperiod\nended\nSeptember\n30, 2022": "-",
                        "Financial\nYear 2023": "100.00%",
                        "Financial\nYear 2022": "-",
                        "Financial\nYear 2021": "-"
                    }
                ],
                "rows": 10,
                "cols": 7
            },
            {
                "page_number": 30,
                "table_data": [
                    {
                        "Sl.\nNo.": "Promoter Selling Shareholders",
                        "Name of the acquirer/\nShareholder": null,
                        "Date of\nacquisition**": null,
                        "Number of Equity\nShares acquired": null,
                        "Face value\n(in \u20b9)@": null,
                        "Cost of acquisition per equity\nshare (in \u20b9)*": null
                    },
                    {
                        "Sl.\nNo.": "1.",
                        "Name of the acquirer/\nShareholder": "Sanjeev Jain",
                        "Date of\nacquisition**": "NA",
                        "Number of Equity\nShares acquired": "Nil",
                        "Face value\n(in \u20b9)@": "NA",
                        "Cost of acquisition per equity\nshare (in \u20b9)*": "NA"
                    },
                    {
                        "Sl.\nNo.": "2.",
                        "Name of the acquirer/\nShareholder": "Sandeep Jain",
                        "Date of\nacquisition**": "NA",
                        "Number of Equity\nShares acquired": "Nil",
                        "Face value\n(in \u20b9)@": "NA",
                        "Cost of acquisition per equity\nshare (in \u20b9)*": "NA"
                    },
                    {
                        "Sl.\nNo.": "Investor Selling Shareholder",
                        "Name of the acquirer/\nShareholder": null,
                        "Date of\nacquisition**": null,
                        "Number of Equity\nShares acquired": null,
                        "Face value\n(in \u20b9)@": null,
                        "Cost of acquisition per equity\nshare (in \u20b9)*": null
                    },
                    {
                        "Sl.\nNo.": "3.",
                        "Name of the acquirer/\nShareholder": "Ruby QC Investment Holdings Pte.\nLtd.#",
                        "Date of\nacquisition**": "NA",
                        "Number of Equity\nShares acquired": "Nil",
                        "Face value\n(in \u20b9)@": "NA",
                        "Cost of acquisition per equity\nshare (in \u20b9)*": "NA"
                    }
                ],
                "rows": 5,
                "cols": 6
            },
            {
                "page_number": 31,
                "table_data": [
                    {
                        "Period": "Last 1 year",
                        "Weighted Average Cost of\nAcquisition (in \u20b9)": "Nil",
                        "Cap Price is \u2018X\u2019 times the\nWeighted Average Cost of\nAcquisition^": "N.A.",
                        "Range of acquisition\nprice: Lowest Price \u2013\nHighest Price\n(in \u20b9 )#": "Nil"
                    },
                    {
                        "Period": "Last 18 months",
                        "Weighted Average Cost of\nAcquisition (in \u20b9)": "Nil",
                        "Cap Price is \u2018X\u2019 times the\nWeighted Average Cost of\nAcquisition^": "N.A.",
                        "Range of acquisition\nprice: Lowest Price \u2013\nHighest Price\n(in \u20b9 )#": "Nil"
                    },
                    {
                        "Period": "Last 3 years",
                        "Weighted Average Cost of\nAcquisition (in \u20b9)": "Nil",
                        "Cap Price is \u2018X\u2019 times the\nWeighted Average Cost of\nAcquisition^": "N.A.",
                        "Range of acquisition\nprice: Lowest Price \u2013\nHighest Price\n(in \u20b9 )#": "Nil"
                    }
                ],
                "rows": 3,
                "cols": 4
            },
            {
                "page_number": 31,
                "table_data": [
                    {
                        "Name": "Promoter Selling Shareholders",
                        "Number of Equity Shares": null,
                        "Average cost of acquisition per\nEquity Share (in \u20b9)*": null
                    },
                    {
                        "Name": "Sanjeev Jain",
                        "Number of Equity Shares": "60,725,940#",
                        "Average cost of acquisition per\nEquity Share (in \u20b9)*": "0.15"
                    },
                    {
                        "Name": "Sandeep Jain",
                        "Number of Equity Shares": "60,739,690#",
                        "Average cost of acquisition per\nEquity Share (in \u20b9)*": "0.14"
                    },
                    {
                        "Name": "Investor Selling Shareholder",
                        "Number of Equity Shares": null,
                        "Average cost of acquisition per\nEquity Share (in \u20b9)*": null
                    },
                    {
                        "Name": "Ruby QC Investment Holdings Pte. Ltd.",
                        "Number of Equity Shares": "21,584,970",
                        "Average cost of acquisition per\nEquity Share (in \u20b9)*": "231.64"
                    }
                ],
                "rows": 5,
                "cols": 3
            },
            {
                "page_number": 33,
                "table_data": [
                    {
                        "Segment": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Segment": null,
                        "For the six months ended\nSeptember 30, 2023": "Sales Returns\n(\u20b9 in\nmillions)",
                        "Col2": "% of segment\nrevenue from\noperations",
                        "For the Financial Year": "Sales\nReturns\n(\u20b9 in\nmillions)",
                        "Col4": "% of segment\nrevenue from\noperations",
                        "Col5": "Sales\nReturns\n(\u20b9 in\nmillions)",
                        "Col6": "% of segment\nrevenue from\noperations",
                        "Col7": "Sales\nReturns\n(\u20b9 in\nmillions)",
                        "Col8": "% of segment\nrevenue from\noperations"
                    },
                    {
                        "Segment": "CDMO",
                        "For the six months ended\nSeptember 30, 2023": "109.52",
                        "Col2": "0.65",
                        "For the Financial Year": "153.41",
                        "Col4": "0.56",
                        "Col5": "101.53",
                        "Col6": "0.38",
                        "Col7": "51.41",
                        "Col8": "0.24"
                    },
                    {
                        "Segment": "Branded and\ngeneric\nformulations",
                        "For the six months ended\nSeptember 30, 2023": "360.29",
                        "Col2": "9.55",
                        "For the Financial Year": "881.32",
                        "Col4": "11.68",
                        "Col5": "633.02",
                        "Col6": "7.02",
                        "Col7": "398.53",
                        "Col8": "6.82"
                    },
                    {
                        "Segment": "API",
                        "For the six months ended\nSeptember 30, 2023": "20.84",
                        "Col2": "2.23",
                        "For the Financial Year": "145.16",
                        "Col4": "8.19",
                        "Col5": "1.26",
                        "Col6": "0.11",
                        "Col7": "\u2500",
                        "Col8": "\u2500"
                    }
                ],
                "rows": 5,
                "cols": 9
            },
            {
                "page_number": 34,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months\nended September 30,\n2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of total\npurchases of\nraw\nmaterials",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of total\npurchases of\nraw\nmaterials",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of total\npurchases of\nraw\nmaterials",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of total\npurchases of\nraw\nmaterials"
                    },
                    {
                        "Particulars": "CDMO business",
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    },
                    {
                        "Particulars": "Purchases of\nraw materials\nfrom our ten\nlargest\nsuppliers",
                        "For the six months\nended September 30,\n2023": "2,492.52",
                        "Col2": "29.79",
                        "For the Financial Year": "3,557.73",
                        "Col4": "24.30",
                        "Col5": "3,601.25",
                        "Col6": "21.96",
                        "Col7": "2,624.97",
                        "Col8": "25.32"
                    },
                    {
                        "Particulars": "Branded and generic formulations business*",
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    },
                    {
                        "Particulars": "Purchases of\nraw materials\nfrom our ten\nlargest\nsuppliers",
                        "For the six months\nended September 30,\n2023": "1,504.27",
                        "Col2": "85.95",
                        "For the Financial Year": "3,042.41",
                        "Col4": "75.94",
                        "Col5": "3,768.70",
                        "Col6": "59.92",
                        "Col7": "2,846.07",
                        "Col8": "67.87"
                    },
                    {
                        "Particulars": "API business",
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    }
                ],
                "rows": 7,
                "cols": 9
            },
            {
                "page_number": 35,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months\nended September 30,\n2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of total\npurchases of\nraw\nmaterials",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of total\npurchases of\nraw\nmaterials",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of total\npurchases of\nraw\nmaterials",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of total\npurchases of\nraw\nmaterials"
                    },
                    {
                        "Particulars": "Purchases of\nraw materials\nfrom our ten\nlargest\nsuppliers",
                        "For the six months\nended September 30,\n2023": "218.18",
                        "Col2": "65.43",
                        "For the Financial Year": "412.17",
                        "Col4": "51.77",
                        "Col5": "978.62",
                        "Col6": "68.45",
                        "Col7": "14.18",
                        "Col8": "94.61"
                    }
                ],
                "rows": 3,
                "cols": 9
            },
            {
                "page_number": 35,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "For the Financial Year": "2023",
                        "Col3": "2022",
                        "Col4": "2021"
                    },
                    {
                        "Particulars": "Expenses on R&D (\u20b9 in million)",
                        "For the six months ended\nSeptember 30, 2023": "516.54",
                        "For the Financial Year": "979.64",
                        "Col3": "713.02",
                        "Col4": "587.56"
                    },
                    {
                        "Particulars": "Percentage of revenue from operations (%)",
                        "For the six months ended\nSeptember 30, 2023": "2.40",
                        "For the Financial Year": "2.68",
                        "Col3": "1.94",
                        "Col4": "2.16"
                    },
                    {
                        "Particulars": "Percentage of total expenses (%)",
                        "For the six months ended\nSeptember 30, 2023": "2.34",
                        "For the Financial Year": "2.82",
                        "Col3": "1.84",
                        "Col4": "2.29"
                    }
                ],
                "rows": 4,
                "cols": 5
            },
            {
                "page_number": 35,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of total\nrevenue from\noperations",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of total\nrevenue from\noperations",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of total\nrevenue from\noperations",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of total\nrevenue from\noperations"
                    },
                    {
                        "Particulars": "Ten largest\nclients of",
                        "For the six months ended\nSeptember 30, 2023": "7,285.62",
                        "Col2": "43.35",
                        "For the Financial Year": "10,597.55",
                        "Col4": "38.92",
                        "Col5": "10,982.66",
                        "Col6": "41.27",
                        "Col7": "7,730.71",
                        "Col8": "36.16"
                    }
                ],
                "rows": 3,
                "cols": 9
            },
            {
                "page_number": 36,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of total\nrevenue from\noperations",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of total\nrevenue from\noperations",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of total\nrevenue from\noperations",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of total\nrevenue from\noperations"
                    },
                    {
                        "Particulars": "our CDMO\nbusiness*",
                        "For the six months ended\nSeptember 30, 2023": "",
                        "Col2": "",
                        "For the Financial Year": "",
                        "Col4": "",
                        "Col5": "",
                        "Col6": "",
                        "Col7": "",
                        "Col8": ""
                    }
                ],
                "rows": 3,
                "cols": 9
            },
            {
                "page_number": 36,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "For the Financial Year": "2023",
                        "Col3": "2022",
                        "Col4": "2021"
                    },
                    {
                        "Particulars": "Total revenue from the international markets (\u20b9 in\nmillion)",
                        "For the six months ended\nSeptember 30, 2023": "1,565.76",
                        "For the Financial Year": "2,316.73",
                        "Col3": "992.63",
                        "Col4": "762.63"
                    },
                    {
                        "Particulars": "Percentage of total revenue from operations (%)",
                        "For the six months ended\nSeptember 30, 2023": "7.28",
                        "For the Financial Year": "6.34",
                        "Col3": "2.70",
                        "Col4": "2.80"
                    }
                ],
                "rows": 3,
                "cols": 5
            },
            {
                "page_number": 37,
                "table_data": [
                    {
                        "Name of Entity": "Company",
                        "Criminal\nproceedings": null,
                        "Tax\nproceedings": null,
                        "Statutory or\nregulatory\nproceedings": null,
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": null,
                        "Material\ncivil\nlitigations": null,
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": null
                    },
                    {
                        "Name of Entity": "By our Company",
                        "Criminal\nproceedings": "25",
                        "Tax\nproceedings": "Not\napplicable",
                        "Statutory or\nregulatory\nproceedings": "Not\napplicable",
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": "Not applicable",
                        "Material\ncivil\nlitigations": "7",
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": "267.33"
                    },
                    {
                        "Name of Entity": "Against our Company",
                        "Criminal\nproceedings": "Nil",
                        "Tax\nproceedings": "14",
                        "Statutory or\nregulatory\nproceedings": "35",
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": "Not applicable",
                        "Material\ncivil\nlitigations": "1",
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": "102.35"
                    },
                    {
                        "Name of Entity": "Directors",
                        "Criminal\nproceedings": null,
                        "Tax\nproceedings": null,
                        "Statutory or\nregulatory\nproceedings": null,
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": null,
                        "Material\ncivil\nlitigations": null,
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": null
                    },
                    {
                        "Name of Entity": "By the Directors",
                        "Criminal\nproceedings": "Nil",
                        "Tax\nproceedings": "Not\napplicable",
                        "Statutory or\nregulatory\nproceedings": "Not\napplicable",
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": "Not applicable",
                        "Material\ncivil\nlitigations": "Nil",
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": "Nil"
                    },
                    {
                        "Name of Entity": "Against the Directors",
                        "Criminal\nproceedings": "Nil",
                        "Tax\nproceedings": "2",
                        "Statutory or\nregulatory\nproceedings": "8",
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": "Not applicable",
                        "Material\ncivil\nlitigations": "Nil",
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": "38.32"
                    },
                    {
                        "Name of Entity": "Promoters",
                        "Criminal\nproceedings": null,
                        "Tax\nproceedings": null,
                        "Statutory or\nregulatory\nproceedings": null,
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": null,
                        "Material\ncivil\nlitigations": null,
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": null
                    },
                    {
                        "Name of Entity": "By the Promoters",
                        "Criminal\nproceedings": "Nil",
                        "Tax\nproceedings": "Not\napplicable",
                        "Statutory or\nregulatory\nproceedings": "Not\napplicable",
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": "Not applicable",
                        "Material\ncivil\nlitigations": "Nil",
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": "Nil"
                    },
                    {
                        "Name of Entity": "Against the Promoters",
                        "Criminal\nproceedings": "Nil",
                        "Tax\nproceedings": "Nil",
                        "Statutory or\nregulatory\nproceedings": "6",
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": "Nil",
                        "Material\ncivil\nlitigations": "Nil",
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": "Nil"
                    },
                    {
                        "Name of Entity": "Subsidiaries",
                        "Criminal\nproceedings": null,
                        "Tax\nproceedings": null,
                        "Statutory or\nregulatory\nproceedings": null,
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": null,
                        "Material\ncivil\nlitigations": null,
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": null
                    },
                    {
                        "Name of Entity": "By the Subsidiaries",
                        "Criminal\nproceedings": "153",
                        "Tax\nproceedings": "Not\napplicable",
                        "Statutory or\nregulatory\nproceedings": "Not\napplicable",
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": "Not applicable",
                        "Material\ncivil\nlitigations": "4",
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": "177.74"
                    },
                    {
                        "Name of Entity": "Against the Subsidiaries",
                        "Criminal\nproceedings": "2",
                        "Tax\nproceedings": "19",
                        "Statutory or\nregulatory\nproceedings": "59",
                        "Disciplinary actions by\nthe SEBI or Stock\nExchanges against our\nPromoters": "Not applicable",
                        "Material\ncivil\nlitigations": "1",
                        "Aggregate\namount\ninvolved (\u20b9 in\nmillion)*": "1020.96"
                    }
                ],
                "rows": 12,
                "cols": 7
            },
            {
                "page_number": 38,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of total\ncost of\nmaterials",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of total\ncost of\nmaterials",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of total\ncost of\nmaterials",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of total\ncost of\nmaterials"
                    },
                    {
                        "Particulars": "CDMO business",
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    },
                    {
                        "Particulars": "Domestic\nsourcing",
                        "For the six months ended\nSeptember 30, 2023": "7,151.55",
                        "Col2": "85.48",
                        "For the Financial Year": "12,728.44",
                        "Col4": "86.92",
                        "Col5": "14,746.92",
                        "Col6": "89.92",
                        "Col7": "9,287.82",
                        "Col8": "89.60"
                    },
                    {
                        "Particulars": "Direct imports\nfrom China",
                        "For the six months ended\nSeptember 30, 2023": "1,075.58",
                        "Col2": "12.86",
                        "For the Financial Year": "1,483.41",
                        "Col4": "10.13",
                        "Col5": "955.53",
                        "Col6": "5.83",
                        "Col7": "394.41",
                        "Col8": "3.81"
                    },
                    {
                        "Particulars": "Direct imports\nfrom other\ncountries",
                        "For the six months ended\nSeptember 30, 2023": "139.67",
                        "Col2": "1.66",
                        "For the Financial Year": "431.49",
                        "Col4": "2.95",
                        "Col5": "697.78",
                        "Col6": "4.25",
                        "Col7": "683.22",
                        "Col8": "6.59"
                    },
                    {
                        "Particulars": "Branded and generic formulations business",
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    },
                    {
                        "Particulars": "Domestic\nsourcing",
                        "For the six months ended\nSeptember 30, 2023": "1,750.14",
                        "Col2": "100",
                        "For the Financial Year": "3,963.20",
                        "Col4": "98.93",
                        "Col5": "6,079.39",
                        "Col6": "96.65",
                        "Col7": "4,097.91",
                        "Col8": "97.72"
                    },
                    {
                        "Particulars": "Direct imports\nfrom China",
                        "For the six months ended\nSeptember 30, 2023": "\u2500",
                        "Col2": "\u2500",
                        "For the Financial Year": "\u2500",
                        "Col4": "\u2500",
                        "Col5": "\u2500",
                        "Col6": "\u2500",
                        "Col7": "\u2500",
                        "Col8": "\u2500"
                    },
                    {
                        "Particulars": "Direct imports\nfrom other\ncountries",
                        "For the six months ended\nSeptember 30, 2023": "\u2500",
                        "Col2": "\u2500",
                        "For the Financial Year": "42.98",
                        "Col4": "1.07",
                        "Col5": "210.46",
                        "Col6": "3.35",
                        "Col7": "95.43",
                        "Col8": "2.28"
                    },
                    {
                        "Particulars": "API business",
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    },
                    {
                        "Particulars": "Domestic\nsourcing",
                        "For the six months ended\nSeptember 30, 2023": "333.36",
                        "Col2": "99.96",
                        "For the Financial Year": "765.21",
                        "Col4": "96.12",
                        "Col5": "635.39",
                        "Col6": "44.44",
                        "Col7": "14.99",
                        "Col8": "100.00"
                    },
                    {
                        "Particulars": "Direct imports\nfrom China",
                        "For the six months ended\nSeptember 30, 2023": "0.12",
                        "Col2": "0.04",
                        "For the Financial Year": "28.04",
                        "Col4": "3.52",
                        "Col5": "791.42",
                        "Col6": "55.36",
                        "Col7": "\u2500",
                        "Col8": "\u2500"
                    },
                    {
                        "Particulars": "Direct imports\nfrom other\ncountries",
                        "For the six months ended\nSeptember 30, 2023": "\u2500",
                        "Col2": "\u2500",
                        "For the Financial Year": "2.88",
                        "Col4": "0.36",
                        "Col5": "2.85",
                        "Col6": "0.20",
                        "Col7": "\u2500",
                        "Col8": "\u2500"
                    },
                    {
                        "Particulars": "Overall",
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    },
                    {
                        "Particulars": "Domestic\nsourcing",
                        "For the six months ended\nSeptember 30, 2023": "9,235.05",
                        "Col2": "88.37",
                        "For the Financial Year": "17,456.85",
                        "Col4": "89.77",
                        "Col5": "21,461.70",
                        "Col6": "88.98",
                        "Col7": "13,400.72",
                        "Col8": "91.95"
                    },
                    {
                        "Particulars": "Direct imports\nfrom China",
                        "For the six months ended\nSeptember 30, 2023": "1,075.70",
                        "Col2": "10.29",
                        "For the Financial Year": "1,511.45",
                        "Col4": "7.77",
                        "Col5": "1,746.95",
                        "Col6": "7.24",
                        "Col7": "394.41",
                        "Col8": "2.71"
                    },
                    {
                        "Particulars": "Direct imports\nfrom other\ncountries",
                        "For the six months ended\nSeptember 30, 2023": "139.67",
                        "Col2": "1.34",
                        "For the Financial Year": "477.35",
                        "Col4": "2.45",
                        "Col5": "911.09",
                        "Col6": "3.78",
                        "Col7": "778.65",
                        "Col8": "5.34"
                    }
                ],
                "rows": 18,
                "cols": 9
            },
            {
                "page_number": 40,
                "table_data": [
                    {
                        "Financial\nYear": "2022",
                        "Instance": "Pramod Sharma, an ex-employee of MNL, acted in a\nmanner prejudicial to the interests of MNL, causing a\nfinancial loss to MNL.",
                        "Action taken": "A complaint has been filed by MNL\nagainst Pramod Sharma.",
                        "Status": "Currently\npending\nadjudication."
                    },
                    {
                        "Financial\nYear": "2018",
                        "Instance": "Sunil Bhatia, a former managing director of our\nSubsidiary, Amazing Research Laboratories Limited,\nconducted affairs in a manner prejudicial to the interests\nof the Subsidiary and our Company, to make a personal\ngain.",
                        "Action taken": "Legal proceedings have been\ninitiated against Sunil Bhatia by\nAmazing Research Laboratories\nLimited.",
                        "Status": "Currently\npending\nadjudication."
                    }
                ],
                "rows": 2,
                "cols": 4
            },
            {
                "page_number": 40,
                "table_data": [
                    {
                        "Particulars": null,
                        "As of September 30,\n2023": null,
                        "Col2": null,
                        "As of March 31,": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "As of September 30,\n2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of total\nassets",
                        "As of March 31,": "(\u20b9 in\nmillions)",
                        "Col4": "% of total\nassets",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of total\nassets",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of total\nassets"
                    },
                    {
                        "Particulars": "Inventories",
                        "As of September 30,\n2023": "6,882.66",
                        "Col2": "19.09",
                        "As of March 31,": "7,297.95",
                        "Col4": "22.34",
                        "Col5": "7,224.48",
                        "Col6": "23.54",
                        "Col7": "4,298.59",
                        "Col8": "19.84"
                    }
                ],
                "rows": 3,
                "cols": 9
            },
            {
                "page_number": 42,
                "table_data": [
                    {
                        "Financial Year": "Financial Year 2024",
                        "Acquisition": "Acquisition of assets of Ankur Drugs and Pharma Limited from Edelweiss Asset Reconstruction\nCompany Limited by PCHL."
                    },
                    {
                        "Financial Year": "Financial Year 2022",
                        "Acquisition": "Acquisition of assets of Origin Formulations Private Limited by AHL."
                    },
                    {
                        "Financial Year": null,
                        "Acquisition": "Acquisition of infrastructural assets of Ankur Drugs and Pharma Limited from Edelweiss Asset\nReconstruction Company Limited by PCHL."
                    },
                    {
                        "Financial Year": "Financial Year 2021",
                        "Acquisition": "Acquisition of ALL (erstwhile Parabolic Drugs Limited) through insolvency proceedings before the\nNational Company Law Tribunal, Chandigarh."
                    },
                    {
                        "Financial Year": null,
                        "Acquisition": "Acquisition of infrastructural assets from Lakhani Shoes & Apparels Private Limited by PCHL."
                    }
                ],
                "rows": 5,
                "cols": 2
            },
            {
                "page_number": 43,
                "table_data": [
                    {
                        "Name": "Ashish Sharma",
                        "Date of change": "August 14, 2023",
                        "Reason for change": "Appointment as Vice President ESG and sustainability of PCHL"
                    },
                    {
                        "Name": "Anil Gaur",
                        "Date of change": "August 3, 2023",
                        "Reason for change": "Resignation as Chief People Officer of MLPL"
                    },
                    {
                        "Name": "Sunil Jaiswal",
                        "Date of change": "July 05, 2023",
                        "Reason for change": "Appointment as the Vice President of Research and Development of our Company"
                    },
                    {
                        "Name": "Arvind Srivastava",
                        "Date of change": "December 16, 2022",
                        "Reason for change": "Appointment as President, Human Resources of our Company"
                    },
                    {
                        "Name": "Sanjay Verma",
                        "Date of change": "July 19, 2022",
                        "Reason for change": "Resignation as Vice President Information Technology of PCHL"
                    },
                    {
                        "Name": "Sumeet Sood",
                        "Date of change": "February 14, 2022",
                        "Reason for change": "Appointment as the Chief Financial Officer of our Company"
                    },
                    {
                        "Name": "Jitendra Mishra",
                        "Date of change": "August 1, 2022",
                        "Reason for change": "Appointment as Vice President Information Technology of PCHL"
                    },
                    {
                        "Name": "Vinod Raheja",
                        "Date of change": "January 4, 2022",
                        "Reason for change": "Resignation as the Chief Financial Officer of our Company"
                    },
                    {
                        "Name": "Anil Gaur",
                        "Date of change": "September 16, 2021",
                        "Reason for change": "Appointment as Chief People Officer of MLPL"
                    },
                    {
                        "Name": "Sanjay Sharma",
                        "Date of change": "December 01, 2021",
                        "Reason for change": "Appointment as President, Strategy, New Projects and Business Excellence of our\nCompany"
                    }
                ],
                "rows": 10,
                "cols": 3
            },
            {
                "page_number": 43,
                "table_data": [
                    {
                        "Particulars": "Number of employees",
                        "For the six months\nended September\n30, 2023": "7,211",
                        "For the Financial\nYear 2023": "6,986",
                        "For the Financial\nYear 2022": "6,870",
                        "For the Financial\nYear 2021": "5,466"
                    },
                    {
                        "Particulars": "Attrition rate of employees (%)",
                        "For the six months\nended September\n30, 2023": "22.35",
                        "For the Financial\nYear 2023": "43.74",
                        "For the Financial\nYear 2022": "39.26",
                        "For the Financial\nYear 2021": "46.61"
                    }
                ],
                "rows": 2,
                "cols": 5
            },
            {
                "page_number": 44,
                "table_data": [
                    {
                        "Capital\nexpenditure": null,
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Capital\nexpenditure": null,
                        "For the six months\nended September 30,\n2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of revenue\nfrom\noperations",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of revenue\nfrom\noperations",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of revenue\nfrom\noperations",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of revenue\nfrom\noperations"
                    },
                    {
                        "Capital\nexpenditure": "CDMO business",
                        "For the six months\nended September 30,\n2023": "1,360.77",
                        "Col2": "6.33",
                        "For the Financial Year": "2,879.10",
                        "Col4": "7.88",
                        "Col5": "1,970.12",
                        "Col6": "5.37",
                        "Col7": "1,066.90",
                        "Col8": "3.92"
                    }
                ],
                "rows": 3,
                "cols": 9
            },
            {
                "page_number": 44,
                "table_data": [
                    {
                        "Particulars": null,
                        "Six months ended September\n30,": "2023",
                        "Col2": "2022",
                        "Financial Year": "2023",
                        "Col4": "2022",
                        "Col5": "2021"
                    },
                    {
                        "Particulars": null,
                        "Six months ended September\n30,": "(in \u20b9 millions)",
                        "Col2": null,
                        "Financial Year": null,
                        "Col4": null,
                        "Col5": null
                    },
                    {
                        "Particulars": "Net cash generated from/ (used in) operating activities",
                        "Six months ended September\n30,": "632.57",
                        "Col2": "(1,348.80)",
                        "Financial Year": "1,766.31",
                        "Col4": "318.54",
                        "Col5": "1,306.14"
                    },
                    {
                        "Particulars": "Net cash (used in) investing activities",
                        "Six months ended September\n30,": "(1,333.55)",
                        "Col2": "(2,159.33)",
                        "Financial Year": "(3,047.02)",
                        "Col4": "(2,348.22)",
                        "Col5": "(1,093.85)"
                    },
                    {
                        "Particulars": "Net cash generated from/ (used in) financing activities",
                        "Six months ended September\n30,": "1,361.20",
                        "Col2": "3,415.41",
                        "Financial Year": "1,245.40",
                        "Col4": "2,360.40",
                        "Col5": "(914.62)"
                    },
                    {
                        "Particulars": "Net increase/ (decrease) in cash and cash equivalents",
                        "Six months ended September\n30,": "660.22",
                        "Col2": "(92.72)",
                        "Financial Year": "(35.31)",
                        "Col4": "330.72",
                        "Col5": "(702.33)"
                    }
                ],
                "rows": 6,
                "cols": 6
            },
            {
                "page_number": 45,
                "table_data": [
                    {
                        "Particulars": null,
                        "Six months ended September 30,\n2023": "(in \u20b9 millions)",
                        "Financial Year\n2023": null,
                        "Financial Year\n2022": null,
                        "Financial Year\n2021": null
                    },
                    {
                        "Particulars": "Put option liability",
                        "Six months ended September 30,\n2023": "12,612.50",
                        "Financial Year\n2023": "10,076.04",
                        "Financial Year\n2022": "10,515.74",
                        "Financial Year\n2021": "5,574.00"
                    },
                    {
                        "Particulars": "Fair value changes to\nfinancial instruments",
                        "Six months ended September 30,\n2023": "2,536.46",
                        "Financial Year\n2023": "(439.69)",
                        "Financial Year\n2022": "4,941.74",
                        "Financial Year\n2021": "538.23"
                    }
                ],
                "rows": 3,
                "cols": 5
            },
            {
                "page_number": 45,
                "table_data": [
                    {
                        "Trade Receivables": null,
                        "Less than 6 months": "(\u20b9 in millions)",
                        "6 months to 1 year": null,
                        "1 to 2 years": null,
                        "2 to 3 years": null,
                        "More than 3 years": null
                    },
                    {
                        "Trade Receivables": "CDMO business",
                        "Less than 6 months": "3,027.00",
                        "6 months to 1 year": "290.64",
                        "1 to 2 years": "93.06",
                        "2 to 3 years": "38.49",
                        "More than 3 years": "56.94"
                    },
                    {
                        "Trade Receivables": "Branded and generic formulations\nbusiness",
                        "Less than 6 months": "803.03",
                        "6 months to 1 year": "135.43",
                        "1 to 2 years": "220.77",
                        "2 to 3 years": "7.50",
                        "More than 3 years": "36.63"
                    },
                    {
                        "Trade Receivables": "API business",
                        "Less than 6 months": "454.68",
                        "6 months to 1 year": "8.83",
                        "1 to 2 years": "2.03",
                        "2 to 3 years": "0.00",
                        "More than 3 years": "\u2500"
                    },
                    {
                        "Trade Receivables": "Elimination",
                        "Less than 6 months": "(11.75)",
                        "6 months to 1 year": "(0.01)",
                        "1 to 2 years": "0.01",
                        "2 to 3 years": "0.01",
                        "More than 3 years": "(0.01)"
                    },
                    {
                        "Trade Receivables": "Total",
                        "Less than 6 months": "4,296.46",
                        "6 months to 1 year": "434.90",
                        "1 to 2 years": "315.84",
                        "2 to 3 years": "45.98",
                        "More than 3 years": "93.58"
                    }
                ],
                "rows": 6,
                "cols": 6
            },
            {
                "page_number": 45,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of revenue\nfrom\noperations",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of revenue\nfrom\noperations",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of revenue\nfrom\noperations",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of revenue\nfrom\noperations"
                    },
                    {
                        "Particulars": "Bad debts",
                        "For the six months ended\nSeptember 30, 2023": "5.13",
                        "Col2": "0.02",
                        "For the Financial Year": "24.58",
                        "Col4": "0.07",
                        "Col5": "67.74",
                        "Col6": "0.18",
                        "Col7": "52.83",
                        "Col8": "0.19"
                    },
                    {
                        "Particulars": "Provision for\nexpected credit\nlosses",
                        "For the six months ended\nSeptember 30, 2023": "56.09",
                        "Col2": "0.26",
                        "For the Financial Year": "18.65",
                        "Col4": "0.05",
                        "Col5": "132.27",
                        "Col6": "0.36",
                        "Col7": "87.11",
                        "Col8": "0.32"
                    }
                ],
                "rows": 4,
                "cols": 9
            },
            {
                "page_number": 46,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "For the Financial Year": "2023",
                        "Col3": "2022",
                        "Col4": "2021"
                    },
                    {
                        "Particulars": "Total assets (in \u20b9 million) (A)",
                        "For the six months ended\nSeptember 30, 2023": "36,046.13",
                        "For the Financial Year": "32,665.27",
                        "Col3": "30,690.48",
                        "Col4": "21,668.71"
                    },
                    {
                        "Particulars": "Total book value of assets on which insurance has\nbeen taken (in \u20b9 million) (B)",
                        "For the six months ended\nSeptember 30, 2023": "17,856.77",
                        "For the Financial Year": "18,007.90",
                        "Col3": "16,520.60",
                        "Col4": "12,320.56"
                    },
                    {
                        "Particulars": "Insurance coverage (in \u20b9 million) (C)",
                        "For the six months ended\nSeptember 30, 2023": "28,837.74",
                        "For the Financial Year": "27,887.46",
                        "Col3": "24,368.41",
                        "Col4": "11,332.10"
                    },
                    {
                        "Particulars": "% of insurance coverage (%) (C/B)",
                        "For the six months ended\nSeptember 30, 2023": "161.49",
                        "For the Financial Year": "154.86",
                        "Col3": "147.50",
                        "Col4": "91.97"
                    }
                ],
                "rows": 5,
                "cols": 5
            },
            {
                "page_number": 47,
                "table_data": [
                    {
                        "Entity": "Maxcure Nutravedics\nLimited",
                        "Period of non-compliance": "Financial Year 2023",
                        "Nature of covenants which were not complied with": "Total debt to EBITDA ratio"
                    },
                    {
                        "Entity": "ALL",
                        "Period of non-compliance": "Financial Year 2023",
                        "Nature of covenants which were not complied with": "EBITDA margin and external debt to EBITDA ratio"
                    }
                ],
                "rows": 2,
                "cols": 3
            },
            {
                "page_number": 47,
                "table_data": [
                    {
                        "Particulars": "Income tax matters",
                        "As of September 30, 2023 (\u20b9 in million)": "768.80"
                    },
                    {
                        "Particulars": "Product pricing related matters",
                        "As of September 30, 2023 (\u20b9 in million)": "106.40"
                    },
                    {
                        "Particulars": "Others",
                        "As of September 30, 2023 (\u20b9 in million)": "3.15"
                    },
                    {
                        "Particulars": "Total",
                        "As of September 30, 2023 (\u20b9 in million)": "878.35"
                    }
                ],
                "rows": 4,
                "cols": 2
            },
            {
                "page_number": 48,
                "table_data": [
                    {
                        "Particulars": null,
                        "During the six months\nended September 30, 2023": null,
                        "During the Financial Year": "2023",
                        "Col3": "2022",
                        "Col4": "2021"
                    },
                    {
                        "Particulars": "Penalties imposed under Section 37 of the Income Tax\nAct, 1961 (\u20b9 in million)",
                        "During the six months\nended September 30, 2023": "0.41",
                        "During the Financial Year": "0.07",
                        "Col3": "0.62",
                        "Col4": "0.18"
                    }
                ],
                "rows": 2,
                "cols": 5
            },
            {
                "page_number": 49,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "For the Financial Year": "2023",
                        "Col3": "2022",
                        "Col4": "2021"
                    },
                    {
                        "Particulars": "Revenue contribution from the Plant (\u20b9 in millions)",
                        "For the six months ended\nSeptember 30, 2023": "867.39",
                        "For the Financial Year": "1,587.27",
                        "Col3": "1,055.23",
                        "Col4": "6.72"
                    },
                    {
                        "Particulars": "% of total revenue from operations",
                        "For the six months ended\nSeptember 30, 2023": "4.03",
                        "For the Financial Year": "4.34",
                        "Col3": "2.87",
                        "Col4": "0.02"
                    },
                    {
                        "Particulars": "% of revenue from our API business",
                        "For the six months ended\nSeptember 30, 2023": "92.93",
                        "For the Financial Year": "89.55",
                        "Col3": "96.53",
                        "Col4": "100.00"
                    }
                ],
                "rows": 4,
                "cols": 5
            },
            {
                "page_number": 51,
                "table_data": [
                    {
                        "Date of allotment/\ntransfer": "January 31, 2009",
                        "Number of\nequity shares": "7,500",
                        "Nature of transaction": "Transfer of 7,500 equity shares from\nAkums Pharmaceuticals Private\nLimited to Sanjeev Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "20"
                    },
                    {
                        "Date of allotment/\ntransfer": "January 31, 2009",
                        "Number of\nequity shares": "7,500",
                        "Nature of transaction": "Transfer of 7,500 equity shares from\nAkums Pharmaceuticals Private\nLimited to Sandeep Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "20"
                    },
                    {
                        "Date of allotment/\ntransfer": "December 14, 2008",
                        "Number of\nequity shares": "50",
                        "Nature of transaction": "Transfer of 50 equity shares from\nVandana Jain jointly with Manan\nJain to Sandeep Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "20"
                    },
                    {
                        "Date of allotment/\ntransfer": "December 14, 2008",
                        "Number of\nequity shares": "76,800",
                        "Nature of transaction": "Transfer of 76,800 equity shares from\nVandana Jain to Sandeep Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "20"
                    },
                    {
                        "Date of allotment/\ntransfer": "December 14, 2008",
                        "Number of\nequity shares": "65,200",
                        "Nature of transaction": "Transfer of 65,200 equity shares from\nDharam Chand Jain jointly with\nSandeep Jain to Sandeep Jain",
                        "Nature of\nconsideration": "Gift",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "Not Applicable"
                    },
                    {
                        "Date of allotment/\ntransfer": "December 14, 2008",
                        "Number of\nequity shares": "1,250",
                        "Nature of transaction": "Transfer of 1,250 equity shares from\nN.D. Sachdeva to Sandeep Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "20"
                    },
                    {
                        "Date of allotment/\ntransfer": "December 14, 2008",
                        "Number of\nequity shares": "65,200",
                        "Nature of transaction": "Transfer of 65,200 equity shares from\nDharam Chand Jain jointly with\nSanjeev Jain to Sanjeev Jain",
                        "Nature of\nconsideration": "Gift",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "Not Applicable"
                    },
                    {
                        "Date of allotment/\ntransfer": "December 14, 2008",
                        "Number of\nequity shares": "1,250",
                        "Nature of transaction": "Transfer of 1,250 equity shares from\nM.P. Singh to Sanjeev Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "20"
                    },
                    {
                        "Date of allotment/\ntransfer": "November 9, 2007",
                        "Number of\nequity shares": "23,375",
                        "Nature of transaction": "Transfer of 23,375 equity shares from\nA.K. Laboratories to Sanjeev Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "20"
                    },
                    {
                        "Date of allotment/\ntransfer": "November 9, 2007",
                        "Number of\nequity shares": "23,375",
                        "Nature of transaction": "Transfer of 23,375 equity shares from\nA.K. Laboratories to Sandeep Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face value\nper equity\nshare (\u20b9)": "10",
                        "Issue Price/\nTransfer price\nper equity share\n(\u20b9)": "20"
                    }
                ],
                "rows": 10,
                "cols": 6
            },
            {
                "page_number": 63,
                "table_data": [
                    {
                        "Offer of Equity Shares(1)(2)(3)": "of which:",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": ""
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "i. Fresh Issue(1)(2)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "Up to [\u25cf] Equity Shares, aggregating up to \u20b9 6,800 million"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "ii. Offer for Sale(3)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "Up to 18,598,365 Equity Shares, aggregating up to \u20b9[\u25cf] million"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "iii Employee Reservation Portion(4)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "Up to [\u25cf] Equity Shares, aggregating up to \u20b9[\u25cf] million"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "The Offer comprises of:",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": ""
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "A) QIB Portion(5)(6)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "Not less than [\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "of which:",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": ""
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Anchor Investor Portion(5)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "Up to [\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Net QIB Portion (assuming Anchor Investor Portion is fully\nsubscribed)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "Up to [\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "of which:",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": ""
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Available for allocation to Mutual Funds only (5% of the Net\nQIB Portion)(6)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "[\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Balance of the Net QIB Portion for all QIBs including Mutual\nFunds",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "[\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "B) Non-Institutional Portion(5)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "Not more than [\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Of which",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": ""
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "One-third available for allocation to Bidders with an\napplication size of more than \u20b9200,000 and up to \u20b91 million",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "[\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Two-third available for allocation to Bidders with an\napplication size of more than \u20b9 1.00 million",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "[\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "C) Retail Portion(5)",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "Not more than [\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Pre-Offer and post-Offer Equity Shares",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": ""
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Equity Shares outstanding prior to the Offer as on the date of this\nDraft Red Herring Prospectus",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "143,064,350 Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Equity Shares outstanding after the Offer",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "[\u25cf] Equity Shares"
                    },
                    {
                        "Offer of Equity Shares(1)(2)(3)": "Use of Net Proceeds by our Company",
                        "Up to [\u25cf] Equity Shares aggregating up to \u20b9[\u25cf] million": "See \u201cObjects of the Offer\u201d on page 89 for details regarding the use of\nproceeds from the Fresh Issue. Our Company will not receive any\nproceeds from the Offer for Sale."
                    }
                ],
                "rows": 21,
                "cols": 2
            },
            {
                "page_number": 63,
                "table_data": [
                    {
                        "Name of the Selling Shareholder": "Promoter Selling Shareholders",
                        "Maximum number of Equity\nShares offered in the Offer for Sale": null,
                        "Date of corporate\nauthorisation/ board approval": null,
                        "Date of consent letter": null
                    },
                    {
                        "Name of the Selling Shareholder": "Sanjeev Jain",
                        "Maximum number of Equity\nShares offered in the Offer for Sale": "2,145,965",
                        "Date of corporate\nauthorisation/ board approval": "NA",
                        "Date of consent letter": "January 16, 2024"
                    },
                    {
                        "Name of the Selling Shareholder": "Sandeep Jain",
                        "Maximum number of Equity\nShares offered in the Offer for Sale": "2,145,965",
                        "Date of corporate\nauthorisation/ board approval": "NA",
                        "Date of consent letter": "January 16, 2024"
                    },
                    {
                        "Name of the Selling Shareholder": "Investor Selling Shareholder",
                        "Maximum number of Equity\nShares offered in the Offer for Sale": null,
                        "Date of corporate\nauthorisation/ board approval": null,
                        "Date of consent letter": null
                    },
                    {
                        "Name of the Selling Shareholder": "Ruby QC Investment Holdings Pte. Ltd.",
                        "Maximum number of Equity\nShares offered in the Offer for Sale": "14,306,435",
                        "Date of corporate\nauthorisation/ board approval": "January 16, 2024",
                        "Date of consent letter": "January 16, 2024"
                    }
                ],
                "rows": 5,
                "cols": 4
            },
            {
                "page_number": 66,
                "table_data": [
                    {
                        "Particulars": "ASSETS",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Non-current assets",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Property, plant and equipment",
                        "As at\n30\nSeptember\n2023": "10,014.46",
                        "As at\n30\nSeptember\n2022": "9,571.10",
                        "As at\n31 March\n2023": "9,631.51",
                        "As at 31\nMarch\n2022": "9,320.28",
                        "As at 31\nMarch\n2021": "8,134.13"
                    },
                    {
                        "Particulars": "Right-of-use assets",
                        "As at\n30\nSeptember\n2023": "1,212.72",
                        "As at\n30\nSeptember\n2022": "804.94",
                        "As at\n31 March\n2023": "1,263.59",
                        "As at 31\nMarch\n2022": "810.59",
                        "As at 31\nMarch\n2021": "701.95"
                    },
                    {
                        "Particulars": "Capital work-in-progress",
                        "As at\n30\nSeptember\n2023": "1,291.93",
                        "As at\n30\nSeptember\n2022": "953.62",
                        "As at\n31 March\n2023": "1,029.93",
                        "As at 31\nMarch\n2022": "308.19",
                        "As at 31\nMarch\n2021": "170.05"
                    },
                    {
                        "Particulars": "Goodwill",
                        "As at\n30\nSeptember\n2023": "20.63",
                        "As at\n30\nSeptember\n2022": "20.63",
                        "As at\n31 March\n2023": "20.63",
                        "As at 31\nMarch\n2022": "20.63",
                        "As at 31\nMarch\n2021": "150.40"
                    },
                    {
                        "Particulars": "Other intangible assets",
                        "As at\n30\nSeptember\n2023": "57.18",
                        "As at\n30\nSeptember\n2022": "46.56",
                        "As at\n31 March\n2023": "57.37",
                        "As at 31\nMarch\n2022": "53.87",
                        "As at 31\nMarch\n2021": "53.45"
                    },
                    {
                        "Particulars": "Intangible assets under development",
                        "As at\n30\nSeptember\n2023": "3.78",
                        "As at\n30\nSeptember\n2022": "704.30",
                        "As at\n31 March\n2023": "1.63",
                        "As at 31\nMarch\n2022": "2.53",
                        "As at 31\nMarch\n2021": "-"
                    },
                    {
                        "Particulars": "Financial assets",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "(i) Investments",
                        "As at\n30\nSeptember\n2023": "1.43",
                        "As at\n30\nSeptember\n2022": "2.16",
                        "As at\n31 March\n2023": "1.43",
                        "As at 31\nMarch\n2022": "3.86",
                        "As at 31\nMarch\n2021": "5.30"
                    },
                    {
                        "Particulars": "(ii) Loans",
                        "As at\n30\nSeptember\n2023": "-",
                        "As at\n30\nSeptember\n2022": "119.22",
                        "As at\n31 March\n2023": "-",
                        "As at 31\nMarch\n2022": "55.00",
                        "As at 31\nMarch\n2021": "-"
                    },
                    {
                        "Particulars": "(iii) Other financial assets",
                        "As at\n30\nSeptember\n2023": "380.55",
                        "As at\n30\nSeptember\n2022": "359.31",
                        "As at\n31 March\n2023": "344.20",
                        "As at 31\nMarch\n2022": "394.03",
                        "As at 31\nMarch\n2021": "454.98"
                    },
                    {
                        "Particulars": "Non-current tax assets (net)",
                        "As at\n30\nSeptember\n2023": "114.75",
                        "As at\n30\nSeptember\n2022": "419.28",
                        "As at\n31 March\n2023": "122.61",
                        "As at 31\nMarch\n2022": "360.43",
                        "As at 31\nMarch\n2021": "136.22"
                    },
                    {
                        "Particulars": "Deferred tax assets (net)",
                        "As at\n30\nSeptember\n2023": "237.81",
                        "As at\n30\nSeptember\n2022": "297.29",
                        "As at\n31 March\n2023": "315.17",
                        "As at 31\nMarch\n2022": "188.53",
                        "As at 31\nMarch\n2021": "147.01"
                    },
                    {
                        "Particulars": "Other non-current assets",
                        "As at\n30\nSeptember\n2023": "356.92",
                        "As at\n30\nSeptember\n2022": "597.78",
                        "As at\n31 March\n2023": "635.61",
                        "As at 31\nMarch\n2022": "256.38",
                        "As at 31\nMarch\n2021": "141.17"
                    },
                    {
                        "Particulars": "Total non-current assets",
                        "As at\n30\nSeptember\n2023": "13,692.16",
                        "As at\n30\nSeptember\n2022": "13,896.19",
                        "As at\n31 March\n2023": "13,423.68",
                        "As at 31\nMarch\n2022": "11,774.32",
                        "As at 31\nMarch\n2021": "10,094.66"
                    },
                    {
                        "Particulars": "",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Current assets",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Inventories",
                        "As at\n30\nSeptember\n2023": "6,882.66",
                        "As at\n30\nSeptember\n2022": "8,502.35",
                        "As at\n31 March\n2023": "7,297.95",
                        "As at 31\nMarch\n2022": "7,224.48",
                        "As at 31\nMarch\n2021": "4,298.59"
                    },
                    {
                        "Particulars": "Financial assets",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "(i) Investments",
                        "As at\n30\nSeptember\n2023": "-",
                        "As at\n30\nSeptember\n2022": "-",
                        "As at\n31 March\n2023": "-",
                        "As at 31\nMarch\n2022": "-",
                        "As at 31\nMarch\n2021": "190.09"
                    },
                    {
                        "Particulars": "(ii) Trade receivables",
                        "As at\n30\nSeptember\n2023": "11,189.99",
                        "As at\n30\nSeptember\n2022": "9,521.89",
                        "As at\n31 March\n2023": "8,450.87",
                        "As at 31\nMarch\n2022": "8,843.12",
                        "As at 31\nMarch\n2021": "5,313.99"
                    },
                    {
                        "Particulars": "(iii) Cash and cash equivalents",
                        "As at\n30\nSeptember\n2023": "1,176.30",
                        "As at\n30\nSeptember\n2022": "458.67",
                        "As at\n31 March\n2023": "516.08",
                        "As at 31\nMarch\n2022": "551.39",
                        "As at 31\nMarch\n2021": "220.67"
                    },
                    {
                        "Particulars": "(iv) Bank balances other than (iii) above",
                        "As at\n30\nSeptember\n2023": "1,288.14",
                        "As at\n30\nSeptember\n2022": "619.03",
                        "As at\n31 March\n2023": "983.81",
                        "As at 31\nMarch\n2022": "477.08",
                        "As at 31\nMarch\n2021": "458.01"
                    },
                    {
                        "Particulars": "(v) Loans",
                        "As at\n30\nSeptember\n2023": "-",
                        "As at\n30\nSeptember\n2022": "-",
                        "As at\n31 March\n2023": "73.73",
                        "As at 31\nMarch\n2022": "-",
                        "As at 31\nMarch\n2021": "80.00"
                    },
                    {
                        "Particulars": "(vi) Other financial assets",
                        "As at\n30\nSeptember\n2023": "230.41",
                        "As at\n30\nSeptember\n2022": "273.55",
                        "As at\n31 March\n2023": "152.30",
                        "As at 31\nMarch\n2022": "208.01",
                        "As at 31\nMarch\n2021": "144.07"
                    },
                    {
                        "Particulars": "Current-tax assets (net)",
                        "As at\n30\nSeptember\n2023": "114.05",
                        "As at\n30\nSeptember\n2022": "79.16",
                        "As at\n31 March\n2023": "114.05",
                        "As at 31\nMarch\n2022": "-",
                        "As at 31\nMarch\n2021": "1.60"
                    },
                    {
                        "Particulars": "Other current assets",
                        "As at\n30\nSeptember\n2023": "1,472.42",
                        "As at\n30\nSeptember\n2022": "1,102.19",
                        "As at\n31 March\n2023": "1,199.93",
                        "As at 31\nMarch\n2022": "1,336.55",
                        "As at 31\nMarch\n2021": "867.03"
                    },
                    {
                        "Particulars": "Total current assets",
                        "As at\n30\nSeptember\n2023": "22,353.97",
                        "As at\n30\nSeptember\n2022": "20,556.84",
                        "As at\n31 March\n2023": "18,788.72",
                        "As at 31\nMarch\n2022": "18,640.63",
                        "As at 31\nMarch\n2021": "11,574.05"
                    },
                    {
                        "Particulars": "Assets classified as held for sale",
                        "As at\n30\nSeptember\n2023": "-",
                        "As at\n30\nSeptember\n2022": "321.26",
                        "As at\n31 March\n2023": "452.87",
                        "As at 31\nMarch\n2022": "275.53",
                        "As at 31\nMarch\n2021": "-"
                    },
                    {
                        "Particulars": "Total assets",
                        "As at\n30\nSeptember\n2023": "36,046.13",
                        "As at\n30\nSeptember\n2022": "34,774.29",
                        "As at\n31 March\n2023": "32,665.27",
                        "As at 31\nMarch\n2022": "30,690.48",
                        "As at 31\nMarch\n2021": "21,668.71"
                    },
                    {
                        "Particulars": "EQUITY AND LIABILITIES",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Equity",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Equity share capital",
                        "As at\n30\nSeptember\n2023": "286.13",
                        "As at\n30\nSeptember\n2022": "143.07",
                        "As at\n31 March\n2023": "286.13",
                        "As at 31\nMarch\n2022": "143.07",
                        "As at 31\nMarch\n2021": "13.01"
                    },
                    {
                        "Particulars": "Other equity",
                        "As at\n30\nSeptember\n2023": "5,317.72",
                        "As at\n30\nSeptember\n2022": "6,758.45",
                        "As at\n31 March\n2023": "6,885.76",
                        "As at 31\nMarch\n2022": "6,076.69",
                        "As at 31\nMarch\n2021": "8,835.46"
                    },
                    {
                        "Particulars": "Equity attributable to equity holders of the Parent",
                        "As at\n30\nSeptember\n2023": "5,603.85",
                        "As at\n30\nSeptember\n2022": "6,901.52",
                        "As at\n31 March\n2023": "7,171.89",
                        "As at 31\nMarch\n2022": "6,219.76",
                        "As at 31\nMarch\n2021": "8,848.47"
                    },
                    {
                        "Particulars": "Non-controlling interests",
                        "As at\n30\nSeptember\n2023": "78.49",
                        "As at\n30\nSeptember\n2022": "36.81",
                        "As at\n31 March\n2023": "61.85",
                        "As at 31\nMarch\n2022": "31.95",
                        "As at 31\nMarch\n2021": "22.88"
                    },
                    {
                        "Particulars": "Total equity",
                        "As at\n30\nSeptember\n2023": "5,682.34",
                        "As at\n30\nSeptember\n2022": "6,938.33",
                        "As at\n31 March\n2023": "7,233.74",
                        "As at 31\nMarch\n2022": "6,251.71",
                        "As at 31\nMarch\n2021": "8,871.35"
                    },
                    {
                        "Particulars": "LIABILITIES",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Non-current liabilities",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Financial liabilities",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "(i) Borrowings",
                        "As at\n30\nSeptember\n2023": "1,009.96",
                        "As at\n30\nSeptember\n2022": "1,369.32",
                        "As at\n31 March\n2023": "1,154.96",
                        "As at 31\nMarch\n2022": "133.33",
                        "As at 31\nMarch\n2021": "11.61"
                    },
                    {
                        "Particulars": "(ii) Lease liabilities",
                        "As at\n30\nSeptember\n2023": "708.19",
                        "As at\n30\nSeptember\n2022": "281.51",
                        "As at\n31 March\n2023": "748.80",
                        "As at 31\nMarch\n2022": "304.08",
                        "As at 31\nMarch\n2021": "278.67"
                    },
                    {
                        "Particulars": "(iii) Other financial liabilities",
                        "As at\n30\nSeptember\n2023": "12,903.78",
                        "As at\n30\nSeptember\n2022": "10,517.71",
                        "As at\n31 March\n2023": "10,356.82",
                        "As at 31\nMarch\n2022": "10,644.88",
                        "As at 31\nMarch\n2021": "6,090.43"
                    },
                    {
                        "Particulars": "Provisions",
                        "As at\n30\nSeptember\n2023": "289.24",
                        "As at\n30\nSeptember\n2022": "253.42",
                        "As at\n31 March\n2023": "262.27",
                        "As at 31\nMarch\n2022": "239.32",
                        "As at 31\nMarch\n2021": "204.44"
                    },
                    {
                        "Particulars": "Deferred tax liabilities (net)",
                        "As at\n30\nSeptember\n2023": "390.10",
                        "As at\n30\nSeptember\n2022": "425.62",
                        "As at\n31 March\n2023": "253.01",
                        "As at 31\nMarch\n2022": "392.98",
                        "As at 31\nMarch\n2021": "412.69"
                    },
                    {
                        "Particulars": "Total non-current liabilities",
                        "As at\n30\nSeptember\n2023": "15,301.27",
                        "As at\n30\nSeptember\n2022": "12,847.58",
                        "As at\n31 March\n2023": "12,775.86",
                        "As at 31\nMarch\n2022": "11,714.59",
                        "As at 31\nMarch\n2021": "6,997.84"
                    },
                    {
                        "Particulars": "Current liabilities",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Financial liabilities",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "(i) Borrowings",
                        "As at\n30\nSeptember\n2023": "6,067.55",
                        "As at\n30\nSeptember\n2022": "5,863.20",
                        "As at\n31 March\n2023": "4,214.77",
                        "As at 31\nMarch\n2022": "3,446.20",
                        "As at 31\nMarch\n2021": "959.03"
                    },
                    {
                        "Particulars": "(ii) Lease liabilities",
                        "As at\n30\nSeptember\n2023": "56.97",
                        "As at\n30\nSeptember\n2022": "72.15",
                        "As at\n31 March\n2023": "72.41",
                        "As at 31\nMarch\n2022": "66.22",
                        "As at 31\nMarch\n2021": "50.44"
                    },
                    {
                        "Particulars": "(iii) Trade payables",
                        "As at\n30\nSeptember\n2023": "",
                        "As at\n30\nSeptember\n2022": "",
                        "As at\n31 March\n2023": "",
                        "As at 31\nMarch\n2022": "",
                        "As at 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "(a) Total outstanding dues to micro and small enterprises; and",
                        "As at\n30\nSeptember\n2023": "651.40",
                        "As at\n30\nSeptember\n2022": "452.93",
                        "As at\n31 March\n2023": "442.16",
                        "As at 31\nMarch\n2022": "331.87",
                        "As at 31\nMarch\n2021": "330.56"
                    },
                    {
                        "Particulars": "(b) Total outstanding dues of creditors other than micro and small\nenterprises",
                        "As at\n30\nSeptember\n2023": "5,457.29",
                        "As at\n30\nSeptember\n2022": "5,782.94",
                        "As at\n31 March\n2023": "5,229.23",
                        "As at 31\nMarch\n2022": "5,564.79",
                        "As at 31\nMarch\n2021": "3,083.58"
                    },
                    {
                        "Particulars": "(iv) Other financial liabilities",
                        "As at\n30\nSeptember\n2023": "659.91",
                        "As at\n30\nSeptember\n2022": "611.09",
                        "As at\n31 March\n2023": "628.10",
                        "As at 31\nMarch\n2022": "702.09",
                        "As at 31\nMarch\n2021": "427.49"
                    },
                    {
                        "Particulars": "Other current liabilities",
                        "As at\n30\nSeptember\n2023": "1,223.53",
                        "As at\n30\nSeptember\n2022": "1,624.32",
                        "As at\n31 March\n2023": "1,421.95",
                        "As at 31\nMarch\n2022": "1,545.77",
                        "As at 31\nMarch\n2021": "263.67"
                    },
                    {
                        "Particulars": "Provisions",
                        "As at\n30\nSeptember\n2023": "476.73",
                        "As at\n30\nSeptember\n2022": "452.82",
                        "As at\n31 March\n2023": "459.37",
                        "As at 31\nMarch\n2022": "589.24",
                        "As at 31\nMarch\n2021": "566.16"
                    },
                    {
                        "Particulars": "Current tax liabilities (net)",
                        "As at\n30\nSeptember\n2023": "469.14",
                        "As at\n30\nSeptember\n2022": "128.94",
                        "As at\n31 March\n2023": "187.68",
                        "As at 31\nMarch\n2022": "478.00",
                        "As at 31\nMarch\n2021": "118.59"
                    },
                    {
                        "Particulars": "Total current liabilities",
                        "As at\n30\nSeptember\n2023": "15,062.52",
                        "As at\n30\nSeptember\n2022": "14,988.39",
                        "As at\n31 March\n2023": "12,655.67",
                        "As at 31\nMarch\n2022": "12,724.18",
                        "As at 31\nMarch\n2021": "5,799.52"
                    },
                    {
                        "Particulars": "Total equity and liabilities",
                        "As at\n30\nSeptember\n2023": "36,046.13",
                        "As at\n30\nSeptember\n2022": "34,774.29",
                        "As at\n31 March\n2023": "32,665.27",
                        "As at 31\nMarch\n2022": "30,690.48",
                        "As at 31\nMarch\n2021": "21,668.71"
                    }
                ],
                "rows": 60,
                "cols": 6
            },
            {
                "page_number": 67,
                "table_data": [
                    {
                        "Particulars": "INCOME",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "",
                        "Year\nended\n31 March\n2023": "",
                        "Year\nended 31\nMarch\n2022": "",
                        "Year\nended 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Revenue from operations",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "21,511.38",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "18,213.63",
                        "Year\nended\n31 March\n2023": "36,548.20",
                        "Year\nended 31\nMarch\n2022": "36,718.93",
                        "Year\nended 31\nMarch\n2021": "27,226.29"
                    },
                    {
                        "Particulars": "Other income",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "148.68",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "307.73",
                        "Year\nended\n31 March\n2023": "461.05",
                        "Year\nended 31\nMarch\n2022": "226.30",
                        "Year\nended 31\nMarch\n2021": "211.56"
                    },
                    {
                        "Particulars": "Total income",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "21,660.06",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "18,521.36",
                        "Year\nended\n31 March\n2023": "37,009.25",
                        "Year\nended 31\nMarch\n2022": "36,945.23",
                        "Year\nended 31\nMarch\n2021": "27,437.85"
                    },
                    {
                        "Particulars": "EXPENSES",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "",
                        "Year\nended\n31 March\n2023": "",
                        "Year\nended 31\nMarch\n2022": "",
                        "Year\nended 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Cost of materials consumed",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "11,830.93",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "10,968.77",
                        "Year\nended\n31 March\n2023": "20,280.85",
                        "Year\nended 31\nMarch\n2022": "20,385.94",
                        "Year\nended 31\nMarch\n2021": "12,837.93"
                    },
                    {
                        "Particulars": "Purchases of stock-in-trade",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "1,009.37",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "1,545.86",
                        "Year\nended\n31 March\n2023": "2,217.88",
                        "Year\nended 31\nMarch\n2022": "3,942.07",
                        "Year\nended 31\nMarch\n2021": "4,545.81"
                    },
                    {
                        "Particulars": "Change in inventories of finished goods, stock-in-trade and work-in-\nprogress",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "111.95",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "(779.08)",
                        "Year\nended\n31 March\n2023": "240.35",
                        "Year\nended 31\nMarch\n2022": "(877.42)",
                        "Year\nended 31\nMarch\n2021": "(474.63)"
                    },
                    {
                        "Particulars": "Employee benefits expense",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "3,204.26",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "2,947.18",
                        "Year\nended\n31 March\n2023": "5,901.33",
                        "Year\nended 31\nMarch\n2022": "5,077.58",
                        "Year\nended 31\nMarch\n2021": "4,245.50"
                    },
                    {
                        "Particulars": "Finance costs",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "258.00",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "179.20",
                        "Year\nended\n31 March\n2023": "462.46",
                        "Year\nended 31\nMarch\n2022": "166.55",
                        "Year\nended 31\nMarch\n2021": "67.44"
                    },
                    {
                        "Particulars": "Depreciation and amortisation expense",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "601.38",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "525.23",
                        "Year\nended\n31 March\n2023": "1,128.09",
                        "Year\nended 31\nMarch\n2022": "946.79",
                        "Year\nended 31\nMarch\n2021": "698.41"
                    },
                    {
                        "Particulars": "Fair value changes to financial instruments",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "2,536.46",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "(263.27)",
                        "Year\nended\n31 March\n2023": "(439.69)",
                        "Year\nended 31\nMarch\n2022": "4,941.74",
                        "Year\nended 31\nMarch\n2021": "538.23"
                    },
                    {
                        "Particulars": "Other expenses",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "2,552.78",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "2,561.16",
                        "Year\nended\n31 March\n2023": "4,967.98",
                        "Year\nended 31\nMarch\n2022": "4,166.21",
                        "Year\nended 31\nMarch\n2021": "3,160.02"
                    },
                    {
                        "Particulars": "Total expenses",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "22,105.13",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "17,685.05",
                        "Year\nended\n31 March\n2023": "34,759.25",
                        "Year\nended 31\nMarch\n2022": "38,749.46",
                        "Year\nended 31\nMarch\n2021": "25,618.71"
                    },
                    {
                        "Particulars": "(Loss)/ profit before share of (loss)/ profit of an associate,\nexceptional items and tax",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(445.07)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "836.31",
                        "Year\nended\n31 March\n2023": "2,250.00",
                        "Year\nended 31\nMarch\n2022": "(1,804.23)",
                        "Year\nended 31\nMarch\n2021": "1,819.14"
                    },
                    {
                        "Particulars": "Share of (loss)/ profit of an associate",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "-",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "(1.70)",
                        "Year\nended\n31 March\n2023": "(2.03)",
                        "Year\nended 31\nMarch\n2022": "2.03",
                        "Year\nended 31\nMarch\n2021": "3.47"
                    },
                    {
                        "Particulars": "(Loss)/ profit before exceptional items and tax",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(445.07)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "834.61",
                        "Year\nended\n31 March\n2023": "2,247.97",
                        "Year\nended 31\nMarch\n2022": "(1,802.20)",
                        "Year\nended 31\nMarch\n2021": "1,822.61"
                    },
                    {
                        "Particulars": "Exceptional items",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "271.66",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "-",
                        "Year\nended\n31 March\n2023": "745.00",
                        "Year\nended 31\nMarch\n2022": "129.77",
                        "Year\nended 31\nMarch\n2021": "100.00"
                    },
                    {
                        "Particulars": "(Loss)/ profit before tax",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(716.73)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "834.61",
                        "Year\nended\n31 March\n2023": "1,502.97",
                        "Year\nended 31\nMarch\n2022": "(1,931.97)",
                        "Year\nended 31\nMarch\n2021": "1,722.61"
                    },
                    {
                        "Particulars": "Tax expense:",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "",
                        "Year\nended\n31 March\n2023": "",
                        "Year\nended 31\nMarch\n2022": "",
                        "Year\nended 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Current tax",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "598.64",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "204.97",
                        "Year\nended\n31 March\n2023": "781.30",
                        "Year\nended 31\nMarch\n2022": "690.45",
                        "Year\nended 31\nMarch\n2021": "552.99"
                    },
                    {
                        "Particulars": "Tax for earlier periods/ years",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "15.53",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "18.69",
                        "Year\nended\n31 March\n2023": "16.09",
                        "Year\nended 31\nMarch\n2022": "(53.26)",
                        "Year\nended 31\nMarch\n2021": "-"
                    },
                    {
                        "Particulars": "Deferred tax charge/ (reversal)",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "216.49",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "(79.90)",
                        "Year\nended\n31 March\n2023": "(272.59)",
                        "Year\nended 31\nMarch\n2022": "(60.42)",
                        "Year\nended 31\nMarch\n2021": "(64.73)"
                    },
                    {
                        "Particulars": "Total tax expense",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "830.66",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "143.76",
                        "Year\nended\n31 March\n2023": "524.80",
                        "Year\nended 31\nMarch\n2022": "576.77",
                        "Year\nended 31\nMarch\n2021": "488.26"
                    },
                    {
                        "Particulars": "(Loss)/ profit for the year/ period",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(1,547.39)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "690.85",
                        "Year\nended\n31 March\n2023": "978.17",
                        "Year\nended 31\nMarch\n2022": "(2,508.74)",
                        "Year\nended 31\nMarch\n2021": "1,234.35"
                    },
                    {
                        "Particulars": "Other comprehensive income",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "",
                        "Year\nended\n31 March\n2023": "",
                        "Year\nended 31\nMarch\n2022": "",
                        "Year\nended 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Items that will not be reclassified to profit or loss",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "",
                        "Year\nended\n31 March\n2023": "",
                        "Year\nended 31\nMarch\n2022": "",
                        "Year\nended 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "(i) Re-measurement gains (losses) on defined benefit plan",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(6.05)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "15.74",
                        "Year\nended\n31 March\n2023": "26.05",
                        "Year\nended 31\nMarch\n2022": "(1.69)",
                        "Year\nended 31\nMarch\n2021": "(2.49)"
                    },
                    {
                        "Particulars": "(ii) Income-tax effect related to items that will not be reclassified to\nprofit and loss",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "2.04",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "(3.78)",
                        "Year\nended\n31 March\n2023": "(5.99)",
                        "Year\nended 31\nMarch\n2022": "0.81",
                        "Year\nended 31\nMarch\n2021": "1.22"
                    },
                    {
                        "Particulars": "Other comprehensive income, net of tax",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(4.01)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "11.96",
                        "Year\nended\n31 March\n2023": "20.06",
                        "Year\nended 31\nMarch\n2022": "(0.88)",
                        "Year\nended 31\nMarch\n2021": "(1.27)"
                    },
                    {
                        "Particulars": "Total comprehensive income (comprising of (loss)/ profit for the\nperiod/ year and other comprehensive income for the period/ year)",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(1,551.40)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "702.81",
                        "Year\nended\n31 March\n2023": "998.23",
                        "Year\nended 31\nMarch\n2022": "(2,509.62)",
                        "Year\nended 31\nMarch\n2021": "1,233.08"
                    },
                    {
                        "Particulars": "Total comprehensive income attributable to:",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "",
                        "Year\nended\n31 March\n2023": "",
                        "Year\nended 31\nMarch\n2022": "",
                        "Year\nended 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Owners of the Parent",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(1,568.04)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "697.95",
                        "Year\nended\n31 March\n2023": "968.33",
                        "Year\nended 31\nMarch\n2022": "(2,526.20)",
                        "Year\nended 31\nMarch\n2021": "1,226.42"
                    },
                    {
                        "Particulars": "Non-controlling interests",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "16.64",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "4.86",
                        "Year\nended\n31 March\n2023": "29.90",
                        "Year\nended 31\nMarch\n2022": "16.58",
                        "Year\nended 31\nMarch\n2021": "6.66"
                    },
                    {
                        "Particulars": "Out of total comprehensive income above, (loss)/ profit for the year/\nperiod attributable to:",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "",
                        "Year\nended\n31 March\n2023": "",
                        "Year\nended 31\nMarch\n2022": "",
                        "Year\nended 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Owners of the Parent",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(1,564.17)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "686.08",
                        "Year\nended\n31 March\n2023": "948.55",
                        "Year\nended 31\nMarch\n2022": "(2,525.36)",
                        "Year\nended 31\nMarch\n2021": "1,227.05"
                    },
                    {
                        "Particulars": "Non-controlling interests",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "16.78",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "4.77",
                        "Year\nended\n31 March\n2023": "29.62",
                        "Year\nended 31\nMarch\n2022": "16.62",
                        "Year\nended 31\nMarch\n2021": "7.30"
                    },
                    {
                        "Particulars": "Out of total comprehensive income above, other comprehensive\nincome attributable to:",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "",
                        "Year\nended\n31 March\n2023": "",
                        "Year\nended 31\nMarch\n2022": "",
                        "Year\nended 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Owners of the Parent",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(3.87)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "11.87",
                        "Year\nended\n31 March\n2023": "19.78",
                        "Year\nended 31\nMarch\n2022": "(0.84)",
                        "Year\nended 31\nMarch\n2021": "(0.63)"
                    },
                    {
                        "Particulars": "Non-controlling interests",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(0.14)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "0.09",
                        "Year\nended\n31 March\n2023": "0.28",
                        "Year\nended 31\nMarch\n2022": "(0.04)",
                        "Year\nended 31\nMarch\n2021": "(0.64)"
                    },
                    {
                        "Particulars": "Earnings per equity share of \u20b9 2/- each",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "",
                        "Year\nended\n31 March\n2023": "",
                        "Year\nended 31\nMarch\n2022": "",
                        "Year\nended 31\nMarch\n2021": ""
                    },
                    {
                        "Particulars": "Basic and diluted",
                        "Six months\nperiod\nended\n30\nSeptember\n2023": "(10.93)",
                        "Six months\nperiod\nended\n30\nSeptember\n2022": "4.80",
                        "Year\nended\n31 March\n2023": "6.63",
                        "Year\nended 31\nMarch\n2022": "(17.65)",
                        "Year\nended 31\nMarch\n2021": "8.58"
                    }
                ],
                "rows": 42,
                "cols": 6
            },
            {
                "page_number": 68,
                "table_data": [
                    {
                        "Particulars": "A. Cash flows from operating activities",
                        "Six months\nperiod ended\n30 September\n2023": "",
                        "Six months\nperiod ended\n30 September\n2022": "",
                        "Year ended\n31 March 2023": "",
                        "Year ended 31\nMarch 2022": "",
                        "Year ended 31\nMarch 2021": ""
                    },
                    {
                        "Particulars": "Net (loss)/ profit before tax",
                        "Six months\nperiod ended\n30 September\n2023": "(716.73)",
                        "Six months\nperiod ended\n30 September\n2022": "834.61",
                        "Year ended\n31 March 2023": "1,502.97",
                        "Year ended 31\nMarch 2022": "(1,931.97)",
                        "Year ended 31\nMarch 2021": "1,722.61"
                    },
                    {
                        "Particulars": "Add/ less: non-cash adjustments",
                        "Six months\nperiod ended\n30 September\n2023": "",
                        "Six months\nperiod ended\n30 September\n2022": "",
                        "Year ended\n31 March 2023": "",
                        "Year ended 31\nMarch 2022": "",
                        "Year ended 31\nMarch 2021": ""
                    },
                    {
                        "Particulars": "Depreciation and amortisation",
                        "Six months\nperiod ended\n30 September\n2023": "601.38",
                        "Six months\nperiod ended\n30 September\n2022": "525.23",
                        "Year ended\n31 March 2023": "1,128.09",
                        "Year ended 31\nMarch 2022": "946.79",
                        "Year ended 31\nMarch 2021": "698.41"
                    },
                    {
                        "Particulars": "Bad debts",
                        "Six months\nperiod ended\n30 September\n2023": "5.13",
                        "Six months\nperiod ended\n30 September\n2022": "11.95",
                        "Year ended\n31 March 2023": "24.58",
                        "Year ended 31\nMarch 2022": "67.74",
                        "Year ended 31\nMarch 2021": "52.83"
                    },
                    {
                        "Particulars": "Provision for expected credit loss on\ntrade receivable",
                        "Six months\nperiod ended\n30 September\n2023": "54.60",
                        "Six months\nperiod ended\n30 September\n2022": "(17.00)",
                        "Year ended\n31 March 2023": "18.56",
                        "Year ended 31\nMarch 2022": "120.88",
                        "Year ended 31\nMarch 2021": "87.11"
                    },
                    {
                        "Particulars": "Liabilities no longer required, written\nback",
                        "Six months\nperiod ended\n30 September\n2023": "(13.32)",
                        "Six months\nperiod ended\n30 September\n2022": "(177.94)",
                        "Year ended\n31 March 2023": "(216.81)",
                        "Year ended 31\nMarch 2022": "(21.00)",
                        "Year ended 31\nMarch 2021": "(32.16)"
                    },
                    {
                        "Particulars": "Loss/ (profit) on sale of property, plant &\nequipment and intangible assets",
                        "Six months\nperiod ended\n30 September\n2023": "0.47",
                        "Six months\nperiod ended\n30 September\n2022": "5.24",
                        "Year ended\n31 March 2023": "(45.75)",
                        "Year ended 31\nMarch 2022": "20.66",
                        "Year ended 31\nMarch 2021": "4.04"
                    },
                    {
                        "Particulars": "Impairment of goodwill",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "-",
                        "Year ended 31\nMarch 2022": "129.77",
                        "Year ended 31\nMarch 2021": "100.00"
                    },
                    {
                        "Particulars": "Impairment of assets held for sale",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "47.50",
                        "Year ended 31\nMarch 2022": "-",
                        "Year ended 31\nMarch 2021": "-"
                    },
                    {
                        "Particulars": "Impairment of intangible assets under\ndevelopment",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "697.50",
                        "Year ended 31\nMarch 2022": "-",
                        "Year ended 31\nMarch 2021": "-"
                    },
                    {
                        "Particulars": "Gain on sale of assets held for sale",
                        "Six months\nperiod ended\n30 September\n2023": "(2.48)",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "-",
                        "Year ended 31\nMarch 2022": "-",
                        "Year ended 31\nMarch 2021": "-"
                    },
                    {
                        "Particulars": "Share of loss/ (profit) from associate",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "1.70",
                        "Year ended\n31 March 2023": "2.03",
                        "Year ended 31\nMarch 2022": "(2.03)",
                        "Year ended 31\nMarch 2021": "(3.47)"
                    },
                    {
                        "Particulars": "Finance costs",
                        "Six months\nperiod ended\n30 September\n2023": "258.00",
                        "Six months\nperiod ended\n30 September\n2022": "179.20",
                        "Year ended\n31 March 2023": "462.46",
                        "Year ended 31\nMarch 2022": "166.55",
                        "Year ended 31\nMarch 2021": "67.44"
                    },
                    {
                        "Particulars": "Losses incurred due to floods",
                        "Six months\nperiod ended\n30 September\n2023": "274.14",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "-",
                        "Year ended 31\nMarch 2022": "-",
                        "Year ended 31\nMarch 2021": "-"
                    },
                    {
                        "Particulars": "Profit on sale of current investments",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "-",
                        "Year ended 31\nMarch 2022": "-",
                        "Year ended 31\nMarch 2021": "(0.77)"
                    },
                    {
                        "Particulars": "Profit on reassessment of right-of-use\nassets",
                        "Six months\nperiod ended\n30 September\n2023": "(1.19)",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "(22.36)",
                        "Year ended 31\nMarch 2022": "(10.55)",
                        "Year ended 31\nMarch 2021": "-"
                    },
                    {
                        "Particulars": "Fair value charges on financial\ninstrument",
                        "Six months\nperiod ended\n30 September\n2023": "2,536.46",
                        "Six months\nperiod ended\n30 September\n2022": "(263.27)",
                        "Year ended\n31 March 2023": "(439.69)",
                        "Year ended 31\nMarch 2022": "4,941.74",
                        "Year ended 31\nMarch 2021": "538.23"
                    },
                    {
                        "Particulars": "Interest income",
                        "Six months\nperiod ended\n30 September\n2023": "(51.55)",
                        "Six months\nperiod ended\n30 September\n2022": "(29.86)",
                        "Year ended\n31 March 2023": "(78.80)",
                        "Year ended 31\nMarch 2022": "(46.31)",
                        "Year ended 31\nMarch 2021": "(61.44)"
                    },
                    {
                        "Particulars": "Operating profit before working\ncapital changes",
                        "Six months\nperiod ended\n30 September\n2023": "2,944.91",
                        "Six months\nperiod ended\n30 September\n2022": "1,069.86",
                        "Year ended\n31 March 2023": "3,080.28",
                        "Year ended 31\nMarch 2022": "4,382.27",
                        "Year ended 31\nMarch 2021": "3,172.83"
                    },
                    {
                        "Particulars": "Adjustments for working capital\nchanges:",
                        "Six months\nperiod ended\n30 September\n2023": "",
                        "Six months\nperiod ended\n30 September\n2022": "",
                        "Year ended\n31 March 2023": "",
                        "Year ended 31\nMarch 2022": "",
                        "Year ended 31\nMarch 2021": ""
                    },
                    {
                        "Particulars": "Inventories",
                        "Six months\nperiod ended\n30 September\n2023": "235.62",
                        "Six months\nperiod ended\n30 September\n2022": "(1,277.87)",
                        "Year ended\n31 March 2023": "(73.47)",
                        "Year ended 31\nMarch 2022": "(2,925.89)",
                        "Year ended 31\nMarch 2021": "(315.41)"
                    },
                    {
                        "Particulars": "Trade receivables",
                        "Six months\nperiod ended\n30 September\n2023": "(2,799.53)",
                        "Six months\nperiod ended\n30 September\n2022": "(673.72)",
                        "Year ended\n31 March 2023": "349.11",
                        "Year ended 31\nMarch 2022": "(3,717.75)",
                        "Year ended 31\nMarch 2021": "361.48"
                    },
                    {
                        "Particulars": "Other assets",
                        "Six months\nperiod ended\n30 September\n2023": "(36.29)",
                        "Six months\nperiod ended\n30 September\n2022": "(243.48)",
                        "Year ended\n31 March 2023": "(183.14)",
                        "Year ended 31\nMarch 2022": "(568.71)",
                        "Year ended 31\nMarch 2021": "2.49"
                    },
                    {
                        "Particulars": "Trade payables",
                        "Six months\nperiod ended\n30 September\n2023": "445.44",
                        "Six months\nperiod ended\n30 September\n2022": "341.93",
                        "Year ended\n31 March 2023": "(183.69)",
                        "Year ended 31\nMarch 2022": "2,505.09",
                        "Year ended 31\nMarch 2021": "(819.04)"
                    },
                    {
                        "Particulars": "Other financial liabilities",
                        "Six months\nperiod ended\n30 September\n2023": "105.50",
                        "Six months\nperiod ended\n30 September\n2022": "58.01",
                        "Year ended\n31 March 2023": "2.41",
                        "Year ended 31\nMarch 2022": "(146.65)",
                        "Year ended 31\nMarch 2021": "(552.12)"
                    },
                    {
                        "Particulars": "Provisions",
                        "Six months\nperiod ended\n30 September\n2023": "38.28",
                        "Six months\nperiod ended\n30 September\n2022": "68.65",
                        "Year ended\n31 March 2023": "94.36",
                        "Year ended 31\nMarch 2022": "56.27",
                        "Year ended 31\nMarch 2021": "(37.66)"
                    },
                    {
                        "Particulars": "Other liabilities",
                        "Six months\nperiod ended\n30 September\n2023": "26.68",
                        "Six months\nperiod ended\n30 September\n2022": "20.56",
                        "Year ended\n31 March 2023": "(348.92)",
                        "Year ended 31\nMarch 2022": "1,282.09",
                        "Year ended 31\nMarch 2021": "(50.89)"
                    },
                    {
                        "Particulars": "Cash flows from operations (gross)",
                        "Six months\nperiod ended\n30 September\n2023": "960.61",
                        "Six months\nperiod ended\n30 September\n2022": "(636.06)",
                        "Year ended\n31 March 2023": "2,736.94",
                        "Year ended 31\nMarch 2022": "866.72",
                        "Year ended 31\nMarch 2021": "1,761.68"
                    },
                    {
                        "Particulars": "Less: direct taxes paid",
                        "Six months\nperiod ended\n30 September\n2023": "(328.04)",
                        "Six months\nperiod ended\n30 September\n2022": "(712.74)",
                        "Year ended\n31 March 2023": "(970.63)",
                        "Year ended 31\nMarch 2022": "(548.18)",
                        "Year ended 31\nMarch 2021": "(455.54)"
                    },
                    {
                        "Particulars": "Net cash flows generated from/ (used\nin) operating activities",
                        "Six months\nperiod ended\n30 September\n2023": "632.57",
                        "Six months\nperiod ended\n30 September\n2022": "(1,348.80)",
                        "Year ended\n31 March 2023": "1,766.31",
                        "Year ended 31\nMarch 2022": "318.54",
                        "Year ended 31\nMarch 2021": "1,306.14"
                    },
                    {
                        "Particulars": "B. Cash flows from investing activities",
                        "Six months\nperiod ended\n30 September\n2023": "",
                        "Six months\nperiod ended\n30 September\n2022": "",
                        "Year ended\n31 March 2023": "",
                        "Year ended 31\nMarch 2022": "",
                        "Year ended 31\nMarch 2021": ""
                    },
                    {
                        "Particulars": "Purchase of property, plant and\nequipment & intangible assets (including\ncapital work-in-progress, capital\nadvances and payable towards property,\nplant and equipment)",
                        "Six months\nperiod ended\n30 September\n2023": "(1,383.99)",
                        "Six months\nperiod ended\n30 September\n2022": "(2,126.19)",
                        "Year ended\n31 March 2023": "(3,287.93)",
                        "Year ended 31\nMarch 2022": "(2,575.82)",
                        "Year ended 31\nMarch 2021": "(828.10)"
                    },
                    {
                        "Particulars": "Proceeds from sale of property, plant and\nequipment",
                        "Six months\nperiod ended\n30 September\n2023": "247.65",
                        "Six months\nperiod ended\n30 September\n2022": "41.71",
                        "Year ended\n31 March 2023": "421.47",
                        "Year ended 31\nMarch 2022": "19.24",
                        "Year ended 31\nMarch 2021": "9.38"
                    },
                    {
                        "Particulars": "Withdrawal from interest in partnership\nfirm",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "0.40",
                        "Year ended 31\nMarch 2022": "3.47",
                        "Year ended 31\nMarch 2021": "5.24"
                    },
                    {
                        "Particulars": "(Investment in)/ proceeds from deposits\nhaving original maturity of more than 3\nmonths (net)",
                        "Six months\nperiod ended\n30 September\n2023": "(322.49)",
                        "Six months\nperiod ended\n30 September\n2022": "(82.29)",
                        "Year ended\n31 March 2023": "(449.93)",
                        "Year ended 31\nMarch 2022": "53.51",
                        "Year ended 31\nMarch 2021": "380.24"
                    },
                    {
                        "Particulars": "Consideration paid to NCI towards\nfurther acquisition of interest in\nsubsidiaries",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "(16.20)",
                        "Year ended\n31 March 2023": "(16.20)",
                        "Year ended 31\nMarch 2022": "(110.02)",
                        "Year ended 31\nMarch 2021": "(605.00)"
                    },
                    {
                        "Particulars": "Proceeds from/ (purchase of) sale of\ncurrent investments (net)",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "-",
                        "Year ended 31\nMarch 2022": "190.09",
                        "Year ended 31\nMarch 2021": "(130.88)"
                    },
                    {
                        "Particulars": "Advance received against assets held for\nsale",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "58.00",
                        "Year ended\n31 March 2023": "225.10",
                        "Year ended 31\nMarch 2022": "-",
                        "Year ended 31\nMarch 2021": "-"
                    },
                    {
                        "Particulars": "Loans given",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "(71.72)",
                        "Year ended\n31 March 2023": "(73.73)",
                        "Year ended 31\nMarch 2022": "-",
                        "Year ended 31\nMarch 2021": "-"
                    },
                    {
                        "Particulars": "Loans repaid",
                        "Six months\nperiod ended\n30 September\n2023": "73.73",
                        "Six months\nperiod ended\n30 September\n2022": "7.50",
                        "Year ended\n31 March 2023": "55.00",
                        "Year ended 31\nMarch 2022": "25.00",
                        "Year ended 31\nMarch 2021": "8.50"
                    },
                    {
                        "Particulars": "Interest received",
                        "Six months\nperiod ended\n30 September\n2023": "51.55",
                        "Six months\nperiod ended\n30 September\n2022": "29.86",
                        "Year ended\n31 March 2023": "78.80",
                        "Year ended 31\nMarch 2022": "46.31",
                        "Year ended 31\nMarch 2021": "66.77"
                    }
                ],
                "rows": 42,
                "cols": 6
            },
            {
                "page_number": 69,
                "table_data": [
                    {
                        "Particulars": "Net cash flows used in investing\nactivities",
                        "Six months\nperiod ended\n30 September\n2023": "(1,333.55)",
                        "Six months\nperiod ended\n30 September\n2022": "(2,159.33)",
                        "Year ended\n31 March 2023": "(3,047.02)",
                        "Year ended 31\nMarch 2022": "(2,348.22)",
                        "Year ended 31\nMarch 2021": "(1,093.85)"
                    },
                    {
                        "Particulars": "C. Cash flows from financing activities",
                        "Six months\nperiod ended\n30 September\n2023": "",
                        "Six months\nperiod ended\n30 September\n2022": "",
                        "Year ended\n31 March 2023": "",
                        "Year ended 31\nMarch 2022": "",
                        "Year ended 31\nMarch 2021": ""
                    },
                    {
                        "Particulars": "Proceeds from non-current borrowings",
                        "Six months\nperiod ended\n30 September\n2023": "103.42",
                        "Six months\nperiod ended\n30 September\n2022": "1,401.79",
                        "Year ended\n31 March 2023": "1,401.60",
                        "Year ended 31\nMarch 2022": "200.19",
                        "Year ended 31\nMarch 2021": "11.61"
                    },
                    {
                        "Particulars": "Repayments of non-current borrowings",
                        "Six months\nperiod ended\n30 September\n2023": "(131.65)",
                        "Six months\nperiod ended\n30 September\n2022": "(47.16)",
                        "Year ended\n31 March 2023": "(107.58)",
                        "Year ended 31\nMarch 2022": "(111.19)",
                        "Year ended 31\nMarch 2021": "(350.24)"
                    },
                    {
                        "Particulars": "Proceeds from/ (repayment of) current\nborrowings (net)",
                        "Six months\nperiod ended\n30 September\n2023": "1,698.28",
                        "Six months\nperiod ended\n30 September\n2022": "2,293.34",
                        "Year ended\n31 March 2023": "485.79",
                        "Year ended 31\nMarch 2022": "2,524.23",
                        "Year ended 31\nMarch 2021": "(396.55)"
                    },
                    {
                        "Particulars": "Payment of lease liabilities",
                        "Six months\nperiod ended\n30 September\n2023": "(89.99)",
                        "Six months\nperiod ended\n30 September\n2022": "(71.60)",
                        "Year ended\n31 March 2023": "(129.98)",
                        "Year ended 31\nMarch 2022": "(163.73)",
                        "Year ended 31\nMarch 2021": "(129.26)"
                    },
                    {
                        "Particulars": "Interest paid",
                        "Six months\nperiod ended\n30 September\n2023": "(218.86)",
                        "Six months\nperiod ended\n30 September\n2022": "(160.96)",
                        "Year ended\n31 March 2023": "(404.43)",
                        "Year ended 31\nMarch 2022": "(89.10)",
                        "Year ended 31\nMarch 2021": "(50.18)"
                    },
                    {
                        "Particulars": "Net cash flows generated from/ (used\nin) financing activities",
                        "Six months\nperiod ended\n30 September\n2023": "1,361.20",
                        "Six months\nperiod ended\n30 September\n2022": "3,415.41",
                        "Year ended\n31 March 2023": "1,245.40",
                        "Year ended 31\nMarch 2022": "2,360.40",
                        "Year ended 31\nMarch 2021": "(914.62)"
                    },
                    {
                        "Particulars": "Net increase/ (decrease) in cash and\ncash equivalents",
                        "Six months\nperiod ended\n30 September\n2023": "660.22",
                        "Six months\nperiod ended\n30 September\n2022": "(92.72)",
                        "Year ended\n31 March 2023": "(35.31)",
                        "Year ended 31\nMarch 2022": "330.72",
                        "Year ended 31\nMarch 2021": "(702.33)"
                    },
                    {
                        "Particulars": "Add: acquired under business\ncombination",
                        "Six months\nperiod ended\n30 September\n2023": "-",
                        "Six months\nperiod ended\n30 September\n2022": "-",
                        "Year ended\n31 March 2023": "-",
                        "Year ended 31\nMarch 2022": "-",
                        "Year ended 31\nMarch 2021": "5.11"
                    },
                    {
                        "Particulars": "Cash and cash equivalents as at the\nbeginning of the period/ year",
                        "Six months\nperiod ended\n30 September\n2023": "516.08",
                        "Six months\nperiod ended\n30 September\n2022": "551.39",
                        "Year ended\n31 March 2023": "551.39",
                        "Year ended 31\nMarch 2022": "220.67",
                        "Year ended 31\nMarch 2021": "917.89"
                    },
                    {
                        "Particulars": "Cash and cash equivalents as at the\nend of the period/ year",
                        "Six months\nperiod ended\n30 September\n2023": "1,176.30",
                        "Six months\nperiod ended\n30 September\n2022": "458.67",
                        "Year ended\n31 March 2023": "516.08",
                        "Year ended 31\nMarch 2022": "551.39",
                        "Year ended 31\nMarch 2021": "220.67"
                    },
                    {
                        "Particulars": "",
                        "Six months\nperiod ended\n30 September\n2023": "",
                        "Six months\nperiod ended\n30 September\n2022": "",
                        "Year ended\n31 March 2023": "",
                        "Year ended 31\nMarch 2022": "",
                        "Year ended 31\nMarch 2021": ""
                    },
                    {
                        "Particulars": "Components of cash and cash\nequivalents are as below:",
                        "Six months\nperiod ended\n30 September\n2023": "",
                        "Six months\nperiod ended\n30 September\n2022": "",
                        "Year ended\n31 March 2023": "",
                        "Year ended 31\nMarch 2022": "",
                        "Year ended 31\nMarch 2021": ""
                    },
                    {
                        "Particulars": "Balance with banks:",
                        "Six months\nperiod ended\n30 September\n2023": "",
                        "Six months\nperiod ended\n30 September\n2022": "",
                        "Year ended\n31 March 2023": "",
                        "Year ended 31\nMarch 2022": "",
                        "Year ended 31\nMarch 2021": ""
                    },
                    {
                        "Particulars": "- in current accounts",
                        "Six months\nperiod ended\n30 September\n2023": "1,165.47",
                        "Six months\nperiod ended\n30 September\n2022": "434.83",
                        "Year ended\n31 March 2023": "513.54",
                        "Year ended 31\nMarch 2022": "479.34",
                        "Year ended 31\nMarch 2021": "190.50"
                    },
                    {
                        "Particulars": "- in deposit accounts with original\nmaturity of less than three months",
                        "Six months\nperiod ended\n30 September\n2023": "5.95",
                        "Six months\nperiod ended\n30 September\n2022": "20.00",
                        "Year ended\n31 March 2023": "-",
                        "Year ended 31\nMarch 2022": "68.00",
                        "Year ended 31\nMarch 2021": "24.86"
                    },
                    {
                        "Particulars": "Cash on hand",
                        "Six months\nperiod ended\n30 September\n2023": "4.88",
                        "Six months\nperiod ended\n30 September\n2022": "3.84",
                        "Year ended\n31 March 2023": "2.54",
                        "Year ended 31\nMarch 2022": "4.05",
                        "Year ended 31\nMarch 2021": "5.31"
                    },
                    {
                        "Particulars": "Cash and cash equivalents as at the\nend of the period/ year",
                        "Six months\nperiod ended\n30 September\n2023": "1,176.30",
                        "Six months\nperiod ended\n30 September\n2022": "458.67",
                        "Year ended\n31 March 2023": "516.08",
                        "Year ended 31\nMarch 2022": "551.39",
                        "Year ended 31\nMarch 2021": "220.67"
                    }
                ],
                "rows": 19,
                "cols": 6
            },
            {
                "page_number": 70,
                "table_data": [
                    {
                        "Name": "Sanjeev Jain",
                        "Designation": "Managing Director",
                        "DIN": "00323433",
                        "Address": "E 1052 Saraswati Vihar, New Delhi - 110 034, Delhi, India"
                    },
                    {
                        "Name": "Sandeep Jain",
                        "Designation": "Managing Director",
                        "DIN": "00323476",
                        "Address": "E 1052 Saraswati Vihar, New Delhi, 110 034, Delhi, India"
                    },
                    {
                        "Name": "Sanjay Sinha",
                        "Designation": "Whole Time Director",
                        "DIN": "03627342",
                        "Address": "H. no. DH-118, Scheme no. 74C, Vijay Nagar, Indore \u2013\n452010, India"
                    },
                    {
                        "Name": "Sunil Kumar Thakur",
                        "Designation": "Non-Executive Director",
                        "DIN": "03266370",
                        "Address": "S-177, Second Floor, Panchsheel Park, Malviya Nagar, South\nDelhi 110 017, Delhi, India"
                    },
                    {
                        "Name": "Kewal Kundanlal Handa",
                        "Designation": "Independent Director",
                        "DIN": "00056826",
                        "Address": "Nair House, 9th Floor, 14 B Road, Khar West, Mumbai, 400\n052, Maharashtra, India"
                    },
                    {
                        "Name": "Matangi Gowrishankar",
                        "Designation": "Independent Director",
                        "DIN": "01518137",
                        "Address": "E 1001/1002 Maestros, Salunke Vihar Road, Wanwadi, Pune,\n411 040, Maharashtra, India"
                    },
                    {
                        "Name": "Nand Lal Kalra",
                        "Designation": "Independent Director",
                        "DIN": "05268554",
                        "Address": "H. no. 4-BA-11, Jawahar Nagar, Jaipur, 302 004, Rajasthan,\nIndia"
                    },
                    {
                        "Name": "Satwinder Singh",
                        "Designation": "Independent Director",
                        "DIN": "00164903",
                        "Address": "Tower 10, Ground Floor, ATS One Hamlet Sector 104 Noida,\nGautam Buddha Nagar, 201 301, Uttar Pradesh, India"
                    }
                ],
                "rows": 8,
                "cols": 4
            },
            {
                "page_number": 74,
                "table_data": [
                    {
                        "Activity": "Capital structuring with the relative components and formalities such as type of instruments,\ncomposition of debt and equity, size of issue, allocation between primary and secondary, etc",
                        "Coordinator": "I-SEC"
                    },
                    {
                        "Activity": "Due Diligence of the company including its operations/ management / business plan/ legal, etc",
                        "Coordinator": "I-SEC"
                    },
                    {
                        "Activity": "Drafting and design of DRHP, RHP, Prospectus, abridged prospectus and application form in\ncompliance with requirement. The BRLMs shall ensure compliance with stipulated requirements and\ncompletion of prescribed formalities with the Stock Exchanges, RoC and SEBI including finalisation of\nProspectus and RoC filing.",
                        "Coordinator": "I-SEC"
                    },
                    {
                        "Activity": "Drafting and approval of all statutory advertisement",
                        "Coordinator": "I-SEC"
                    },
                    {
                        "Activity": "Drafting and approval of all publicity material other than statutory advertisement as mentioned above\nincluding corporate advertising, brochure, etc. and filing of media compliance report",
                        "Coordinator": "Axis"
                    },
                    {
                        "Activity": "Appointment of Intermediaries i.e., Registrar, Banker(s) to the Offer, Sponsor Bank, including\ncoordination of all agreements to be entered into with such intermediaries",
                        "Coordinator": "Axis"
                    },
                    {
                        "Activity": "Appointment of Intermediaries i.e., advertising agency, printers, Syndicate, Monitoring Agency and\nother intermediaries, including coordination of all agreements to be entered into with such intermediaries",
                        "Coordinator": "Axis"
                    },
                    {
                        "Activity": "Preparation of road show presentation, FAQs and analyst presentation",
                        "Coordinator": "Citi"
                    },
                    {
                        "Activity": "Coordination and finalization of industry report and Industry Overview Section\nto be included in Draft Red Herring Prospectus, Red Herring Prospectus and Prospectus",
                        "Coordinator": "Ambit"
                    },
                    {
                        "Activity": "International Institutional marketing of the Offer, which will cover, inter alia:\n- Institutional marketing strategy;\n- Finalizing the list and division of international investors for one-to-one meetings; and\n- Finalizing international road shows and investor meeting schedule",
                        "Coordinator": "Citi"
                    },
                    {
                        "Activity": "Domestic Institutional marketing of the Offer, which will cover, inter alia:\n- Institutional marketing strategy;\n- Finalizing the list and division of domestic investors for one-to-one meetings; and\n- Finalizing domestic road shows and investor meeting schedule",
                        "Coordinator": "I-SEC"
                    },
                    {
                        "Activity": "Retail marketing of the Offer, which will cover, inter alia,\n- Formulating marketing strategies and preparation of publicity budget;\n- Finalising media, marketing and public relations strategy including list of frequently asked questions\nat retail roadshows;\n- Finalising centres for holding conferences for brokers, etc;\n- Follow-up on distribution of publicity and Offer material including form, the Prospectus and\ndeciding on the quantum of the Offer material; and\n- Finalising collection centres",
                        "Coordinator": "Ambit"
                    }
                ],
                "rows": 12,
                "cols": 2
            },
            {
                "page_number": 75,
                "table_data": [
                    {
                        "Activity": "Non-Institutional marketing of the Offer, which will cover, inter alia:\n- Formulating marketing strategies for non-institutional investors",
                        "Coordinator": "Axis"
                    },
                    {
                        "Activity": "Managing the book and finalization of pricing in consultation with the Company and the Selling\nShareholders",
                        "Coordinator": "Citi"
                    },
                    {
                        "Activity": "Coordination with Stock-Exchanges for book building software, bidding terminals, mock trading,\npayment of 1% security deposit, anchor coordination, anchor CAN and intimation of anchor allocation.",
                        "Coordinator": "Ambit"
                    },
                    {
                        "Activity": "Post bidding activities, including management of escrow accounts, coordinate non-institutional\nallocation, coordination with Registrar, SCSBs, Sponsor Banks and other Bankers to the Offer,\nintimation of allocation and dispatch of refund to Bidders, etc.\nOther post-Offer activities, which shall involve essential follow-up with bankers to the Offer and SCSBs\nto get quick estimates of collection and advising our Company about the closure of the Offer, based on\ncorrect figures, finalisation of the basis of allotment or weeding out of multiple applications, listing of\ninstruments, dispatch of certificates or demat credit and refunds, payment of STT on behalf of the Selling\nShareholders and coordination with various agencies connected with the post- Offer activity such as\nRegistrar to the Offer, Bankers to the Offer, Sponsor Bank, SCSBs including responsibility for\nunderwriting arrangements, as applicable. Coordinating with Stock Exchanges and SEBI for submission\nof all post-Offer reports including the final post-Offer report to SEBI and refund/release of 1% security\ndeposit post closure of the Offer.",
                        "Coordinator": "Axis"
                    }
                ],
                "rows": 4,
                "cols": 2
            },
            {
                "page_number": 76,
                "table_data": [
                    {
                        "Name, Address, Telephone Number and Email Address of\nthe Underwriters": "[\u25cf]",
                        "Indicative Number of Equity Shares to be\nUnderwritten": "[\u25cf]",
                        "Amount\nUnderwritten\n(\u20b9 in million)": "[\u25cf]"
                    }
                ],
                "rows": 1,
                "cols": 3
            },
            {
                "page_number": 77,
                "table_data": [
                    {
                        "Col0": "A",
                        "Particulars": "AUTHORISED SHARE CAPITAL(1)",
                        "Aggregate value at face\nvalue": null,
                        "Aggregate value at\nOffer Price*": null
                    },
                    {
                        "Col0": "",
                        "Particulars": "Equity shares comprising:",
                        "Aggregate value at face\nvalue": null,
                        "Aggregate value at\nOffer Price*": null
                    },
                    {
                        "Col0": "",
                        "Particulars": "200,000,000 Equity Shares",
                        "Aggregate value at face\nvalue": "400,000,000",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "",
                        "Particulars": "",
                        "Aggregate value at face\nvalue": "",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "B",
                        "Particulars": "ISSUED, SUBSCRIBED AND PAID-UP SHARE CAPITAL BEFORE THE OFFER",
                        "Aggregate value at face\nvalue": null,
                        "Aggregate value at\nOffer Price*": null
                    },
                    {
                        "Col0": "",
                        "Particulars": "143,064,350 Equity Shares#",
                        "Aggregate value at face\nvalue": "286,128,700",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "",
                        "Particulars": "",
                        "Aggregate value at face\nvalue": "",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "D",
                        "Particulars": "PRESENT OFFER",
                        "Aggregate value at face\nvalue": null,
                        "Aggregate value at\nOffer Price*": null
                    },
                    {
                        "Col0": "",
                        "Particulars": "Offer of up to [\u25cf] Equity Shares (2)(3)",
                        "Aggregate value at face\nvalue": "[\u25cf]",
                        "Aggregate value at\nOffer Price*": "[\u25cf]"
                    },
                    {
                        "Col0": "",
                        "Particulars": "of which",
                        "Aggregate value at face\nvalue": "",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "",
                        "Particulars": "Fresh Issue of up to [\u25cf] Equity Shares(2)(3)",
                        "Aggregate value at face\nvalue": "[\u25cf]",
                        "Aggregate value at\nOffer Price*": "[\u25cf]"
                    },
                    {
                        "Col0": "",
                        "Particulars": "Offer for Sale of up to 18,598,365 Equity Shares(4)",
                        "Aggregate value at face\nvalue": "[\u25cf]",
                        "Aggregate value at\nOffer Price*": "[\u25cf]"
                    },
                    {
                        "Col0": "",
                        "Particulars": "The Offer includes:",
                        "Aggregate value at face\nvalue": "",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "",
                        "Particulars": "Employee Reservation Portion of up to [\u25cf] Equity Shares aggregating up to \u20b9 [\u25cf]\nmillion(5)",
                        "Aggregate value at face\nvalue": "[\u25cf]",
                        "Aggregate value at\nOffer Price*": "[\u25cf]"
                    },
                    {
                        "Col0": "",
                        "Particulars": "Net Offer of up to [\u25cf] Equity Shares",
                        "Aggregate value at face\nvalue": "",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "",
                        "Particulars": "",
                        "Aggregate value at face\nvalue": "",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "E",
                        "Particulars": "ISSUED, SUBSCRIBED AND PAID-UP SHARE CAPITAL AFTER THE OFFER",
                        "Aggregate value at face\nvalue": null,
                        "Aggregate value at\nOffer Price*": null
                    },
                    {
                        "Col0": "",
                        "Particulars": "[\u25cf] Equity Shares",
                        "Aggregate value at face\nvalue": "[\u25cf]",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "",
                        "Particulars": "",
                        "Aggregate value at face\nvalue": "",
                        "Aggregate value at\nOffer Price*": ""
                    },
                    {
                        "Col0": "F",
                        "Particulars": "SECURITIES PREMIUM ACCOUNT",
                        "Aggregate value at face\nvalue": null,
                        "Aggregate value at\nOffer Price*": null
                    },
                    {
                        "Col0": "",
                        "Particulars": "Before the Offer (as on date of this Draft Red Herring Prospectus)",
                        "Aggregate value at face\nvalue": "1,271,663,000.00",
                        "Aggregate value at\nOffer Price*": null
                    },
                    {
                        "Col0": "",
                        "Particulars": "After the Offer",
                        "Aggregate value at face\nvalue": "[\u25cf]",
                        "Aggregate value at\nOffer Price*": null
                    }
                ],
                "rows": 22,
                "cols": 4
            },
            {
                "page_number": 78,
                "table_data": [
                    {
                        "Date of\nallotment of\nequity shares": "April 15, 2004",
                        "Nature of\nallotment": "Initial\nsubscription to\nMoA",
                        "Nature of\nconsideration": "Cash",
                        "Number of\nequity\nshares": "50,000",
                        "Face value\nper equity\nshare (in \u20b9)": "10",
                        "Issue price\nper equity\nshare (in \u20b9)": "10",
                        "Name of allottees/ shareholders": "Allotment of 600 equity shares to Dharam Chand Jain, 24,500 equity shares\nto Sanjeev Jain, 24,500 equity shares to Sandeep Jain, 100 equity shares to\nKiran Jain, 100 equity shares to Lata Jain, 100 equity shares to Vandana\nJain and 100 equity shares to Neetu Jain.",
                        "Cumulative\nnumber of\nEquity Shares": "50,000",
                        "Cumulative\npaid-up\nEquity Share\ncapital": "500,000"
                    },
                    {
                        "Date of\nallotment of\nequity shares": "December 13,\n2004#",
                        "Nature of\nallotment": "Further issue",
                        "Nature of\nconsideration": "Cash",
                        "Number of\nequity\nshares": "1,005,000",
                        "Face value\nper equity\nshare (in \u20b9)": "10",
                        "Issue price\nper equity\nshare (in \u20b9)": "20",
                        "Name of allottees/ shareholders": "Allotment of 61,675 equity shares to Dharam Chand Jain jointly with\nSanjeev Jain, 61,675 equity shares to Dharam Chand Jain jointly with\nSandeep Jain, 197,700 equity shares to Sanjeev Jain, 229,750 equity shares\nto Sandeep Jain, 75,000 equity shares to Lata Jain, 42,950 equity shares to\nVandana Jain, 1,750 equity shares to Kiran Jain jointly with Sanjeev Jain,\n1,750 equity shares to Kiran Jain jointly with Sandeep Jain, 85,000 equity\nshares to Dharam Chand Jain and sons HUF jointly with Sanjeev Jain,\n85,000 equity shares to Dharam Chand Jain and sons HUF jointly with\nSandeep Jain, 1,250 equity shares to Mata Pher Singh, 1,250 equity shares\nto Narendra Dev Sachdeva, 15,000 equity Shares to Amazing Research\nLaboratories Limited, 15,000 equity shares to Maxcure Drugs and\nPharmaceuticals Limited, 25,000 equity shares to Power Pack (India),\n15,000 equity shares to Life Line India, 5,000 equity shares to Ajay Kakkar,\n500 equity shares to Ajay Kumar Pandey, 2,000 equity shares to Ambika\nSukumar, 1,500 equity shares to Anju Chauhan, 1,000 equity shares to\nAshtik Kumar Sinha, 2,000 equity shares to Balraj Bidaliya, 500 equity\nshares to Belal Arshad Faridi, 1,000 equity shares to Bhushan Kumar Goel,\n1,000 equity shares to Bhajesh Sharma, 10,500 equity shares to Bhijesh\nSharma, 10,000 equity shares to Chandra Mohan Khurana, 1,000 equity\nshares to Chandrani Banik Chowdhury, 1,000 equity shares to Dalip Singh\nBhuraria, 500 equity shares to Devendra Dhyani, 4,500 equity shares to\nDevi Deen Singh, 1,000 equity shares to Dharmendra Singh, 500 equity\nshares to Dinesh Kumar, 1,000 equity shares to Ekta Malhotra, 2,000 equity\nshares to Gopi Nath Sahu, 3,500 equity shares to Himanshu Chachra, 1,250\nequity shares to Jagdish Prasad, 1,250 equity shares to Khyall Dutt, 2000\nequity shares to Kuldeep Kaur, 2,000 equity shares to Kusum Pal, 1,500\nequity shares to Lalita Rani, 1,000 equity shares to Manisha Manocha, 1,000\nequity shares to Manju Bist, 1,000 equity shares to Meenakshi Prasad, 1000\nequity shares to Mohan Lal Bansal, 500 equity shares to Neeraj Kumar\nNirala, 2,000 equity shares to Parta Sarthi Mahaptra, 1,500 equity shares to\nPooja Babbar, 2,500 equity shares to Pradeep Kumar Sharma, 1,000 equity\nshares to Praveen Soni, 2,500 equity shares to Puneet Sharma, 1,000 equity\nshares to Rajeshwar Prasad, 1,250 equity shares to Rakesh Kumar, 2000",
                        "Cumulative\nnumber of\nEquity Shares": "1,055,000",
                        "Cumulative\npaid-up\nEquity Share\ncapital": "10,550,000"
                    }
                ],
                "rows": 2,
                "cols": 9
            },
            {
                "page_number": 79,
                "table_data": [
                    {
                        "Date of\nallotment of\nequity shares": "",
                        "Nature of\nallotment": "",
                        "Nature of\nconsideration": "",
                        "Number of\nequity\nshares": "",
                        "Face value\nper equity\nshare (in \u20b9)": "",
                        "Issue price\nper equity\nshare (in \u20b9)": "",
                        "Name of allottees/ shareholders": "equity shares to Ramashankar, 2,500 equity shares to Ramesh Chand Saini,\n2,000 equity shares to Sapna Sharma, 1,250 equity shares to Satya Prakash,\n500 equity shares to Shiv Prasad Nautiyal, 1,250 equity shares to Srinath\nPrasad Ojha, 2500 equity shares to Sudama Prasad, 1,500 equity shares to\nSurendra Kumar Saini, 500 equity shares to Veni Sethi, 1,500 equity shares\nto Vijay Pal Singh Rawat, 500 equity shares to Vikas Rajput.",
                        "Cumulative\nnumber of\nEquity Shares": "",
                        "Cumulative\npaid-up\nEquity Share\ncapital": ""
                    },
                    {
                        "Date of\nallotment of\nequity shares": "March 31,\n2005#",
                        "Nature of\nallotment": "Further issue",
                        "Nature of\nconsideration": "Cash",
                        "Number of\nequity\nshares": "120,000",
                        "Face value\nper equity\nshare (in \u20b9)": "10",
                        "Issue price\nper equity\nshare (in \u20b9)": "20",
                        "Name of allottees/ shareholders": "Allotment of 200 equity shares to Amresh Kumar Rai, 4,000 equity shares\nto Brajesh Sharma, 3,525 equity shares to Dharam Chand Jain jointly with\nSanjeev Jain, 3,525 equity shares to Dharam Chand Jain jointly with\nSandeep Jain, 12,500 equity shares to Sanjeev Jain, 20,000 equity shares to\nSanjeev Jain and sons HUF, 10,000 equity shares to Sandeep Jain, 5,000\nequity shares to Sandeep Jain and sons HUF, 11,000 equity shares to Lata\nJain, 3,500 equity shares to Vandana Jain, 46,750 equity shares to A.K.\nLaboratories Limited.",
                        "Cumulative\nnumber of\nEquity Shares": "1,175,000",
                        "Cumulative\npaid-up\nEquity Share\ncapital": "11,750,000"
                    },
                    {
                        "Date of\nallotment of\nequity shares": "November 13,\n2019",
                        "Nature of\nallotment": "Private\nplacement",
                        "Nature of\nconsideration": "Cash",
                        "Number of\nequity\nshares": "125,585",
                        "Face value\nper equity\nshare (in \u20b9)": "10",
                        "Issue price\nper equity\nshare (in \u20b9)": "25,480.85",
                        "Name of allottees/ shareholders": "Allotment of 125,585 equity shares to Ruby QC Investment Holdings Pte.\nLtd.",
                        "Cumulative\nnumber of\nEquity Shares": "1,300,585",
                        "Cumulative\npaid-up\nEquity Share\ncapital": "13,005,850"
                    },
                    {
                        "Date of\nallotment of\nequity shares": "Pursuant to resolutions each dated December 24, 2021 passed by our Board and the Shareholders, the authorized share capital of our Company was sub-divided from \u20b915,000,000 divided into 1,500,000\nequity shares of face value of \u20b910 each to \u20b915,000,000 divided into 7,500,000 Equity Shares of face value of \u20b92 each. Accordingly, the issued, subscribed and paid-up equity share capital of our Company\nwas sub-divided from \u20b913,005,850 divided into 1,300,585 equity shares of face value of \u20b910 per equity share to \u20b913,005,850 divided into 6,502,925 Equity Shares of face value of \u20b92 per Equity Share.",
                        "Nature of\nallotment": null,
                        "Nature of\nconsideration": null,
                        "Number of\nequity\nshares": null,
                        "Face value\nper equity\nshare (in \u20b9)": null,
                        "Issue price\nper equity\nshare (in \u20b9)": null,
                        "Name of allottees/ shareholders": null,
                        "Cumulative\nnumber of\nEquity Shares": null,
                        "Cumulative\npaid-up\nEquity Share\ncapital": null
                    },
                    {
                        "Date of\nallotment of\nequity shares": "December 24,\n2021",
                        "Nature of\nallotment": "Bonus issue in\nthe ratio of 10\nEquity Shares\nfor every 1\nEquity Share\nheld by our\nShareholders*",
                        "Nature of\nconsideration": "N.A.",
                        "Number of\nequity\nshares": "65,029,250",
                        "Face value\nper equity\nshare (in \u20b9)": "2",
                        "Issue price\nper equity\nshare (in \u20b9)": "N.A.",
                        "Name of allottees/ shareholders": "Allotment of 27,587,700 Equity Shares to Sanjeev Jain, 3,750 Equity Shares\nto Lata Jain, 15,000 Equity Shares to Sanjeev Jain jointly with Arushi Jain,\n2,500 Equity Shares to Lata Jain jointly with Umang Jain, 27,603,950\nEquity Shares to Sandeep Jain, 2,500 Equity Shares to Sandeep Jain jointly\nwith Kanishk Jain, 2,500 Equity Shares to Sandeep Jain jointly with Manan\nJain and 9,811,350 Equity Shares to Ruby QC Investment Holdings Pte. Ltd.",
                        "Cumulative\nnumber of\nEquity Shares": "71,532,175",
                        "Cumulative\npaid-up\nEquity Share\ncapital": "143,064,350"
                    },
                    {
                        "Date of\nallotment of\nequity shares": "March 17,\n2023",
                        "Nature of\nallotment": "Bonus issue in\nthe ratio of 1\nEquity Share\nfor every 1\nEquity Share\nheld by our\nShareholders^",
                        "Nature of\nconsideration": "N.A.",
                        "Number of\nequity\nshares": "71,532,175",
                        "Face value\nper equity\nshare (in \u20b9)": "2",
                        "Issue price\nper equity\nshare (in \u20b9)": "N.A.",
                        "Name of allottees/ shareholders": "Allotment of 30,346,470 Equity Shares to Sanjeev Jain, 4,125 Equity Shares\nto Lata Jain, 16,500 Equity Shares to Sanjeev Jain jointly with Arushi, 2,750\nEquity Shares to Lata Jain jointly with Umang Jain, 30,364,345 Equity\nShares to Sandeep Jain, 2,750 Equity Shares to Sandeep Jain jointly with\nKanishk Jain, 2,750 Equity Shares to Sandeep Jain jointly with Manan Jain\nand 10,792,485 Equity Shares to Ruby QC Investment Holdings Pte. Ltd.",
                        "Cumulative\nnumber of\nEquity Shares": "143,064,350",
                        "Cumulative\npaid-up\nEquity Share\ncapital": "286,128,700"
                    }
                ],
                "rows": 6,
                "cols": 9
            },
            {
                "page_number": 81,
                "table_data": [
                    {
                        "Date of\nallotment": "December\n24, 2021",
                        "No. of\nequity\nshares\nallotted": "65,029,250",
                        "Face value\nper equity\nshare (\u20b9)": "2",
                        "Issue price\nper equity\nshare (\u20b9)": "N.A.",
                        "Reason for\nallotment": "Bonus issue of\nEquity Shares\nin the ratio of\n10:1*",
                        "Name of Allottees": "Allotment of 27,587,700 Equity\nShares to Sanjeev Jain, 3,750\nEquity Shares to Lata Jain,\n15,000 Equity Shares to Sanjeev\nJain jointly with Arushi Jain,\n2,500 Equity Shares to Lata Jain\njointly with Umang Jain,\n27,603,950 Equity Shares to\nSandeep Jain, 2,500 Equity\nShares to Sandeep Jain jointly\nwith Kanishk Jain, 2,500 Equity\nShares to Sandeep Jain jointly\nwith Manan Jain, 9,811,350\nEquity Shares to Ruby QC\nInvestment Holdings Pte. Ltd.",
                        "Benefits\naccrued to our\nCompany": "N.A."
                    },
                    {
                        "Date of\nallotment": "March 17,\n2023",
                        "No. of\nequity\nshares\nallotted": "71,532,175",
                        "Face value\nper equity\nshare (\u20b9)": "2",
                        "Issue price\nper equity\nshare (\u20b9)": "N.A.",
                        "Reason for\nallotment": "Bonus issue of\nEquity Shares\nin the ratio of\n1:1^",
                        "Name of Allottees": "Allotment of 30,346,470 Equity\nShares to Sanjeev Jain, 4,125\nEquity Shares to Lata Jain,\n16,500 Equity Shares to Sanjeev\nJain jointly with Arushi Jain,\n2,750 Equity Shares to Lata Jain\njointly with Umang Jain,\n30,364,345 Equity Shares to\nSandeep Jain, 2,750 Equity\nShares to Sandeep Jain jointly\nwith Kanishk Jain, 2,750 Equity\nShares to Sandeep Jain jointly\nwith Manan Jain, 10,792,485\nEquity Shares to Ruby QC\nInvestment Holdings Pte. Ltd.",
                        "Benefits\naccrued to our\nCompany": "N.A."
                    }
                ],
                "rows": 2,
                "cols": 7
            },
            {
                "page_number": 82,
                "table_data": [
                    {
                        "Category\n(I)": null,
                        "Category of\nshareholder\n(II)": null,
                        "Number of\nshareholders\n(III)": null,
                        "Number of\nfully paid-\nup Equity\nShares held\n(IV)#": null,
                        "Number\nof\nPartly\npaid-up\nEquity\nShares\nheld\n(V)": null,
                        "Number of\nshares\nunderlying\nDepository\nReceipts\n(VI)": null,
                        "Total\nnumber of\nshares held\n(VII)\n=(IV)+(V)+\n(VI)": null,
                        "Shareholding\nas a % of\ntotal number\nof shares\n(calculated\nas per\nSCRR, 1957)\n(VIII) As a\n% of\n(A+B+C2)": null,
                        "Number of Voting Rights held in each\nclass of securities\n(IX)": "Number of Voting\nRights",
                        "Col9": null,
                        "Col10": "Total as a %\nof (A+B+ C)",
                        "Number of\nshares\nUnderlying\nOutstanding\nconvertible\nsecurities\n(including\nWarrants)\n(X)": null,
                        "Shareholding,\nas a %\nassuming full\nconversion of\nconvertible\nsecurities (as\na percentage\nof diluted\nshare capital)\n(XI)=\n(VII)+(X) As\na % of\n(A+B+C2)": null,
                        "Number of\nLocked in\nshares\n(XII)": "Number\n(a)",
                        "Col14": "As a\n% of\ntotal\nShares\nheld\n(b)",
                        "Number of\nShares pledged\nor otherwise\nencumbered\n(XIII)": "Number\n(a)",
                        "Col16": "As a\n% of\ntotal\nShares\nheld\n(b) on\na fully\ndiluted\nbasis",
                        "Number of\nEquity Shares\nheld in\ndematerialised\nform\n(XIV)": null
                    },
                    {
                        "Category\n(I)": null,
                        "Category of\nshareholder\n(II)": null,
                        "Number of\nshareholders\n(III)": null,
                        "Number of\nfully paid-\nup Equity\nShares held\n(IV)#": null,
                        "Number\nof\nPartly\npaid-up\nEquity\nShares\nheld\n(V)": null,
                        "Number of\nshares\nunderlying\nDepository\nReceipts\n(VI)": null,
                        "Total\nnumber of\nshares held\n(VII)\n=(IV)+(V)+\n(VI)": null,
                        "Shareholding\nas a % of\ntotal number\nof shares\n(calculated\nas per\nSCRR, 1957)\n(VIII) As a\n% of\n(A+B+C2)": null,
                        "Number of Voting Rights held in each\nclass of securities\n(IX)": "Class:\nEquity\nShares",
                        "Col9": "Total",
                        "Col10": null,
                        "Number of\nshares\nUnderlying\nOutstanding\nconvertible\nsecurities\n(including\nWarrants)\n(X)": null,
                        "Shareholding,\nas a %\nassuming full\nconversion of\nconvertible\nsecurities (as\na percentage\nof diluted\nshare capital)\n(XI)=\n(VII)+(X) As\na % of\n(A+B+C2)": null,
                        "Number of\nLocked in\nshares\n(XII)": null,
                        "Col14": null,
                        "Number of\nShares pledged\nor otherwise\nencumbered\n(XIII)": null,
                        "Col16": null,
                        "Number of\nEquity Shares\nheld in\ndematerialised\nform\n(XIV)": null
                    },
                    {
                        "Category\n(I)": "(A)",
                        "Category of\nshareholder\n(II)": "Promoters\nand\nPromoter\nGroup",
                        "Number of\nshareholders\n(III)": "7",
                        "Number of\nfully paid-\nup Equity\nShares held\n(IV)#": "121,479,380",
                        "Number\nof\nPartly\npaid-up\nEquity\nShares\nheld\n(V)": "-",
                        "Number of\nshares\nunderlying\nDepository\nReceipts\n(VI)": "NA",
                        "Total\nnumber of\nshares held\n(VII)\n=(IV)+(V)+\n(VI)": "121,479,380",
                        "Shareholding\nas a % of\ntotal number\nof shares\n(calculated\nas per\nSCRR, 1957)\n(VIII) As a\n% of\n(A+B+C2)": "84.91",
                        "Number of Voting Rights held in each\nclass of securities\n(IX)": "121,479,380",
                        "Col9": "121,479,380",
                        "Col10": "84.91",
                        "Number of\nshares\nUnderlying\nOutstanding\nconvertible\nsecurities\n(including\nWarrants)\n(X)": "-",
                        "Shareholding,\nas a %\nassuming full\nconversion of\nconvertible\nsecurities (as\na percentage\nof diluted\nshare capital)\n(XI)=\n(VII)+(X) As\na % of\n(A+B+C2)": "-",
                        "Number of\nLocked in\nshares\n(XII)": "-",
                        "Col14": "-",
                        "Number of\nShares pledged\nor otherwise\nencumbered\n(XIII)": "-",
                        "Col16": "-",
                        "Number of\nEquity Shares\nheld in\ndematerialised\nform\n(XIV)": "121,479,380"
                    },
                    {
                        "Category\n(I)": "(B)",
                        "Category of\nshareholder\n(II)": "Public",
                        "Number of\nshareholders\n(III)": "1",
                        "Number of\nfully paid-\nup Equity\nShares held\n(IV)#": "21,584,970",
                        "Number\nof\nPartly\npaid-up\nEquity\nShares\nheld\n(V)": "-",
                        "Number of\nshares\nunderlying\nDepository\nReceipts\n(VI)": "-",
                        "Total\nnumber of\nshares held\n(VII)\n=(IV)+(V)+\n(VI)": "21,584,970",
                        "Shareholding\nas a % of\ntotal number\nof shares\n(calculated\nas per\nSCRR, 1957)\n(VIII) As a\n% of\n(A+B+C2)": "15.09",
                        "Number of Voting Rights held in each\nclass of securities\n(IX)": "21,584,970",
                        "Col9": "21,584,970",
                        "Col10": "15.09",
                        "Number of\nshares\nUnderlying\nOutstanding\nconvertible\nsecurities\n(including\nWarrants)\n(X)": "-",
                        "Shareholding,\nas a %\nassuming full\nconversion of\nconvertible\nsecurities (as\na percentage\nof diluted\nshare capital)\n(XI)=\n(VII)+(X) As\na % of\n(A+B+C2)": "-",
                        "Number of\nLocked in\nshares\n(XII)": "-",
                        "Col14": "-",
                        "Number of\nShares pledged\nor otherwise\nencumbered\n(XIII)": "-",
                        "Col16": "-",
                        "Number of\nEquity Shares\nheld in\ndematerialised\nform\n(XIV)": "21,584,970"
                    },
                    {
                        "Category\n(I)": "(C)",
                        "Category of\nshareholder\n(II)": "Non\nPromoter-\nNon Public",
                        "Number of\nshareholders\n(III)": "-",
                        "Number of\nfully paid-\nup Equity\nShares held\n(IV)#": "-",
                        "Number\nof\nPartly\npaid-up\nEquity\nShares\nheld\n(V)": "-",
                        "Number of\nshares\nunderlying\nDepository\nReceipts\n(VI)": "-",
                        "Total\nnumber of\nshares held\n(VII)\n=(IV)+(V)+\n(VI)": "-",
                        "Shareholding\nas a % of\ntotal number\nof shares\n(calculated\nas per\nSCRR, 1957)\n(VIII) As a\n% of\n(A+B+C2)": "-",
                        "Number of Voting Rights held in each\nclass of securities\n(IX)": "-",
                        "Col9": "-",
                        "Col10": "-",
                        "Number of\nshares\nUnderlying\nOutstanding\nconvertible\nsecurities\n(including\nWarrants)\n(X)": "-",
                        "Shareholding,\nas a %\nassuming full\nconversion of\nconvertible\nsecurities (as\na percentage\nof diluted\nshare capital)\n(XI)=\n(VII)+(X) As\na % of\n(A+B+C2)": "-",
                        "Number of\nLocked in\nshares\n(XII)": "-",
                        "Col14": "-",
                        "Number of\nShares pledged\nor otherwise\nencumbered\n(XIII)": "-",
                        "Col16": "-",
                        "Number of\nEquity Shares\nheld in\ndematerialised\nform\n(XIV)": "-"
                    },
                    {
                        "Category\n(I)": "(C1)",
                        "Category of\nshareholder\n(II)": "Shares\nunderlying\ndepository\nreceipts",
                        "Number of\nshareholders\n(III)": "-",
                        "Number of\nfully paid-\nup Equity\nShares held\n(IV)#": "-",
                        "Number\nof\nPartly\npaid-up\nEquity\nShares\nheld\n(V)": "-",
                        "Number of\nshares\nunderlying\nDepository\nReceipts\n(VI)": "-",
                        "Total\nnumber of\nshares held\n(VII)\n=(IV)+(V)+\n(VI)": "-",
                        "Shareholding\nas a % of\ntotal number\nof shares\n(calculated\nas per\nSCRR, 1957)\n(VIII) As a\n% of\n(A+B+C2)": "-",
                        "Number of Voting Rights held in each\nclass of securities\n(IX)": "-",
                        "Col9": "-",
                        "Col10": "-",
                        "Number of\nshares\nUnderlying\nOutstanding\nconvertible\nsecurities\n(including\nWarrants)\n(X)": "-",
                        "Shareholding,\nas a %\nassuming full\nconversion of\nconvertible\nsecurities (as\na percentage\nof diluted\nshare capital)\n(XI)=\n(VII)+(X) As\na % of\n(A+B+C2)": "-",
                        "Number of\nLocked in\nshares\n(XII)": "-",
                        "Col14": "-",
                        "Number of\nShares pledged\nor otherwise\nencumbered\n(XIII)": "-",
                        "Col16": "-",
                        "Number of\nEquity Shares\nheld in\ndematerialised\nform\n(XIV)": "-"
                    },
                    {
                        "Category\n(I)": "(C2)",
                        "Category of\nshareholder\n(II)": "Shares held\nby\nemployee\ntrusts",
                        "Number of\nshareholders\n(III)": "-",
                        "Number of\nfully paid-\nup Equity\nShares held\n(IV)#": "-",
                        "Number\nof\nPartly\npaid-up\nEquity\nShares\nheld\n(V)": "-",
                        "Number of\nshares\nunderlying\nDepository\nReceipts\n(VI)": "-",
                        "Total\nnumber of\nshares held\n(VII)\n=(IV)+(V)+\n(VI)": "-",
                        "Shareholding\nas a % of\ntotal number\nof shares\n(calculated\nas per\nSCRR, 1957)\n(VIII) As a\n% of\n(A+B+C2)": "-",
                        "Number of Voting Rights held in each\nclass of securities\n(IX)": "-",
                        "Col9": "-",
                        "Col10": "-",
                        "Number of\nshares\nUnderlying\nOutstanding\nconvertible\nsecurities\n(including\nWarrants)\n(X)": "-",
                        "Shareholding,\nas a %\nassuming full\nconversion of\nconvertible\nsecurities (as\na percentage\nof diluted\nshare capital)\n(XI)=\n(VII)+(X) As\na % of\n(A+B+C2)": "-",
                        "Number of\nLocked in\nshares\n(XII)": "-",
                        "Col14": "-",
                        "Number of\nShares pledged\nor otherwise\nencumbered\n(XIII)": "-",
                        "Col16": "-",
                        "Number of\nEquity Shares\nheld in\ndematerialised\nform\n(XIV)": "-"
                    },
                    {
                        "Category\n(I)": "",
                        "Category of\nshareholder\n(II)": "Total\n(A+B+C)",
                        "Number of\nshareholders\n(III)": "8",
                        "Number of\nfully paid-\nup Equity\nShares held\n(IV)#": "143,064,350",
                        "Number\nof\nPartly\npaid-up\nEquity\nShares\nheld\n(V)": "-",
                        "Number of\nshares\nunderlying\nDepository\nReceipts\n(VI)": "NA",
                        "Total\nnumber of\nshares held\n(VII)\n=(IV)+(V)+\n(VI)": "143,064,350",
                        "Shareholding\nas a % of\ntotal number\nof shares\n(calculated\nas per\nSCRR, 1957)\n(VIII) As a\n% of\n(A+B+C2)": "100.00",
                        "Number of Voting Rights held in each\nclass of securities\n(IX)": "143,064,350",
                        "Col9": "143,064,350",
                        "Col10": "100.00",
                        "Number of\nshares\nUnderlying\nOutstanding\nconvertible\nsecurities\n(including\nWarrants)\n(X)": "-",
                        "Shareholding,\nas a %\nassuming full\nconversion of\nconvertible\nsecurities (as\na percentage\nof diluted\nshare capital)\n(XI)=\n(VII)+(X) As\na % of\n(A+B+C2)": "-",
                        "Number of\nLocked in\nshares\n(XII)": "-",
                        "Col14": "-",
                        "Number of\nShares pledged\nor otherwise\nencumbered\n(XIII)": "-",
                        "Col16": "-",
                        "Number of\nEquity Shares\nheld in\ndematerialised\nform\n(XIV)": "143,064,350"
                    }
                ],
                "rows": 8,
                "cols": 18
            },
            {
                "page_number": 83,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Name of the Shareholder": "Sanjeev Jain#",
                        "Number of Equity Shares*": "60,725,940\u03b2",
                        "Percentage of the pre-Offer Equity\nShare Capital* (%)": "42.45"
                    },
                    {
                        "S. No.": "2.",
                        "Name of the Shareholder": "Sandeep Jain#",
                        "Number of Equity Shares*": "60,739,690\u03b1",
                        "Percentage of the pre-Offer Equity\nShare Capital* (%)": "42.46"
                    },
                    {
                        "S. No.": "3.",
                        "Name of the Shareholder": "Ruby QC Investment Holdings Pte. Ltd.",
                        "Number of Equity Shares*": "21,584,970",
                        "Percentage of the pre-Offer Equity\nShare Capital* (%)": "15.09"
                    },
                    {
                        "S. No.": "",
                        "Name of the Shareholder": "Total",
                        "Number of Equity Shares*": "143,050,600",
                        "Percentage of the pre-Offer Equity\nShare Capital* (%)": "100.00"
                    }
                ],
                "rows": 4,
                "cols": 4
            },
            {
                "page_number": 83,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Name of the Shareholder": "Sanjeev Jain",
                        "Number of Equity Shares*": "60,725,940\u03b2",
                        "Percentage of the pre-Offer\nEquity Share Capital* (%)": "42.45"
                    },
                    {
                        "S. No.": "2.",
                        "Name of the Shareholder": "Sandeep Jain",
                        "Number of Equity Shares*": "60,739,690\u03b1",
                        "Percentage of the pre-Offer\nEquity Share Capital* (%)": "42.46"
                    },
                    {
                        "S. No.": "3.",
                        "Name of the Shareholder": "Ruby QC Investment Holdings Pte. Ltd.",
                        "Number of Equity Shares*": "21,584,970",
                        "Percentage of the pre-Offer\nEquity Share Capital* (%)": "15.09"
                    },
                    {
                        "S. No.": "",
                        "Name of the Shareholder": "Total",
                        "Number of Equity Shares*": "143,050,600",
                        "Percentage of the pre-Offer\nEquity Share Capital* (%)": "100.00"
                    }
                ],
                "rows": 4,
                "cols": 4
            },
            {
                "page_number": 83,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Name of the Shareholder": "Sanjeev Jain",
                        "Number of equity shares*": "30,362,970 \u03b2",
                        "Percentage of the pre-Offer equity\nshare capital* (%)": "42.45"
                    },
                    {
                        "S. No.": "2.",
                        "Name of the Shareholder": "Sandeep Jain",
                        "Number of equity shares*": "30,369,845 \u03b1",
                        "Percentage of the pre-Offer equity\nshare capital* (%)": "42.46"
                    },
                    {
                        "S. No.": "3.",
                        "Name of the Shareholder": "Ruby QC Investment Holdings Pte. Ltd.",
                        "Number of equity shares*": "10,792,485",
                        "Percentage of the pre-Offer equity\nshare capital* (%)": "15.09"
                    },
                    {
                        "S. No.": "",
                        "Name of the Shareholder": "Total",
                        "Number of equity shares*": "71,525,300",
                        "Percentage of the pre-Offer equity\nshare capital* (%)": "100.00"
                    }
                ],
                "rows": 4,
                "cols": 4
            },
            {
                "page_number": 83,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Name of the Shareholder": "Sanjeev Jain",
                        "Number of equity shares*": "30,362,970 \u03b2",
                        "Percentage of the pre-Offer equity\nshare capital* (%)": "42.45"
                    },
                    {
                        "S. No.": "2.",
                        "Name of the Shareholder": "Sandeep Jain",
                        "Number of equity shares*": "30,369,845 \u03b1",
                        "Percentage of the pre-Offer equity\nshare capital* (%)": "42.46"
                    },
                    {
                        "S. No.": "3.",
                        "Name of the Shareholder": "Ruby QC Investment Holdings Pte. Ltd.",
                        "Number of equity shares*": "10,792,485",
                        "Percentage of the pre-Offer equity\nshare capital* (%)": "15.09"
                    },
                    {
                        "S. No.": "",
                        "Name of the Shareholder": "Total",
                        "Number of equity shares*": "71,525,300",
                        "Percentage of the pre-Offer equity\nshare capital* (%)": "100.00"
                    }
                ],
                "rows": 4,
                "cols": 4
            },
            {
                "page_number": 84,
                "table_data": [
                    {
                        "Date of\nallotment/\ntransfer": "Sanjeev Jain",
                        "No. of\nequity\nshares": null,
                        "Nature of\ntransaction": null,
                        "Nature of\nconsideration": null,
                        "Face\nValue\nper\nequity\nshare (\u20b9)": null,
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": null,
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": null,
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": null
                    },
                    {
                        "Date of\nallotment/\ntransfer": "May 23,\n2004",
                        "No. of\nequity\nshares": "24,500",
                        "Nature of\ntransaction": "Allotment of 24,500\nequity shares pursuant\nto initial subscription\nto the MoA.",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "10",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.01",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n13, 2004",
                        "No. of\nequity\nshares": "197,700",
                        "Nature of\ntransaction": "Further issue",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.14",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "March 31,\n2005",
                        "No. of\nequity\nshares": "12,500",
                        "Nature of\ntransaction": "Further issue",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "February\n20, 2006#",
                        "No. of\nequity\nshares": "3,500",
                        "Nature of\ntransaction": "Transfer of 3,500\nequity shares from\nBalraj Bidaliya to\nSanjeev Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "6",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "August 14,\n2006#",
                        "No. of\nequity\nshares": "250",
                        "Nature of\ntransaction": "Transfer of 250 equity\nshares from Manish\nMinocha to Sanjeev\nJain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "10",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "January\n28, 2007",
                        "No. of\nequity\nshares": "7,500",
                        "Nature of\ntransaction": "Transfer of 7,500\nequity shares from\nMaxcure Drugs &\nPharmaceuticals\nLimited to Sanjeev\nJain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "November\n9, 2007",
                        "No. of\nequity\nshares": "23,375",
                        "Nature of\ntransaction": "Transfer of 23,375\nequity shares from\nA.K. Laboratories to\nSanjeev Jain^",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.02",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n14, 2008",
                        "No. of\nequity\nshares": "1,250",
                        "Nature of\ntransaction": "Transfer of 1,250\nequity shares from\nM.P. Singh to Sanjeev\nJain^",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n14, 2008",
                        "No. of\nequity\nshares": "65,200",
                        "Nature of\ntransaction": "Transfer of 65,200\nequity shares from\nDharam Chand Jain\njointly with Sanjeev\nJain to Sanjeev Jain^$",
                        "Nature of\nconsideration": "Gift",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.05",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n14, 2008",
                        "No. of\nequity\nshares": "300",
                        "Nature of\ntransaction": "Transfer of 300 equity\nshares from D.C. Jain\njointly with Arushi\nJain to Sanjeev Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    }
                ],
                "rows": 11,
                "cols": 8
            },
            {
                "page_number": 85,
                "table_data": [
                    {
                        "Date of\nallotment/\ntransfer": "",
                        "No. of\nequity\nshares": "",
                        "Nature of\ntransaction": "jointly with Arushi\nJain",
                        "Nature of\nconsideration": "",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": ""
                    },
                    {
                        "Date of\nallotment/\ntransfer": "January\n31, 2009",
                        "No. of\nequity\nshares": "7,500",
                        "Nature of\ntransaction": "Transfer of 7,500\nequity shares from\nAkums\nPharmaceuticals\nPrivate Limited to\nSanjeev Jain^",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "January\n16, 2011",
                        "No. of\nequity\nshares": "135,000",
                        "Nature of\ntransaction": "Transfer of 135,000\nequity shares from\nLata Jain to Sanjeev\nJain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.10",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "July 27,\n2013",
                        "No. of\nequity\nshares": "85,000",
                        "Nature of\ntransaction": "Transfer of 85,000\nequity shares from\nSanjeev Jain jointly\nwith D.C. Jain & Sons\nHUF to Sanjeev Jain$",
                        "Nature of\nconsideration": "Gift",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.06",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "July 27,\n2013",
                        "No. of\nequity\nshares": "22,000",
                        "Nature of\ntransaction": "Transfer of 22,000\nequity shares from\nSanjeev Jain & Sons\nHUF to Sanjeev Jain$",
                        "Nature of\nconsideration": "Gift",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.02",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "February\n28, 2016",
                        "No. of\nequity\nshares": "1,800",
                        "Nature of\ntransaction": "Transfer of 1,800\nequity shares from\nSanjeev Jain jointly\nwith Kiran Jain to\nSanjeev Jain$",
                        "Nature of\nconsideration": "Gift",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "November\n13, 2019",
                        "No. of\nequity\nshares": "(35,321)",
                        "Nature of\ntransaction": "Transfer of 35,321\nequity shares from\nSanjeev Jain to Ruby\nQC Investment\nHoldings Pte. Ltd.",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "25,480.85",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.03",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "Pursuant to resolutions each dated December 24, 2021 passed by our Board and the Shareholders, the authorized share capital of\nour Company was sub-divided from \u20b915,000,000 divided into 1,500,000 equity shares of face value of \u20b910 each to \u20b915,000,000\ndivided into 7,500,000 Equity Shares of face value of \u20b92 each. Accordingly, 551,754 equity shares of face value of \u20b910 each held\nby Sanjeev Jain were sub-divided into 2,758,770 equity shares of face value of \u20b92 each and 300 equity shares of face value of \u20b910\neach held by Sanjeev Jain jointly with Arushi Jain were sub-divided into 1,500 equity shares of face value of \u20b92 each.",
                        "No. of\nequity\nshares": null,
                        "Nature of\ntransaction": null,
                        "Nature of\nconsideration": null,
                        "Face\nValue\nper\nequity\nshare (\u20b9)": null,
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": null,
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": null,
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": null
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n24, 2021",
                        "No. of\nequity\nshares": "27,587,700",
                        "Nature of\ntransaction": "Bonus issue in the\nratio of 10 Equity\nShares for every 1\nEquity Share held by\nour Shareholders**",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "19.28",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n24, 2021",
                        "No. of\nequity\nshares": "15,000",
                        "Nature of\ntransaction": "Bonus issue in the\nratio of 10 Equity\nShares for every 1\nEquity Shares held by\nSanjeev Jain jointly\nwith Arushi Jain",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.01",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "March 17,\n2023",
                        "No. of\nequity\nshares": "30,346,470",
                        "Nature of\ntransaction": "Bonus issue in the\nratio of 1 Equity Share\nfor every 1 Equity\nShare held by our\nShareholders^^",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "21.21",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    }
                ],
                "rows": 11,
                "cols": 8
            },
            {
                "page_number": 86,
                "table_data": [
                    {
                        "Date of\nallotment/\ntransfer": "March 17,\n2023",
                        "No. of\nequity\nshares": "16,500",
                        "Nature of\ntransaction": "Bonus issue of Equity\nShares in the ratio of 1\nEquity Shares for\nevery 1 Equity Shares\nheld by Sanjeev Jain\njointly with Arushi\nJain.",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.01",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "Sub Total\n(A)",
                        "No. of\nequity\nshares": "60,725,940",
                        "Nature of\ntransaction": "",
                        "Nature of\nconsideration": "42.45",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": null,
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": null,
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": null,
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "Sandeep Jain",
                        "No. of\nequity\nshares": null,
                        "Nature of\ntransaction": null,
                        "Nature of\nconsideration": null,
                        "Face\nValue\nper\nequity\nshare (\u20b9)": null,
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": null,
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": null,
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": null
                    },
                    {
                        "Date of\nallotment/\ntransfer": "May 23,\n2004",
                        "No. of\nequity\nshares": "24,500",
                        "Nature of\ntransaction": "Allotment of 24,500\nequity shares pursuant\nto initial subscription\nto the MoA",
                        "Nature of\nconsideration": "Cash*",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "10",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.02",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n13, 2004",
                        "No. of\nequity\nshares": "229,750",
                        "Nature of\ntransaction": "Further issue",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.16",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "March 31,\n2005",
                        "No. of\nequity\nshares": "10,000",
                        "Nature of\ntransaction": "Further issue",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "August 14,\n2006#",
                        "No. of\nequity\nshares": "1,500",
                        "Nature of\ntransaction": "Transfer of 1,500\nequity shares from\nLalita Rani to Sandeep\nJain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "10",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "January\n28, 2007",
                        "No. of\nequity\nshares": "7,500",
                        "Nature of\ntransaction": "Transfer of 7,500\nequity shares from\nMaxcure Drugs &\nPharmaceuticals\nLimited to Sandeep\nJain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "November\n9, 2007",
                        "No. of\nequity\nshares": "23,375",
                        "Nature of\ntransaction": "Transfer of 23,375\nequity shares from\nA.K. Laboratories to\nSandeep Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.02",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n14, 2008",
                        "No. of\nequity\nshares": "1,250",
                        "Nature of\ntransaction": "Transfer of 1,250\nequity shares from\nN.D. Sachdeva to\nSandeep Jain^",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n14, 2008",
                        "No. of\nequity\nshares": "65,200",
                        "Nature of\ntransaction": "Transfer of 65,200\nequity shares from\nDharam Chand Jain\njointly with Sandeep\nJain to Sandeep Jain^$",
                        "Nature of\nconsideration": "Gift",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.05",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n14, 2008",
                        "No. of\nequity\nshares": "76,800",
                        "Nature of\ntransaction": "Transfer of 76,800\nequity shares from\nVandana Jain to\nSandeep Jain^",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.05",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n14, 2008",
                        "No. of\nequity\nshares": "50",
                        "Nature of\ntransaction": "Transfer of 50 equity\nshares from Vandana\nJain jointly with\nManan Jain to\nSandeep Jain^",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    }
                ],
                "rows": 13,
                "cols": 8
            },
            {
                "page_number": 87,
                "table_data": [
                    {
                        "Date of\nallotment/\ntransfer": "December\n14, 2008",
                        "No. of\nequity\nshares": "300",
                        "Nature of\ntransaction": "Transfer of 300 equity\nshares from D.C. Jain\njointly with Kanishk\nJain to Sandeep Jain\njointly with Kanishk\nJain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "January\n31, 2009",
                        "No. of\nequity\nshares": "7,500",
                        "Nature of\ntransaction": "Transfer of 7,500\nequity shares from\nAkums\nPharmaceuticals\nPrivate Limited to\nSandeep Jain^",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "20",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "January\n16, 2011",
                        "No. of\nequity\nshares": "50",
                        "Nature of\ntransaction": "Transfer of 50 equity\nshares from Sandeep\nJain & Sons HUF to\nSandeep Jain jointly\nwith Manan Jain",
                        "Nature of\nconsideration": "Gift",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "July 10,\n2013",
                        "No. of\nequity\nshares": "52,925",
                        "Nature of\ntransaction": "Transfer of 52,925\nequity shares from\nSandeep Jain & Sons\nHUF to Sandeep Jain$",
                        "Nature of\nconsideration": "Gift",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.04",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "July 27,\n2013",
                        "No. of\nequity\nshares": "85,000",
                        "Nature of\ntransaction": "Transfer of 85,000\nequity shares from\nSandeep Jain jointly\nwith D.C. Jain & Sons\nHUF to Sandeep Jain$",
                        "Nature of\nconsideration": "Gift",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "0.06",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "February\n28, 2016",
                        "No. of\nequity\nshares": "1,800",
                        "Nature of\ntransaction": "Transfer of 1,800\nequity shares from\nSandeep Jain jointly\nwith Kiran Jain to\nSandeep Jain$",
                        "Nature of\nconsideration": "Gift",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "November\n3, 2019",
                        "No. of\nequity\nshares": "250",
                        "Nature of\ntransaction": "Transfer of 250 equity\nshares from Sandeep\nJain jointly with\nKanishk Jain to\nSandeep Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "10",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "November\n13, 2019",
                        "No. of\nequity\nshares": "(35,321)",
                        "Nature of\ntransaction": "Transfer of 35,321\nequity shares from\nSandeep Jain to Ruby\nQC Investment\nHoldings Pte. Ltd.",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "25,480.85",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "November\n3, 2019",
                        "No. of\nequity\nshares": "(250)",
                        "Nature of\ntransaction": "Transfer of 250 equity\nshares from Sandeep\nJain jointly with\nKanishk Jain to\nSandeep Jain",
                        "Nature of\nconsideration": "Cash",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "10",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "10",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "Pursuant to resolutions each dated December 24, 2021 passed by our Board and the Shareholders, the authorized share capital of\nour Company was sub-divided from \u20b915,000,000 divided into 1,500,000 equity shares of face value of \u20b910 each to \u20b915,000,000\ndivided into 7,500,000 Equity Shares of face value of \u20b92 each. Accordingly, 552,079 equity shares of face value of \u20b910 each held\nby Sandeep Jain were sub-divided into 2,760,395 equity shares of face value of \u20b92 each; 50 equity shares of face value of \u20b910\neach held by Sandeep Jain jointly with Kanishk Jain were sub-divided into 250 equity shares of face value of \u20b92 each and 50\nequity shares of face value of \u20b910 each held by Sandeep Jain jointly with Manan Jain were sub-divided into 250 equity shares of\nface value of \u20b92 each.",
                        "No. of\nequity\nshares": null,
                        "Nature of\ntransaction": null,
                        "Nature of\nconsideration": null,
                        "Face\nValue\nper\nequity\nshare (\u20b9)": null,
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": null,
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": null,
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": null
                    }
                ],
                "rows": 10,
                "cols": 8
            },
            {
                "page_number": 88,
                "table_data": [
                    {
                        "Date of\nallotment/\ntransfer": "December\n24, 2021",
                        "No. of\nequity\nshares": "27,603,950",
                        "Nature of\ntransaction": "Bonus issue in the\nratio of 10 Equity\nShares for every 1\nequity share held by\nour Shareholders**",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "19.30",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n24, 2021",
                        "No. of\nequity\nshares": "2,500",
                        "Nature of\ntransaction": "Bonus issue in the\nratio of 10 Equity\nShares for every 1\nEquity Shares held by\nSandeep Jain jointly\nwith Kanishk Jain",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "December\n24, 2021",
                        "No. of\nequity\nshares": "2,500",
                        "Nature of\ntransaction": "Bonus issue in the\nratio of 10 Equity\nShares for every 1\nEquity Shares held by\nSandeep Jain jointly\nwith Manan Jain",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "March 17,\n2023",
                        "No. of\nequity\nshares": "30,364,345",
                        "Nature of\ntransaction": "Bonus issue in the\nratio of 1 Equity Share\nfor every 1 Equity\nShare held by our\nShareholders^^",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "21.22",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "March 17,\n2023",
                        "No. of\nequity\nshares": "2,750",
                        "Nature of\ntransaction": "Allotment pursuant to\nbonus issue of Equity\nShares in the ratio of 1\nEquity Shares for\nevery 1 Equity Shares\nheld by Sandeep Jain\njointly with Kanishk\nJain.",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "March 17,\n2023",
                        "No. of\nequity\nshares": "2,750",
                        "Nature of\ntransaction": "Allotment pursuant to\nbonus issue of Equity\nShares in the ratio of 1\nEquity Shares for\nevery 1 Equity Shares\nheld by Sandeep Jain\njointly with Manan\nJain.",
                        "Nature of\nconsideration": "Not\napplicable",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": "2",
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": "Not\napplicable",
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": "Negligible",
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "Sub Total\n(B)",
                        "No. of\nequity\nshares": "60,739,690",
                        "Nature of\ntransaction": "",
                        "Nature of\nconsideration": "42.46",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": null,
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": null,
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": null,
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    },
                    {
                        "Date of\nallotment/\ntransfer": "Total",
                        "No. of\nequity\nshares": "121,465,630",
                        "Nature of\ntransaction": "",
                        "Nature of\nconsideration": "84.90",
                        "Face\nValue\nper\nequity\nshare (\u20b9)": null,
                        "Issue\nPrice/\nTransfer\nprice per\nequity\nshare (\u20b9)": null,
                        "Percentage of the pre-\nOffer Equity share\ncapital\n(%)": null,
                        "Percentage\nof the\npost- Offer\ncapital\n(%)": "[\u25cf]"
                    }
                ],
                "rows": 8,
                "cols": 8
            },
            {
                "page_number": 89,
                "table_data": [
                    {
                        "S.\nNo.": "Promoters",
                        "Name of the\nshareholder": null,
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": null,
                        "Percentage of the\npre-Offer equity\nshare capital (%)": null,
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": null,
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": null
                    },
                    {
                        "S.\nNo.": "1.",
                        "Name of the\nshareholder": "Sandeep Jain",
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": "60,739,690\u03b1",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "42.46 \u03b1",
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "2.",
                        "Name of the\nshareholder": "Sanjeev Jain",
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": "60,725,940\u03b2",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "42.45 \u03b2",
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "3.",
                        "Name of the\nshareholder": "Akums Master Trust**",
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": "-",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "-",
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "Promoter Group",
                        "Name of the\nshareholder": null,
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": null,
                        "Percentage of the\npre-Offer equity\nshare capital (%)": null,
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": null,
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": null
                    },
                    {
                        "S.\nNo.": "4.",
                        "Name of the\nshareholder": "Arushi Jain (jointly with\nSanjeev Jain)",
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": "33,000",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "0.02",
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "5.",
                        "Name of the\nshareholder": "Lata Jain",
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": "13,750\u221e",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "0.01\u221e",
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "6.",
                        "Name of the\nshareholder": "Umang Jain (jointly with\nLata Jain)",
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": "5,500",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "Negligible",
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "7.",
                        "Name of the\nshareholder": "Kanishk Jain (jointly\nwith Sandeep Jain)",
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": "5,500",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "Negligible",
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "8.",
                        "Name of the\nshareholder": "Manan Jain (jointly with\nSandeep Jain)",
                        "Col2": null,
                        "Pre-Offer number\nof Equity Shares": "5,500",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": "Negligible",
                        "Col5": null,
                        "Post-Offer number\nof Equity Shares*": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "Total",
                        "Name of the\nshareholder": null,
                        "Col2": "121,479,380",
                        "Pre-Offer number\nof Equity Shares": "84.91",
                        "Percentage of the\npre-Offer equity\nshare capital (%)": null,
                        "Col5": "[\u25cf]",
                        "Post-Offer number\nof Equity Shares*": null,
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    }
                ],
                "rows": 11,
                "cols": 8
            },
            {
                "page_number": 89,
                "table_data": [
                    {
                        "Name of\nthe\nPromoter": "[\u25cf]",
                        "Number of\nEquity\nShares\nlocked-in": "[\u25cf]",
                        "Date of\nallotment/\ntransfer of\nthe Equity\nShares": "[\u25cf]",
                        "Nature of\ntransaction": "[\u25cf]",
                        "Face value\nper Equity\nShare (\u20b9)": "[\u25cf]",
                        "Issue/\nacquisition\nprice per\nEquity\nShare (\u20b9)": "[\u25cf]",
                        "Percentage\nof pre-\nOffer paid-\nup equity\nshare\ncapital": "[\u25cf]",
                        "Percentage\nof post-\nOffer paid-\nup Equity\nShare\ncapital": "[\u25cf]",
                        "Date up to\nwhich the\nEquity\nShares are\nsubject to\nlock in": "[\u25cf]"
                    },
                    {
                        "Name of\nthe\nPromoter": "[\u25cf]",
                        "Number of\nEquity\nShares\nlocked-in": "[\u25cf]",
                        "Date of\nallotment/\ntransfer of\nthe Equity\nShares": "[\u25cf]",
                        "Nature of\ntransaction": "[\u25cf]",
                        "Face value\nper Equity\nShare (\u20b9)": "[\u25cf]",
                        "Issue/\nacquisition\nprice per\nEquity\nShare (\u20b9)": "[\u25cf]",
                        "Percentage\nof pre-\nOffer paid-\nup equity\nshare\ncapital": "[\u25cf]",
                        "Percentage\nof post-\nOffer paid-\nup Equity\nShare\ncapital": "[\u25cf]",
                        "Date up to\nwhich the\nEquity\nShares are\nsubject to\nlock in": "[\u25cf]"
                    },
                    {
                        "Name of\nthe\nPromoter": "Total",
                        "Number of\nEquity\nShares\nlocked-in": "[\u25cf]",
                        "Date of\nallotment/\ntransfer of\nthe Equity\nShares": "[\u25cf]",
                        "Nature of\ntransaction": "[\u25cf]",
                        "Face value\nper Equity\nShare (\u20b9)": "[\u25cf]",
                        "Issue/\nacquisition\nprice per\nEquity\nShare (\u20b9)": "[\u25cf]",
                        "Percentage\nof pre-\nOffer paid-\nup equity\nshare\ncapital": "[\u25cf]",
                        "Percentage\nof post-\nOffer paid-\nup Equity\nShare\ncapital": "[\u25cf]",
                        "Date up to\nwhich the\nEquity\nShares are\nsubject to\nlock in": "[\u25cf]"
                    }
                ],
                "rows": 3,
                "cols": 9
            },
            {
                "page_number": 92,
                "table_data": [
                    {
                        "Particulars": null,
                        "Details": "F.Y. 2021-22",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "F.Y. 2022-23",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "April 1, 2023 till the date of\nthis Draft Red Herring\nProspectus",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Options granted during the\nyear/period",
                        "Details": "Cumulative options granted\nas on March 31, 2022:\nCurrently no option is\noutstanding / granted",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "Cumulative options granted\nas on March 31, 2023:\nCurrently no option is\noutstanding / granted",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "Cumulative options granted\nas on the date of this Draft\nRed Herring Prospectus:\n14,000",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "No. of employees to whom options\nwere granted",
                        "Details": "Employees of the\nCompany: NA\nEmployees of the\nSubsidiaries: NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "Employees of the\nCompany: NA\nEmployees of the\nSubsidiaries: NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "Employees of the Company:\nOne\nEmployees of the\nSubsidiaries: NA",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Options outstanding",
                        "Details": "NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "NA",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Exercise price of options",
                        "Details": "NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "INR 1,010 per option",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Options vested [(excluding options\nthat have been exercised)]",
                        "Details": "NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "NA",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Options exercised",
                        "Details": "NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "NA",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Total no. of Equity Shares that would\narise as a result of full exercise of\noptions granted [(net of cancelled\noptions)]",
                        "Details": "NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "NA",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Options forfeited/lapsed/cancelled",
                        "Details": "NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "14,000",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Variation in terms of options",
                        "Details": "NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "The ESOP 2022 was modified\non October 26, 2023 &\nFebruary 7, 2024.\nOn both the occasion, the\nvariances in ESOP 2022 were\ncarried out in order to make it\nin compliance with SEBI\nSBEB & SE Regulations",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Money realised by exercise of options",
                        "Details": "NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "NA",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Total no. of options in force",
                        "Details": "NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "NA",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "Employee wise details of options\ngranted to:",
                        "Details": "",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "(i) Key management personnel",
                        "Details": "",
                        "Col2": "Name of\nkey\nmanagerial\npersonnel",
                        "Col3": "Total no.\nof options\ngranted",
                        "Col4": "",
                        "Col5": "",
                        "Col6": "Name of\nkey\nmanagerial\npersonnel",
                        "Col7": "Total no.\nof options\ngranted",
                        "Col8": "",
                        "Col9": "",
                        "Col10": "Name of\nkey\nmanagerial\npersonnel",
                        "Col11": "Total no.\nof options\ngranted",
                        "Col12": ""
                    },
                    {
                        "Particulars": null,
                        "Details": null,
                        "Col2": "NA",
                        "Col3": "NA",
                        "Col4": null,
                        "Col5": null,
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": null,
                        "Col9": null,
                        "Col10": "NA",
                        "Col11": "NA",
                        "Col12": null
                    },
                    {
                        "Particulars": "(ii) Any other employee who\nreceived a grant in any one\nyear of options amounting\nto 5% or more of the\noptions granted during the\nyear",
                        "Details": "Name of Total no.\nemployee of options\ngranted\nNA NA",
                        "Col2": "Name of\nemployee",
                        "Col3": "Total no.\nof options\ngranted",
                        "Col4": null,
                        "Col5": "Name of Total no.\nemployee of options\ngranted\nNA NA",
                        "Col6": "Name of\nemployee",
                        "Col7": "Total no.\nof options\ngranted",
                        "Col8": null,
                        "Col9": "Name of Total no.\nemployee of options\ngranted\nRajat Kalra 14,000",
                        "Col10": "Name of\nemployee",
                        "Col11": "Total no.\nof options\ngranted",
                        "Col12": null
                    },
                    {
                        "Particulars": null,
                        "Details": null,
                        "Col2": "NA",
                        "Col3": "NA",
                        "Col4": null,
                        "Col5": null,
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": null,
                        "Col9": null,
                        "Col10": "Rajat Kalra",
                        "Col11": "14,000",
                        "Col12": null
                    },
                    {
                        "Particulars": null,
                        "Details": null,
                        "Col2": "",
                        "Col3": "",
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": null,
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    },
                    {
                        "Particulars": "(iii) Identified employees who\nare granted options, during\nany one year equal to or\nexceeding 1% of the issued\ncapital (excluding\noutstanding warrants and\nconversions) of our",
                        "Details": "Name of Total no.\nemployee of options\ngranted\nNA NA",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": "Name of Total no.\nemployee of options\ngranted\nNA NA",
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": "Name of Total no.\nemployee of options\ngranted\nNA NA",
                        "Col10": null,
                        "Col11": null,
                        "Col12": null
                    }
                ],
                "rows": 19,
                "cols": 13
            },
            {
                "page_number": 92,
                "table_data": [
                    {
                        "Name of\nemployee": "NA",
                        "Total no.\nof options\ngranted": "NA"
                    }
                ],
                "rows": 1,
                "cols": 2
            },
            {
                "page_number": 92,
                "table_data": [
                    {
                        "Name of\nemployee": "NA",
                        "Total no.\nof options\ngranted": "NA"
                    }
                ],
                "rows": 1,
                "cols": 2
            },
            {
                "page_number": 92,
                "table_data": [
                    {
                        "Name of\nemployee": "NA",
                        "Total no.\nof options\ngranted": "NA"
                    }
                ],
                "rows": 1,
                "cols": 2
            },
            {
                "page_number": 93,
                "table_data": [
                    {
                        "Particulars": null,
                        "Details": "F.Y. 2021-22",
                        "Col2": "F.Y. 2022-23",
                        "Col3": "April 1, 2023 till the date of\nthis Draft Red Herring\nProspectus"
                    },
                    {
                        "Particulars": "Company at the time of\ngrant",
                        "Details": "",
                        "Col2": "",
                        "Col3": ""
                    },
                    {
                        "Particulars": "Fully diluted EPS on a pre-Offer basis\non exercise of options calculated in\naccordance with the applicable\naccounting standard \u2018Earning Per\nShare\u2019",
                        "Details": "NA",
                        "Col2": "NA",
                        "Col3": "NA"
                    },
                    {
                        "Particulars": "Difference between employee\ncompensation cost calculated using\nthe intrinsic value of stock options\nand the employee compensation cost\nthat shall have been recognised if our\nCompany had used fair value of\noptions and impact of this difference\non profits and EPS of our Company\nfor the last three fiscals",
                        "Details": "NA",
                        "Col2": "NA",
                        "Col3": "NA"
                    },
                    {
                        "Particulars": "Description of the pricing formula and\nthe method and significant\nassumptions used during the year to\nestimate the fair values of options,\nincluding weighted-average\ninformation, namely, risk-free interest\nrate, expected life, expected volatility,\nexpected dividends and the price of\nthe underlying share in market at the\ntime of grant of the option",
                        "Details": "NA",
                        "Col2": "NA",
                        "Col3": "NA"
                    },
                    {
                        "Particulars": "Impact on profits and EPS of the last\nthree years if our Company had\nfollowed the accounting policies\nspecified in Regulation 15 of the\nESOP Regulations in respect of\noptions granted in the last three years",
                        "Details": "NA",
                        "Col2": "NA",
                        "Col3": "NA"
                    },
                    {
                        "Particulars": "Method of option valuation",
                        "Details": "Black Scholes pricing model",
                        "Col2": null,
                        "Col3": null
                    },
                    {
                        "Particulars": "- Expected life of options (years)\n- Expected Volatility (% p.a.\n- Risk Free Rate of Return (%)\n- Dividend Yield (% p.a.)\n- Exercise price per share (\u20b9)\n- Weighted average share price on the\ndate of grant of option (in \u20b9)",
                        "Details": "NA",
                        "Col2": "NA*",
                        "Col3": "-5 years;\n-38.82%-37.72%\n-6.87%- 7.03%\n-NA\n-Exercise price INR 1,010\n-INR 1,010.34"
                    }
                ],
                "rows": 8,
                "cols": 4
            },
            {
                "page_number": 94,
                "table_data": [
                    {
                        "Particulars": "Gross proceeds from the Fresh Issue*",
                        "Estimated Amount (in \u20b9 million) (1)": "6,800.00"
                    },
                    {
                        "Particulars": "Less: Offer related expenses to be borne by our Company (2)",
                        "Estimated Amount (in \u20b9 million) (1)": "[\u25cf]"
                    },
                    {
                        "Particulars": "Net proceeds from the Fresh Issue after deducting the Offer related expenses\nto be borne by our Company (\u201cNet Proceeds\u201d)",
                        "Estimated Amount (in \u20b9 million) (1)": "[\u25cf]"
                    }
                ],
                "rows": 3,
                "cols": 2
            },
            {
                "page_number": 94,
                "table_data": [
                    {
                        "Objects": "Repayment/prepayment of all or certain borrowings of our Company and Subsidiaries",
                        "Estimated Amount\n(in \u20b9 million)": "3,870.00"
                    },
                    {
                        "Objects": "Funding incremental working capital requirements of our Company",
                        "Estimated Amount\n(in \u20b9 million)": "550.00"
                    },
                    {
                        "Objects": "Pursuing inorganic growth initiatives through acquisitions(1)",
                        "Estimated Amount\n(in \u20b9 million)": "[\u25cf]"
                    },
                    {
                        "Objects": "General corporate purposes(1)",
                        "Estimated Amount\n(in \u20b9 million)": "[\u25cf]"
                    },
                    {
                        "Objects": "Net Proceeds(1)(2)",
                        "Estimated Amount\n(in \u20b9 million)": "[\u25cf]"
                    }
                ],
                "rows": 5,
                "cols": 2
            },
            {
                "page_number": 95,
                "table_data": [
                    {
                        "Particulars": null,
                        "Amount to be\nfunded from the Net\nProceeds": null,
                        "Estimated deployment of the Net\nProceeds in Fiscals": "2025",
                        "Col3": "2026",
                        "Col4": "2027"
                    },
                    {
                        "Particulars": "Repayment/prepayment of all or certain borrowings of our Company\nand Subsidiaries",
                        "Amount to be\nfunded from the Net\nProceeds": "3,870.00",
                        "Estimated deployment of the Net\nProceeds in Fiscals": "3,870.00",
                        "Col3": "-",
                        "Col4": "-"
                    },
                    {
                        "Particulars": "Funding incremental working capital requirements of our Company",
                        "Amount to be\nfunded from the Net\nProceeds": "550.00",
                        "Estimated deployment of the Net\nProceeds in Fiscals": "550.00",
                        "Col3": "-",
                        "Col4": "-"
                    },
                    {
                        "Particulars": "Pursuing inorganic growth initiatives through acquisitions(1)(2)",
                        "Amount to be\nfunded from the Net\nProceeds": "[\u25cf]",
                        "Estimated deployment of the Net\nProceeds in Fiscals": "[\u25cf]",
                        "Col3": "[\u25cf]",
                        "Col4": "[\u25cf]"
                    },
                    {
                        "Particulars": "General corporate purposes(1)(2)",
                        "Amount to be\nfunded from the Net\nProceeds": "[\u25cf]",
                        "Estimated deployment of the Net\nProceeds in Fiscals": "[\u25cf]",
                        "Col3": "[\u25cf]",
                        "Col4": "[\u25cf]"
                    },
                    {
                        "Particulars": "Net Proceeds(1)",
                        "Amount to be\nfunded from the Net\nProceeds": "[\u25cf]",
                        "Estimated deployment of the Net\nProceeds in Fiscals": "[\u25cf]",
                        "Col3": "[\u25cf]",
                        "Col4": "[\u25cf]"
                    }
                ],
                "rows": 6,
                "cols": 5
            },
            {
                "page_number": 96,
                "table_data": [
                    {
                        "Sr.\nNo.": "Utilisation of Loans by the Company",
                        "Name of the\nLender": null,
                        "Name of the\nborrower": null,
                        "Date of sanction\nletter / facility\nagreement": null,
                        "Nature of\nborrowing": null,
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": null,
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": null,
                        "Repayment\ndate/\nSchedule": null,
                        "Tenor": null,
                        "Interest rate\nas at 30\nSeptember\n2023": null,
                        "Purpose of\nraising the loan": null,
                        "Prepayment\nclause (if any)": null,
                        "Security": null
                    },
                    {
                        "Sr.\nNo.": "1",
                        "Name of the\nLender": "HDFC Bank\nLimited",
                        "Name of the\nborrower": "Akums Drugs and\nPharmaceuticals\nLimited",
                        "Date of sanction\nletter / facility\nagreement": "Sanction letter\ndated April 11,\n2023",
                        "Nature of\nborrowing": "Working\ncapital\ndemand loan",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "600.00",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "480.00",
                        "Repayment\ndate/\nSchedule": "Up to 180\ndays,\nrevolving,\nPayable on\ndemand",
                        "Tenor": "-",
                        "Interest rate\nas at 30\nSeptember\n2023": "7.60%",
                        "Purpose of\nraising the loan": "For Working\ncapital\nrequirements",
                        "Prepayment\nclause (if any)": "Prepayment\nallowed\nwithout any\npenalty",
                        "Security": "\u2022 Industrial\nproperty\u2013- First\npari passu charge\nby way of\nEquitable\nMortgage on Plot\nno. 19,20 & 21\nSector 6A, IIE,\nRanipur,\nHaridwar,\nUttarakhand\n\u2022 Industrial\nproperty -First\npari passu charge\nby way of\nEquitable\nMortgage on Plot\nno. 2,3,4 & 5,\nSector 6B, IIE,\nRanipur,\nHaridwar,\nUttarakhand\n\u2022 Immovable fixed\nassets\u2013- First pari\npassu charge by\nEquitable\nMortgage on\nland and building\nlocated at Plot\nNo. 47-48, Sec\n6A IIE,\nSIDCUL,"
                    },
                    {
                        "Sr.\nNo.": "2",
                        "Name of the\nLender": "HDFC Bank\nLimited",
                        "Name of the\nborrower": "Akums Drugs and\nPharmaceuticals\nLimited",
                        "Date of sanction\nletter / facility\nagreement": null,
                        "Nature of\nborrowing": "Cash Credit",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": null,
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "15.62",
                        "Repayment\ndate/\nSchedule": "Up to 180\ndays,\nrevolving,\nPayable on\ndemand",
                        "Tenor": "-",
                        "Interest rate\nas at 30\nSeptember\n2023": "8.33%",
                        "Purpose of\nraising the loan": "For Working\ncapital\nrequirements",
                        "Prepayment\nclause (if any)": "Prepayment\nallowed\nwithout any\npenalty",
                        "Security": null
                    }
                ],
                "rows": 3,
                "cols": 13
            },
            {
                "page_number": 97,
                "table_data": [
                    {
                        "Sr.\nNo.": "",
                        "Name of the\nLender": "",
                        "Name of the\nborrower": "",
                        "Date of sanction\nletter / facility\nagreement": "",
                        "Nature of\nborrowing": "",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "",
                        "Repayment\ndate/\nSchedule": "",
                        "Tenor": "",
                        "Interest rate\nas at 30\nSeptember\n2023": "",
                        "Purpose of\nraising the loan": "",
                        "Prepayment\nclause (if any)": "",
                        "Security": "Ranipur,\nHaridwar\n\u2022 Industrial\nproperty\u2013- First\npari passu charge\nby way of\nEquitable\nMortgage on Plot\nno 22, Sector 6A,\nIIE, Ranipur,\nHaridwar,\nUttarakhand\n\u2022 Plant and\nmachinery \u2013 First\ncharge on pari\npassu basis with\nbanks/ financial\ninstitutions on\nentire movable\nfixed assets of\nthe company\nboth present and\nfuture\n\u2022 Stocks and\nreceivables \u2013\nFirst pari passu\ncharge on the\ncurrent assets of\nthe Company\nboth present and\nfuture"
                    },
                    {
                        "Sr.\nNo.": "3",
                        "Name of the\nLender": "HDFC Bank\nLimited",
                        "Name of the\nborrower": "Akums Drugs and\nPharmaceuticals\nLimited",
                        "Date of sanction\nletter / facility\nagreement": "Sanction letter\ndated October 9,\n2023",
                        "Nature of\nborrowing": "Working\ncapital\ndemand loan",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "500.00",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "500.00",
                        "Repayment\ndate/\nSchedule": "Repayable in\n90 days,\nrevolving",
                        "Tenor": "-",
                        "Interest rate\nas at 30\nSeptember\n2023": "7.30%",
                        "Purpose of\nraising the loan": "For Working\ncapital\nrequirements",
                        "Prepayment\nclause (if any)": "Prepayment\nallowed\nwithout any\npenalty",
                        "Security": "\u2022 PDC from the\nCompany of INR\n500mn. In case\ncompany avails\nlower than"
                    }
                ],
                "rows": 2,
                "cols": 13
            },
            {
                "page_number": 98,
                "table_data": [
                    {
                        "Sr.\nNo.": "",
                        "Name of the\nLender": "",
                        "Name of the\nborrower": "",
                        "Date of sanction\nletter / facility\nagreement": "",
                        "Nature of\nborrowing": "",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "",
                        "Repayment\ndate/\nSchedule": "",
                        "Tenor": "",
                        "Interest rate\nas at 30\nSeptember\n2023": "",
                        "Purpose of\nraising the loan": "",
                        "Prepayment\nclause (if any)": "",
                        "Security": "500mn, then\nPDC will come\nfor the lower\namount."
                    },
                    {
                        "Sr.\nNo.": "5",
                        "Name of the\nLender": "Yes Bank\nLimited",
                        "Name of the\nborrower": "Akums Drugs and\nPharmaceuticals\nLimited",
                        "Date of sanction\nletter / facility\nagreement": "Sanction letter\ndated December\n13, 2022",
                        "Nature of\nborrowing": "Working\ncapital\ndemand loan",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "600.00",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "500.00",
                        "Repayment\ndate/\nSchedule": "Up to 28\ndays,\nrevolving",
                        "Tenor": "-",
                        "Interest rate\nas at 30\nSeptember\n2023": "7.60%",
                        "Purpose of\nraising the loan": "For Working\ncapital\nrequirements",
                        "Prepayment\nclause (if any)": "Prepayment\nallowed\nwithout any\npenalty",
                        "Security": "\u2022 First pari passu\ncharge by way of\nHypothecation\non entire current\nassets of the\nCompany (both\npresent and\nfuture),\n\u2022 First pari passu\ncharge by way of\nHypothecation\non All Movable\nFixed Assets of\nthe Company\n(both present and\nfuture)\n\u2022 First pari passu\ncharge by way of\nEquitable\nMortgage on\nIndustrial\nProperty (of the\nCompany)\nlocated at\nUnit I \u2013 L&B situated\nat Plot No. 19,20 &\n21, Sector 6A, IIE,\nRanipur, Haridwar,\nUttarakhand.\nUnit II \u2013 L&B situated\nat Plot No. 22, Sector"
                    }
                ],
                "rows": 2,
                "cols": 13
            },
            {
                "page_number": 99,
                "table_data": [
                    {
                        "Sr.\nNo.": "",
                        "Name of the\nLender": "",
                        "Name of the\nborrower": "",
                        "Date of sanction\nletter / facility\nagreement": "",
                        "Nature of\nborrowing": "",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "",
                        "Repayment\ndate/\nSchedule": "",
                        "Tenor": "",
                        "Interest rate\nas at 30\nSeptember\n2023": "",
                        "Purpose of\nraising the loan": "",
                        "Prepayment\nclause (if any)": "",
                        "Security": "6A, IIE, Ranipur,\nHaridwar,\nUttarakhand\nUnit III \u2013 L&B\nsituated at Plot No.\n2,3,4 & 5, Sector 6A,\nIIE, Ranipur,\nHaridwar,\nUttarakhand\nUnit IV & V \u2013 L&B\nsituated at Plot No. 47\n& 48, Sector 6A,IIE\nRanipur, Haridwar,\nUttarakhand."
                    },
                    {
                        "Sr.\nNo.": "6",
                        "Name of the\nLender": "Hong Kong\nand Shanghai\nBanking\nCorporation\nLimited",
                        "Name of the\nborrower": "Akums Drugs and\nPharmaceuticals\nLimited",
                        "Date of sanction\nletter / facility\nagreement": "Sanction letter\ndated June 2,\n2022",
                        "Nature of\nborrowing": "Term loan",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "250.00",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "250.00",
                        "Repayment\ndate/\nSchedule": "Repayment in\n16 quarterly\ninstalments\nstarting from\n10 November\n2023 until 10\nAugust 2027",
                        "Tenor": "-",
                        "Interest rate\nas at 30\nSeptember\n2023": "7.94%",
                        "Purpose of\nraising the loan": "Reimbursement\nof capex incurred\nand fresh capex to\nbe incurred",
                        "Prepayment\nclause (if any)": "Any\ncancellation or\nprepayment is\nsubject to\nfunding\npenalties at the\nBank\u2019s\ndiscretion.\nHowever, any\npenalty for\ncancellation or\nprepayment on\nthe interest\nreset date will\nbe NIL.",
                        "Security": "\u2022 First pari passu\ncharge on the\nentire current\nassets of\ncompany (both\npresent and\nfuture)\n\u2022 First pari passu\ncharge over\nentire movable\nfixed assets (both\npresent and\nfuture) except\nthose exclusively\ncharged to other\nlenders\n\u2022 First pari passu\ncharge, by way of\nEquitable\nMortgage on\nimmovable fixed"
                    }
                ],
                "rows": 2,
                "cols": 13
            },
            {
                "page_number": 100,
                "table_data": [
                    {
                        "Sr.\nNo.": "",
                        "Name of the\nLender": "",
                        "Name of the\nborrower": "",
                        "Date of sanction\nletter / facility\nagreement": "",
                        "Nature of\nborrowing": "",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "",
                        "Repayment\ndate/\nSchedule": "",
                        "Tenor": "",
                        "Interest rate\nas at 30\nSeptember\n2023": "",
                        "Purpose of\nraising the loan": "",
                        "Prepayment\nclause (if any)": "",
                        "Security": "assets (Land and\nBuilding of the\nCompany) at\nUnit I,II,III and\nIV and IV at\nHaridwar."
                    },
                    {
                        "Sr.\nNo.": "Utilisation of Loans by Subsidiaries",
                        "Name of the\nLender": null,
                        "Name of the\nborrower": null,
                        "Date of sanction\nletter / facility\nagreement": null,
                        "Nature of\nborrowing": null,
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": null,
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": null,
                        "Repayment\ndate/\nSchedule": null,
                        "Tenor": null,
                        "Interest rate\nas at 30\nSeptember\n2023": null,
                        "Purpose of\nraising the loan": null,
                        "Prepayment\nclause (if any)": null,
                        "Security": null
                    },
                    {
                        "Sr.\nNo.": "8",
                        "Name of the\nLender": "Citibank N.A.",
                        "Name of the\nborrower": "Maxcure\nNutravedics\nLimited",
                        "Date of sanction\nletter / facility\nagreement": "Sanction letter\ndated April 27,\n2023",
                        "Nature of\nborrowing": "Working\ncapital\ndemand loan",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "800.00",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "250.00",
                        "Repayment\ndate/\nSchedule": "Maximum\n180 days,\nrevolving",
                        "Tenor": "-",
                        "Interest rate\nas at 30\nSeptember\n2023": "7.83% to\n7.90%",
                        "Purpose of\nraising the loan": "For Working\ncapital\nrequirements",
                        "Prepayment\nclause (if any)": "Prepayment\nsubject to\npenalty of 2%\nof principle\noutstanding at\nthe discretion\nof bank",
                        "Security": "\u2022 First pari passu\ncharge on present\nand future stocks\n& book debts of\nborrower\n\u2022 First pari passu\ncharge on present\n& future\nmovable fixed\nassets of\ncompany\n\u2022 First pari passu\ncharge by way of\nequitable\nmortgage on land\n& building\nlocated at Plot\nNo 13, Sec 6A,\nIIE, SIDCUL,\nRanipur,\nHaridwar\n\u2022 Demand\npromissory note\nand letter of\ncontinuity\n\u2022 Drawing power\nwill be calculated"
                    }
                ],
                "rows": 3,
                "cols": 13
            },
            {
                "page_number": 101,
                "table_data": [
                    {
                        "Sr.\nNo.": "",
                        "Name of the\nLender": "",
                        "Name of the\nborrower": "",
                        "Date of sanction\nletter / facility\nagreement": "",
                        "Nature of\nborrowing": "",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "",
                        "Repayment\ndate/\nSchedule": "",
                        "Tenor": "",
                        "Interest rate\nas at 30\nSeptember\n2023": "",
                        "Purpose of\nraising the loan": "",
                        "Prepayment\nclause (if any)": "",
                        "Security": "as per the internal\nguidelines of the\nBank.\nNo drawing power\nwill be assigned to\nreceivables from\ngroup entities."
                    },
                    {
                        "Sr.\nNo.": "9",
                        "Name of the\nLender": "HDFC Bank\nLimited",
                        "Name of the\nborrower": "Pure and Cure\nHealthcare Private\nLimited",
                        "Date of sanction\nletter / facility\nagreement": "Sanction letter\ndated April 12,\n2023",
                        "Nature of\nborrowing": "Working\ncapital\ndemand loan",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "740.00",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "580.00",
                        "Repayment\ndate/\nSchedule": "Maximum\n180 days,\nrevolving,\npayable on\ndemand",
                        "Tenor": "-",
                        "Interest rate\nas at 30\nSeptember\n2023": "7.63%",
                        "Purpose of\nraising the loan": "For Working\ncapital\nrequirements",
                        "Prepayment\nclause (if any)": "Prepayment\nallowed\nwithout any\npenalty",
                        "Security": "\u2022 Current assets \u2013\nFirst pari passu\ncharge on all\ncurrent assets of\nthe Company\nboth present and\nfuture\n\u2022 Movable Fixed\nassets \u2013 First pari\npassu charge on\nall movable fixed\nassets of the\nCompany both\npresent and\nfuture other than\nexclusively\nfinanced by any\nother bank\n\u2022 Factory Land and\nBuilding \u2013 First\npari passu charge\non Land &\nBuilding of\nHaridwar Plant"
                    },
                    {
                        "Sr.\nNo.": "10",
                        "Name of the\nLender": "HDFC Bank\nLimited",
                        "Name of the\nborrower": "Pure and Cure\nHealthcare Private\nLimited",
                        "Date of sanction\nletter / facility\nagreement": null,
                        "Nature of\nborrowing": "Cash credit",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": null,
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "141.86",
                        "Repayment\ndate/\nSchedule": "Maximum\n180 days,\nrevolving,\npayable on\ndemand",
                        "Tenor": "-",
                        "Interest rate\nas at 30\nSeptember\n2023": "8.40%",
                        "Purpose of\nraising the loan": "For Working\ncapital\nrequirements",
                        "Prepayment\nclause (if any)": "Prepayment\nallowed\nwithout any\npenalty",
                        "Security": null
                    },
                    {
                        "Sr.\nNo.": "11",
                        "Name of the\nLender": "HDFC Bank\nLimited",
                        "Name of the\nborrower": "Pure and Cure\nHealthcare Private\nLimited",
                        "Date of sanction\nletter / facility\nagreement": "Sanction letter\ndated October 9,\n2023",
                        "Nature of\nborrowing": "Working\nCapital loan",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "500.00",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "500.00",
                        "Repayment\ndate/\nSchedule": "Repayable in\n90 days,\nrevolving",
                        "Tenor": "-",
                        "Interest rate\nas at 30\nSeptember\n2023": "7.30%",
                        "Purpose of\nraising the loan": "For Working\ncapital\nrequirements",
                        "Prepayment\nclause (if any)": "Prepayment\nallowed",
                        "Security": "\u2022 PDC from the\nCompany. The\nPDC amount\nshall be"
                    }
                ],
                "rows": 4,
                "cols": 13
            },
            {
                "page_number": 102,
                "table_data": [
                    {
                        "Sr.\nNo.": "",
                        "Name of the\nLender": "",
                        "Name of the\nborrower": "",
                        "Date of sanction\nletter / facility\nagreement": "",
                        "Nature of\nborrowing": "",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "",
                        "Repayment\ndate/\nSchedule": "",
                        "Tenor": "",
                        "Interest rate\nas at 30\nSeptember\n2023": "",
                        "Purpose of\nraising the loan": "",
                        "Prepayment\nclause (if any)": "without any\npenalty",
                        "Security": "equivalent to the\nfacility being\navailed."
                    },
                    {
                        "Sr.\nNo.": "12",
                        "Name of the\nLender": "HDFC Bank\nLimited",
                        "Name of the\nborrower": "Pure and Cure\nHealthcare Private\nLimited",
                        "Date of sanction\nletter / facility\nagreement": "Sanction letter\ndated March 3,\n2022",
                        "Nature of\nborrowing": "Term loan",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "800.00",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "181.82",
                        "Repayment\ndate/\nSchedule": "Quarterly\nequal\nrepayment",
                        "Tenor": "Door to\ndoor\ntenor of\n36\nmonths",
                        "Interest rate\nas at 30\nSeptember\n2023": "8.10% to\n8.47%",
                        "Purpose of\nraising the loan": "Capex /\nReimbursement\non capex",
                        "Prepayment\nclause (if any)": "Prepayment\nallowed\nwithout any\npenalty",
                        "Security": "\u2022 Exclusive charge\non movable fixed\nassets located at\nPlot no. 38,\nSector 8A,\nSIDCUL,\nIndustrial Area,\nHaridwar,\nUttarakhand\n\u2022 Exclusive charge\non factory land\nand Building\nlocated at Plot\nno. 38, Sector\n8A, SIDCUL,\nIndustrial Area,\nHaridwar,\nUttarakhand"
                    },
                    {
                        "Sr.\nNo.": "13",
                        "Name of the\nLender": "Hong Kong\nand Shanghai\nBanking\nCorporation\nLimited",
                        "Name of the\nborrower": "Pure and Cure\nHealthcare Private\nLimited *",
                        "Date of sanction\nletter / facility\nagreement": "Sanction letter\ndated May 20,\n2022",
                        "Nature of\nborrowing": "Term loan",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "1,000.00",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "937.50",
                        "Repayment\ndate/\nSchedule": "Repayment in\n16 quarterly\ninstalments\nstarting from\n28 September\n2023 until 28\nJune 2027",
                        "Tenor": "Door to\ndoor\ntenor of\n5 years",
                        "Interest rate\nas at 30\nSeptember\n2023": "7.70%",
                        "Purpose of\nraising the loan": "Reimbursement\nof capex and\nreimbursement/\nfresh payment to\nresolution\nprofessional for\npurchase of\nerstwhile\ncompany\n\u2018Parabolic Drugs\nLimited\u2019 under\nNCLT, on slump\nsale basis.",
                        "Prepayment\nclause (if any)": "Any\ncancellation or\nprepayment\nsubject to\nfunding\npenalties at the\nBank\u2019s\ndiscretion.",
                        "Security": "\u2022 First pari passu\ncharge on the\nentire current\nassets of\ncompany (both\npresent and\nfuture)\n\u2022 First pari passu\ncharge on entire\nmovable fixed\nassets (both\npresent and\nfuture) of the\nCompany except\nthose exclusively"
                    }
                ],
                "rows": 3,
                "cols": 13
            },
            {
                "page_number": 103,
                "table_data": [
                    {
                        "Sr.\nNo.": "",
                        "Name of the\nLender": "",
                        "Name of the\nborrower": "",
                        "Date of sanction\nletter / facility\nagreement": "",
                        "Nature of\nborrowing": "",
                        "Amount\nSanctioned/\nAvailed as at\n30 September\n2023\n(\u20b9 in million)": "",
                        "Outstanding\namount as on\n30 September\n2023\n(\u20b9 in million)": "",
                        "Repayment\ndate/\nSchedule": "",
                        "Tenor": "",
                        "Interest rate\nas at 30\nSeptember\n2023": "",
                        "Purpose of\nraising the loan": "",
                        "Prepayment\nclause (if any)": "",
                        "Security": "charged to other\nlenders\n\u2022 First pari passu\ncharge on\nEquitable\nMortgage on\nimmovable fixed\nassets (Land &\nBuilding of the\nCompany) at\nPanchkula,\nDerabassi &\nLalru\n\u2022 Corporate\nGuarantee (CGT)\nfrom Akums\nDrugs and\nPharmaceuticals\nLimited along\nwith relevant\ncertified true\ncopy of the\nBoard Resolution\nand\nMemorandum of\nAssociation and\nArticles of\nAssociation\n\u2022 Note: Security\ndeferral of 6\nmonths"
                    }
                ],
                "rows": 1,
                "cols": 13
            },
            {
                "page_number": 104,
                "table_data": [
                    {
                        "Col0": null,
                        "Particulars": null,
                        "As at": "March 31,\n2021",
                        "Col3": "March 31,\n2022",
                        "Col4": "March 31,\n2023",
                        "Col5": "September 30,\n2023"
                    },
                    {
                        "Col0": "I.",
                        "Particulars": "Current assets",
                        "As at": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Col0": "A.",
                        "Particulars": "Inventories",
                        "As at": "4,298.59",
                        "Col3": "7,224.48",
                        "Col4": "7,297.95",
                        "Col5": "6,882.66"
                    },
                    {
                        "Col0": "B.",
                        "Particulars": "Financial assets:",
                        "As at": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Col0": "",
                        "Particulars": "(i) Investments",
                        "As at": "190.09",
                        "Col3": "-",
                        "Col4": "-",
                        "Col5": "-"
                    },
                    {
                        "Col0": "",
                        "Particulars": "(ii) Trade receivables",
                        "As at": "5,313.99",
                        "Col3": "8,843.12",
                        "Col4": "8,450.87",
                        "Col5": "11,189.99"
                    },
                    {
                        "Col0": "",
                        "Particulars": "(iii) Cash and cash equivalents",
                        "As at": "220.67",
                        "Col3": "551.39",
                        "Col4": "516.08",
                        "Col5": "1,176.30"
                    },
                    {
                        "Col0": "",
                        "Particulars": "(iv) Bank balances other than (ii) above",
                        "As at": "458.01",
                        "Col3": "477.08",
                        "Col4": "983.81",
                        "Col5": "1,288.14"
                    },
                    {
                        "Col0": "",
                        "Particulars": "(v) Loans",
                        "As at": "80.00",
                        "Col3": "-",
                        "Col4": "73.73",
                        "Col5": "-"
                    },
                    {
                        "Col0": "",
                        "Particulars": "(vi) Others financial assets",
                        "As at": "144.07",
                        "Col3": "208.01",
                        "Col4": "152.30",
                        "Col5": "230.41"
                    },
                    {
                        "Col0": "C.",
                        "Particulars": "Current tax assets (net)",
                        "As at": "1.60",
                        "Col3": "-",
                        "Col4": "114.05",
                        "Col5": "114.05"
                    },
                    {
                        "Col0": "D.",
                        "Particulars": "Other current assets",
                        "As at": "867.03",
                        "Col3": "1,336.55",
                        "Col4": "1,199.93",
                        "Col5": "1,472.42"
                    },
                    {
                        "Col0": "",
                        "Particulars": "Total current assets (I)",
                        "As at": "11,574.05",
                        "Col3": "18,640.63",
                        "Col4": "18,788.72",
                        "Col5": "22,353.97"
                    },
                    {
                        "Col0": "",
                        "Particulars": "",
                        "As at": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Col0": "II.",
                        "Particulars": "Current liabilities",
                        "As at": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Col0": "A.",
                        "Particulars": "Financial liabilities",
                        "As at": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Col0": "",
                        "Particulars": "(i) Lease liability",
                        "As at": "50.44",
                        "Col3": "66.22",
                        "Col4": "72.41",
                        "Col5": "56.97"
                    },
                    {
                        "Col0": "",
                        "Particulars": "(ii) Trade payables",
                        "As at": "3,414.14",
                        "Col3": "5,896.66",
                        "Col4": "5,671.39",
                        "Col5": "6,108.69"
                    },
                    {
                        "Col0": "",
                        "Particulars": "(ii) Other financial liabilities",
                        "As at": "427.49",
                        "Col3": "702.09",
                        "Col4": "628.10",
                        "Col5": "659.91"
                    },
                    {
                        "Col0": "B.",
                        "Particulars": "Other current liabilities",
                        "As at": "263.67",
                        "Col3": "1,545.77",
                        "Col4": "1,421.95",
                        "Col5": "1,223.53"
                    },
                    {
                        "Col0": "C.",
                        "Particulars": "Provisions",
                        "As at": "566.16",
                        "Col3": "589.24",
                        "Col4": "459.37",
                        "Col5": "476.73"
                    },
                    {
                        "Col0": "D.",
                        "Particulars": "Current tax liabilities (net)",
                        "As at": "118.59",
                        "Col3": "478.00",
                        "Col4": "187.68",
                        "Col5": "469.14"
                    },
                    {
                        "Col0": "",
                        "Particulars": "Total current liabilities (II)",
                        "As at": "4,840.49",
                        "Col3": "9,277.98",
                        "Col4": "8,440.90",
                        "Col5": "8,994.97"
                    },
                    {
                        "Col0": "",
                        "Particulars": "",
                        "As at": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    }
                ],
                "rows": 24,
                "cols": 6
            },
            {
                "page_number": 105,
                "table_data": [
                    {
                        "Col0": null,
                        "Particulars": null,
                        "As at": "March 31,\n2021",
                        "Col3": "March 31,\n2022",
                        "Col4": "March 31,\n2023",
                        "Col5": "September 30,\n2023"
                    },
                    {
                        "Col0": "III.",
                        "Particulars": "Net Current Assets (III) = [(I) - (II)]",
                        "As at": "6,733.56",
                        "Col3": "9,362.65",
                        "Col4": "10,347.82",
                        "Col5": "13,359.00"
                    },
                    {
                        "Col0": "IV.",
                        "Particulars": "Funding pattern",
                        "As at": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Col0": "A.",
                        "Particulars": "Borrowings from banks*",
                        "As at": "860.50",
                        "Col3": "3,379.34",
                        "Col4": "3,875.52",
                        "Col5": "5,611.53"
                    },
                    {
                        "Col0": "B.",
                        "Particulars": "Internal accruals or equity",
                        "As at": "5,873.06",
                        "Col3": "5,983.31",
                        "Col4": "6,472.30",
                        "Col5": "7,747.47"
                    }
                ],
                "rows": 5,
                "cols": 6
            },
            {
                "page_number": 105,
                "table_data": [
                    {
                        "S. No": "I.",
                        "Particulars": "Current assets",
                        "For the financial year ending on\nMarch 31, 2025": ""
                    },
                    {
                        "S. No": "A.",
                        "Particulars": "Inventories",
                        "For the financial year ending on\nMarch 31, 2025": "8,690.67"
                    },
                    {
                        "S. No": "B.",
                        "Particulars": "Trade receivables",
                        "For the financial year ending on\nMarch 31, 2025": "10,758.07"
                    },
                    {
                        "S. No": "C.",
                        "Particulars": "Others financial assets",
                        "For the financial year ending on\nMarch 31, 2025": "263.51"
                    },
                    {
                        "S. No": "D.",
                        "Particulars": "Other current assets",
                        "For the financial year ending on\nMarch 31, 2025": "786.72"
                    },
                    {
                        "S. No": "",
                        "Particulars": "Total current assets (I) excluding cash and bank balances",
                        "For the financial year ending on\nMarch 31, 2025": "20,498.97"
                    },
                    {
                        "S. No": "",
                        "Particulars": "",
                        "For the financial year ending on\nMarch 31, 2025": ""
                    },
                    {
                        "S. No": "II.",
                        "Particulars": "Current liabilities",
                        "For the financial year ending on\nMarch 31, 2025": ""
                    },
                    {
                        "S. No": "A.",
                        "Particulars": "Lease liability",
                        "For the financial year ending on\nMarch 31, 2025": "58.65"
                    },
                    {
                        "S. No": "B.",
                        "Particulars": "Trade payables",
                        "For the financial year ending on\nMarch 31, 2025": "7,249.75"
                    },
                    {
                        "S. No": "C.",
                        "Particulars": "Other financial liabilities",
                        "For the financial year ending on\nMarch 31, 2025": "1,217.94"
                    },
                    {
                        "S. No": "D.",
                        "Particulars": "Other current liabilities",
                        "For the financial year ending on\nMarch 31, 2025": "524.54"
                    },
                    {
                        "S. No": "E.",
                        "Particulars": "Provisions",
                        "For the financial year ending on\nMarch 31, 2025": "570.74"
                    },
                    {
                        "S. No": "F.",
                        "Particulars": "Current tax liabilities (net)",
                        "For the financial year ending on\nMarch 31, 2025": "96.72"
                    },
                    {
                        "S. No": "",
                        "Particulars": "Total current liabilities (II) excluding borrowings",
                        "For the financial year ending on\nMarch 31, 2025": "9,718.35"
                    },
                    {
                        "S. No": "",
                        "Particulars": "",
                        "For the financial year ending on\nMarch 31, 2025": ""
                    },
                    {
                        "S. No": "III.",
                        "Particulars": "Net Current Assets (III) = (I) - (II)",
                        "For the financial year ending on\nMarch 31, 2025": "10,780.62"
                    },
                    {
                        "S. No": "IV.",
                        "Particulars": "Fund pattern",
                        "For the financial year ending on\nMarch 31, 2025": ""
                    },
                    {
                        "S. No": "A.",
                        "Particulars": "Working Capital Facilities",
                        "For the financial year ending on\nMarch 31, 2025": "4,879.53"
                    },
                    {
                        "S. No": "B.",
                        "Particulars": "Internal accruals or equity",
                        "For the financial year ending on\nMarch 31, 2025": "5,351.09"
                    },
                    {
                        "S. No": "C.",
                        "Particulars": "Usage from Net Proceeds",
                        "For the financial year ending on\nMarch 31, 2025": "550.00"
                    },
                    {
                        "S. No": "",
                        "Particulars": "",
                        "For the financial year ending on\nMarch 31, 2025": ""
                    }
                ],
                "rows": 22,
                "cols": 3
            },
            {
                "page_number": 105,
                "table_data": [
                    {
                        "Particulars": "A. Current Assets",
                        "No of days for\nthe Fiscal\nended\nMarch 31,\n2021\n(Actual)": "",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2022\n(Actual)": "",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2023\n(Actual)": "",
                        "No of days for\nthe six months\nperiod ended\nSeptember 30,\n2023\n(Actual)": "",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2025\n(Assumed)": ""
                    },
                    {
                        "Particulars": "(a) Inventory",
                        "No of days for\nthe Fiscal\nended\nMarch 31,\n2021\n(Actual)": "93",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2022\n(Actual)": "112",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2023\n(Actual)": "117",
                        "No of days for\nthe six months\nperiod ended\nSeptember 30,\n2023\n(Actual)": "97",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2025\n(Assumed)": "108"
                    },
                    {
                        "Particulars": "(b) Trade Receivables",
                        "No of days for\nthe Fiscal\nended\nMarch 31,\n2021\n(Actual)": "71",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2022\n(Actual)": "88",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2023\n(Actual)": "84",
                        "No of days for\nthe six months\nperiod ended\nSeptember 30,\n2023\n(Actual)": "95",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2025\n(Assumed)": "80"
                    },
                    {
                        "Particulars": "(c) Other current Assets",
                        "No of days for\nthe Fiscal\nended\nMarch 31,\n2021\n(Actual)": "17",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2022\n(Actual)": "15",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2023\n(Actual)": "15",
                        "No of days for\nthe six months\nperiod ended\nSeptember 30,\n2023\n(Actual)": "15",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2025\n(Assumed)": "8"
                    },
                    {
                        "Particulars": "B. Current Liabilities",
                        "No of days for\nthe Fiscal\nended\nMarch 31,\n2021\n(Actual)": "",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2022\n(Actual)": "",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2023\n(Actual)": "",
                        "No of days for\nthe six months\nperiod ended\nSeptember 30,\n2023\n(Actual)": "",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2025\n(Assumed)": ""
                    },
                    {
                        "Particulars": "(a) Trade payables",
                        "No of days for\nthe Fiscal\nended\nMarch 31,\n2021\n(Actual)": "62",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2022\n(Actual)": "78",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2023\n(Actual)": "75",
                        "No of days for\nthe six months\nperiod ended\nSeptember 30,\n2023\n(Actual)": "72",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2025\n(Assumed)": "75"
                    },
                    {
                        "Particulars": "(b) Other current Liabilities",
                        "No of days for\nthe Fiscal\nended\nMarch 31,\n2021\n(Actual)": "26",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2022\n(Actual)": "45",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2023\n(Actual)": "36",
                        "No of days for\nthe six months\nperiod ended\nSeptember 30,\n2023\n(Actual)": "34",
                        "No of days for\nthe Fiscal\nended\nMarch 31, 2025\n(Assumed)": "25"
                    }
                ],
                "rows": 7,
                "cols": 6
            },
            {
                "page_number": 106,
                "table_data": [
                    {
                        "Particulars": "Inventories",
                        "Assumptions": "This has been taken as a % to the cost of goods sold in each segment in which they are operating.\nInventories include raw materials, finished goods, packing material, work in progress, stores and\nspares etc. Our Company had maintained inventory days of 93 days in Fiscal 2021, 112 days in Fiscal\n2022, 117 days in Fiscal 2023 and 97 days in the six months ended September 30, 2023. It is\nanticipated to be 108 days for Fiscal 2025."
                    },
                    {
                        "Particulars": "Trade receivables",
                        "Assumptions": "This has been calculated as a % of sales. Our Company had maintained trade receivable days of 71\ndays in Fiscal 2021, 88 days in Fiscal 2022, 84 days in Fiscal 2023 and 95 days in the six months\nended September 30, 2023. Our Company anticipates to reduce trade receivables by improving\ncollection efficiency and by bringing down the DSO (\u201cDaily Sales Outstanding\u201d) and project trade\nreceivables days to 80 days for Fiscal 2025."
                    },
                    {
                        "Particulars": "Other current assets",
                        "Assumptions": "Other current assets include investments, loans, other financial assets, current tax assets (net) and\nother current assets. For Fiscal 2021, Fiscal 2022, Fiscal 2023 and the six months ended September\n30, 2023, our Company\u2019s other current assets were 17 days, 15 days, 15 days and 15 days,\nrespectively. It is anticipated to be at 8 days for Fiscal 2025."
                    },
                    {
                        "Particulars": "Trade payable",
                        "Assumptions": "This has been calculated as a % of cost of material consumed and other expenses. Our Company had\nmaintained trade payable days of 62 days in Fiscal 2021, 78 days in Fiscal 2022, 75 days in Fiscal\n2023 and 72 days for the six months ended September 30, 2023. It is projected to be 74 days for the\nFiscal 2025."
                    },
                    {
                        "Particulars": "Other current liabilities",
                        "Assumptions": "Other current liabilities include lease liability, other financial liabilities, other current liabilities,\nprovisions and current tax liabilities (net). For Fiscal 2021, Fiscal 2022, Fiscal 2023 and for the six\nmonths ended September 30, 2023, our Company\u2019s other current liabilities were 26 days, 45 days,\n36 days and 34 days, respectively. It is anticipated to be at 25 day for Fiscal 2025."
                    }
                ],
                "rows": 5,
                "cols": 2
            },
            {
                "page_number": 106,
                "table_data": [
                    {
                        "Name of the target entity/\nentity from which the\nbusiness/asset has been\npurchased": "Acquisition of infrastructural\nassets of Ankur Drugs and\nPharma Limited from\nEdelweiss Asset\nReconstruction Company\nLimited by Pure and Cure\nHealthcare Private Limited.",
                        "Year of\nacquisition": "FY 2023-\n2024",
                        "Country/\nState of\nincorporation\nof the target\nentity": "Himachal\nPradesh",
                        "Purchase\nconsideration\n(in \u20b9 million)": "360.10",
                        "Mode of\nacquisition": "Assets\npurchase",
                        "Benefit of\nacquisition": "Capacity\nEnhancement",
                        "Property, plant\nand equipment\nand intangible\nassets as on\nMarch 31, 2023\n(in \u20b9 million)": "N.A."
                    },
                    {
                        "Name of the target entity/\nentity from which the\nbusiness/asset has been\npurchased": "Acquisition of infrastructural\nassets of Origin Formulations\nPrivate Limited by Akums\nHealthcare Limited",
                        "Year of\nacquisition": "FY 2021-\n2022",
                        "Country/\nState of\nincorporation\nof the target\nentity": "Uttarakhand",
                        "Purchase\nconsideration\n(in \u20b9 million)": "130.60",
                        "Mode of\nacquisition": "Assets\npurchase",
                        "Benefit of\nacquisition": "Capacity\nenhancement",
                        "Property, plant\nand equipment\nand intangible\nassets as on\nMarch 31, 2023\n(in \u20b9 million)": "256.65"
                    },
                    {
                        "Name of the target entity/\nentity from which the\nbusiness/asset has been\npurchased": "Acquisition of infrastructural\nassets of Ankur Drugs and\nPharma Limited from\nEdelweiss Asset\nReconstruction Company\nLimited by Pure and Cure\nHealthcare Private Limited",
                        "Year of\nacquisition": "FY 2021-\n2022",
                        "Country/\nState of\nincorporation\nof the target\nentity": "Himachal\nPradesh",
                        "Purchase\nconsideration\n(in \u20b9 million)": "573.30",
                        "Mode of\nacquisition": "Assets\npurchase",
                        "Benefit of\nacquisition": "Capacity\nenhancement",
                        "Property, plant\nand equipment\nand intangible\nassets as on\nMarch 31, 2023\n(in \u20b9 million)": "708.45"
                    }
                ],
                "rows": 3,
                "cols": 7
            },
            {
                "page_number": 107,
                "table_data": [
                    {
                        "Name of the target entity/\nentity from which the\nbusiness/asset has been\npurchased": "Acquisition of Akums\nLifesciences Limited\n(erstwhile \u2018Parabolic Drugs\nLimited\u2019)",
                        "Year of\nacquisition": "FY 2020-\n2021",
                        "Country/\nState of\nincorporation\nof the target\nentity": "Punjab and\nHaryana",
                        "Purchase\nconsideration\n(in \u20b9 million)": "969.15",
                        "Mode of\nacquisition": "Business\npurchase",
                        "Benefit of\nacquisition": "Entry in the\nAPI business",
                        "Property, plant\nand equipment\nand intangible\nassets as on\nMarch 31, 2023\n(in \u20b9 million)": "3,997.91"
                    },
                    {
                        "Name of the target entity/\nentity from which the\nbusiness/asset has been\npurchased": "Acquisition of infrastructural\nassets from Lakhani Shoes &\nApparels Private Limited by\nPure and Cure Healthcare\nPrivate Limited",
                        "Year of\nacquisition": "FY 2020-\n2021",
                        "Country/\nState of\nincorporation\nof the target\nentity": "Uttarakhand",
                        "Purchase\nconsideration\n(in \u20b9 million)": "157.60",
                        "Mode of\nacquisition": "Assets\npurchase",
                        "Benefit of\nacquisition": "Capacity\nenhancement",
                        "Property, plant\nand equipment\nand intangible\nassets as on\nMarch 31, 2023\n(in \u20b9 million)": "192.98"
                    }
                ],
                "rows": 2,
                "cols": 7
            },
            {
                "page_number": 109,
                "table_data": [
                    {
                        "S. No": "1.",
                        "Activity": "BRLMs fees and commissions (including underwriting\ncommission)",
                        "Estimated amount(1)\n(\u20b9 in million)": "[\u25cf]",
                        "As a % of total\nestimated Offer\nExpenses(1)": "[\u25cf]",
                        "As a % of Offer\nSize(1)": "[\u25cf]"
                    },
                    {
                        "S. No": "2.",
                        "Activity": "Brokerage, selling commission, bidding charges,\nprocessing fees and bidding charges for the Members of the\nSyndicate, Registered\nBrokers, SCSBs, RTAs and CDPs (2)(3)(4)(5)(6)",
                        "Estimated amount(1)\n(\u20b9 in million)": "[\u25cf]",
                        "As a % of total\nestimated Offer\nExpenses(1)": "[\u25cf]",
                        "As a % of Offer\nSize(1)": "[\u25cf]"
                    },
                    {
                        "S. No": "3.",
                        "Activity": "Advertising and marketing expenses for the Offer",
                        "Estimated amount(1)\n(\u20b9 in million)": "[\u25cf]",
                        "As a % of total\nestimated Offer\nExpenses(1)": "[\u25cf]",
                        "As a % of Offer\nSize(1)": "[\u25cf]"
                    },
                    {
                        "S. No": "4.",
                        "Activity": "Other expenses\n(i) Listing fees, SEBI filing fees, BSE & NSE\nprocessing fees, book building software fees,\n(ii) Other regulatory expenses,\n(iii) Printing and stationery expenses\n(iv) Fees payable to the legal counsel\n(v) Fees payable to other advisors to the Offer\n(vi) Fees payable to the Registrar to the Offer\n(vii) Miscellaneous",
                        "Estimated amount(1)\n(\u20b9 in million)": "[\u25cf]\n[\u25cf]\n[\u25cf]",
                        "As a % of total\nestimated Offer\nExpenses(1)": "[\u25cf]\n[\u25cf]\n[\u25cf]",
                        "As a % of Offer\nSize(1)": "[\u25cf]\n[\u25cf]\n[\u25cf]"
                    },
                    {
                        "S. No": "",
                        "Activity": "Total Estimated Offer Expenses",
                        "Estimated amount(1)\n(\u20b9 in million)": "[\u25cf]",
                        "As a % of total\nestimated Offer\nExpenses(1)": "[\u25cf]",
                        "As a % of Offer\nSize(1)": "[\u25cf]"
                    }
                ],
                "rows": 5,
                "cols": 5
            },
            {
                "page_number": 109,
                "table_data": [
                    {
                        "SCSBs, would be as follows:": "Portion for Retail Individual Bidders*",
                        "Col1": "[\u25cf]% of the Amount Allotted* (plus applicable taxes)"
                    },
                    {
                        "SCSBs, would be as follows:": "Portion for Non-Institutional Bidders*",
                        "Col1": "[\u25cf]% of the Amount Allotted* (plus applicable taxes)"
                    },
                    {
                        "SCSBs, would be as follows:": "Employee Reservation Portion",
                        "Col1": "[\u25cf]% of the Amount Allotted* (plus applicable taxes)"
                    }
                ],
                "rows": 3,
                "cols": 2
            },
            {
                "page_number": 109,
                "table_data": [
                    {
                        "Portion for Retail Individual Bidders": "Portion for Non-Institutional Bidders",
                        "\u20b9[\u25cf] per valid application (plus applicable taxes)": "\u20b9[\u25cf] per valid application (plus applicable taxes)"
                    },
                    {
                        "Portion for Retail Individual Bidders": "Employee Reservation Portion",
                        "\u20b9[\u25cf] per valid application (plus applicable taxes)": "[\u25cf]% of the Amount Allotted* (plus applicable taxes)"
                    }
                ],
                "rows": 2,
                "cols": 2
            },
            {
                "page_number": 109,
                "table_data": [
                    {
                        "Members of the Syndicate / RTAs / CDPs": "Sponsor Bank",
                        "\u20b9[\u25cf] per valid application (plus applicable taxes)": "[\u25cf] per valid Bid cum Application Form* (plus applicable taxes)\nThe Sponsor Bank shall be responsible for making payments to the third\nparties such as remitter bank, NCPI and such other parties as required in\nconnection with the performance of its duties under the SEBI circulars, the\nSyndicate Agreement and other applicable laws."
                    }
                ],
                "rows": 1,
                "cols": 2
            },
            {
                "page_number": 109,
                "table_data": [
                    {
                        "Portion for Retail Individual Bidders": "Portion for Non-Institutional Bidders",
                        "[\u25cf]% of the Amount Allotted* (plus applicable taxes)": "[\u25cf]% of the Amount Allotted* (plus applicable taxes)"
                    },
                    {
                        "Portion for Retail Individual Bidders": "Employee Reservation Portion",
                        "[\u25cf]% of the Amount Allotted* (plus applicable taxes)": "[\u25cf]% of the Amount Allotted* (plus applicable taxes)"
                    }
                ],
                "rows": 2,
                "cols": 2
            },
            {
                "page_number": 111,
                "table_data": [
                    {
                        "Fiscal/ Period ended": "March 31, 2023",
                        "Basic EPS (\u20b9)": "6.63",
                        "Diluted EPS (\u20b9)": "6.63",
                        "Weight": "3"
                    },
                    {
                        "Fiscal/ Period ended": "March 31, 2022",
                        "Basic EPS (\u20b9)": "(17.65)",
                        "Diluted EPS (\u20b9)": "(17.65)",
                        "Weight": "2"
                    },
                    {
                        "Fiscal/ Period ended": "March 31, 2021",
                        "Basic EPS (\u20b9)": "8.58",
                        "Diluted EPS (\u20b9)": "8.58",
                        "Weight": "1"
                    },
                    {
                        "Fiscal/ Period ended": "Weighted Average",
                        "Basic EPS (\u20b9)": "(1.14)",
                        "Diluted EPS (\u20b9)": "(1.14)",
                        "Weight": ""
                    },
                    {
                        "Fiscal/ Period ended": "Six months ended September 30, 2023*",
                        "Basic EPS (\u20b9)": "(10.93)",
                        "Diluted EPS (\u20b9)": "(10.93)",
                        "Weight": "-"
                    },
                    {
                        "Fiscal/ Period ended": "Six months ended September 30, 2022*",
                        "Basic EPS (\u20b9)": "4.80",
                        "Diluted EPS (\u20b9)": "4.80",
                        "Weight": ""
                    }
                ],
                "rows": 6,
                "cols": 4
            },
            {
                "page_number": 111,
                "table_data": [
                    {
                        "Particulars": "Based on basic EPS as per the Restated Consolidated\nFinancial Information for the financial year ended\nMarch 31, 2023",
                        "P/E at Floor Price (number of\ntimes)": "The details shall be provided post the fixing of the price band by our\nCompany at the stage of the red herring prospectus or the filing of the\nprice band advertisement",
                        "P/E at Cap Price (number of\ntimes)": null
                    }
                ],
                "rows": 1,
                "cols": 3
            },
            {
                "page_number": 112,
                "table_data": [
                    {
                        "Particulars": "Based on diluted EPS as per the Restated Consolidated\nFinancial Information for the financial year ended\nMarch 31, 2022",
                        "P/E at Floor Price (number of\ntimes)": "",
                        "P/E at Cap Price (number of\ntimes)": null
                    }
                ],
                "rows": 1,
                "cols": 3
            },
            {
                "page_number": 112,
                "table_data": [
                    {
                        "Particulars": "Highest",
                        "P/E Ratio": "71.86"
                    },
                    {
                        "Particulars": "Lowest",
                        "P/E Ratio": "31.56"
                    },
                    {
                        "Particulars": "Average",
                        "P/E Ratio": "48.32"
                    }
                ],
                "rows": 3,
                "cols": 2
            },
            {
                "page_number": 112,
                "table_data": [
                    {
                        "Fiscal ended": "March 31, 2023",
                        "Return on Net Worth (%)": "13.23",
                        "Weight": "3"
                    },
                    {
                        "Fiscal ended": "March 31, 2022",
                        "Return on Net Worth (%)": "(40.60)",
                        "Weight": "2"
                    },
                    {
                        "Fiscal ended": "March 31, 2021",
                        "Return on Net Worth (%)": "13.87",
                        "Weight": "1"
                    },
                    {
                        "Fiscal ended": "Weighted Average",
                        "Return on Net Worth (%)": "(4.61)",
                        "Weight": ""
                    },
                    {
                        "Fiscal ended": "Six months ended September 30, 2023*",
                        "Return on Net Worth (%)": "(27.91)",
                        "Weight": "-"
                    },
                    {
                        "Fiscal ended": "Six months ended September 30, 2022*",
                        "Return on Net Worth (%)": "9.94%",
                        "Weight": ""
                    }
                ],
                "rows": 6,
                "cols": 3
            },
            {
                "page_number": 112,
                "table_data": [
                    {
                        "Net Asset Value per Equity Share": "As on March 31, 2023",
                        "(in \u20b9)": "50.13"
                    },
                    {
                        "Net Asset Value per Equity Share": "As on September 30, 2023*",
                        "(in \u20b9)": "39.17"
                    },
                    {
                        "Net Asset Value per Equity Share": "As on September 30, 2022*",
                        "(in \u20b9)": "48.24"
                    },
                    {
                        "Net Asset Value per Equity Share": "After the Offer",
                        "(in \u20b9)": ""
                    },
                    {
                        "Net Asset Value per Equity Share": "- At the Floor Price",
                        "(in \u20b9)": "[\u25cf]"
                    },
                    {
                        "Net Asset Value per Equity Share": "- At the Cap Price",
                        "(in \u20b9)": "[\u25cf]"
                    },
                    {
                        "Net Asset Value per Equity Share": "At Offer Price",
                        "(in \u20b9)": "[\u25cf]"
                    }
                ],
                "rows": 7,
                "cols": 2
            },
            {
                "page_number": 112,
                "table_data": [
                    {
                        "Name of Company": null,
                        "Face\nValue\nPer\nShare\n(\u20b9)": null,
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": null,
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": null,
                        "EPS (\u20b9)": "Basic",
                        "Col5": "Diluted",
                        "P/E": null,
                        "Return on\ntangible\nNet Worth\n(%)": null,
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": null
                    },
                    {
                        "Name of Company": "Akums Drugs and\nPharmaceuticals",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "2.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "[\u25cf]",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "36,548.20",
                        "EPS (\u20b9)": "6.63",
                        "Col5": "6.63",
                        "P/E": "[\u25cf]",
                        "Return on\ntangible\nNet Worth\n(%)": "13.23%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "50.13"
                    },
                    {
                        "Name of Company": "Peer Group",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "",
                        "EPS (\u20b9)": "",
                        "Col5": "",
                        "P/E": "",
                        "Return on\ntangible\nNet Worth\n(%)": "",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": ""
                    },
                    {
                        "Name of Company": "Divi's Laboratories",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "2.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "3,699.50",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "77,675.10",
                        "EPS (\u20b9)": "68.69",
                        "Col5": "68.69",
                        "P/E": "53.86",
                        "Return on\ntangible\nNet Worth\n(%)": "14.28%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "480.93"
                    },
                    {
                        "Name of Company": "Suven Pharma",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "1.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "653.10",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "13,403.30",
                        "EPS (\u20b9)": "16.16",
                        "Col5": "16.16",
                        "P/E": "40.41",
                        "Return on\ntangible\nNet Worth\n(%)": "23.70%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "68.16"
                    },
                    {
                        "Name of Company": "Gland Pharma",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "1.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "2,018.00",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "36,246.01",
                        "EPS (\u20b9)": "47.44",
                        "Col5": "47.43",
                        "P/E": "42.55",
                        "Return on\ntangible\nNet Worth\n(%)": "9.81%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "483.41"
                    },
                    {
                        "Name of Company": "Torrent Pharma",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "5.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "2,643.70",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "96,201.50",
                        "EPS (\u20b9)": "36.79",
                        "Col5": "36.79",
                        "P/E": "71.86",
                        "Return on\ntangible\nNet Worth\n(%)": "20.09%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "183.13"
                    }
                ],
                "rows": 7,
                "cols": 9
            },
            {
                "page_number": 113,
                "table_data": [
                    {
                        "Name of Company": null,
                        "Face\nValue\nPer\nShare\n(\u20b9)": null,
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": null,
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": null,
                        "EPS (\u20b9)": "Basic",
                        "Col5": "Diluted",
                        "P/E": null,
                        "Return on\ntangible\nNet Worth\n(%)": null,
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": null
                    },
                    {
                        "Name of Company": "Alkem Laboratories",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "2.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "4,924.05",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "1,15,992.60",
                        "EPS (\u20b9)": "82.31",
                        "Col5": "82.31",
                        "P/E": "59.82",
                        "Return on\ntangible\nNet Worth\n(%)": "10.88%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "756.52"
                    },
                    {
                        "Name of Company": "Eris Lifesciences",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "10.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "885.80",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "16,851.49",
                        "EPS (\u20b9)": "28.10",
                        "Col5": "28.07",
                        "P/E": "31.56",
                        "Return on\ntangible\nNet Worth\n(%)": "17.40%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "161.49"
                    },
                    {
                        "Name of Company": "JB Chemicals",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "2.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "1,708.40",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "31,492.82",
                        "EPS (\u20b9)": "53.00",
                        "Col5": "52.34",
                        "P/E": "32.64",
                        "Return on\ntangible\nNet Worth\n(%)": "16.52%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "320.77"
                    },
                    {
                        "Name of Company": "Mankind Pharma",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "1.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "2,057.45",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "87,494.33",
                        "EPS (\u20b9)": "32.00",
                        "Col5": "32.00",
                        "P/E": "64.30",
                        "Return on\ntangible\nNet Worth\n(%)": "17.24%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "185.61"
                    },
                    {
                        "Name of Company": "Innova Captab",
                        "Face\nValue\nPer\nShare\n(\u20b9)": "10.00",
                        "Closing\nprice on\n5th\nFebruary,\n2024\n(\u20b9)": "536.75",
                        "Operating\nrevenue for\nFiscal 2023\n(\u20b9 million)": "9,263.80",
                        "EPS (\u20b9)": "14.16",
                        "Col5": "14.16",
                        "P/E": "37.91",
                        "Return on\ntangible\nNet Worth\n(%)": "24.58%",
                        "Net\nAsset\nValue\nper\nEquity\nShare\n(\u20b9)": "57.61"
                    }
                ],
                "rows": 6,
                "cols": 9
            },
            {
                "page_number": 113,
                "table_data": [
                    {
                        "S.\nNo.": "",
                        "Financial KPIs": null,
                        "Col2": "Unit",
                        "Six months period ended": "30\nSeptember\n2023",
                        "Col4": "30\nSeptember\n2022",
                        "For the year ended": "31 March\n2023",
                        "Col6": "31 March\n2022",
                        "Col7": "31 March\n2021"
                    },
                    {
                        "S.\nNo.": "(a)",
                        "Financial KPIs": "Revenue from operations",
                        "Col2": "(\u20b9 in million)",
                        "Six months period ended": "21,511.38",
                        "Col4": "18,213.63",
                        "For the year ended": "36,548.20",
                        "Col6": "36,718.93",
                        "Col7": "27,226.29"
                    },
                    {
                        "S.\nNo.": "(b)",
                        "Financial KPIs": "EBITDA(1)",
                        "Col2": "(\u20b9 in million)",
                        "Six months period ended": "414.31",
                        "Col4": "1,540.74",
                        "For the year ended": "3,840.55",
                        "Col6": "(690.89)",
                        "Col7": "2,584.99"
                    },
                    {
                        "S.\nNo.": "(c)",
                        "Financial KPIs": "EBITDA margin(2)",
                        "Col2": "%",
                        "Six months period ended": "1.91%",
                        "Col4": "8.32%",
                        "For the year ended": "10.38%",
                        "Col6": "-1.87%",
                        "Col7": "9.42%"
                    },
                    {
                        "S.\nNo.": "(d)",
                        "Financial KPIs": "EBIT(3)",
                        "Col2": "(\u20b9 in million)",
                        "Six months period ended": "(187.07)",
                        "Col4": "1,015.51",
                        "For the year ended": "2,712.46",
                        "Col6": "(1,637.68)",
                        "Col7": "1,886.58"
                    },
                    {
                        "S.\nNo.": "(e)",
                        "Financial KPIs": "EBIT margin(4)",
                        "Col2": "%",
                        "Six months period ended": "-0.86%",
                        "Col4": "5.48%",
                        "For the year ended": "7.33%",
                        "Col6": "-4.43%",
                        "Col7": "6.88%"
                    },
                    {
                        "S.\nNo.": "(f)",
                        "Financial KPIs": "Profit for the period/year",
                        "Col2": "(\u20b9 in million)",
                        "Six months period ended": "(1,547.39)",
                        "Col4": "690.85",
                        "For the year ended": "978.17",
                        "Col6": "(2,508.74)",
                        "Col7": "1,234.35"
                    },
                    {
                        "S.\nNo.": "(g)",
                        "Financial KPIs": "Profit after tax margin(5)",
                        "Col2": "%",
                        "Six months period ended": "-7.14%",
                        "Col4": "3.73%",
                        "For the year ended": "2.64%",
                        "Col6": "-6.79%",
                        "Col7": "4.50%"
                    },
                    {
                        "S.\nNo.": "(h)",
                        "Financial KPIs": "Fixed asset turnover ratio(6)*",
                        "Col2": "Times",
                        "Six months period ended": "1.89",
                        "Col4": "1.62",
                        "For the year ended": "3.41",
                        "Col6": "3.79",
                        "Col7": "3.26"
                    },
                    {
                        "S.\nNo.": "(i)",
                        "Financial KPIs": "Debt-equity ratio(7)",
                        "Col2": "Times",
                        "Six months period ended": "1.26",
                        "Col4": "1.05",
                        "For the year ended": "0.75",
                        "Col6": "0.58",
                        "Col7": "0.11"
                    },
                    {
                        "S.\nNo.": "(j)",
                        "Financial KPIs": "Return on equity(8)*",
                        "Col2": "%",
                        "Six months period ended": "-27.23%",
                        "Col4": "9.96%",
                        "For the year ended": "13.52%",
                        "Col6": "-40.13%",
                        "Col7": "13.91%"
                    },
                    {
                        "S.\nNo.": "(k)",
                        "Financial KPIs": "Return on capital employed(9)*",
                        "Col2": "%",
                        "Six months period ended": "-1.83%",
                        "Col4": "7.80%",
                        "For the year ended": "24.60%",
                        "Col6": "-18.89%",
                        "Col7": "21.06%"
                    },
                    {
                        "S.\nNo.": "(l)",
                        "Financial KPIs": "Segment results before\ndepreciation*",
                        "Col2": "(\u20b9 in million)",
                        "Six months period ended": "",
                        "Col4": "",
                        "For the year ended": "",
                        "Col6": "",
                        "Col7": ""
                    },
                    {
                        "S.\nNo.": "",
                        "Financial KPIs": "- CDMO",
                        "Col2": "",
                        "Six months period ended": "2,950.39",
                        "Col4": "1,576.53",
                        "For the year ended": "3,922.87",
                        "Col6": "4,001.51",
                        "Col7": "2,765.15"
                    },
                    {
                        "S.\nNo.": "",
                        "Financial KPIs": "- API",
                        "Col2": "",
                        "Six months period ended": "(210.48)",
                        "Col4": "(532.19)",
                        "For the year ended": "(1,034.45)",
                        "Col6": "(223.74)",
                        "Col7": "(21.14)"
                    },
                    {
                        "S.\nNo.": "",
                        "Financial KPIs": "- Branded & Generic\nFormulations",
                        "Col2": "",
                        "Six months period ended": "157.04",
                        "Col4": "185.74",
                        "For the year ended": "451.05",
                        "Col6": "339.99",
                        "Col7": "319.24"
                    }
                ],
                "rows": 16,
                "cols": 8
            },
            {
                "page_number": 114,
                "table_data": [
                    {
                        "S.\nNo.": "",
                        "Financial KPIs": null,
                        "Col2": "Unit",
                        "Six months period ended": "30\nSeptember\n2023",
                        "Col4": "30\nSeptember\n2022",
                        "For the year ended": "31 March\n2023",
                        "Col6": "31 March\n2022",
                        "Col7": "31 March\n2021"
                    },
                    {
                        "S.\nNo.": "(m)",
                        "Financial KPIs": "Segment results before\ndepreciation margin(10)*",
                        "Col2": "%",
                        "Six months period ended": "",
                        "Col4": "",
                        "For the year ended": "",
                        "Col6": "",
                        "Col7": ""
                    },
                    {
                        "S.\nNo.": "",
                        "Financial KPIs": "- CDMO",
                        "Col2": "",
                        "Six months period ended": "17.56%",
                        "Col4": "11.94%",
                        "For the year ended": "14.41%",
                        "Col6": "15.04%",
                        "Col7": "12.93%"
                    },
                    {
                        "S.\nNo.": "",
                        "Financial KPIs": "- API",
                        "Col2": "",
                        "Six months period ended": "-22.55%",
                        "Col4": "-58.18%",
                        "For the year ended": "-58.36%",
                        "Col6": "-20.47%",
                        "Col7": "-314.58%"
                    },
                    {
                        "S.\nNo.": "",
                        "Financial KPIs": "- Branded & generic formulations",
                        "Col2": "",
                        "Six months period ended": "4.16%",
                        "Col4": "4.54%",
                        "For the year ended": "5.98%",
                        "Col6": "3.77%",
                        "Col7": "5.46%"
                    },
                    {
                        "S.\nNo.": "(n)",
                        "Financial KPIs": "Adjusted EBITDA(11)#",
                        "Col2": "(\u20b9 in million)",
                        "Six months period ended": "2,950.77",
                        "Col4": "1,277.47",
                        "For the year ended": "3,400.86",
                        "Col6": "4,250.85",
                        "Col7": "3,123.22"
                    },
                    {
                        "S.\nNo.": "(o)",
                        "Financial KPIs": "Adjusted EBITDA margin(12)",
                        "Col2": "%",
                        "Six months period ended": "13.62%",
                        "Col4": "6.90%",
                        "For the year ended": "9.19%",
                        "Col6": "11.51%",
                        "Col7": "11.38%"
                    },
                    {
                        "S.\nNo.": "(p)",
                        "Financial KPIs": "Adjusted EBIT(13)#",
                        "Col2": "(\u20b9 in million)",
                        "Six months period ended": "2,349.39",
                        "Col4": "752.24",
                        "For the year ended": "2,272.77",
                        "Col6": "3,304.06",
                        "Col7": "2,424.81"
                    },
                    {
                        "S.\nNo.": "(q)",
                        "Financial KPIs": "Adjusted EBIT margin(14)",
                        "Col2": "%",
                        "Six months period ended": "10.85%",
                        "Col4": "4.06%",
                        "For the year ended": "6.14%",
                        "Col6": "8.94%",
                        "Col7": "8.84%"
                    },
                    {
                        "S.\nNo.": "(r)",
                        "Financial KPIs": "Adjusted Return on equity(15)*#",
                        "Col2": "%",
                        "Six months period ended": "5.41%",
                        "Col4": "2.49%",
                        "For the year ended": "3.11%",
                        "Col6": "14.51%",
                        "Col7": "12.27%"
                    },
                    {
                        "S.\nNo.": "(s)",
                        "Financial KPIs": "Adjusted Return on Capital\nemployed(16)*#",
                        "Col2": "%",
                        "Six months period ended": "10.30%",
                        "Col4": "3.23%",
                        "For the year ended": "10.77%",
                        "Col6": "17.22%",
                        "Col7": "16.69%"
                    }
                ],
                "rows": 11,
                "cols": 8
            },
            {
                "page_number": 114,
                "table_data": [
                    {
                        "KPI": "Revenue from\noperations",
                        "Explanation": "Revenue from operations represents the income generated by our Company from its core operating operations. This\ngives information regarding the scale of operations."
                    },
                    {
                        "KPI": "EBITDA",
                        "Explanation": "Tracking EBITDA helps us identify underlying trends in our business and facilitates evaluation of year-on-year\noperating performance of our operations by eliminating items that are variable in nature and not considered by us in\nthe evaluation of ongoing operating performance and allowing comparison of our recurring core business operating"
                    }
                ],
                "rows": 2,
                "cols": 2
            },
            {
                "page_number": 115,
                "table_data": [
                    {
                        "KPI": "",
                        "Explanation": "results over multiple periods."
                    },
                    {
                        "KPI": "EBITDA margin",
                        "Explanation": "Tracking EBITDA Margin assists in tracking the margin profile of our business and in understanding areas of our\nbusiness operations which have scope for improvement."
                    },
                    {
                        "KPI": "EBIT",
                        "Explanation": "EBIT provides information regarding the true cost of running the company because it takes into account depreciation\nand amortization cost. This is important because parts of our Company's properties, manufacturing plants and\nequipment will eventually need to be replaced as they get used, broken down, decayed, etc."
                    },
                    {
                        "KPI": "EBIT margin",
                        "Explanation": "Tracking EBIT margin assists in tracking the operational efficiency of our business and allows comparison of results\nover multiple periods."
                    },
                    {
                        "KPI": "Profit for the period\n/year",
                        "Explanation": "Tracking restated profit for the year helps us track the overall profitability of our business after tax."
                    },
                    {
                        "KPI": "PAT margin",
                        "Explanation": "Tracking PAT margin assists in tracking the margin profile of our business and allows comparison of results over\nmultiple periods."
                    },
                    {
                        "KPI": "Fixed Asset\nturnover ratio",
                        "Explanation": "This formula helps us assess how efficiently sales are being generated from existing fixed assets over multiple periods."
                    },
                    {
                        "KPI": "Debt-equity ratio",
                        "Explanation": "This metric helps our Company track the leverage position over multiple periods and deploy the modified strategies."
                    },
                    {
                        "KPI": "Return on equity",
                        "Explanation": "This ratio helps our Company in measuring the returns generated from equity financing."
                    },
                    {
                        "KPI": "Return on Capital\nEmployed",
                        "Explanation": "This ratio helps our Company in measuring the operating returns generated from total capital employed in the business."
                    },
                    {
                        "KPI": "Segment results before depreciation",
                        "Explanation": null
                    },
                    {
                        "KPI": "- CDMO",
                        "Explanation": "This metric helps our Company to track the EBITDA from CDMO business."
                    },
                    {
                        "KPI": "- Branded &\ngeneric\nformulations",
                        "Explanation": "This metric helps our Company to track the EBITDA from Branded & Generic formulations business."
                    },
                    {
                        "KPI": "- API",
                        "Explanation": "This metric helps our Company to track the EBITDA from API business."
                    },
                    {
                        "KPI": "Segment results before depreciation margin (%)",
                        "Explanation": null
                    },
                    {
                        "KPI": "CDMO",
                        "Explanation": "Tracking EBITDA Margin of CDMO segment assists in tracking the margin profile of our CDMO business and in\nunderstanding areas which have scope for improvement."
                    },
                    {
                        "KPI": "- Branded &\ngeneric\nformulations",
                        "Explanation": "Tracking EBITDA Margin of Branded & Generic Formulations segment assists in tracking the margin profile of our\nBranded and Generic Formulations business and in understanding areas which have scope for improvement."
                    },
                    {
                        "KPI": "- API",
                        "Explanation": "Tracking EBITDA Margin of API segment assists in tracking the margin profile of our API business and in\nunderstanding areas which have scope for improvement."
                    },
                    {
                        "KPI": "Adjusted EBITDA",
                        "Explanation": "Adjusted EBITDA is EBITDA adjusted for fair value changes to financial instruments."
                    },
                    {
                        "KPI": "Adjusted EBITDA\nmargin",
                        "Explanation": "Adjusted EBITA margin is EBITDA margin adjusted for fair value changes to financial instruments."
                    },
                    {
                        "KPI": "Adjusted EBIT",
                        "Explanation": "Adjusted EBIT is EBIT adjusted for fair value changes to financial instruments."
                    },
                    {
                        "KPI": "Adjusted EBIT\nmargin",
                        "Explanation": "Adjusted EBIT margin is EBIT margin adjusted for fair value changes to financial instruments."
                    },
                    {
                        "KPI": "Adjusted Return on\nequity",
                        "Explanation": "Adjusted Return on Equity is Return on Equity adjusted for fair value changes to financial instruments and\ncorresponding put option liability."
                    },
                    {
                        "KPI": "Adjusted Return on\nCapital employed",
                        "Explanation": "Adjusted Return on Capital Employed is Return on Capital Employed adjusted for fair value changes to financial\ninstruments and corresponding put option liability."
                    }
                ],
                "rows": 24,
                "cols": 2
            },
            {
                "page_number": 116,
                "table_data": [
                    {
                        "As at and for Fiscal 2023": "Parameter",
                        "Col1": "Units",
                        "Col2": "Akums Drugs\nand\nPharmaceuticals",
                        "Col3": "Divi's\nLaboratories",
                        "Col4": "Suven Pharma",
                        "Col5": "Gland Pharma",
                        "Col6": "Torrent\nPharma",
                        "Col7": "Alkem\nLaboratories",
                        "Col8": "Eris\nLifesciences",
                        "Col9": "JB Chemicals",
                        "Col10": "Mankind\nPharma",
                        "Col11": "Innova\nCaptab"
                    },
                    {
                        "As at and for Fiscal 2023": "Revenue from\noperations",
                        "Col1": "Rs Million",
                        "Col2": "36,548.20",
                        "Col3": "77,675.10",
                        "Col4": "13,403.30",
                        "Col5": "36,246.01",
                        "Col6": "96,201.50",
                        "Col7": "1,15,992.60",
                        "Col8": "16,851.49",
                        "Col9": "31,492.80",
                        "Col10": "87,494.30",
                        "Col11": "9,263.80"
                    },
                    {
                        "As at and for Fiscal 2023": "EBIT(1)",
                        "Col1": "Rs Million",
                        "Col2": "2,712.46",
                        "Col3": "23,693.00",
                        "Col4": "5,651.70",
                        "Col5": "11,184.90",
                        "Col6": "21,806.00",
                        "Col7": "15,151.10",
                        "Col8": "4308.11",
                        "Col9": "5912.88",
                        "Col10": "17032.87",
                        "Col11": "1,117.68"
                    },
                    {
                        "As at and for Fiscal 2023": "EBIT margin(2)",
                        "Col1": "%",
                        "Col2": "7.33%",
                        "Col3": "29.21%",
                        "Col4": "40.76%",
                        "Col5": "28.94%",
                        "Col6": "22.56%",
                        "Col7": "12.82%",
                        "Col8": "25.40%",
                        "Col9": "18.72%",
                        "Col10": "19.19%",
                        "Col11": "11.95%"
                    },
                    {
                        "As at and for Fiscal 2023": "EBITDA(3)",
                        "Col1": "Rs Million",
                        "Col2": "3,840.55",
                        "Col3": "27,124.80",
                        "Col4": "6,129.02",
                        "Col5": "12,652.26",
                        "Col6": "28,871.90",
                        "Col7": "18,255.30",
                        "Col8": "5,478.99",
                        "Col9": "7,056.94",
                        "Col10": "20,292.06",
                        "Col11": "1,228.45"
                    },
                    {
                        "As at and for Fiscal 2023": "EBITDA\nmargin(4)",
                        "Col1": "%",
                        "Col2": "10.38%",
                        "Col3": "33.44%",
                        "Col4": "44.20%",
                        "Col5": "32.73%",
                        "Col6": "29.87%",
                        "Col7": "15.45%",
                        "Col8": "32.30%",
                        "Col9": "22.34%",
                        "Col10": "22.86%",
                        "Col11": "13.13%"
                    },
                    {
                        "As at and for Fiscal 2023": "Profit for the\nperiod /year",
                        "Col1": "Rs Million",
                        "Col2": "978.17",
                        "Col3": "18,233.80",
                        "Col4": "4,112.95",
                        "Col5": "7,810.49",
                        "Col6": "12,452.30",
                        "Col7": "10,068.10",
                        "Col8": "3,741.60",
                        "Col9": "4,100.08",
                        "Col10": "13,096.80",
                        "Col11": "679.54"
                    },
                    {
                        "As at and for Fiscal 2023": "PAT margin(5)",
                        "Col1": "%",
                        "Col2": "2.64%",
                        "Col3": "22.48%",
                        "Col4": "29.66%",
                        "Col5": "20.21%",
                        "Col6": "12.88%",
                        "Col7": "8.52%",
                        "Col8": "22.06%",
                        "Col9": "12.98%",
                        "Col10": "14.75%",
                        "Col11": "7.26%"
                    },
                    {
                        "As at and for Fiscal 2023": "Fixed Asset\nturnover(6) ratio",
                        "Col1": "Times",
                        "Col2": "3.41",
                        "Col3": "1.58",
                        "Col4": "1.65",
                        "Col5": "2.07",
                        "Col6": "1.16",
                        "Col7": "4.75",
                        "Col8": "0.76",
                        "Col9": "1.69",
                        "Col10": "1.90",
                        "Col11": "5.37"
                    },
                    {
                        "As at and for Fiscal 2023": "Debt-equity\nratio(7)",
                        "Col1": "Times",
                        "Col2": "0.75",
                        "Col3": "0.00",
                        "Col4": "0.04",
                        "Col5": "0.00",
                        "Col6": "0.85",
                        "Col7": "0.14",
                        "Col8": "0.38",
                        "Col9": "0.22",
                        "Col10": "0.02",
                        "Col11": "0.85"
                    },
                    {
                        "As at and for Fiscal 2023": "Return on\nequity(8)",
                        "Col1": "%",
                        "Col2": "13.52%",
                        "Col3": "14.28%",
                        "Col4": "23.70%",
                        "Col5": "9.81%",
                        "Col6": "20.09%",
                        "Col7": "10.67%",
                        "Col8": "16.85%",
                        "Col9": "16.53%",
                        "Col10": "17.18%",
                        "Col11": "24.58%"
                    },
                    {
                        "As at and for Fiscal 2023": "Return on Capital\nEmployed(9)",
                        "Col1": "%",
                        "Col2": "24.60%",
                        "Col3": "27.70%",
                        "Col4": "32.55%",
                        "Col5": "26.68%",
                        "Col6": "20.01%",
                        "Col7": "19.26%",
                        "Col8": "14.40%",
                        "Col9": "20.14%",
                        "Col10": "23.51%",
                        "Col11": "22.68%"
                    },
                    {
                        "As at and for Fiscal 2023": "Segment results before depreciation",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": null,
                        "Col10": null,
                        "Col11": null
                    },
                    {
                        "As at and for Fiscal 2023": "- CDMO",
                        "Col1": "Rs Million",
                        "Col2": "3,922.87",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "- API",
                        "Col1": "Rs Million",
                        "Col2": "(1,034.45)",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "- Branded &\ngeneric\nformulations",
                        "Col1": "Rs Million",
                        "Col2": "451.05",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "Segment results before depreciation margin(10)",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": null,
                        "Col10": null,
                        "Col11": null
                    },
                    {
                        "As at and for Fiscal 2023": "- CDMO",
                        "Col1": "%",
                        "Col2": "14.41%",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "- API",
                        "Col1": "%",
                        "Col2": "-58.36%",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "- Branded &\ngeneric\nformulations",
                        "Col1": "%",
                        "Col2": "5.98%",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null,
                        "Col9": null,
                        "Col10": null,
                        "Col11": null
                    },
                    {
                        "As at and for Fiscal 2023": "Adjusted EBIT(11)",
                        "Col1": "(\u20b9 in\nmillion)",
                        "Col2": "2,272.77",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "Adjusted EBIT",
                        "Col1": "",
                        "Col2": "6.14%",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    }
                ],
                "rows": 23,
                "cols": 12
            },
            {
                "page_number": 117,
                "table_data": [
                    {
                        "As at and for Fiscal 2023": "Parameter",
                        "Col1": "Units",
                        "Col2": "Akums Drugs\nand\nPharmaceuticals",
                        "Col3": "Divi's\nLaboratories",
                        "Col4": "Suven Pharma",
                        "Col5": "Gland Pharma",
                        "Col6": "Torrent\nPharma",
                        "Col7": "Alkem\nLaboratories",
                        "Col8": "Eris\nLifesciences",
                        "Col9": "JB Chemicals",
                        "Col10": "Mankind\nPharma",
                        "Col11": "Innova\nCaptab"
                    },
                    {
                        "As at and for Fiscal 2023": "margin(12)",
                        "Col1": "%",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": "",
                        "Col6": "",
                        "Col7": "",
                        "Col8": "",
                        "Col9": "",
                        "Col10": "",
                        "Col11": ""
                    },
                    {
                        "As at and for Fiscal 2023": "Adjusted\nEBITDA(13)",
                        "Col1": "(\u20b9 in\nmillion)",
                        "Col2": "3,400.86",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "Adjusted\nEBITDA\nmargin(14)",
                        "Col1": "%",
                        "Col2": "9.19%",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "Adjusted Return\non equity(15)",
                        "Col1": "%",
                        "Col2": "3.11%",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    },
                    {
                        "As at and for Fiscal 2023": "Adjusted Return\non Capital\nemployed(16)",
                        "Col1": "%",
                        "Col2": "10.77%",
                        "Col3": "NA",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA",
                        "Col9": "NA",
                        "Col10": "NA",
                        "Col11": "NA"
                    }
                ],
                "rows": 6,
                "cols": 12
            },
            {
                "page_number": 118,
                "table_data": [
                    {
                        "Date of\nallotment": "NA",
                        "Number of\nequity shares\ntransacted": "Nil",
                        "Face value of\nequity shares\n(\u20b9)": "Nil",
                        "Offer price per\nEquity share": "Nil",
                        "Nature of\nallotment": "NA",
                        "Nature of\nconsideration": "NA",
                        "Total\nconsideration\n(\u20b9)": "Nil"
                    }
                ],
                "rows": 1,
                "cols": 7
            },
            {
                "page_number": 118,
                "table_data": [
                    {
                        "Type of transactions": "Weighted average cost of acquisition for last 18 months for primary / new\nissue of shares (equity/ convertible securities), excluding shares issued\nunder ESOP 2022 and issuance of bonus shares, during the 18 months\npreceding the date of this certificate, where such issuance is equal to or\nmore than five per cent of the fully diluted paid-up share capital of our\nCompany (calculated based on the pre-issue capital before such\ntransaction/s and excluding employee stock options granted but not\nvested), in a single transaction or multiple transactions combined together\nover a span of rolling 30 days",
                        "WACA (in \u20b9)": "NA",
                        "Floor Price (\u20b9\n[\u25cf])*": "[\u25cf]",
                        "Cap Price (\u20b9\n[\u25cf])*": "[\u25cf]"
                    },
                    {
                        "Type of transactions": "Weighted average cost of acquisition for last 18 months for secondary sale\n/ acquisition of shares equity/convertible securities), where our Promoters\nor Promoter Group entities or Selling Shareholders or shareholder(s)\nhaving the right to nominate director(s) in our Board are a party to the\ntransaction (excluding gifts), during the 18 months preceding the date of\nthis certificate, where either acquisition or sale is equal to or more than\nfive per cent of the fully diluted paid-up share capital of our Company\n(calculated based on the pre-issue capital before such transaction/s and\nexcluding employee stock options granted but not vested), in a single\ntransaction or multiple transactions combined together over a span of\nrolling 30 days",
                        "WACA (in \u20b9)": "NA",
                        "Floor Price (\u20b9\n[\u25cf])*": "[\u25cf]",
                        "Cap Price (\u20b9\n[\u25cf])*": "[\u25cf]"
                    }
                ],
                "rows": 2,
                "cols": 4
            },
            {
                "page_number": 145,
                "table_data": [
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "Parameter/ Company",
                        "Col1": "Torrent\nPharma",
                        "Col2": "Alkem\nLaboratories",
                        "Col3": "Eris\nLifesciences\nLtd.",
                        "Col4": "JB Chemicals",
                        "Col5": "Mankind\nPharma"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "Operating Revenue",
                        "Col1": "96,201.50",
                        "Col2": "1,15,992.60",
                        "Col3": "16,851.49",
                        "Col4": "31,492.82",
                        "Col5": "87,494.33"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "Total Revenue",
                        "Col1": "96,652.90",
                        "Col2": "1,18,153.40",
                        "Col3": "16,963.02",
                        "Col4": "31,592.22",
                        "Col5": "88,779.99"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "Total Revenue CAGR\n(FY19 - FY23)",
                        "Col1": "5.75%",
                        "Col2": "12.24%",
                        "Col3": "13.73%",
                        "Col4": "17.02%",
                        "Col5": "14.11%"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "EBITDA",
                        "Col1": "28,871.90",
                        "Col2": "18,255.30",
                        "Col3": "5,478.99",
                        "Col4": "7,056.94",
                        "Col5": "20,292.06"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "EBIT",
                        "Col1": "21,806.00",
                        "Col2": "15,151.10",
                        "Col3": "4,308.11",
                        "Col4": "5,912.88",
                        "Col5": "17,032.87"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "PAT",
                        "Col1": "12,452.30",
                        "Col2": "10,068.10",
                        "Col3": "3,741.60",
                        "Col4": "4,100.08",
                        "Col5": "13,096.80"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "PAT CAGR (FY19 -\nFY23)",
                        "Col1": "29.98%",
                        "Col2": "7.27%",
                        "Col3": "6.50%",
                        "Col4": "20.65%",
                        "Col5": "7.83%"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "ROCE",
                        "Col1": "20.01%",
                        "Col2": "19.26%",
                        "Col3": "14.40%",
                        "Col4": "20.14%",
                        "Col5": "23.51%"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "Return on Equity",
                        "Col1": "20.09%",
                        "Col2": "10.67%",
                        "Col3": "16.85%",
                        "Col4": "16.53%",
                        "Col5": "17.18%"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "Return on Net Worth",
                        "Col1": "20.09%",
                        "Col2": "10.88%",
                        "Col3": "17.40%",
                        "Col4": "16.52%",
                        "Col5": "17.24%"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "EBITDA Margin",
                        "Col1": "29.87%",
                        "Col2": "15.45%",
                        "Col3": "32.30%",
                        "Col4": "22.34%",
                        "Col5": "22.86%"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "EBIT Margin",
                        "Col1": "22.56%",
                        "Col2": "12.82%",
                        "Col3": "25.40%",
                        "Col4": "18.72%",
                        "Col5": "19.19%"
                    },
                    {
                        "Exhibit 2.9: Financial Analysis of Select IPM Companies, FY23, INR Million": "PAT Margin",
                        "Col1": "12.88%",
                        "Col2": "8.52%",
                        "Col3": "22.06%",
                        "Col4": "12.98%",
                        "Col5": "14.75%"
                    }
                ],
                "rows": 14,
                "cols": 6
            },
            {
                "page_number": 146,
                "table_data": [
                    {
                        "Interest Coverage": "R&D\nExpense/Operating\nRevenue",
                        "6.54": "5.36%",
                        "14.11": "4.65%",
                        "16.46": "-",
                        "16.40": "1.13%",
                        "38.30": "2.15%"
                    },
                    {
                        "Interest Coverage": "Fixed Asset Turnover\nRatio",
                        "6.54": "1.16",
                        "14.11": "4.75",
                        "16.46": "0.76",
                        "16.40": "1.69",
                        "38.30": "1.90"
                    },
                    {
                        "Interest Coverage": "Debt/Equity Ratio",
                        "6.54": "0.85",
                        "14.11": "0.14",
                        "16.46": "0.38",
                        "16.40": "0.22",
                        "38.30": "0.02"
                    },
                    {
                        "Interest Coverage": "NAV/share (INR)",
                        "6.54": "183.13",
                        "14.11": "756.52",
                        "16.46": "161.49",
                        "16.40": "320.77",
                        "38.30": "185.61"
                    },
                    {
                        "Interest Coverage": "EPS diluted (INR)",
                        "6.54": "36.79",
                        "14.11": "82.31",
                        "16.46": "28.07",
                        "16.40": "52.34",
                        "38.30": "32.00"
                    },
                    {
                        "Interest Coverage": "EPS basic (INR)",
                        "6.54": "36.79",
                        "14.11": "82.31",
                        "16.46": "28.10",
                        "16.40": "53.00",
                        "38.30": "32.00"
                    },
                    {
                        "Interest Coverage": "Face Value (INR)",
                        "6.54": "5.00",
                        "14.11": "2.00",
                        "16.46": "10.00",
                        "16.40": "2.00",
                        "38.30": "1.00"
                    }
                ],
                "rows": 7,
                "cols": 6
            },
            {
                "page_number": 156,
                "table_data": [
                    {
                        "Exhibit 3.8: Benefits of Outsourcing to India, China vs. India": "Criteria",
                        "Col1": "China",
                        "Col2": "India"
                    },
                    {
                        "Exhibit 3.8: Benefits of Outsourcing to India, China vs. India": "2022 Cost of Labor (Monthly\nMinimum Wage)",
                        "Col1": "USD 286.5",
                        "Col2": "USD 58.9"
                    },
                    {
                        "Exhibit 3.8: Benefits of Outsourcing to India, China vs. India": "Median Working Age",
                        "Col1": "38.4 years",
                        "Col2": "28.4 years"
                    },
                    {
                        "Exhibit 3.8: Benefits of Outsourcing to India, China vs. India": "Working Age Population as\na proportion of the total\npopulation",
                        "Col1": "69%",
                        "Col2": "68%"
                    },
                    {
                        "Exhibit 3.8: Benefits of Outsourcing to India, China vs. India": "2023 \u2013 2027 Ease of Doing\nBusiness (EIU Ratings)",
                        "Col1": "Finance: 5.9\nPrivate Enterprise Policy: 4.8\nInfrastructure: 6.8\nTax Regime: 5.1\nForeign Trade Exchange: 6.3",
                        "Col2": "Finance: 6.3\nPrivate Enterprise Policy: 5.8\nInfrastructure: 5.4\nTax Regime: 6.1\nForeign Trade Exchange: 7.3"
                    },
                    {
                        "Exhibit 3.8: Benefits of Outsourcing to India, China vs. India": "Infrastructure \u2013 GDUFA\nRegistered Facilities",
                        "Col1": "169 facilities for FY24, including\n112 API facilities\n38 FDF facilities",
                        "Col2": "376 facilities for FY24, including\n200 API facilities\n134 FDF facilities"
                    }
                ],
                "rows": 6,
                "cols": 3
            },
            {
                "page_number": 157,
                "table_data": [
                    {
                        "Col0": "Language Barrier",
                        "11 facilities engaged in API and\nFDF\n8 CMO facilities": "There is a high language barrier as\nthe limited working population is\nEnglish-speaking",
                        "21 facilities engaged in both API and\nFDF\n21 CMO facilities": "Large English-speaking workforce"
                    }
                ],
                "rows": 1,
                "cols": 3
            },
            {
                "page_number": 162,
                "table_data": [
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Target CDMO",
                        "Col1": "PE Buyer",
                        "Col2": "Stake"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Aragen",
                        "Col1": "Goldman Sachs",
                        "Col2": "33%"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Rubicon Research",
                        "Col1": "Everstone Capital Management",
                        "Col2": "70%"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Accutest Research Labs",
                        "Col1": "Greater Pacific Capital",
                        "Col2": "34%"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Fermenta Biotech",
                        "Col1": "Evolvence India Life Sciences Fund",
                        "Col2": "21.05%"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Strides Pharma",
                        "Col1": "Apax Partners India Advisers",
                        "Col2": "1.2%"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "RA Chem Pharma",
                        "Col1": "Advent International (Cohance Lifesciences)",
                        "Col2": "Majority"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Piramal Pharma Solutions",
                        "Col1": "The Carlyle Group",
                        "Col2": "20%"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Tirupati Medicare",
                        "Col1": "Affirma",
                        "Col2": "Undisclosed"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "ACME",
                        "Col1": "PAG",
                        "Col2": "Majority"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Suven Pharma",
                        "Col1": "Advent (Cohance Lifesciences)",
                        "Col2": "50.1%"
                    },
                    {
                        "Exhibit 3.14: Select PE Investments in Indian CDMOs, 2010-2023": "Akums",
                        "Col1": "Quadria Capital",
                        "Col2": "15.09%"
                    }
                ],
                "rows": 12,
                "cols": 3
            },
            {
                "page_number": 164,
                "table_data": [
                    {
                        "Exhibit 3.15: Operational Analysis of Select Indian CDMOs, India, FY23": "Name",
                        "Col1": "HQ",
                        "Col2": "No. of\nMfg.\nFacilities",
                        "Col3": "Facility\nLocations",
                        "Col4": "Annual Production Capacity/ Capacity\nUtilization"
                    },
                    {
                        "Exhibit 3.15: Operational Analysis of Select Indian CDMOs, India, FY23": "Tirupati\nMedicare",
                        "Col1": "Himachal\nPradesh, India",
                        "Col2": "3*",
                        "Col3": "HP, India",
                        "Col4": "Total Formulations: 2.67 billion\n2) Tablets: 1803.2 million\n3) Capsules: 720 million\n4) Oral Liquids: 132.1 million\n5) Oral Power: 47.7K Ton\n6) Ointments and Creams: 6.8 million\n7) Oils: 6.8 million units"
                    },
                    {
                        "Exhibit 3.15: Operational Analysis of Select Indian CDMOs, India, FY23": "Innova Captab\nLtd. (Innova\nCaptab)",
                        "Col1": "Maharashtra,\nIndia",
                        "Col2": "3",
                        "Col3": "HP, India",
                        "Col4": "Total Formulations: 10.87 billion\n1) Tablets: 8192 million\n2) Capsules: 2473 million\n3) Ointments: 23 million\n4) Dry Powder Injections: 61 million\n5) Dry Syrup: 54 million\n6) Oral Liquids: 71 million"
                    },
                    {
                        "Exhibit 3.15: Operational Analysis of Select Indian CDMOs, India, FY23": "Synokem\nPharma",
                        "Col1": "Delhi, India",
                        "Col2": "3",
                        "Col3": "UK, India",
                        "Col4": "Total Formulations: 10.96 billion\n1) Tablets: 4480 million\n2) Capsules: 567 million\n3) Oral Liquids: 4800 million\n4) Ointment: 1080 million\n5) Gel: 14.6 million\n1) Sachets 14.6 million"
                    },
                    {
                        "Exhibit 3.15: Operational Analysis of Select Indian CDMOs, India, FY23": "Akums",
                        "Col1": "Delhi, India",
                        "Col2": "10**",
                        "Col3": "Pan India",
                        "Col4": "Total Formulations: 49.21 billion***\n1) Oral Solids: 47.9 billion\n2) Sterile Preparations: 744.2 million\n3) Liquids: 417.6 million\n4) External: 158.4 million"
                    }
                ],
                "rows": 5,
                "cols": 5
            },
            {
                "page_number": 165,
                "table_data": [
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "Dosage Forms",
                        "Col1": null,
                        "Col2": "Tirupati\nMedicare",
                        "Col3": "Innova\nCaptab",
                        "Col4": "Synokem\nPharma",
                        "Col5": "Akums"
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "",
                        "Col1": "Presence in the total number of dosage\nforms (34)",
                        "Col2": "12",
                        "Col3": "6",
                        "Col4": "8",
                        "Col5": "29"
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OL",
                        "Col1": "Dry syrups",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OL",
                        "Col1": "Solutions, suspension",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OL",
                        "Col1": "Liquid Orals, Syrups",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Tablets",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Capsules",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Lozenges",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Gummies/ Jellies",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Chewable Tablets",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Orally Disintegrating tablets/powder",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Tablet-in-Tablet",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Bi-layered tablet",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Controlled/ Modified Release",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Powders",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Granules",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Effervescent Tablets",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "OS",
                        "Col1": "Soft Gels",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "PR",
                        "Col1": "Emulsions",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "PR",
                        "Col1": "Dry Powder Injections",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "PR",
                        "Col1": "Pre-Filled Syringe",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "PR",
                        "Col1": "Injectables \u2013 Vials",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "PR",
                        "Col1": "Injectables \u2013 Ampoules",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "PR",
                        "Col1": "Injectables \u2013 Lyophilized",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "PR",
                        "Col1": "Injectables \u2013 Cartridge",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "PR",
                        "Col1": "Injectables/Sterile Prep \u2013 Blow-filled\nSeal/Respules",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "PR",
                        "Col1": "Nanoparticles and Liposomes",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "TP",
                        "Col1": "Ointments",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "TP",
                        "Col1": "Creams",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "TP",
                        "Col1": "Gels",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "TP",
                        "Col1": "Sprays/Aerosols",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "TP",
                        "Col1": "Eye Drops",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "IH",
                        "Col1": "Pressurized metered dose inhaler",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "IH",
                        "Col1": "Dry powder inhaler",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "IH",
                        "Col1": "Nebulizer",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    },
                    {
                        "Exhibit 3.16: Dosage Forms Analysis of Select Indian CDMOs, FY23": "IH",
                        "Col1": "Nasal aerosols, Spray and Powders",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": ""
                    }
                ],
                "rows": 36,
                "cols": 6
            },
            {
                "page_number": 166,
                "table_data": [
                    {
                        "Exhibit 3.17: Comparison of R&D Capabilities of Select Indian CDMOs, FY23": "Company",
                        "Col1": "R&D Centres",
                        "Col2": "R&D capabilities"
                    },
                    {
                        "Exhibit 3.17: Comparison of R&D Capabilities of Select Indian CDMOs, FY23": "Tirupati Medicare",
                        "Col1": "1",
                        "Col2": "No DCGI approvals in FY23"
                    },
                    {
                        "Exhibit 3.17: Comparison of R&D Capabilities of Select Indian CDMOs, FY23": "Synokem Pharma",
                        "Col1": "Not Available",
                        "Col2": "22 DCGI approvals in FY23"
                    },
                    {
                        "Exhibit 3.17: Comparison of R&D Capabilities of Select Indian CDMOs, FY23": "Innova Captab",
                        "Col1": "1",
                        "Col2": "4 DCGI approvals in FY23"
                    },
                    {
                        "Exhibit 3.17: Comparison of R&D Capabilities of Select Indian CDMOs, FY23": "Akums48",
                        "Col1": "4",
                        "Col2": "69 DCGI approvals in FY23\n901 DCGI approvals as of 30th Sept 2023\n5 patents"
                    }
                ],
                "rows": 5,
                "cols": 3
            },
            {
                "page_number": 166,
                "table_data": [
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Parameter/ Company",
                        "Col1": "Tirupati Medicare\n(FY23)",
                        "Col2": "Innova Captab\n(FY23)",
                        "Col3": "Synokem Pharma\n(FY22)",
                        "Col4": "Akums (FY23) (As\nper Audited RFS)"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Operating Revenue",
                        "Col1": "9,691.01",
                        "Col2": "9,263.80",
                        "Col3": "6,856.54",
                        "Col4": "36,548.20"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Total Revenue",
                        "Col1": "9,702.51",
                        "Col2": "9,355.78",
                        "Col3": "6,909.02",
                        "Col4": "37,009.25"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Total Revenue CAGR\nFY19 \u2013 FY23",
                        "Col1": "15.93%",
                        "Col2": "27.32%",
                        "Col3": "19.89%",
                        "Col4": "16.28%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EBITDA",
                        "Col1": "886.93",
                        "Col2": "1,228.45",
                        "Col3": "1,135.92",
                        "Col4": "3,840.55"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EBIT",
                        "Col1": "650.85",
                        "Col2": "1,117.68",
                        "Col3": "1,064.14",
                        "Col4": "2,712.46"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "PAT",
                        "Col1": "407.45",
                        "Col2": "679.54",
                        "Col3": "800.26",
                        "Col4": "978.17"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "PAT CAGR FY19 \u2013\nFY23",
                        "Col1": "27.35%",
                        "Col2": "35.98%",
                        "Col3": "35.61%",
                        "Col4": "9.50%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "ROCE",
                        "Col1": "15.17%",
                        "Col2": "22.68%",
                        "Col3": "33.69%",
                        "Col4": "24.60%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Return on Equity",
                        "Col1": "10.32%",
                        "Col2": "24.58%",
                        "Col3": "23.66%",
                        "Col4": "13.52%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Return on Net Worth",
                        "Col1": "10.29%",
                        "Col2": "24.58%",
                        "Col3": "23.66%",
                        "Col4": "13.23%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EBITDA Margin",
                        "Col1": "9.14%",
                        "Col2": "13.13%",
                        "Col3": "16.44%",
                        "Col4": "10.38%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EBIT Margin",
                        "Col1": "6.71%",
                        "Col2": "11.95%",
                        "Col3": "15.40%",
                        "Col4": "7.33%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "PAT Margin",
                        "Col1": "4.20%",
                        "Col2": "7.26%",
                        "Col3": "11.58%",
                        "Col4": "2.64%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Interest Coverage",
                        "Col1": "6.53",
                        "Col2": "5.60",
                        "Col3": "217.30",
                        "Col4": "5.87"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "R&D\nExpense/Operating\nRevenue",
                        "Col1": "-",
                        "Col2": "1.19%",
                        "Col3": "1.10%",
                        "Col4": "2.68%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Fixed Asset Turnover\nRatio",
                        "Col1": "3.71",
                        "Col2": "5.37",
                        "Col3": "8.65",
                        "Col4": "3.41"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Debt/Equity Ratio",
                        "Col1": "0.10",
                        "Col2": "0.85",
                        "Col3": "0.04",
                        "Col4": "0.75"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "NAV/share (INR)",
                        "Col1": "2,897.75",
                        "Col2": "57.61",
                        "Col3": "674.96",
                        "Col4": "50.13"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EPS diluted (INR)",
                        "Col1": "121.83",
                        "Col2": "14.16",
                        "Col3": "160.00",
                        "Col4": "6.63"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EPS basic (INR)",
                        "Col1": "299.96",
                        "Col2": "14.16",
                        "Col3": "160.00",
                        "Col4": "6.63"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Face Value (INR)",
                        "Col1": "10.00",
                        "Col2": "10.00",
                        "Col3": "10.00",
                        "Col4": "2.00"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Adjusted EBITDA",
                        "Col1": "-",
                        "Col2": "-",
                        "Col3": "-",
                        "Col4": "3,400.86"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Adjusted EBITDA\nMargin",
                        "Col1": "-",
                        "Col2": "-",
                        "Col3": "-",
                        "Col4": "9.19%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Adjusted EBIT",
                        "Col1": "-",
                        "Col2": "-",
                        "Col3": "-",
                        "Col4": "2,272.77"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Adjusted EBIT Margin",
                        "Col1": "-",
                        "Col2": "-",
                        "Col3": "-",
                        "Col4": "6.14%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Adjusted ROE",
                        "Col1": "-",
                        "Col2": "-",
                        "Col3": "-",
                        "Col4": "3.11%"
                    },
                    {
                        "Exhibit 3.20: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Adjusted ROCE",
                        "Col1": "-",
                        "Col2": "-",
                        "Col3": "-",
                        "Col4": "10.77%"
                    }
                ],
                "rows": 28,
                "cols": 5
            },
            {
                "page_number": 169,
                "table_data": [
                    {
                        "Exhibit 3.21: Client Concentration: Contribution of Top 10 Customers to Revenue": "Tirupati Medicare",
                        "Col1": "FY 21= ~65%."
                    },
                    {
                        "Exhibit 3.21: Client Concentration: Contribution of Top 10 Customers to Revenue": "Innova Captab",
                        "Col1": "FY 23= 56% (of CDMO revenue)\nFY 22= 49% (of CDMO revenue)"
                    },
                    {
                        "Exhibit 3.21: Client Concentration: Contribution of Top 10 Customers to Revenue": "Synokem Pharma",
                        "Col1": "FY22= 30-35%,\nthe largest customer accounted for 5%"
                    }
                ],
                "rows": 3,
                "cols": 2
            },
            {
                "page_number": 170,
                "table_data": [
                    {
                        "Exhibit 3.21: Client Concentration: Contribution of Top 10 Customers to Revenue": "Akums",
                        "Col1": "FY23= 39%\nFY22 = 41%"
                    }
                ],
                "rows": 1,
                "cols": 2
            },
            {
                "page_number": 170,
                "table_data": [
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Name",
                        "Col1": "HQ",
                        "Col2": "No. of\nMfg.\nFacilities",
                        "Col3": "Facility\nLocations",
                        "Col4": "Annual Production Capacity/ Capacity\nUtilization"
                    },
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Catalent",
                        "Col1": "New Jersey, US",
                        "Col2": "50",
                        "Col3": "Global",
                        "Col4": "Total Formulations: 70.00 billion\n1) 8000 products: 70 billion doses"
                    },
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Lonza",
                        "Col1": "Basel,\nSwitzerland",
                        "Col2": "35",
                        "Col3": "Global",
                        "Col4": "Total Formulations: 260.00 billion\n1) ~260 billion capsule capacity in 2022\n2) API: 2,500 Metric Tons"
                    },
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Patheon Pharma\nServices",
                        "Col1": "Massachusetts,\nUS",
                        "Col2": "30",
                        "Col3": "Global",
                        "Col4": "Total Formulations: 10.17 to 12.17 billion\n1) Soft gels: 10 billion to 12 billion\n2) Sterile Liquid and Lyophilized vials: >172\nmillion (in 2022)"
                    },
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Bora Pharma",
                        "Col1": "Taipei, Taiwan",
                        "Col2": "6",
                        "Col3": "Taiwan &\nCanada",
                        "Col4": "Total Formulations: 2.75 billion\n1) Bulk tablets: 2 billion\n2) Capsules: 690 million\n3) Semi-solid tubes (Creams, gels, Ointments)\n30 million\n4) Nasal Spray Bottles: 29 million"
                    },
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Procaps Group",
                        "Col1": "Colombia, South\nAmerica",
                        "Col2": "8",
                        "Col3": "US &\nSouth\nAmerica",
                        "Col4": "Total Formulations: 9.13 billion\n1) Soft Gels/Gummies: 6.5 billion\n2) Tablets/Capsules: 1.9 billion\n3) Hormonal Drugs: 684 million\n4) Injectables: 138 million"
                    },
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Aenova Group",
                        "Col1": "Starnberg,\nGermany",
                        "Col2": "15",
                        "Col3": "14 in EU, 1\nin US, 10\nsites are\nFDA\napproved",
                        "Col4": "Total Formulations: 34.75 billion\n1) Tablets/Capsules: 22 billion\n2) Blisters: 1.4 billion\n3) Soft gel Capsules: 11 billion\n4) Semi-solids/Liquids: 350 million"
                    },
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Nipro Pharma\nCorporation",
                        "Col1": "Osaka, Japan",
                        "Col2": "6",
                        "Col3": "1 Vietnam\n& 5 Japan",
                        "Col4": "Total Formulations: >16.12 billion\n1) Ampoules and Vials: >740 million"
                    }
                ],
                "rows": 8,
                "cols": 5
            },
            {
                "page_number": 171,
                "table_data": [
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Name",
                        "Col1": "HQ",
                        "Col2": "No. of\nMfg.\nFacilities",
                        "Col3": "Facility\nLocations",
                        "Col4": "Annual Production Capacity/ Capacity\nUtilization"
                    },
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "",
                        "Col1": "",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "2) Prefilled Syringes: >160 million\n3) Tablets: >14.8 billion\n4) Capsules: >400 million\n5) Granules, Dry Syrups: >610 tons\n6) Syrups: >460,000 bottles\n7) Ointments and Creams: >16.3 million tubes"
                    },
                    {
                        "Exhibit 3.22: Operational Analysis of Select Global and Regional CDMOs, 2023": "Akums",
                        "Col1": "Delhi, India",
                        "Col2": "10*",
                        "Col3": "Pan India",
                        "Col4": "Total Formulations: 49.21 billion\n1) Oral Solids: 47.9 billion\n2) Sterile Preparations: 744.2 million\n3) Liquids: 417.6 million\n4) External: 158.4 million"
                    }
                ],
                "rows": 3,
                "cols": 5
            },
            {
                "page_number": 171,
                "table_data": [
                    {
                        "Table 3.23: Presence in Key Markets of Select Global and Regional CDMOs, 2023": "Name",
                        "Col1": "No. of Customers"
                    },
                    {
                        "Table 3.23: Presence in Key Markets of Select Global and Regional CDMOs, 2023": "Catalent",
                        "Col1": "1200"
                    },
                    {
                        "Table 3.23: Presence in Key Markets of Select Global and Regional CDMOs, 2023": "Lonza",
                        "Col1": "7000"
                    },
                    {
                        "Table 3.23: Presence in Key Markets of Select Global and Regional CDMOs, 2023": "Patheon Pharma Services",
                        "Col1": "700"
                    },
                    {
                        "Table 3.23: Presence in Key Markets of Select Global and Regional CDMOs, 2023": "Procaps Group",
                        "Col1": "120"
                    },
                    {
                        "Table 3.23: Presence in Key Markets of Select Global and Regional CDMOs, 2023": "Aenova Group",
                        "Col1": "450"
                    },
                    {
                        "Table 3.23: Presence in Key Markets of Select Global and Regional CDMOs, 2023": "Akums",
                        "Col1": "1543"
                    }
                ],
                "rows": 7,
                "cols": 2
            },
            {
                "page_number": 171,
                "table_data": [
                    {
                        "Table 3.24: R&D Capabilities of Select Global and Regional CDMOs, 2023": "Company",
                        "Col1": "R&D Centres",
                        "Col2": "R&D capabilities"
                    },
                    {
                        "Table 3.24: R&D Capabilities of Select Global and Regional CDMOs, 2023": "Catalent",
                        "Col1": "Not Available",
                        "Col2": "1400 patent applications\nAssisted 50% of the FDA approvals in the last 10 years"
                    },
                    {
                        "Table 3.24: R&D Capabilities of Select Global and Regional CDMOs, 2023": "Lonza",
                        "Col1": "Not Available",
                        "Col2": "Trademark filings: 2,605\nActive patent families: 344\nIngredient patent families: 40"
                    },
                    {
                        "Table 3.24: R&D Capabilities of Select Global and Regional CDMOs, 2023": "Patheon Pharma\nServices",
                        "Col1": "Not Available",
                        "Col2": "Supported 135 regulatory approvals (NDAs/BLAs) over the\nlast five years (2018-2022)"
                    },
                    {
                        "Table 3.24: R&D Capabilities of Select Global and Regional CDMOs, 2023": "Procaps Group",
                        "Col1": "Not Available",
                        "Col2": "84 patents (of which 53 are pending and 31 are already granted\nin different countries)"
                    }
                ],
                "rows": 5,
                "cols": 3
            },
            {
                "page_number": 172,
                "table_data": [
                    {
                        "Table 3.24: R&D Capabilities of Select Global and Regional CDMOs, 2023": "Akums49",
                        "Col1": "4",
                        "Col2": "69 DCGI approvals in FY23\n901 DCGI approvals as of 30th Sept 2023\n5 patents"
                    }
                ],
                "rows": 1,
                "cols": 3
            },
            {
                "page_number": 172,
                "table_data": [
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Parameter/\nCompany",
                        "Col1": "Catalent",
                        "Col2": "Lonza",
                        "Col3": "TFS",
                        "Col4": "Bora\nPharma",
                        "Col5": "Procaps\nGroup",
                        "Col6": "Aenova\nGroup",
                        "Col7": "Nipro\nPharma",
                        "Col8": "Akums (As\nper RFS)"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Operating\nRevenue",
                        "Col1": "4,263.00",
                        "Col2": "6,730.80",
                        "Col3": "44,915.00",
                        "Col4": "343.63",
                        "Col5": "409.92",
                        "Col6": "803.59",
                        "Col7": "4,042.73",
                        "Col8": "444.73"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Total Revenue",
                        "Col1": "4,256.00",
                        "Col2": "6,730.80",
                        "Col3": "44,915.00",
                        "Col4": "340.94",
                        "Col5": "409.92",
                        "Col6": "813.03",
                        "Col7": "4,098.76",
                        "Col8": "450.34"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Total Revenue\nCAGR (18 \u2013 22)",
                        "Col1": "14.05%",
                        "Col2": "4.59%",
                        "Col3": "16.53%",
                        "Col4": "60.09%",
                        "Col5": "8.07%",
                        "Col6": "(2.01)%",
                        "Col7": "2.42%",
                        "Col8": "11.46%"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "EBITDA",
                        "Col1": "266.00",
                        "Col2": "2,321.11",
                        "Col3": "12,666.00",
                        "Col4": "74.46",
                        "Col5": "107.52",
                        "Col6": "92.89",
                        "Col7": "584.58",
                        "Col8": "46.71"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "EBIT",
                        "Col1": "(156.00)",
                        "Col2": "1,676.48",
                        "Col3": "8,389.00",
                        "Col4": "63.81",
                        "Col5": "90.68",
                        "Col6": "4.93",
                        "Col7": "230.68",
                        "Col8": "32.98"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "PAT",
                        "Col1": "(256.00)",
                        "Col2": "1,317.39",
                        "Col3": "6,960.00",
                        "Col4": "45.89",
                        "Col5": "42.54",
                        "Col6": "(49.55)",
                        "Col7": "123.10",
                        "Col8": "11.90"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "PAT CAGR (18 \u2013\n22)",
                        "Col1": "-",
                        "Col2": "23.22%",
                        "Col3": "24.06%",
                        "Col4": "33.59%",
                        "Col5": "-",
                        "Col6": "-",
                        "Col7": "1.55%",
                        "Col8": "4.96%"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "ROCE",
                        "Col1": "(1.70)%",
                        "Col2": "13.41%",
                        "Col3": "11.98%",
                        "Col4": "18.22%",
                        "Col5": "37.62%",
                        "Col6": "0.89%",
                        "Col7": "5.59%",
                        "Col8": "24.58%"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Return on Equity",
                        "Col1": "(5.55)%",
                        "Col2": "11.42%",
                        "Col3": "15.81%",
                        "Col4": "27.26%",
                        "Col5": "-",
                        "Col6": "-",
                        "Col7": "8.95%",
                        "Col8": "13.52%"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Return on Net\nWorth",
                        "Col1": "(5.55)%",
                        "Col2": "11.49%",
                        "Col3": "15.80%",
                        "Col4": "30.74%",
                        "Col5": "-",
                        "Col6": "-",
                        "Col7": "7.99%",
                        "Col8": "13.23%"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "EBITDA Margin",
                        "Col1": "6.25%",
                        "Col2": "34.48%",
                        "Col3": "28.20%",
                        "Col4": "21.84%",
                        "Col5": "26.23%",
                        "Col6": "11.42%",
                        "Col7": "14.26%",
                        "Col8": "10.37%"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "EBIT Margin",
                        "Col1": "(3.67)%",
                        "Col2": "24.91%",
                        "Col3": "18.68%",
                        "Col4": "18.72%",
                        "Col5": "22.12%",
                        "Col6": "0.61%",
                        "Col7": "5.63%",
                        "Col8": "7.32%"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "PAT Margin",
                        "Col1": "(6.02)%",
                        "Col2": "19.57%",
                        "Col3": "15.50%",
                        "Col4": "13.46%",
                        "Col5": "10.38%",
                        "Col6": "(9.09)%",
                        "Col7": "3.00%",
                        "Col8": "2.64%"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Interest Coverage",
                        "Col1": "(0.84)",
                        "Col2": "14.90",
                        "Col3": "11.56",
                        "Col4": "17.92",
                        "Col5": "2.39",
                        "Col6": "0.09",
                        "Col7": "6.83",
                        "Col8": "5.86"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "R&D\nExpense/Operati\nng Revenue",
                        "Col1": "0.42%",
                        "Col2": "3.12%",
                        "Col3": "3.28%",
                        "Col4": "1.23%",
                        "Col5": "4.42%",
                        "Col6": "-",
                        "Col7": "3.79%",
                        "Col8": "2.68%"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Fixed Asset\nTurnover Ratio",
                        "Col1": "0.91",
                        "Col2": "0.75",
                        "Col3": "1.68",
                        "Col4": "1.19",
                        "Col5": "3.86",
                        "Col6": "1.46",
                        "Col7": "1.21",
                        "Col8": "3.41"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Debt/ Equity\nratio",
                        "Col1": "1.05",
                        "Col2": "0.21",
                        "Col3": "0.78",
                        "Col4": "1.23",
                        "Col5": "-",
                        "Col6": "-",
                        "Col7": "2.70",
                        "Col8": "0.75"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "NAV/share\n(USD)",
                        "Col1": "25.62",
                        "Col2": "153.65",
                        "Col3": "99.80",
                        "Col4": "1.91",
                        "Col5": "(0.01)",
                        "Col6": "-",
                        "Col7": "8.02",
                        "Col8": "0.61"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "EPS diluted\n(USD)",
                        "Col1": "(1.42)",
                        "Col2": "17.67",
                        "Col3": "17.63",
                        "Col4": "0.33",
                        "Col5": "420.00",
                        "Col6": "-",
                        "Col7": "0.59",
                        "Col8": "0.08"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "EPS basic (USD)",
                        "Col1": "(1.42)",
                        "Col2": "17.71",
                        "Col3": "23.24",
                        "Col4": "0.36",
                        "Col5": "420.00",
                        "Col6": "-",
                        "Col7": "0.63",
                        "Col8": "0.08"
                    },
                    {
                        "Exhibit 3.25: Financial Analysis of Select Global and Regional CDMOs, CY 2022/FY23, USD Million": "Face Value\n(USD)",
                        "Col1": "0.01",
                        "Col2": "1.08",
                        "Col3": "1.00",
                        "Col4": "0.33",
                        "Col5": "0.01",
                        "Col6": "-",
                        "Col7": "-",
                        "Col8": "0.02"
                    }
                ],
                "rows": 22,
                "cols": 9
            },
            {
                "page_number": 173,
                "table_data": [
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "Ranking",
                        "Col1": "Company Name",
                        "Col2": "FY22 Revenue\n(INR Cr)"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "1",
                        "Col1": "Sun Pharmaceutical Industries Ltd.",
                        "Col2": "38,654"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "2",
                        "Col1": "Serum Institute of India Pvt. Ltd.",
                        "Col2": "25,645"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "3",
                        "Col1": "Aurobindo Pharma Ltd.",
                        "Col2": "23,455"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "4",
                        "Col1": "Cipla Ltd.",
                        "Col2": "21,763"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "5",
                        "Col1": "Dr Reddy's Laboratories Ltd.",
                        "Col2": "21,545"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "6",
                        "Col1": "Intas Pharmaceuticals Ltd.",
                        "Col2": "18,351"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "7",
                        "Col1": "Lupin Ltd.",
                        "Col2": "16,405"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "8",
                        "Col1": "Zydus Lifesciences Ltd.",
                        "Col2": "15,110"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "9",
                        "Col1": "Glenmark Pharmaceuticals Ltd.",
                        "Col2": "12,305"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "10",
                        "Col1": "Hetero Labs Ltd.",
                        "Col2": "11,897"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "11",
                        "Col1": "Alkem Laboratories Ltd.",
                        "Col2": "10,634"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "12",
                        "Col1": "Divi's Laboratories Ltd.",
                        "Col2": "8,960"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "13",
                        "Col1": "Torrent Pharmaceuticals Ltd.",
                        "Col2": "8,508"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "14",
                        "Col1": "Biocon Ltd.",
                        "Col2": "8,184"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "15",
                        "Col1": "Macleods Pharmaceuticals Ltd.",
                        "Col2": "8,172"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "16",
                        "Col1": "Bharat Biotech International Ltd.",
                        "Col2": "8,116"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "17",
                        "Col1": "Mankind Pharma Ltd.",
                        "Col2": "7,782"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "18",
                        "Col1": "Piramal Pharma Solutions",
                        "Col2": "6,559"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "19",
                        "Col1": "Jubilant Pharmova Ltd.",
                        "Col2": "6,130"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "20",
                        "Col1": "Emcure Pharmaceuticals Ltd.",
                        "Col2": "5,855"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "21",
                        "Col1": "IPCA Laboratories Ltd.",
                        "Col2": "5,797"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "22",
                        "Col1": "Nirayu Pvt. Ltd.",
                        "Col2": "5,656"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "23",
                        "Col1": "Alembic Pharmaceuticals Ltd.",
                        "Col2": "5,306"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "24",
                        "Col1": "Micro Labs Ltd.",
                        "Col2": "5,168"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "25",
                        "Col1": "Laurus Labs Ltd.",
                        "Col2": "4,936"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "26",
                        "Col1": "Abbott India Ltd.",
                        "Col2": "4,919"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "27",
                        "Col1": "Gland Pharma Ltd.",
                        "Col2": "4,401"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "28",
                        "Col1": "MSN Laboratories Pvt. Ltd.",
                        "Col2": "4,122"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "29",
                        "Col1": "USV Pvt. Ltd.",
                        "Col2": "3,893"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "30",
                        "Col1": "Granules India Ltd.",
                        "Col2": "3,765"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "31",
                        "Col1": "Akums",
                        "Col2": "3,672"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "32",
                        "Col1": "Biocon Biologics Ltd.",
                        "Col2": "3,464"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "33",
                        "Col1": "Ajanta Pharma Ltd.",
                        "Col2": "3,341"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "34",
                        "Col1": "GlaxoSmithKline Pharmaceuticals Ltd.",
                        "Col2": "3,278"
                    },
                    {
                        "Table 4.1: Revenue of Leading 35 Companies in the Indian Pharma Landscape, FY22": "35",
                        "Col1": "Wockhardt Ltd.",
                        "Col2": "3,230"
                    }
                ],
                "rows": 36,
                "cols": 3
            },
            {
                "page_number": 173,
                "table_data": [
                    {
                        "Table 4.2: Revenue of Select Large Global CDMOs, CY22/FY23": "Ranking",
                        "Col1": "Company Name",
                        "Col2": "Approximated CY 2022/ FY23 CDMO\nRevenue (USD Million)"
                    },
                    {
                        "Table 4.2: Revenue of Select Large Global CDMOs, CY22/FY23": "1",
                        "Col1": "Lonza",
                        "Col2": "6,730.8"
                    },
                    {
                        "Table 4.2: Revenue of Select Large Global CDMOs, CY22/FY23": "2",
                        "Col1": "Catalent",
                        "Col2": "4,828.0"
                    },
                    {
                        "Table 4.2: Revenue of Select Large Global CDMOs, CY22/FY23": "3",
                        "Col1": "Patheon Pharma Solutions",
                        "Col2": "4,222.0"
                    },
                    {
                        "Table 4.2: Revenue of Select Large Global CDMOs, CY22/FY23": "4",
                        "Col1": "WuXi AppTec Co., Ltd./ Wuxi Chemistry",
                        "Col2": "3,010.0"
                    },
                    {
                        "Table 4.2: Revenue of Select Large Global CDMOs, CY22/FY23": "5",
                        "Col1": "WuXi Biologics Co., Ltd.",
                        "Col2": "2,272.8"
                    },
                    {
                        "Table 4.2: Revenue of Select Large Global CDMOs, CY22/FY23": "6",
                        "Col1": "Fareva SA",
                        "Col2": "2,188.1"
                    }
                ],
                "rows": 7,
                "cols": 3
            },
            {
                "page_number": 174,
                "table_data": [
                    {
                        "7": "8",
                        "Samsung Biologics Co., Ltd.": "FUJIFILM Diosynth Biotechnologies",
                        "1,796.2": "1,474.4"
                    },
                    {
                        "7": "9",
                        "Samsung Biologics Co., Ltd.": "Pfizer CenterOne",
                        "1,796.2": "1,342.0"
                    },
                    {
                        "7": "10",
                        "Samsung Biologics Co., Ltd.": "Siegfried Holding AG",
                        "1,796.2": "1,330.4"
                    },
                    {
                        "7": "11",
                        "Samsung Biologics Co., Ltd.": "Recipharm AB",
                        "1,796.2": "1,316.1"
                    },
                    {
                        "7": "12",
                        "Samsung Biologics Co., Ltd.": "Seqens UK Ltd.",
                        "1,796.2": "1,200.0"
                    },
                    {
                        "7": "13",
                        "Samsung Biologics Co., Ltd.": "Delpharm",
                        "1,796.2": "1,072.6"
                    },
                    {
                        "7": "14",
                        "Samsung Biologics Co., Ltd.": "Boehringer Ingelheim - CDMO",
                        "1,796.2": "1036.1"
                    },
                    {
                        "7": "15",
                        "Samsung Biologics Co., Ltd.": "Vetter Pharma-Fertigung GmbH & Co. KG",
                        "1,796.2": "956.8"
                    },
                    {
                        "7": "16",
                        "Samsung Biologics Co., Ltd.": "MilliporeSigma",
                        "1,796.2": "953.8"
                    },
                    {
                        "7": "17",
                        "Samsung Biologics Co., Ltd.": "Divi's Laboratories Ltd.",
                        "1,796.2": "945.2"
                    },
                    {
                        "7": "18",
                        "Samsung Biologics Co., Ltd.": "Corden Pharma GmbH",
                        "1,796.2": "933.2"
                    },
                    {
                        "7": "19",
                        "Samsung Biologics Co., Ltd.": "Almac Group Ltd.",
                        "1,796.2": "901.0"
                    },
                    {
                        "7": "20",
                        "Samsung Biologics Co., Ltd.": "Aenova Group",
                        "1,796.2": "813.0"
                    },
                    {
                        "7": "21",
                        "Samsung Biologics Co., Ltd.": "Curia Global, Inc.",
                        "1,796.2": "800.0"
                    },
                    {
                        "7": "22",
                        "Samsung Biologics Co., Ltd.": "DPT Laboratories Ltd.",
                        "1,796.2": "700.0"
                    },
                    {
                        "7": "23",
                        "Samsung Biologics Co., Ltd.": "Simtra BioPharma Solutions (formerly Baxter\nBiopharma Solutions)",
                        "1,796.2": "644.0"
                    },
                    {
                        "7": "24",
                        "Samsung Biologics Co., Ltd.": "Cambrex Corporation",
                        "1,796.2": "600.0"
                    },
                    {
                        "7": "25",
                        "Samsung Biologics Co., Ltd.": "Nipro Pharma",
                        "1,796.2": "523.1"
                    },
                    {
                        "7": "26",
                        "Samsung Biologics Co., Ltd.": "Piramal Pharma Solutions",
                        "1,796.2": "491.2"
                    },
                    {
                        "7": "27",
                        "Samsung Biologics Co., Ltd.": "Akums",
                        "1,796.2": "476.3"
                    },
                    {
                        "7": "28",
                        "Samsung Biologics Co., Ltd.": "Hovione",
                        "1,796.2": "465.0"
                    },
                    {
                        "7": "29",
                        "Samsung Biologics Co., Ltd.": "NextPharma Technologies Holding Limited",
                        "1,796.2": "429.0"
                    },
                    {
                        "7": "30",
                        "Samsung Biologics Co., Ltd.": "Procaps Group",
                        "1,796.2": "409.9"
                    },
                    {
                        "7": "31",
                        "Samsung Biologics Co., Ltd.": "Bora Pharma",
                        "1,796.2": "340.9"
                    },
                    {
                        "7": "32",
                        "Samsung Biologics Co., Ltd.": "Pharmaron Beijing Co. Ltd.",
                        "1,796.2": "377.2"
                    },
                    {
                        "7": "33",
                        "Samsung Biologics Co., Ltd.": "PCI Pharma Services",
                        "1,796.2": "260.0"
                    }
                ],
                "rows": 26,
                "cols": 3
            },
            {
                "page_number": 174,
                "table_data": [
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Parameter/ Company",
                        "Col1": "Divi's Laboratories (FY23)",
                        "Col2": "Suven Pharma (FY23)",
                        "Col3": "Gland Pharma (FY23)"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Operating Revenue",
                        "Col1": "77,675.10",
                        "Col2": "13,403.30",
                        "Col3": "36,246.01"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Total Revenue",
                        "Col1": "81,121.70",
                        "Col2": "13,866.93",
                        "Col3": "38,650.64"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Total Revenue CAGR\nFY19 \u2013 FY23",
                        "Col1": "12.29%",
                        "Col2": "38.36%",
                        "Col3": "16.07%"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EBITDA",
                        "Col1": "27,124.80",
                        "Col2": "6,129.02",
                        "Col3": "12,652.26"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EBIT",
                        "Col1": "23,693.00",
                        "Col2": "5,651.70",
                        "Col3": "11,184.90"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "PAT",
                        "Col1": "18,233.80",
                        "Col2": "4,112.95",
                        "Col3": "7,810.49"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "PAT CAGR FY19 \u2013 FY23",
                        "Col1": "7.75%",
                        "Col2": "39.29%",
                        "Col3": "14.66%"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "ROCE",
                        "Col1": "27.70%",
                        "Col2": "32.55%",
                        "Col3": "26.68%"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Return on Equity",
                        "Col1": "14.28%",
                        "Col2": "23.70%",
                        "Col3": "9.81%"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Return on Net Worth",
                        "Col1": "14.28%",
                        "Col2": "23.70%",
                        "Col3": "9.81%"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EBITDA Margin",
                        "Col1": "33.44%",
                        "Col2": "44.20%",
                        "Col3": "32.73%"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EBIT Margin",
                        "Col1": "29.21%",
                        "Col2": "40.76%",
                        "Col3": "28.94%"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "PAT Margin",
                        "Col1": "22.48%",
                        "Col2": "29.66%",
                        "Col3": "20.21%"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Interest Coverage",
                        "Col1": "3,536.27",
                        "Col2": "103.97",
                        "Col3": "150.19"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "R&D Expense/Operating\nRevenue",
                        "Col1": "0.89%",
                        "Col2": "0.64%",
                        "Col3": "5.56%"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Fixed Asset Turnover\nRatio",
                        "Col1": "1.58",
                        "Col2": "1.65",
                        "Col3": "2.07"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "Debt/Equity Ratio",
                        "Col1": "0.00",
                        "Col2": "0.04",
                        "Col3": "0.00"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "NAV/share (INR)",
                        "Col1": "480.93",
                        "Col2": "68.16",
                        "Col3": "483.41"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EPS diluted (INR)",
                        "Col1": "68.69",
                        "Col2": "16.16",
                        "Col3": "47.43"
                    },
                    {
                        "Exhibit 4.3: Financial Analysis of Select Indian CDMOs, FY23, INR Million": "EPS basic (INR)",
                        "Col1": "68.69",
                        "Col2": "16.16",
                        "Col3": "47.44"
                    }
                ],
                "rows": 21,
                "cols": 4
            },
            {
                "page_number": 175,
                "table_data": [
                    {
                        "Col0": "",
                        "Exhibit 4.4: Segmental Revenue for Select Indian CDMOs, FY21 \u2013 FY23, INR Million": "Segment",
                        "Col2": "FY23",
                        "Col3": "FY22",
                        "Col4": "FY21"
                    },
                    {
                        "Col0": "Akums",
                        "Exhibit 4.4: Segmental Revenue for Select Indian CDMOs, FY21 \u2013 FY23, INR Million": "CDMO",
                        "Col2": "27,230.07",
                        "Col3": "26,610.96",
                        "Col4": "21,377.88"
                    },
                    {
                        "Col0": null,
                        "Exhibit 4.4: Segmental Revenue for Select Indian CDMOs, FY21 \u2013 FY23, INR Million": "API",
                        "Col2": "1,772.49",
                        "Col3": "1,093.21",
                        "Col4": "6.72"
                    },
                    {
                        "Col0": null,
                        "Exhibit 4.4: Segmental Revenue for Select Indian CDMOs, FY21 \u2013 FY23, INR Million": "Branded and\nGeneric\nFormulations",
                        "Col2": "7,545.63",
                        "Col3": "9,014.76",
                        "Col4": "5,841.69"
                    },
                    {
                        "Col0": "Innova\nCaptab",
                        "Exhibit 4.4: Segmental Revenue for Select Indian CDMOs, FY21 \u2013 FY23, INR Million": "CDMO",
                        "Col2": "6,795.56",
                        "Col3": "6,866.94",
                        "Col4": "3,708.71"
                    },
                    {
                        "Col0": null,
                        "Exhibit 4.4: Segmental Revenue for Select Indian CDMOs, FY21 \u2013 FY23, INR Million": "Domestic\nBranded\nGenerics",
                        "Col2": "1,661.61",
                        "Col3": "370.51",
                        "Col4": "0.00"
                    },
                    {
                        "Col0": null,
                        "Exhibit 4.4: Segmental Revenue for Select Indian CDMOs, FY21 \u2013 FY23, INR Million": "International\nBranded\nGenerics",
                        "Col2": "806.63",
                        "Col3": "767.81",
                        "Col4": "397.91"
                    }
                ],
                "rows": 7,
                "cols": 5
            },
            {
                "page_number": 175,
                "table_data": [
                    {
                        "Exhibit 4.5: Segmental Financial Analysis for Akums, FY21 \u2013 FY23, INR Million": "Segment",
                        "Col1": "Parameter",
                        "Col2": "FY23",
                        "Col3": "FY22",
                        "Col4": "FY21"
                    },
                    {
                        "Exhibit 4.5: Segmental Financial Analysis for Akums, FY21 \u2013 FY23, INR Million": "CDMO",
                        "Col1": "EBITDA",
                        "Col2": "3,922.87",
                        "Col3": "4,001.51",
                        "Col4": "2,765.15"
                    },
                    {
                        "Exhibit 4.5: Segmental Financial Analysis for Akums, FY21 \u2013 FY23, INR Million": null,
                        "Col1": "EBITDA\nMargin",
                        "Col2": "14.41%",
                        "Col3": "15.04%",
                        "Col4": "12.93%"
                    },
                    {
                        "Exhibit 4.5: Segmental Financial Analysis for Akums, FY21 \u2013 FY23, INR Million": "API",
                        "Col1": "EBITDA",
                        "Col2": "(1,034.45)",
                        "Col3": "(223.74)",
                        "Col4": "(21.14)"
                    },
                    {
                        "Exhibit 4.5: Segmental Financial Analysis for Akums, FY21 \u2013 FY23, INR Million": null,
                        "Col1": "EBITDA\nMargin",
                        "Col2": "(58.36)%",
                        "Col3": "(20.47)%",
                        "Col4": "(314.58)%"
                    },
                    {
                        "Exhibit 4.5: Segmental Financial Analysis for Akums, FY21 \u2013 FY23, INR Million": "Branded\nGenerics and\nFormulations",
                        "Col1": "EBITDA",
                        "Col2": "451.05",
                        "Col3": "339.99",
                        "Col4": "319.24"
                    },
                    {
                        "Exhibit 4.5: Segmental Financial Analysis for Akums, FY21 \u2013 FY23, INR Million": null,
                        "Col1": "EBITDA\nMargin",
                        "Col2": "5.98%",
                        "Col3": "3.77%",
                        "Col4": "5.46%"
                    }
                ],
                "rows": 7,
                "cols": 5
            },
            {
                "page_number": 177,
                "table_data": [
                    {
                        "Particulars": "Client base for CDMO\nbusiness(1)",
                        "Six months ended\nSeptember 30, 2023": "1,345",
                        "Financial Year 2023": "1,543",
                        "Financial Year 2022": "1,386",
                        "Financial Year 2021": "1,161"
                    },
                    {
                        "Particulars": "Revenue contributions\nfrom our ten largest clients\nby revenue in our CDMO\nbusiness (in %)",
                        "Six months ended\nSeptember 30, 2023": "43.35",
                        "Financial Year 2023": "38.92",
                        "Financial Year 2022": "41.27",
                        "Financial Year 2021": "36.16"
                    }
                ],
                "rows": 2,
                "cols": 5
            },
            {
                "page_number": 179,
                "table_data": [
                    {
                        "Particulars": null,
                        "Six months ended\nSeptember 30, 2023": "(in \u20b9 million, unless otherwise specified)",
                        "Financial Year\n2023": null,
                        "Financial Year\n2022": null,
                        "Financial Year\n2021": null
                    },
                    {
                        "Particulars": "Revenue from operations",
                        "Six months ended\nSeptember 30, 2023": "21,511.38",
                        "Financial Year\n2023": "36,548.20",
                        "Financial Year\n2022": "36,718.93",
                        "Financial Year\n2021": "27,226.29"
                    },
                    {
                        "Particulars": "EBITDA(1)",
                        "Six months ended\nSeptember 30, 2023": "414.31",
                        "Financial Year\n2023": "3,840.55",
                        "Financial Year\n2022": "(690.89)",
                        "Financial Year\n2021": "2,584.99"
                    },
                    {
                        "Particulars": "EBITDA margin(2)",
                        "Six months ended\nSeptember 30, 2023": "1.91%",
                        "Financial Year\n2023": "10.38%",
                        "Financial Year\n2022": "(1.87)%",
                        "Financial Year\n2021": "9.42%"
                    },
                    {
                        "Particulars": "EBIT(3)",
                        "Six months ended\nSeptember 30, 2023": "(187.07)",
                        "Financial Year\n2023": "2,712.46",
                        "Financial Year\n2022": "(1,637.68)",
                        "Financial Year\n2021": "1,886.58"
                    },
                    {
                        "Particulars": "EBIT margin(4)",
                        "Six months ended\nSeptember 30, 2023": "(0.86)%",
                        "Financial Year\n2023": "7.33%",
                        "Financial Year\n2022": "(4.43)%",
                        "Financial Year\n2021": "6.88%"
                    },
                    {
                        "Particulars": "Profit for the period / year",
                        "Six months ended\nSeptember 30, 2023": "(1,547.39)",
                        "Financial Year\n2023": "978.17",
                        "Financial Year\n2022": "(2,508.74)",
                        "Financial Year\n2021": "1,234.35"
                    },
                    {
                        "Particulars": "Profit after tax margin(5) (%)",
                        "Six months ended\nSeptember 30, 2023": "(7.14)%",
                        "Financial Year\n2023": "2.64%",
                        "Financial Year\n2022": "(6.79)%",
                        "Financial Year\n2021": "4.50%"
                    },
                    {
                        "Particulars": "Fixed asset turnover ratio(6)*",
                        "Six months ended\nSeptember 30, 2023": "1.89",
                        "Financial Year\n2023": "3.41",
                        "Financial Year\n2022": "3.79",
                        "Financial Year\n2021": "3.26"
                    },
                    {
                        "Particulars": "Debt-equity ratio(7)",
                        "Six months ended\nSeptember 30, 2023": "1.26",
                        "Financial Year\n2023": "0.75",
                        "Financial Year\n2022": "0.58",
                        "Financial Year\n2021": "0.11"
                    },
                    {
                        "Particulars": "Return on equity(8)* (%)",
                        "Six months ended\nSeptember 30, 2023": "(27.23)%",
                        "Financial Year\n2023": "13.52%",
                        "Financial Year\n2022": "(40.13)%",
                        "Financial Year\n2021": "13.91%"
                    },
                    {
                        "Particulars": "Return on capital employed(9)*",
                        "Six months ended\nSeptember 30, 2023": "(1.83)%",
                        "Financial Year\n2023": "24.60%",
                        "Financial Year\n2022": "(18.89)%",
                        "Financial Year\n2021": "21.06%"
                    },
                    {
                        "Particulars": "Segment results before depreciation*",
                        "Six months ended\nSeptember 30, 2023": "",
                        "Financial Year\n2023": "",
                        "Financial Year\n2022": "",
                        "Financial Year\n2021": ""
                    },
                    {
                        "Particulars": "- CDMO",
                        "Six months ended\nSeptember 30, 2023": "2,950.39",
                        "Financial Year\n2023": "3,922.87",
                        "Financial Year\n2022": "4,001.51",
                        "Financial Year\n2021": "2,765.15"
                    },
                    {
                        "Particulars": "- Branded and generic formulations",
                        "Six months ended\nSeptember 30, 2023": "157.04",
                        "Financial Year\n2023": "451.05",
                        "Financial Year\n2022": "339.99",
                        "Financial Year\n2021": "319.24"
                    },
                    {
                        "Particulars": "- API",
                        "Six months ended\nSeptember 30, 2023": "(210.48)",
                        "Financial Year\n2023": "(1,034.45)",
                        "Financial Year\n2022": "(223.74)",
                        "Financial Year\n2021": "(21.14)"
                    },
                    {
                        "Particulars": "Segment results before depreciation margin (%)(10)*",
                        "Six months ended\nSeptember 30, 2023": "",
                        "Financial Year\n2023": "",
                        "Financial Year\n2022": "",
                        "Financial Year\n2021": ""
                    },
                    {
                        "Particulars": "- CDMO",
                        "Six months ended\nSeptember 30, 2023": "17.56%",
                        "Financial Year\n2023": "14.41%",
                        "Financial Year\n2022": "15.04%",
                        "Financial Year\n2021": "12.93%"
                    },
                    {
                        "Particulars": "- Branded and generic formulations",
                        "Six months ended\nSeptember 30, 2023": "4.16%",
                        "Financial Year\n2023": "5.98%",
                        "Financial Year\n2022": "3.77%",
                        "Financial Year\n2021": "5.46%"
                    },
                    {
                        "Particulars": "- API",
                        "Six months ended\nSeptember 30, 2023": "(22.55)%",
                        "Financial Year\n2023": "(58.36)%",
                        "Financial Year\n2022": "(20.47)%",
                        "Financial Year\n2021": "(314.58)%"
                    },
                    {
                        "Particulars": "Adjusted EBITDA(11)#",
                        "Six months ended\nSeptember 30, 2023": "2,950.77",
                        "Financial Year\n2023": "3,400.86",
                        "Financial Year\n2022": "4,250.85",
                        "Financial Year\n2021": "3,123.22"
                    },
                    {
                        "Particulars": "Adjusted EBITDA margin(12) #*",
                        "Six months ended\nSeptember 30, 2023": "13.62%",
                        "Financial Year\n2023": "9.19%",
                        "Financial Year\n2022": "11.51%",
                        "Financial Year\n2021": "11.38%"
                    },
                    {
                        "Particulars": "Adjusted EBIT(13)#",
                        "Six months ended\nSeptember 30, 2023": "2,349.39",
                        "Financial Year\n2023": "2,272.77",
                        "Financial Year\n2022": "3,304.06",
                        "Financial Year\n2021": "2,424.81"
                    },
                    {
                        "Particulars": "Adjusted EBIT margin(14)#*",
                        "Six months ended\nSeptember 30, 2023": "10.85%",
                        "Financial Year\n2023": "6.14%",
                        "Financial Year\n2022": "8.94%",
                        "Financial Year\n2021": "8.84%"
                    },
                    {
                        "Particulars": "Adjusted Return on equity(15)#*",
                        "Six months ended\nSeptember 30, 2023": "5.41%",
                        "Financial Year\n2023": "3.11%",
                        "Financial Year\n2022": "14.51%",
                        "Financial Year\n2021": "12.27%"
                    },
                    {
                        "Particulars": "Adjusted Return on Capital employed(16) #*",
                        "Six months ended\nSeptember 30, 2023": "10.30%",
                        "Financial Year\n2023": "10.77%",
                        "Financial Year\n2022": "17.22%",
                        "Financial Year\n2021": "16.69%"
                    }
                ],
                "rows": 26,
                "cols": 5
            },
            {
                "page_number": 180,
                "table_data": [
                    {
                        "Particulars": "Revenue contributions\nfrom our ten largest clients",
                        "Six months ended\nSeptember 30, 2023": "43.35",
                        "Financial Year 2023": "38.92",
                        "Financial Year 2022": "41.27",
                        "Financial Year 2021": "36.16"
                    }
                ],
                "rows": 1,
                "cols": 5
            },
            {
                "page_number": 181,
                "table_data": [
                    {
                        "Particulars": "by revenue in our CDMO\nbusiness (in %)",
                        "Six months ended\nSeptember 30, 2023": "",
                        "Financial Year 2023": "",
                        "Financial Year 2022": "",
                        "Financial Year 2021": ""
                    }
                ],
                "rows": 1,
                "cols": 5
            },
            {
                "page_number": 183,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of revenue\nfrom\noperations",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of revenue\nfrom\noperations",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of revenue\nfrom\noperations",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of revenue\nfrom\noperations"
                    },
                    {
                        "Particulars": "CDMO",
                        "For the six months ended\nSeptember 30, 2023": "16,805.98",
                        "Col2": "78.13",
                        "For the Financial Year": "27,230.08",
                        "Col4": "74.50",
                        "Col5": "26,610.96",
                        "Col6": "72.47",
                        "Col7": "21,377.88",
                        "Col8": "78.52"
                    },
                    {
                        "Particulars": "Branded and generic\nformulations",
                        "For the six months ended\nSeptember 30, 2023": "3,771.98",
                        "Col2": "17.53",
                        "For the Financial Year": "7,545.63",
                        "Col4": "20.65",
                        "Col5": "9,014.76",
                        "Col6": "24.55",
                        "Col7": "5,841.69",
                        "Col8": "21.46"
                    },
                    {
                        "Particulars": "API",
                        "For the six months ended\nSeptember 30, 2023": "933.42",
                        "Col2": "4.34",
                        "For the Financial Year": "1,772.49",
                        "Col4": "4.85",
                        "Col5": "1,093.21",
                        "Col6": "2.98",
                        "Col7": "6.72",
                        "Col8": "0.02"
                    },
                    {
                        "Particulars": "Total",
                        "For the six months ended\nSeptember 30, 2023": "21,511.38",
                        "Col2": "100.00",
                        "For the Financial Year": "36,548.20",
                        "Col4": "100.00",
                        "Col5": "36,718.93",
                        "Col6": "100.00",
                        "Col7": "27,226.29",
                        "Col8": "100.00"
                    }
                ],
                "rows": 6,
                "cols": 9
            },
            {
                "page_number": 184,
                "table_data": [
                    {
                        "Particulars": "Total formulations manufactured (as of September 30, 2023)",
                        "As of /for the six months ended September 30, 2023": "4,025"
                    },
                    {
                        "Particulars": "DCGI approvals received (as of September 30, 2023)",
                        "As of /for the six months ended September 30, 2023": "901"
                    },
                    {
                        "Particulars": "SKUs manufactured (for the six months ended September 30, 2023)",
                        "As of /for the six months ended September 30, 2023": "13,028"
                    }
                ],
                "rows": 3,
                "cols": 2
            },
            {
                "page_number": 184,
                "table_data": [
                    {
                        "Main Classification": "Oral Solids",
                        "Sub Classification": "Tablets",
                        "Form": "Uncoated tablets\nFilm coated tablets\nSugar coated tablets\nSustained release tablets\nBi-layered tablets\nChewable tablets\nEffervescent tablets\nTablet in tablet\nBi-layered tablet in tablet\nInlay tablets"
                    },
                    {
                        "Main Classification": null,
                        "Sub Classification": "Capsules",
                        "Form": "Hard gelatin capsules"
                    }
                ],
                "rows": 2,
                "cols": 3
            },
            {
                "page_number": 185,
                "table_data": [
                    {
                        "Main Classification": "",
                        "Sub Classification": "",
                        "Form": "Soft gelatin capsules\nTablet-in-capsules\nTwist-off tips\nVegetarian capsules\nRotacap"
                    },
                    {
                        "Main Classification": null,
                        "Sub Classification": "Powders",
                        "Form": "Effervescent powders\nPowder in sachet\nMouth-melt powder"
                    },
                    {
                        "Main Classification": null,
                        "Sub Classification": "Others",
                        "Form": "Soup\nLozenges\nReady mix\nBolus\nDiskette\nGummies\nKits\nGranules/ Pellets"
                    },
                    {
                        "Main Classification": "Oral Liquids",
                        "Sub Classification": "\u2014",
                        "Form": "Oral spray\nSyrups\nSuspensions\nOral solutions\nOral jellies in sachet\nOral drops\nEmulsion\nDry syrup\nLiquid shots"
                    },
                    {
                        "Main Classification": "Sterile",
                        "Sub Classification": "Injectable",
                        "Form": "Ampoules\nDry powder injections\nSingle dose vials\nPre-filled syringes\nMulti dose vials\nLarge volume parenteral (100 ml)/ Infusions"
                    },
                    {
                        "Main Classification": null,
                        "Sub Classification": "Others",
                        "Form": "Ear drops\nThree-piece eye drops\nForm fill seal eye drops\nUnit dose individual medication systems"
                    }
                ],
                "rows": 6,
                "cols": 3
            },
            {
                "page_number": 186,
                "table_data": [
                    {
                        "Main Classification": "",
                        "Sub Classification": "",
                        "Form": "Respules"
                    },
                    {
                        "Main Classification": "Topicals",
                        "Sub Classification": "\u2014",
                        "Form": "Creams\nOintments\nGels\nLotions\nOils\nShampoo\nFacewash/ Scrub\nBalm\nLiniment\nPaint\nToothpaste\nMouthwash"
                    }
                ],
                "rows": 2,
                "cols": 3
            },
            {
                "page_number": 186,
                "table_data": [
                    {
                        "Particulars": "Number of CDMO clients",
                        "Six months ended\nSeptember 30, 2023": "1,345",
                        "Financial Year 2023": "1,543",
                        "Financial Year\n2022": "1,386",
                        "Financial Year\n2021": "1,161"
                    },
                    {
                        "Particulars": "Revenue generated from CDMO segment\n(\u20b9 in millions)",
                        "Six months ended\nSeptember 30, 2023": "16,805.98",
                        "Financial Year 2023": "27,230.08",
                        "Financial Year\n2022": "26,610.96",
                        "Financial Year\n2021": "21,377.88"
                    },
                    {
                        "Particulars": "Revenue generated from 50 largest CDMO\nclients by revenue with legacy of less than\nten years (\u20b9 in millions)",
                        "Six months ended\nSeptember 30, 2023": "3,759.19",
                        "Financial Year 2023": "5,314.98",
                        "Financial Year\n2022": "3,033.45",
                        "Financial Year\n2021": "1,846.40"
                    },
                    {
                        "Particulars": "Revenue generated from 50 largest CDMO\nclients by revenue with legacy longer than\nten years (\u20b9 in millions)",
                        "Six months ended\nSeptember 30, 2023": "8,329.13",
                        "Financial Year 2023": "12,900.83",
                        "Financial Year\n2022": "14,329.67",
                        "Financial Year\n2021": "9,948.21"
                    },
                    {
                        "Particulars": "Revenue contributions from our ten largest\nclients by revenue in our CDMO business\n(in %)",
                        "Six months ended\nSeptember 30, 2023": "43.35",
                        "Financial Year 2023": "38.92",
                        "Financial Year\n2022": "41.27",
                        "Financial Year\n2021": "36.16"
                    }
                ],
                "rows": 5,
                "cols": 5
            },
            {
                "page_number": 187,
                "table_data": [
                    {
                        "Particulars": "Dossiers owned by Unosource",
                        "Six months ended\nSeptember 30, 2023": "67",
                        "Financial Year\n2023": "206",
                        "Financial Year\n2022": "140",
                        "Financial Year\n2021": "86"
                    },
                    {
                        "Particulars": "Third party dossiers",
                        "Six months ended\nSeptember 30, 2023": "24",
                        "Financial Year\n2023": "40",
                        "Financial Year\n2022": "39",
                        "Financial Year\n2021": "39"
                    },
                    {
                        "Particulars": "Total",
                        "Six months ended\nSeptember 30, 2023": "91",
                        "Financial Year\n2023": "246",
                        "Financial Year\n2022": "179",
                        "Financial Year\n2021": "125"
                    }
                ],
                "rows": 3,
                "cols": 5
            },
            {
                "page_number": 188,
                "table_data": [
                    {
                        "Unit": "Dera Bassi, Punjab",
                        "Annual Installed Capacity* (MT)": "557.00"
                    },
                    {
                        "Unit": "Lalru, Punjab",
                        "Annual Installed Capacity* (MT)": "180.00"
                    },
                    {
                        "Unit": "Barwala, Haryana",
                        "Annual Installed Capacity* (MT)": "0.38"
                    }
                ],
                "rows": 3,
                "cols": 2
            },
            {
                "page_number": 188,
                "table_data": [
                    {
                        "Unit": "Unit 1, Haridwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2004",
                        "Dosage Forms": "Oral solids",
                        "Number of\nproduction blocks": "1",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 QMS Certification Services Private\nLimited (ISO 9001:2015, ISO\n14001:2015 and Hazard Analysis\nCritical Control Point)\n\u2022 RIR Certification Private Limited (ISO\n45001:2018)\n\u2022 BSI Certification (ISO 50001:2018)\n\u2022 Bulgarian Drug Agency\n\u2022 Food Safety and Drug Administration,\nUttarakhand\n\u2022 Ministry of Health, Cambodia"
                    }
                ],
                "rows": 1,
                "cols": 5
            },
            {
                "page_number": 189,
                "table_data": [
                    {
                        "Unit": "",
                        "Year of commencement\nof operations": "",
                        "Dosage Forms": "",
                        "Number of\nproduction blocks": "",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 Pharmacy, Medicines and Poisons\nBoard, Malawi\n\u2022 National Agency for Food and Drug\nAdministration and Control, Nigeria\n\u2022 Food and Drug Administration,\nPhilippines\n\u2022 Rwanda Food and Drug Authority\n\u2022 National Medicines Regulatory\nAuthority, Sri Lanka\n\u2022 Ministry of Health, Vietnam"
                    },
                    {
                        "Unit": "Unit 2, Haridwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2007",
                        "Dosage Forms": "Oral liquids",
                        "Number of\nproduction blocks": "1",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 QMS Certification Services Private\nLimited (ISO 9001:2015 and ISO\n14001:2015)\n\u2022 RIR Certification Private Limited (ISO\n45001:2018)\n\u2022 BSI Certification (ISO 50001:2018)\n\u2022 Food Safety and Drug Administration,\nUttarakhand\n\u2022 Ministry of Health, Cambodia\n\u2022 Pharmacy, Medicines and Poisons\nBoard, Malawi\n\u2022 National Agency for Food and Drug\nAdministration and Control, Nigeria\n\u2022 Food and Drug Administration,\nPhilippines\n\u2022 Ministry of Health, Vietnam"
                    },
                    {
                        "Unit": "Unit 3, Haridwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2007",
                        "Dosage Forms": "Sterile preparations",
                        "Number of\nproduction blocks": "4",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 QMS Certification Services Private\nLimited (ISO 9001:2015 and ISO\n14001:2015)\n\u2022 RIR Certification Private Limited (ISO\n45001:2018)\n\u2022 BSI Certification (ISO 50001:2018)\n\u2022 Food Safety and Drug Administration,\nUttarakhand\n\u2022 Bulgarian Drug Agency\n\u2022 Ministry of Health, Cambodia\n\u2022 Food Medicine and Healthcare\nAdministration and Control Authority,\nEthiopia\n\u2022 Pharmacy, Medicines and Poisons\nBoard, Malawi\n\u2022 Ministry of Health and Population,\nNepal"
                    }
                ],
                "rows": 3,
                "cols": 5
            },
            {
                "page_number": 190,
                "table_data": [
                    {
                        "Unit": "",
                        "Year of commencement\nof operations": "",
                        "Dosage Forms": "",
                        "Number of\nproduction blocks": "",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 National Agency for Food and Drug\nAdministration and Control, Nigeria\n\u2022 Food and Drug Administration,\nPhilippines\n\u2022 National Medicines & Poisons Board,\nSudan\n\u2022 National Drug Authority, Uganda"
                    },
                    {
                        "Unit": "Unit 4, Haridwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2010",
                        "Dosage Forms": "Hormonal (oral,\ninjectables and\ntopical)",
                        "Number of\nproduction blocks": "1",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 QMS Certification Services Private\nLimited (ISO 9001:2015 and ISO\n14001:2015)\n\u2022 RIR Certification Private Limited (ISO\n45001:2018)\n\u2022 BSI Certification (ISO 50001:2018)\n\u2022 Food Safety and Drug Administration,\nUttarakhand\n\u2022 Ministry of Health, Cambodia\n\u2022 Food Medicine and Healthcare\nAdministration and Control Authority,\nEthiopia\n\u2022 National Agency of Drug and Food\nControl, Indonesia\n\u2022 Pharmacy, Medicines and Poisons\nBoard, Malawi\n\u2022 Ministry of Health and Population,\nNepal\n\u2022 National Agency for Food and Drug\nAdministration and Control, Nigeria\n\u2022 Food and Drug Administration,\nPhilippines\n\u2022 Ministry of Health, Vietnam"
                    },
                    {
                        "Unit": "Unit 5, Haridwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2010",
                        "Dosage Forms": "Dermatology and\ncosmetics",
                        "Number of\nproduction blocks": "1",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 QMS Certification Services Private\nLimited (ISO 9001:2015 and ISO\n14001:2015)\n\u2022 RIR Certification Private Limited (ISO\n45001:2018)\n\u2022 BSI Certification (ISO 50001:2018)\n\u2022 Food Safety and Drug Administration,\nUttarakhand"
                    },
                    {
                        "Unit": "Unit 6, Haridwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2010",
                        "Dosage Forms": "Ayurvedic /\nNutraceuticals",
                        "Number of\nproduction blocks": "1",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 RIR Certification Private Limited (ISO\n45001:2018, ISO 22000:2018, ISO\n9001:2015 and ISO 14001:2015)\n\u2022 BSI Certification (ISO 50001:2018)\n\u2022 QMS Certification Services Private\nLimited (Hazard Analysis Critical\nControl Point)"
                    }
                ],
                "rows": 4,
                "cols": 5
            },
            {
                "page_number": 191,
                "table_data": [
                    {
                        "Unit": "",
                        "Year of commencement\nof operations": "",
                        "Dosage Forms": "",
                        "Number of\nproduction blocks": "",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 NSF International\n\u2022 System and Solution Private Limited\n\u2022 The United States Food and Drug\nAdministration\n\u2022 Jamiat Ulama-i-Hind Halal Trust\n\u2022 State Licence Authority of Ayurvedic &\nUnani, Uttarakhand"
                    },
                    {
                        "Unit": "Unit 7, Haridwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2014",
                        "Dosage Forms": "Oral solids, oral\nliquids, topical and\ninjectable",
                        "Number of\nproduction blocks": "4",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 RIR Certification Private Limited (ISO\n45001:2018, ISO 9001:2015 and ISO\n14001:2015)\n\u2022 BSI Certification (ISO 50001:2018)\n\u2022 Food Safety and Drug Administration,\nUttarakhand\n\u2022 Ministry of Public Health and\nPopulation, Yemen"
                    },
                    {
                        "Unit": "Unit 8, Haridwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2014",
                        "Dosage Forms": "Anti-bacterials and\nsteroids",
                        "Number of\nproduction blocks": "4",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 RIR Certification Private Limited (ISO\n45001:2018, ISO 9001:2015 and ISO\n14001:2015)\n\u2022 BSI Certification (ISO 50001:2018)\n\u2022 Food Safety and Drug Administration,\nUttarakhand\n\u2022 Ministry of Health, Cambodia\n\u2022 Pharmacy and Poisons Board, Kenya\n\u2022 Pharmacy, Medicines and Poisons\nBoard, Malawi\n\u2022 National Agency for Food and Drug\nAdministration and Control, Nigeria\n\u2022 Tanzania Medicines and Medical\nDevices Authority\n\u2022 National Drug Authority, Uganda"
                    },
                    {
                        "Unit": "Unit 9, Kotdwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2021",
                        "Dosage Forms": "Penam anti-infectives",
                        "Number of\nproduction blocks": "2",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 RIR Certification Private Limited (ISO\n45001:2018, ISO 9001:2015 and ISO\n14001:2015)\n\u2022 Food Safety and Drug Administration,\nUttarakhand"
                    },
                    {
                        "Unit": "Unit 10, Baddi,\nHimachal Pradesh",
                        "Year of commencement\nof operations": "2023",
                        "Dosage Forms": "Oral solids and oral\nliquids",
                        "Number of\nproduction blocks": "4",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2014"
                    },
                    {
                        "Unit": "Unit 11, Haridwar,\nUttarakhand",
                        "Year of commencement\nof operations": "2023",
                        "Dosage Forms": "Injectables",
                        "Number of\nproduction blocks": "1",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2014"
                    },
                    {
                        "Unit": "Unit 12, Baddi,\nHimachal Pradesh",
                        "Year of commencement\nof operations": "2023",
                        "Dosage Forms": "\u2014",
                        "Number of\nproduction blocks": "\u2014",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2014"
                    }
                ],
                "rows": 7,
                "cols": 5
            },
            {
                "page_number": 192,
                "table_data": [
                    {
                        "Unit": "Dera Bassi, Punjab",
                        "API": "Beta-lactam range",
                        "Number of\nproduction blocks": "6",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 QMS Certification Services Private\nLimited (ISO 9001:2015 and ISO\n14001:2015)\n\u2022 RIR Certification Private Limited (ISO\n45001:2018)\n\u2022 Food and Drugs Administration, Punjab"
                    },
                    {
                        "Unit": "Lalru, Punjab",
                        "API": "General range of APIs",
                        "Number of\nproduction blocks": "3",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 RIR Certification Private Limited (ISO\n45001:2018, ISO 9001:2015 and ISO\n14001:2015)"
                    },
                    {
                        "Unit": "Barwala, Haryana",
                        "API": "HPAPI, Oncology and other high potent APIs",
                        "Number of\nproduction blocks": "1",
                        "Major Accreditations/Certifications and\nCertifying Authorities": "\u2022 RIR Certification Private Limited (ISO\n45001:2018, ISO 9001:2015 and ISO\n14001:2015)"
                    }
                ],
                "rows": 3,
                "cols": 4
            },
            {
                "page_number": 192,
                "table_data": [
                    {
                        "Unit": null,
                        "As of/for the six months\nended September 30, 2023": null,
                        "Col2": null,
                        "As of/for the year ended March 31,": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Unit": null,
                        "As of/for the six months\nended September 30, 2023": "Installed\ncapacity*\n(in millions)",
                        "Col2": "Capacity\nutilization\nas % of\ninstalled\ncapacity*",
                        "As of/for the year ended March 31,": "Installed\ncapacity\n(in millions)",
                        "Col4": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col5": "Installed\ncapacity\n(in millions)",
                        "Col6": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col7": "Installed\ncapacity\n(in millions)",
                        "Col8": "Capacity\nutilization\nas % of\ninstalled\ncapacity"
                    },
                    {
                        "Unit": "Unit 1,\nHaridwar,\nUttarakhand",
                        "As of/for the six months\nended September 30, 2023": "6,492.00",
                        "Col2": "31.50%",
                        "As of/for the year ended March 31,": "6,492.00",
                        "Col4": "24.36%",
                        "Col5": "6,492.00",
                        "Col6": "39.84%",
                        "Col7": "6,492.00",
                        "Col8": "50.11%"
                    },
                    {
                        "Unit": "Unit 2,\nHaridwar,\nUttarakhand",
                        "As of/for the six months\nended September 30, 2023": "150.00",
                        "Col2": "66.85%",
                        "As of/for the year ended March 31,": "150.00",
                        "Col4": "55.96%",
                        "Col5": "150.00",
                        "Col6": "67.06%",
                        "Col7": "150.00",
                        "Col8": "33.73%"
                    },
                    {
                        "Unit": "Unit 3,\nHaridwar,\nUttarakhand",
                        "As of/for the six months\nended September 30, 2023": "369.60",
                        "Col2": "60.95%",
                        "As of/for the year ended March 31,": "369.60",
                        "Col4": "54.33%",
                        "Col5": "369.60",
                        "Col6": "62.01%",
                        "Col7": "369.60",
                        "Col8": "53.35%"
                    },
                    {
                        "Unit": "Unit 4,\nHaridwar,\nUttarakhand",
                        "As of/for the six months\nended September 30, 2023": "2,436.00",
                        "Col2": "17.06%",
                        "As of/for the year ended March 31,": "2,436.00",
                        "Col4": "11.95%",
                        "Col5": "2,436.00",
                        "Col6": "14.04%",
                        "Col7": "2,436.00",
                        "Col8": "9.28%"
                    },
                    {
                        "Unit": "Unit 5,\nHaridwar,\nUttarakhand",
                        "As of/for the six months\nended September 30, 2023": "57.60",
                        "Col2": "55.43%",
                        "As of/for the year ended March 31,": "57.60",
                        "Col4": "35.35%",
                        "Col5": "57.60",
                        "Col6": "33.15%",
                        "Col7": "57.60",
                        "Col8": "39.49%"
                    },
                    {
                        "Unit": "Unit 6,\nHaridwar,\nUttarakhand",
                        "As of/for the six months\nended September 30, 2023": "2,519.60",
                        "Col2": "27.41%",
                        "As of/for the year ended March 31,": "2,509.60",
                        "Col4": "24.09%",
                        "Col5": "2,509.60",
                        "Col6": "28.58%",
                        "Col7": "2,148.00",
                        "Col8": "36.06%"
                    },
                    {
                        "Unit": "Unit 7,\nHaridwar,\nUttarakhand",
                        "As of/for the six months\nended September 30, 2023": "26,025.00",
                        "Col2": "51.48%",
                        "As of/for the year ended March 31,": "26,025.00",
                        "Col4": "44.41%",
                        "Col5": "25,971.00",
                        "Col6": "49.31%",
                        "Col7": "20,175.00",
                        "Col8": "56.81%"
                    },
                    {
                        "Unit": "Unit 8,\nHaridwar,\nUttarakhand",
                        "As of/for the six months\nended September 30, 2023": "7,316.40",
                        "Col2": "28.75%",
                        "As of/for the year ended March 31,": "7,316.40",
                        "Col4": "21.54%",
                        "Col5": "7,316.40",
                        "Col6": "28.30%",
                        "Col7": "7,316.40",
                        "Col8": "19.37%"
                    }
                ],
                "rows": 10,
                "cols": 9
            },
            {
                "page_number": 193,
                "table_data": [
                    {
                        "Unit": null,
                        "As of/for the six months\nended September 30, 2023": null,
                        "Col2": null,
                        "As of/for the year ended March 31,": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Unit": null,
                        "As of/for the six months\nended September 30, 2023": "Installed\ncapacity*\n(in millions)",
                        "Col2": "Capacity\nutilization\nas % of\ninstalled\ncapacity*",
                        "As of/for the year ended March 31,": "Installed\ncapacity\n(in millions)",
                        "Col4": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col5": "Installed\ncapacity\n(in millions)",
                        "Col6": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col7": "Installed\ncapacity\n(in millions)",
                        "Col8": "Capacity\nutilization\nas % of\ninstalled\ncapacity"
                    },
                    {
                        "Unit": "Unit 9,\nKotdwar,\nUttarakhand",
                        "As of/for the six months\nended September 30, 2023": "168.00",
                        "Col2": "1.19%",
                        "As of/for the year ended March 31,": "168.00",
                        "Col4": "0.94%",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA"
                    },
                    {
                        "Unit": "Unit 10, Baddi,\nHimachal\nPradesh",
                        "As of/for the six months\nended September 30, 2023": "3,674.78",
                        "Col2": "0.63%",
                        "As of/for the year ended March 31,": "3674.78",
                        "Col4": "NA",
                        "Col5": "NA",
                        "Col6": "NA",
                        "Col7": "NA",
                        "Col8": "NA"
                    }
                ],
                "rows": 4,
                "cols": 9
            },
            {
                "page_number": 193,
                "table_data": [
                    {
                        "Unit": null,
                        "As of/for the six months\nended September 30, 2023": null,
                        "Col2": null,
                        "As of/for the year ended March 31,": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Unit": null,
                        "As of/for the six months\nended September 30, 2023": "Installed\ncapacity*\n(in MT)",
                        "Col2": "Capacity\nutilization\nas % of\ninstalled\ncapacity*",
                        "As of/for the year ended March 31,": "Installed\ncapacity\n(in MT)",
                        "Col4": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col5": "Installed\ncapacity\n(in MT)",
                        "Col6": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col7": "Installed\ncapacity\n(in MT)",
                        "Col8": "Capacity\nutilization\nas % of\ninstalled\ncapacity"
                    },
                    {
                        "Unit": "Dera Bassi,\nPunjab",
                        "As of/for the six months\nended September 30, 2023": "557.00",
                        "Col2": "36.10%",
                        "As of/for the year ended March 31,": "530.00",
                        "Col4": "28.14%",
                        "Col5": "530.00",
                        "Col6": "29.47%",
                        "Col7": "530.00",
                        "Col8": "NA"
                    },
                    {
                        "Unit": "Lalru, Punjab",
                        "As of/for the six months\nended September 30, 2023": "180.00",
                        "Col2": "11.29%",
                        "As of/for the year ended March 31,": "109.00",
                        "Col4": "37.11%",
                        "Col5": "109.00",
                        "Col6": "1.56%",
                        "Col7": "109.00",
                        "Col8": "NA"
                    }
                ],
                "rows": 4,
                "cols": 9
            },
            {
                "page_number": 193,
                "table_data": [
                    {
                        "Particulars": null,
                        "As of/for the six months\nended September 30, 2023": null,
                        "Col2": null,
                        "As of/for the year ended March 31,": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "As of/for the six months\nended September 30, 2023": "Installed\ncapacity*\n(production\nvolume in\nmillions)",
                        "Col2": "Capacity\nutilization\nas % of\ninstalled\ncapacity*",
                        "As of/for the year ended March 31,": "Installed\ncapacity\n(production\nvolume in\nmillions)",
                        "Col4": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col5": "Installed\ncapacity\n(production\nvolume in\nmillions)",
                        "Col6": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col7": "Installed\ncapacity\n(production\nvolume in\nmillions)",
                        "Col8": "Capacity\nutilization\nas % of\ninstalled\ncapacity"
                    },
                    {
                        "Particulars": "Oral solids",
                        "As of/for the six months\nended September 30, 2023": "47,888.78",
                        "Col2": "38.52%",
                        "As of/for the year ended March 31,": "47,878.78",
                        "Col4": "32.16%",
                        "Col5": "44,138.20",
                        "Col6": "41.47%",
                        "Col7": "37,984.20",
                        "Col8": "44.75%"
                    },
                    {
                        "Particulars": "Sterile",
                        "As of/for the six months\nended September 30, 2023": "744.20",
                        "Col2": "50.32%",
                        "As of/for the year ended March 31,": "744.20",
                        "Col4": "46.95%",
                        "Col5": "722.40",
                        "Col6": "52.54%",
                        "Col7": "722.40",
                        "Col8": "40.33%"
                    },
                    {
                        "Particulars": "Liquids",
                        "As of/for the six months\nended September 30, 2023": "417.60",
                        "Col2": "37.88%",
                        "As of/for the year ended March 31,": "417.60",
                        "Col4": "31.05%",
                        "Col5": "283.20",
                        "Col6": "52.51%",
                        "Col7": "279.60",
                        "Col8": "28.43%"
                    },
                    {
                        "Particulars": "External",
                        "As of/for the six months\nended September 30, 2023": "158.40",
                        "Col2": "34.62%",
                        "As of/for the year ended March 31,": "158.40",
                        "Col4": "25.21%",
                        "Col5": "158.40",
                        "Col6": "23.25%",
                        "Col7": "158.40",
                        "Col8": "21.12%"
                    }
                ],
                "rows": 6,
                "cols": 9
            },
            {
                "page_number": 194,
                "table_data": [
                    {
                        "Location": "Haridwar, Uttarakhand",
                        "Segment": "CDMO",
                        "Description": "R&D centre for formulations across various dosage forms, including oral solids,\nliquids, injectables and topicals."
                    }
                ],
                "rows": 1,
                "cols": 3
            },
            {
                "page_number": 195,
                "table_data": [
                    {
                        "Location": "Haridwar, Uttarakhand",
                        "Segment": "CDMO",
                        "Description": "R&D centre for drugs and nutraceutical formulation, across dosage forms such as\nmodified-release oral solids, injectables, nasal sprays, gummies, protein powders and\noral liquids."
                    },
                    {
                        "Location": "Mumbai, Maharashtra",
                        "Segment": "CDMO",
                        "Description": "R&D centre for export-oriented branded formulations for regulated and semi-\nregulated countries. Capabilities include tablets, capsules, ophthalmics, lyophilized\ninjectable, sterile products and hormones."
                    },
                    {
                        "Location": "Barwala, Haryana",
                        "Segment": "API",
                        "Description": "R&D centre dedicated to APIs, intermediates and key starting material."
                    }
                ],
                "rows": 3,
                "cols": 3
            },
            {
                "page_number": 195,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of revenue\nfrom\noperations",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of revenue\nfrom\noperations",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of revenue\nfrom\noperations",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of revenue\nfrom\noperations"
                    },
                    {
                        "Particulars": "R&D expenses",
                        "For the six months ended\nSeptember 30, 2023": "516.54",
                        "Col2": "2.40",
                        "For the Financial Year": "979.64",
                        "Col4": "2.68",
                        "Col5": "713.02",
                        "Col6": "1.94",
                        "Col7": "587.56",
                        "Col8": "2.16"
                    }
                ],
                "rows": 3,
                "cols": 9
            },
            {
                "page_number": 196,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six\nmonths ended\nSeptember 30,\n2023": null,
                        "For the Financial Year": "2023",
                        "Col3": "2022",
                        "Col4": "2021"
                    },
                    {
                        "Particulars": "Corporate Social Responsibility expenses (\u20b9 in millions)",
                        "For the six\nmonths ended\nSeptember 30,\n2023": "19.38",
                        "For the Financial Year": "33.72",
                        "Col3": "21.62",
                        "Col4": "39.01"
                    },
                    {
                        "Particulars": "Percentage of total expenses (%)",
                        "For the six\nmonths ended\nSeptember 30,\n2023": "0.09",
                        "For the Financial Year": "0.10",
                        "Col3": "0.06",
                        "Col4": "0.15"
                    }
                ],
                "rows": 3,
                "cols": 5
            },
            {
                "page_number": 196,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months\nended September 30,\n2023": null,
                        "For the Financial Year": "2023",
                        "Col3": "2022",
                        "Col4": "2021"
                    },
                    {
                        "Particulars": "Total assets (in \u20b9 million) (A)",
                        "For the six months\nended September 30,\n2023": "36,046.13",
                        "For the Financial Year": "32,665.27",
                        "Col3": "30,690.48",
                        "Col4": "21,668.71"
                    },
                    {
                        "Particulars": "Total book value of assets on which insurance has been taken (in \u20b9\nmillion) (B)",
                        "For the six months\nended September 30,\n2023": "17,856.77",
                        "For the Financial Year": "18,007.90",
                        "Col3": "16,520.60",
                        "Col4": "12,320.56"
                    },
                    {
                        "Particulars": "Insurance coverage (in \u20b9 million) (C)",
                        "For the six months\nended September 30,\n2023": "28,837.74",
                        "For the Financial Year": "27,887.46",
                        "Col3": "24,368.41",
                        "Col4": "11,332.10"
                    },
                    {
                        "Particulars": "% of insurance coverage (%) (C/B)",
                        "For the six months\nended September 30,\n2023": "161.49",
                        "For the Financial Year": "154.86",
                        "Col3": "147.50",
                        "Col4": "91.97"
                    }
                ],
                "rows": 5,
                "cols": 5
            },
            {
                "page_number": 198,
                "table_data": [
                    {
                        "Function": "Production/operations",
                        "Number of Employees": "7,728"
                    },
                    {
                        "Function": "Sales and marketing",
                        "Number of Employees": "2,037"
                    },
                    {
                        "Function": "Finance and accounts",
                        "Number of Employees": "128"
                    },
                    {
                        "Function": "Supply chain",
                        "Number of Employees": "1,649"
                    },
                    {
                        "Function": "Research and development",
                        "Number of Employees": "514"
                    },
                    {
                        "Function": "Quality control/quality assurance",
                        "Number of Employees": "2,132"
                    },
                    {
                        "Function": "Human resources, Admin, Legal, and Managing Directors\u2019 office",
                        "Number of Employees": "1,084"
                    },
                    {
                        "Function": "Information technology",
                        "Number of Employees": "68"
                    },
                    {
                        "Function": "Environment, health and safety, and CSR",
                        "Number of Employees": "128"
                    },
                    {
                        "Function": "Engineering",
                        "Number of Employees": "995"
                    },
                    {
                        "Function": "Total",
                        "Number of Employees": "16,463"
                    }
                ],
                "rows": 11,
                "cols": 2
            },
            {
                "page_number": 198,
                "table_data": [
                    {
                        "Educational Qualification": "Postgraduate",
                        "Number of Employees": "1,955"
                    },
                    {
                        "Educational Qualification": "Graduate",
                        "Number of Employees": "4,188"
                    },
                    {
                        "Educational Qualification": "Undergraduate",
                        "Number of Employees": "10,320"
                    },
                    {
                        "Educational Qualification": "Total",
                        "Number of Employees": "16,463"
                    }
                ],
                "rows": 4,
                "cols": 2
            },
            {
                "page_number": 210,
                "table_data": [
                    {
                        "Date of Shareholders\u2019\nresolution/Effective date": "September 29, 2019",
                        "Details of the amendments": "Clause V of the Memorandum of Association was amended to reflect an increase in the authorised share\ncapital of our Company from \u20b912, 000, 000 divided into 1,200,000 equity shares of \u20b910 each to \u20b915,000,000\ndivided into 1,500,000 equity shares of face value of \u20b910 each."
                    },
                    {
                        "Date of Shareholders\u2019\nresolution/Effective date": "December 24, 2021",
                        "Details of the amendments": "Clause V of the Memorandum of Association was amended to reflect a sub-division in the authorised share\ncapital of our Company from \u20b915,000,000 divided into 1,500,000 equity shares of face value of \u20b910 each to\n\u20b915,000,000 divided into 7,500,000 of face value of \u20b92 each, ranking pari passu in all respects with the\nexisting equity shares of the Company."
                    },
                    {
                        "Date of Shareholders\u2019\nresolution/Effective date": "March 17, 2023",
                        "Details of the amendments": "Clause V of the Memorandum of Association was amended to reflect an increase in the authorised share\ncapital of our Company from \u20b915,000,000 divided into 7,500,000 equity shares of face value of \u20b92 each to\n\u20b9300,000,000 divided into 150,000,000 equity shares of face value of \u20b92 each, ranking pari passu in all\nrespects with the existing equity shares of the Company."
                    },
                    {
                        "Date of Shareholders\u2019\nresolution/Effective date": "October 26, 2023",
                        "Details of the amendments": "Clause V of the Memorandum of Association was amended to reflect an increase in the authorised share\ncapital of our Company from \u20b9300,000,000 divided into 150,000,000 equity shares of face value of \u20b92 each"
                    }
                ],
                "rows": 4,
                "cols": 2
            },
            {
                "page_number": 211,
                "table_data": [
                    {
                        "Date of Shareholders\u2019\nresolution/Effective date": "",
                        "Details of the amendments": "to \u20b9400,000,000 divided into 200,000,000 equity shares of face value \u20b92 each, ranking pari passu in all\nrespects with the existing equity shares of the Company."
                    },
                    {
                        "Date of Shareholders\u2019\nresolution/Effective date": "February 7, 2024",
                        "Details of the amendments": "Adoption of the Memorandum of Association in substitution of the existing memorandum of association,\nwith suitable amendments to comply with provisions of the Companies Act, 2013, substituting Companies\nAct, 1956 with Companies Act, 2013, wherever necessary and to completely remove Clause III(c) \u2018the other\nobjects clause\u2019 from the Memorandum of Association."
                    }
                ],
                "rows": 2,
                "cols": 2
            },
            {
                "page_number": 211,
                "table_data": [
                    {
                        "Financial Year": "2004",
                        "Milestone": "Incorporation of the Company"
                    },
                    {
                        "Financial Year": null,
                        "Milestone": "Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand"
                    },
                    {
                        "Financial Year": "2007",
                        "Milestone": "Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar,\nUttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand"
                    },
                    {
                        "Financial Year": "2009",
                        "Milestone": "Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals"
                    },
                    {
                        "Financial Year": "2010",
                        "Milestone": "Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand"
                    },
                    {
                        "Financial Year": null,
                        "Milestone": "Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand"
                    },
                    {
                        "Financial Year": null,
                        "Milestone": "Incorporated Akumentis Healthcare Limited to venture into branded formulations"
                    },
                    {
                        "Financial Year": "2011",
                        "Milestone": "Innovated bi-layered sustained release tablets for the first time"
                    },
                    {
                        "Financial Year": "2012",
                        "Milestone": "Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities"
                    },
                    {
                        "Financial Year": "2013",
                        "Milestone": "Innovated tablet-in-tablet sustained release tablets for the first time"
                    },
                    {
                        "Financial Year": null,
                        "Milestone": "Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities"
                    },
                    {
                        "Financial Year": null,
                        "Milestone": "Expanded into the African market"
                    },
                    {
                        "Financial Year": "2015",
                        "Milestone": "Expanded into the Asian market"
                    },
                    {
                        "Financial Year": null,
                        "Milestone": "Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market"
                    },
                    {
                        "Financial Year": "2016",
                        "Milestone": "Maxcure Nutravedics Limited received US-NSF certification"
                    },
                    {
                        "Financial Year": "2019",
                        "Milestone": "Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder"
                    },
                    {
                        "Financial Year": "2021",
                        "Milestone": "Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs"
                    },
                    {
                        "Financial Year": null,
                        "Milestone": "Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited"
                    },
                    {
                        "Financial Year": "2022",
                        "Milestone": "Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL,\nHaridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to\nEuropean markets"
                    },
                    {
                        "Financial Year": null,
                        "Milestone": "Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi,\nHimachal Pradesh by Pure and Cure Healthcare Private Limited"
                    },
                    {
                        "Financial Year": "2023",
                        "Milestone": "Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited"
                    },
                    {
                        "Financial Year": null,
                        "Milestone": "Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited"
                    }
                ],
                "rows": 22,
                "cols": 2
            },
            {
                "page_number": 212,
                "table_data": [
                    {
                        "Financial Year": "2018",
                        "Name of the award": "Received India Pharma Leader Award by Government of India"
                    },
                    {
                        "Financial Year": "2019",
                        "Name of the award": "Received India Pharma Leader Award by Government of India"
                    },
                    {
                        "Financial Year": "2021",
                        "Name of the award": "Award for India Pharma Award for Excellence in Contract Research and Manufacturing by Informamarkets"
                    },
                    {
                        "Financial Year": "2022",
                        "Name of the award": "Award for Excellence in R&D and Innovation by ET Ascent."
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Awarded the International Healthcare award as Pharmaceutical Company of the Year in contract\nmanufacturing by Times Cyber Media."
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Awarded the Excellence in Operations \u2013 Manufacturing by CPHI Awards."
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Awarded Asia\u2019s Pharma Excellence Awards in Innovation in Nutraceutical, Cosmetic and Wellness Award\nby CMO Asia."
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Our Promoters, Sanjeev Jain and Sandeep Jain were awarded Leading Entrepreneurs in the Pharmaceutical\nIndustry by Times Ascent"
                    },
                    {
                        "Financial Year": "2023",
                        "Name of the award": "Awarded Dream Employer of the Year by Times Ascent"
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Awarded the Excellence Award in Nutraceutical category by IHW Council."
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Award for the best brand based in North India by Exchange4Media."
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Awarded the best Technology Adaption \u2013 Cash Management Services by HDFC Bank"
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Awarded 2nd Runner up in Best Trademarks portfolio by CII Industrial Intellectual Property Awards."
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Awarded the Excellence in Formulations by India Pharma World Awards, The Economic Times."
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Awarded the Most Admired Quality Pharmaceutical Manufacturer of India 2023 by Observe Now."
                    },
                    {
                        "Financial Year": null,
                        "Name of the award": "Awarded the Certificate of Appreciation for Excellence in Innovative Formulations \u2013 Nutraceutical and\nWellness Award by Food Safety and Nutrition Summit and Awards 2023"
                    }
                ],
                "rows": 16,
                "cols": 2
            },
            {
                "page_number": 214,
                "table_data": [
                    {
                        "Name of the shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "2,699,994",
                        "% of total issued and\nsubscribed capital": "99.99%"
                    },
                    {
                        "Name of the shareholder": "Kanishk Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Archana Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Lata Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Arushi Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "2,700,000",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 8,
                "cols": 3
            },
            {
                "page_number": 214,
                "table_data": [
                    {
                        "Name of the shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "49,994",
                        "% of total issued and\nsubscribed capital": "99.98%"
                    },
                    {
                        "Name of the shareholder": "Kanishk Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Archana Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Lata Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Arushi Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    }
                ],
                "rows": 7,
                "cols": 3
            },
            {
                "page_number": 215,
                "table_data": [
                    {
                        "Name of the shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "50,000",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 1,
                "cols": 3
            },
            {
                "page_number": 215,
                "table_data": [
                    {
                        "Name of the shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "466,994",
                        "% of total issued and\nsubscribed capital": "99.99%"
                    },
                    {
                        "Name of the shareholder": "Kanishk Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Archana Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Lata Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Arushi Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "467,000",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 8,
                "cols": 3
            },
            {
                "page_number": 216,
                "table_data": [
                    {
                        "Name of Shareholder(s)": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910/-": "50,951",
                        "Series A CCCP Shares\nof face value \u20b9100/": "5,918",
                        "% of total issued and\nsubscribed capital": "91.49%"
                    },
                    {
                        "Name of Shareholder(s)": "Sanjeev Jain",
                        "No. of equity shares of\nface value \u20b910/-": "2,642",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "4.25%"
                    },
                    {
                        "Name of Shareholder(s)": "Sandeep Jain",
                        "No. of equity shares of\nface value \u20b910/-": "2,641",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "4.25%"
                    },
                    {
                        "Name of Shareholder(s)": "Sanjeev Jain jointly with Lata Jain",
                        "No. of equity shares of\nface value \u20b910/-": "1",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of Shareholder(s)": "Lata Jain jointly with Sanjeev Jain",
                        "No. of equity shares of\nface value \u20b910/-": "1",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of Shareholder(s)": "Sandeep Jain jointly with Archana Jain",
                        "No. of equity shares of\nface value \u20b910/-": "1",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of Shareholder(s)": "Archana Jain jointly with Sandeep Jain",
                        "No. of equity shares of\nface value \u20b910/-": "1",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of Shareholder(s)": "Sanjeev Jain jointly with Arushi Jain",
                        "No. of equity shares of\nface value \u20b910/-": "1",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of Shareholder(s)": "Lata Jain jointly with Umang Jain",
                        "No. of equity shares of\nface value \u20b910/-": "1",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of Shareholder(s)": "Sandeep Jain jointly with Kanishk Jain",
                        "No. of equity shares of\nface value \u20b910/-": "1",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of Shareholder(s)": "Sandeep Jain jointly with Manan Jain",
                        "No. of equity shares of\nface value \u20b910/-": "1",
                        "Series A CCCP Shares\nof face value \u20b9100/": "-",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of Shareholder(s)": "Total",
                        "No. of equity shares of\nface value \u20b910/-": "56,242",
                        "Series A CCCP Shares\nof face value \u20b9100/": "5,918",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 12,
                "cols": 4
            },
            {
                "page_number": 216,
                "table_data": [
                    {
                        "Name of shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "18,019,994",
                        "% of total issued and\nsubscribed capital": "99.99%"
                    },
                    {
                        "Name of shareholder": "Kanishk Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Archana Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Lata Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Arushi Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "18,020,000",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 8,
                "cols": 3
            },
            {
                "page_number": 217,
                "table_data": [
                    {
                        "Name of shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "9,998",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "52.74%"
                    },
                    {
                        "Name of shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Pure and Cure Healthcare Private Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "-",
                        "No. of OCRPS\nof face value\n\u20b910": "8,956",
                        "% of total issued\nand subscribed\ncapital": "47.25%"
                    },
                    {
                        "Name of shareholder": "Total",
                        "No. of equity\nshares of face\nvalue \u20b910": "10,000",
                        "No. of OCRPS\nof face value\n\u20b910": "8,956",
                        "% of total issued\nand subscribed\ncapital": "100.00%"
                    }
                ],
                "rows": 5,
                "cols": 4
            },
            {
                "page_number": 217,
                "table_data": [
                    {
                        "Name of shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "49,994",
                        "% of total issued and\nsubscribed capital": "99.98%"
                    },
                    {
                        "Name of shareholder": "Kanishk Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Archana Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Lata Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Arushi Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "50,000",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 8,
                "cols": 3
            },
            {
                "page_number": 218,
                "table_data": [
                    {
                        "Name of shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "49,994",
                        "% of total issued and\nsubscribed capital": "99.98%"
                    },
                    {
                        "Name of shareholder": "Kanishk Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Archana Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Lata Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Arushi Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "50,000",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 8,
                "cols": 3
            },
            {
                "page_number": 218,
                "table_data": [
                    {
                        "Name of shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "49,994",
                        "% of total issued and\nsubscribed capital": "99.98%"
                    },
                    {
                        "Name of shareholder": "Kanishk Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Archana Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Lata Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Arushi Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "50,000",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 8,
                "cols": 3
            },
            {
                "page_number": 219,
                "table_data": [
                    {
                        "Name of shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "49,994",
                        "No. of\npreference\nshares of face\nvalue \u20b9": "-",
                        "% of total\nissued and\nsubscribed\ncapital": "46.14%"
                    },
                    {
                        "Name of shareholder": "Kanishk Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of\npreference\nshares of face\nvalue \u20b9": "-",
                        "% of total\nissued and\nsubscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Archana Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of\npreference\nshares of face\nvalue \u20b9": "-",
                        "% of total\nissued and\nsubscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of\npreference\nshares of face\nvalue \u20b9": "-",
                        "% of total\nissued and\nsubscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Lata Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of\npreference\nshares of face\nvalue \u20b9": "-",
                        "% of total\nissued and\nsubscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of\npreference\nshares of face\nvalue \u20b9": "-",
                        "% of total\nissued and\nsubscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Arushi Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of\npreference\nshares of face\nvalue \u20b9": "-",
                        "% of total\nissued and\nsubscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Pure and Cure Healthcare Private Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "-",
                        "No. of\npreference\nshares of face\nvalue \u20b9": "58,337",
                        "% of total\nissued and\nsubscribed\ncapital": "53.84%"
                    },
                    {
                        "Name of shareholder": "Total",
                        "No. of equity\nshares of face\nvalue \u20b910": "50,000",
                        "No. of\npreference\nshares of face\nvalue \u20b9": "58,337",
                        "% of total\nissued and\nsubscribed\ncapital": "100.00%"
                    }
                ],
                "rows": 9,
                "cols": 4
            },
            {
                "page_number": 219,
                "table_data": [
                    {
                        "Name of shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "99,994",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "13.83%"
                    },
                    {
                        "Name of shareholder": "Kanishk Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Archana Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Lata Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Arushi Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "1",
                        "No. of OCRPS\nof face value\n\u20b910": "-",
                        "% of total issued\nand subscribed\ncapital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Pure and Cure Healthcare Private Limited",
                        "No. of equity\nshares of face\nvalue \u20b910": "-",
                        "No. of OCRPS\nof face value\n\u20b910": "622,568",
                        "% of total issued\nand subscribed\ncapital": "86.16%"
                    }
                ],
                "rows": 8,
                "cols": 4
            },
            {
                "page_number": 220,
                "table_data": [
                    {
                        "Name of shareholder": "Total",
                        "No. of equity\nshares of face\nvalue \u20b910": "100,000",
                        "No. of OCRPS\nof face value\n\u20b910": "622,568",
                        "% of total issued\nand subscribed\ncapital": "100.00%"
                    }
                ],
                "rows": 1,
                "cols": 4
            },
            {
                "page_number": 220,
                "table_data": [
                    {
                        "Name of shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "998",
                        "% of total issued and\nsubscribed capital": "99.98%"
                    },
                    {
                        "Name of shareholder": "Sanjeev Jain",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Sandeep Jain",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "1,000",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 4,
                "cols": 3
            },
            {
                "page_number": 221,
                "table_data": [
                    {
                        "Name of Shareholder": "Maxcure Nutravedics Limited.",
                        "No. of equity shares of\nface value \u20b910": "231,182",
                        "Shareholding\n(%)": "60%"
                    },
                    {
                        "Name of Shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "154,121",
                        "Shareholding\n(%)": "40%"
                    },
                    {
                        "Name of Shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "385,303",
                        "Shareholding\n(%)": "100.00%"
                    }
                ],
                "rows": 3,
                "cols": 3
            },
            {
                "page_number": 221,
                "table_data": [
                    {
                        "Name of the shareholder": "Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "9,998",
                        "% of total issued and\nsubscribed capital": "99.98%"
                    },
                    {
                        "Name of the shareholder": "Sanjeev Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Sandeep Jain jointly with Akums Drugs and Pharmaceuticals Limited",
                        "No. of equity shares of\nface value \u20b910": "1",
                        "% of total issued and\nsubscribed capital": "Negligible"
                    },
                    {
                        "Name of the shareholder": "Total",
                        "No. of equity shares of\nface value \u20b910": "10,000",
                        "% of total issued and\nsubscribed capital": "100.00%"
                    }
                ],
                "rows": 4,
                "cols": 3
            },
            {
                "page_number": 224,
                "table_data": [
                    {
                        "S.\nNo.": "1.",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "Sanjeev Jain\nDesignation: Managing Director\nPeriod of Directorship: Director since April 19, 2004\nTerm: With effect from June 30, 2023 for a period of 5 years, Liable to retire\nby rotation\nAddress: E-1052 Saraswati Vihar, New Delhi, 110 034, Delhi, India\nOccupation: Service\nDate of Birth: April 11, 1966\nDIN: 00323433",
                        "Age\n(in years)": "57",
                        "Other directorships": "\u2022 Akums Foundation\n\u2022 Welcure Pharmaceuticals Private\nLimited."
                    },
                    {
                        "S.\nNo.": "2.",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "Sandeep Jain\nDesignation: Managing Director\nPeriod of Directorship: Director since April 19, 2004\nTerm: With effect from June 30, 2023 for a period of 5 years, Liable to retire\nby rotation\nAddress: E-1052 Saraswati Vihar, New Delhi, 110 034, Delhi, India\nOccupation: Service\nDate of Birth: August 5, 1967\nDIN: 00323476",
                        "Age\n(in years)": "56",
                        "Other directorships": "\u2022 Akums Foundation\n\u2022 Welcure Pharmaceuticals Private\nLimited."
                    },
                    {
                        "S.\nNo.": "3.",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "Sanjay Sinha\nDesignation: Whole Time Director\nPeriod of Directorship: Director since January 17, 2024\nTerm: With effect from January 17, 2024 for a period of 5 years, Liable to\nretire by rotation\nAddress: House No. DH-118, Scheme No. 74-C, Vijay Nagar, Indore,\nMadhya Pradesh 452 010, India\nOccupation: Service\nDate of Birth: November 01, 1958\nDIN: 03627342",
                        "Age\n(in years)": "65",
                        "Other directorships": "Nil"
                    },
                    {
                        "S.\nNo.": "4.",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "Sunil Kumar Thakur*\nDesignation: Non-Executive Director\nPeriod of Directorship: Director since January 17, 2024\nTerm: With effect from January 17, 2024, Liable to retire by rotation",
                        "Age\n(in years)": "46",
                        "Other directorships": "\u2022 Health Care at Home India Private\nLimited\n\u2022 Healthquad Advisors Private\nLimited\n\u2022 Healthquad Capital Advisors Private\nLimited"
                    }
                ],
                "rows": 4,
                "cols": 4
            },
            {
                "page_number": 225,
                "table_data": [
                    {
                        "S.\nNo.": "",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "Address: S-177, Second Floor, Panchsheel Park, Malviya Nagar, South\nDelhi 110 017, Delhi, India\nOccupation: Service\nDate of Birth: February 03, 1978\nDIN: 03266370",
                        "Age\n(in years)": "",
                        "Other directorships": "\u2022 IBOF Investment Management\nPrivate Limited\n\u2022 Maxivision Eye Hospitals Private\nLimited\n\u2022 Nathealth Foundation\n\u2022 Nobel Hygiene Private Limited\n\u2022 Phasorz Technologies Private\nLimited\n\u2022 Quadria Capital Advisors Private\nLimited"
                    },
                    {
                        "S.\nNo.": "5.",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "Kewal Kundanlal Handa\nDesignation: Independent Director\nPeriod of Directorship: Director since March 16, 2022\nTerm: With effect from March 16, 2022 for a period of 5 years\nAddress: Nair House, 9th Floor, 14 B Road, Khar West, Mumbai, 400 052,\nMaharashtra, India\nOccupation: Business\nDate of Birth: August 22, 1952\nDIN: 00056826",
                        "Age\n(in years)": "71",
                        "Other directorships": "\u2022 Borosil Limited\n\u2022 Borosil Scientific Limited\n\u2022 Conexus Social Responsibility\nServices Private Limited\n\u2022 Ganga Care Hospital Limited\n\u2022 Heubach Colorants India Limited\n\u2022 Infiiloom India Private Limited\n\u2022 Mukta Arts Limited\n\u2022 Omsav Pharma Research Private\nLimited\n\u2022 Quality Care India Limited\n\u2022 Ramakrishna Care Medical Sciences\nPrivate Limited\n\u2022 Salus Lifecare Private Limited\n\u2022 United Ciigma Institute of Medical\nSciences Private Limited\n\u2022 Wellness Forever Medicare Limited"
                    },
                    {
                        "S.\nNo.": "6.",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "Matangi Gowrishankar\nDesignation: Independent Director\nPeriod of Directorship: Director since March 16, 2022\nTerm: With effect from March 16, 2022 for a period of 5 years\nAddress: E-1001/1002 Maestros, Salunke Vihar Road, Wanwadi, Pune, 411\n040, Maharashtra, India\nOccupation: Consultancy\nDate of Birth: February 27, 1958\nDIN: 01518137",
                        "Age\n(in years)": "65",
                        "Other directorships": "\u2022 Anudip Foundation for Social\nWelfare\n\u2022 Cyient Limited\n\u2022 Gabriel India Limited\n\u2022 Greenlam Industries Limited\n\u2022 Gujarat Pipavav Port Limited\n\u2022 IDFC First Bank Limited\n\u2022 Intellecap Advisory Services Private\nLimited\n\u2022 Premium Motion Private Limited\n\u2022 Premium Transmission Private\nLimited"
                    }
                ],
                "rows": 3,
                "cols": 4
            },
            {
                "page_number": 226,
                "table_data": [
                    {
                        "S.\nNo.": "",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "",
                        "Age\n(in years)": "",
                        "Other directorships": "\u2022 Suven Pharmaceuticals Limited\nForeign Companies\n\u2022 Cyient Inc\n\u2022 JSC MFO Crystal"
                    },
                    {
                        "S.\nNo.": "7.",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "Nand Lal Kalra\nDesignation: Independent Director\nPeriod of Directorship: Director since June 01, 2012\nTerm: With effect from February 13, 2020 for a period of 5 years\nAddress: H. no. 4-BA-11, Jawahar Nagar, Jaipur, 302 004, Rajasthan, India\nOccupation: Retired\nDate of Birth: February 05, 1950\nDIN: 05268554",
                        "Age\n(in years)": "74",
                        "Other directorships": "\u2022 PCHL"
                    },
                    {
                        "S.\nNo.": "8.",
                        "Name, designation, period of directorship, term, address, occupation,\ndate of birth and DIN": "Satwinder Singh\nDesignation: Independent Director\nPeriod of Directorship: Director since January 17, 2024\nTerm: With effect from January 17, 2024 for a period of 5 years\nAddress: Tower 10, Ground Floor, ATS One Hamlet Sector 104 Noida,\nGautam Buddha Nagar, 201 301, Uttar Pradesh, India\nOccupation: Corporate Lawyer\nDate of Birth: July 06, 1964\nDIN: 00164903",
                        "Age\n(in years)": "59",
                        "Other directorships": "\u2022 DS (Assam) Hospitality\nLimited\n\u2022 Seven R Hotels Private Limited"
                    }
                ],
                "rows": 3,
                "cols": 4
            },
            {
                "page_number": 228,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Name of Executive Director": "Sanjeev Jain",
                        "Annual Remuneration (in \u20b9 million)": "38.00"
                    },
                    {
                        "S. No.": "2.",
                        "Name of Executive Director": "Sandeep Jain",
                        "Annual Remuneration (in \u20b9 million)": "38.00"
                    }
                ],
                "rows": 2,
                "cols": 3
            },
            {
                "page_number": 228,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Name of Non-Executive Director": "Kewal Kundanlal Handa",
                        "Annual Remuneration (in \u20b9 million)": "2.40"
                    },
                    {
                        "S. No.": "2.",
                        "Name of Non-Executive Director": "Matangi Gowrishankar",
                        "Annual Remuneration (in \u20b9 million)": "2.20"
                    },
                    {
                        "S. No.": "3.",
                        "Name of Non-Executive Director": "Nand Lal Kalra",
                        "Annual Remuneration (in \u20b9 million)": "0.47"
                    }
                ],
                "rows": 3,
                "cols": 3
            },
            {
                "page_number": 229,
                "table_data": [
                    {
                        "S.\nNo.": "Promoters",
                        "Name of the\nshareholder": null,
                        "Pre-Offer number of\nEquity Shares": null,
                        "Percentage of the pre-\nOffer equity share\ncapital (%)": null,
                        "Post-Offer number of\nEquity Shares": null,
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": null
                    },
                    {
                        "S.\nNo.": "1.",
                        "Name of the\nshareholder": "Sanjeev Jain",
                        "Pre-Offer number of\nEquity Shares": "60,725,940\u03b2",
                        "Percentage of the pre-\nOffer equity share\ncapital (%)": "42.42 \u03b2",
                        "Post-Offer number of\nEquity Shares": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "2.",
                        "Name of the\nshareholder": "Sandeep Jain",
                        "Pre-Offer number of\nEquity Shares": "60,739,690\u03b1",
                        "Percentage of the pre-\nOffer equity share\ncapital (%)": "42.45 \u03b1",
                        "Post-Offer number of\nEquity Shares": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    },
                    {
                        "S.\nNo.": "3.",
                        "Name of the\nshareholder": "Akums Master Trust*",
                        "Pre-Offer number of\nEquity Shares": "-",
                        "Percentage of the pre-\nOffer equity share\ncapital (%)": "-",
                        "Post-Offer number of\nEquity Shares": "[\u25cf]",
                        "Percentage of the post-\nOffer Equity Share\ncapital (%)": "[\u25cf]"
                    }
                ],
                "rows": 4,
                "cols": 6
            },
            {
                "page_number": 229,
                "table_data": [
                    {
                        "Name": "Sanjay Sinha",
                        "Date of Change": "January 17, 2024",
                        "Reason for change in board": "Appointment as a Whole Time Director of the Company"
                    }
                ],
                "rows": 1,
                "cols": 3
            },
            {
                "page_number": 230,
                "table_data": [
                    {
                        "Name": "Satwinder Singh",
                        "Date of Change": "January 17, 2024",
                        "Reason for change in board": "Appointment as an Independent Director of the Company"
                    },
                    {
                        "Name": "Sunil Kumar Thakur",
                        "Date of Change": "January 17, 2024",
                        "Reason for change in board": "Appointment as a Non-executive Director of the Company"
                    },
                    {
                        "Name": "Amit Varma",
                        "Date of Change": "January 17, 2024",
                        "Reason for change in board": "Resignation as the Director of the Company"
                    },
                    {
                        "Name": "Basant Kumar Singh",
                        "Date of Change": "January 17, 2024",
                        "Reason for change in board": "Resignation as the Whole Time Director of the Company"
                    },
                    {
                        "Name": "Deepak Gurudas Haldankar",
                        "Date of Change": "March 31, 2022",
                        "Reason for change in board": "Resignation as the Whole Time Director of the Company"
                    },
                    {
                        "Name": "Neena Vivek",
                        "Date of Change": "April 15, 2022",
                        "Reason for change in board": "Resignation as the Director of the Company"
                    }
                ],
                "rows": 6,
                "cols": 3
            },
            {
                "page_number": 238,
                "table_data": [
                    {
                        "Sanjeev Jain\n(Managing Director)\nSanjay Sharma Dharamvir\nMalik\nSumeet Sood (President \u2013\nStrategy, New (Company\n(Chief Financial\nProjects and Secretary and\nOfficer)\nBusiness Compliance\nExcellence ) Officer)": "Sumeet Sood\n(Chief Financial\nOfficer)",
                        "Col1": "Dharamvir\nMalik\n(Company\nSecretary and\nCompliance\nOfficer)"
                    }
                ],
                "rows": 1,
                "cols": 2
            },
            {
                "page_number": 238,
                "table_data": [
                    {
                        "Sandeep Jain\n(Managing Director)\nJitendra Rajkumar Ashish\nSanjay Sinha Arvind\nMishra Sunil Jaiswal Singh Sharma\nSrivastava\n(President,\n(Vice President, (Vice President, (Senior General (Vice President,\nOperations and (President,\nInformation Research and Manager, Drug ESG and\nWhole Time Human\nTechnology - Development) Regulatory sustainability -\nDirector) Resources)\nPCHL) Affairs - PCHL) PCHL)": "Sanjay Sinha\n(President,\nOperations and\nWhole Time\nDirector)",
                        "Col1": "Ashish\nSharma\n(Vice President,\nESG and\nsustainability -\nPCHL)"
                    }
                ],
                "rows": 1,
                "cols": 2
            },
            {
                "page_number": 240,
                "table_data": [
                    {
                        "Name": "Ashish Sharma",
                        "Date of change": "August 14, 2023",
                        "Reason for change": "Appointment as Vice President ESG and sustainability of PCHL"
                    },
                    {
                        "Name": "Anil Gaur",
                        "Date of change": "August 3, 2023",
                        "Reason for change": "Resignation as Chief People Officer of MLPL"
                    },
                    {
                        "Name": "Sunil Jaiswal",
                        "Date of change": "July 05, 2023",
                        "Reason for change": "Appointment as the Vice President of Research and Development of our\nCompany"
                    },
                    {
                        "Name": "Arvind Srivastava",
                        "Date of change": "December 16, 2022",
                        "Reason for change": "Appointment as President, Human Resources of the Company"
                    },
                    {
                        "Name": "Sanjay Verma",
                        "Date of change": "July 19, 2022",
                        "Reason for change": "Resignation as Vice President Information Technology of PCHL"
                    },
                    {
                        "Name": "Sumeet Sood",
                        "Date of change": "February 14, 2022",
                        "Reason for change": "Appointment as the Chief Financial Officer of the Company"
                    },
                    {
                        "Name": "Jitendra Mishra",
                        "Date of change": "August 1, 2022",
                        "Reason for change": "Appointment as Vice President Information Technology of PCHL"
                    },
                    {
                        "Name": "Vinod Raheja",
                        "Date of change": "January 4, 2022",
                        "Reason for change": "Resignation as the Chief Financial Officer of the Company"
                    },
                    {
                        "Name": "Anil Gaur",
                        "Date of change": "September 16, 2021",
                        "Reason for change": "Appointment as Chief People Officer of MLPL"
                    },
                    {
                        "Name": "Sanjay Sharma",
                        "Date of change": "December 01, 2021",
                        "Reason for change": "Appointment as President, Strategy, New Projects and Business Excellence\nof the Company"
                    }
                ],
                "rows": 10,
                "cols": 3
            },
            {
                "page_number": 242,
                "table_data": [
                    {
                        "Col0": "",
                        "Sanjeev Jain (DIN: 00323433), aged 57 years, is the Managing Director of our Company.\nFor a complete profile of Sanjeev Jain, along with details of his date of birth, residential address,\neducational qualifications, professional experience and posts held in the past, directorships held, other\nventures, special achievements, business and other financial activities, see \u201cOur Management\u201d on page\n219, respectively.\nHis PAN is AAAPJ1897J.": "Sandeep Jain (DIN: 00323476), aged 56 years, is the Managing Director of our Company.\nFor a complete profile of Sandeep Jain, along with details of his date of birth, residential address,\neducational qualifications, professional experience and posts held in the past, directorships held, other\nventures, special achievements, business and other financial activities, see \u201cOur Management\u201d on page\n219, respectively.\nHis PAN is AAAPJ1891Q."
                    }
                ],
                "rows": 1,
                "cols": 2
            },
            {
                "page_number": 244,
                "table_data": [
                    {
                        "Name of Company from which\nPromoters have disassociated": "Sanjeev Jain",
                        "Reasons and circumstances leading to\nthe disassociation": null,
                        "Date of disassociation": null
                    },
                    {
                        "Name of Company from which\nPromoters have disassociated": "Welcure Drugs and Pharmaceuticals\nLimited",
                        "Reasons and circumstances leading to\nthe disassociation": "Divestment of stake",
                        "Date of disassociation": "Equity shares of Welcure Drugs and\nPharmaceuticals Limited were transferred\nin various tranches in September, 2022"
                    },
                    {
                        "Name of Company from which\nPromoters have disassociated": "Sandeep Jain",
                        "Reasons and circumstances leading to\nthe disassociation": null,
                        "Date of disassociation": null
                    },
                    {
                        "Name of Company from which\nPromoters have disassociated": "Welcure Drugs and Pharmaceuticals\nLimited",
                        "Reasons and circumstances leading to\nthe disassociation": "Divestment of stake",
                        "Date of disassociation": "Equity shares of Welcure Drugs and\nPharmaceuticals Limited were transferred\nin various tranches in September, 2022"
                    }
                ],
                "rows": 4,
                "cols": 3
            },
            {
                "page_number": 244,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Name of the Promoter": "Sanjeev Jain",
                        "Name": "D.C. Jain",
                        "Relationship": "Father"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Kiran Jain",
                        "Relationship": "Mother"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Sandeep Jain",
                        "Relationship": "Brother"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Anita Jain",
                        "Relationship": "Sister"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Kusum Jain",
                        "Relationship": "Sister"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Lata Jain",
                        "Relationship": "Wife"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Arushi Jain",
                        "Relationship": "Daughter"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Umang Jain",
                        "Relationship": "Son"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Rajiv Mittal",
                        "Relationship": "Wife\u2019s brother"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Neerja Gupta",
                        "Relationship": "Wife\u2019s sister"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Sudha Jain",
                        "Relationship": "Wife\u2019s sister"
                    },
                    {
                        "S. No.": "2.",
                        "Name of the Promoter": "Sandeep Jain",
                        "Name": "D.C. Jain",
                        "Relationship": "Father"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Kiran Jain",
                        "Relationship": "Mother"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Archana Jain",
                        "Relationship": "Wife"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Sanjeev Jain",
                        "Relationship": "Brother"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Kusum Jain",
                        "Relationship": "Sister"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Anita Jain",
                        "Relationship": "Sister"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Kanishk Jain",
                        "Relationship": "Son"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Manan Jain",
                        "Relationship": "Son"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Shivangi Jain",
                        "Relationship": "Daughter"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Rajesh Sharma",
                        "Relationship": "Wife\u2019s brother"
                    },
                    {
                        "S. No.": null,
                        "Name of the Promoter": null,
                        "Name": "Anuradha Pal",
                        "Relationship": "Wife\u2019s sister"
                    }
                ],
                "rows": 22,
                "cols": 4
            },
            {
                "page_number": 244,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Name of the Entity": "Akome Lifecare Private Limited"
                    },
                    {
                        "S. No.": "2.",
                        "Name of the Entity": "Akums Foundation"
                    },
                    {
                        "S. No.": "3.",
                        "Name of the Entity": "Akum Impex LLP"
                    },
                    {
                        "S. No.": "4.",
                        "Name of the Entity": "American Remedies Lifesciences Limited"
                    }
                ],
                "rows": 4,
                "cols": 2
            },
            {
                "page_number": 245,
                "table_data": [
                    {
                        "S. No.": "5.",
                        "Name of the Entity": "Archimani Real Estate Private Limited"
                    },
                    {
                        "S. No.": "6.",
                        "Name of the Entity": "Avha Lifesciences Private Limited"
                    },
                    {
                        "S. No.": "7.",
                        "Name of the Entity": "AUSL Trust"
                    },
                    {
                        "S. No.": "8.",
                        "Name of the Entity": "Delcure Lifesciences Limited"
                    },
                    {
                        "S. No.": "9.",
                        "Name of the Entity": "Dhanwantri Vedaresearch LLP"
                    },
                    {
                        "S. No.": "10.",
                        "Name of the Entity": "Parke Davis Healthcare Limited"
                    },
                    {
                        "S. No.": "11.",
                        "Name of the Entity": "Sarvodaya Industries and Skyscraper Private Limited"
                    },
                    {
                        "S. No.": "12.",
                        "Name of the Entity": "Sandeep Jain Trust"
                    },
                    {
                        "S. No.": "13.",
                        "Name of the Entity": "Welcure Pharmaceuticals Private Limited"
                    }
                ],
                "rows": 9,
                "cols": 2
            },
            {
                "page_number": 246,
                "table_data": [
                    {
                        "S. no.": "1.",
                        "Group Company": "Akome Lifecare Private Limited",
                        "Registered office address": "210, 2nd Floor, LSC, Mohan Place, Block C, Saraswati Vihar, Pitampura, North West Delhi,\nDelhi -110 034, India"
                    },
                    {
                        "S. no.": "2.",
                        "Group Company": "American Remedies Lifesciences\nLimited",
                        "Registered office address": "101, Plot 4, 1st Floor, Mohan Place, LSC, BLK-C, Saraswati Vihar, North West Delhi, Delhi\n- 110 034, India"
                    },
                    {
                        "S. no.": "3.",
                        "Group Company": "Welcure Pharmaceuticals Private\nLimited",
                        "Registered office address": "301, 3rd Floor, Laxmi Tower LSC, Saraswati Vihar, Pitampura, Delhi \u2013 110 034, India"
                    },
                    {
                        "S. no.": "4.",
                        "Group Company": "Akums Foundation",
                        "Registered office address": "101, 1st Floor, Mohan Place, LSC, BLK-C, Saraswati Vihar, North West Delhi, Delhi - 110\n034, India"
                    }
                ],
                "rows": 4,
                "cols": 3
            },
            {
                "page_number": 254,
                "table_data": [
                    {
                        "As at/\nAs at/\nfor the six months\nfor the year ended\nParticulars period ended\n30 September 30 September 31 March 31 March 31 March\n2023 2022 2023 2022 2021": "Total assets 4,352.27 4,437.09 4,227.66 3,849.92 3,063.64",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null
                    },
                    {
                        "As at/\nAs at/\nfor the six months\nfor the year ended\nParticulars period ended\n30 September 30 September 31 March 31 March 31 March\n2023 2022 2023 2022 2021": "Total revenues 1,508.17 2,015.13 3,202.73 5,727.61 4,295.92",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null
                    },
                    {
                        "As at/\nAs at/\nfor the six months\nfor the year ended\nParticulars period ended\n30 September 30 September 31 March 31 March 31 March\n2023 2022 2023 2022 2021": "Net cash inflow/\n6.49 (11.77) 785.87 1.05 (32.56)\n(outflows)",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null
                    },
                    {
                        "As at/\nAs at/\nfor the six months\nfor the year ended\nParticulars period ended\n30 September 30 September 31 March 31 March 31 March\n2023 2022 2023 2022 2021": "Share of profit/\n(loss) in its\nassociate",
                        "Col1": "Not applicable",
                        "Col2": "(1.70)",
                        "Col3": "(2.03)",
                        "Col4": "2.03",
                        "Col5": "3.47"
                    }
                ],
                "rows": 4,
                "cols": 6
            },
            {
                "page_number": 255,
                "table_data": [
                    {
                        "As at/\nAs at/\nfor the six months\nfor the year ended\nParticulars period ended #\n30 September 30 September 31 March 31 March 31 March\n2023 2022 2023 2022 2021": "Total assets Not applicable Not applicable 0.00* 0.20 0.21",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null
                    },
                    {
                        "As at/\nAs at/\nfor the six months\nfor the year ended\nParticulars period ended #\n30 September 30 September 31 March 31 March 31 March\n2023 2022 2023 2022 2021": "Total revenues Not applicable Not applicable 0.00* Nil 0.01",
                        "Col1": null,
                        "Col2": null,
                        "Col3": null,
                        "Col4": null,
                        "Col5": null
                    },
                    {
                        "As at/\nAs at/\nfor the six months\nfor the year ended\nParticulars period ended #\n30 September 30 September 31 March 31 March 31 March\n2023 2022 2023 2022 2021": "Net cash inflow/\n(outflows)",
                        "Col1": "Not applicable",
                        "Col2": "Not applicable",
                        "Col3": "(0.00*)",
                        "Col4": "(0.01)",
                        "Col5": "0.10"
                    }
                ],
                "rows": 3,
                "cols": 6
            },
            {
                "page_number": 330,
                "table_data": [
                    {
                        "Particulars": "Basic earnings per share (in \u20b9)",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2023*": "(10.93)",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2022*": "4.80",
                        "As at and for\nthe year ended\nMarch 31,\n2023": "6.63",
                        "As at and for\nthe year ended\nMarch 31,\n2022": "(17.65)",
                        "As at and for\nthe year ended\nMarch 31,\n2021": "8.58"
                    },
                    {
                        "Particulars": "Diluted earnings per share (in \u20b9)",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2023*": "(10.93)",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2022*": "4.80",
                        "As at and for\nthe year ended\nMarch 31,\n2023": "6.63",
                        "As at and for\nthe year ended\nMarch 31,\n2022": "(17.65)",
                        "As at and for\nthe year ended\nMarch 31,\n2021": "8.58"
                    },
                    {
                        "Particulars": "Return on Net Worth (%)",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2023*": "(27.91)",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2022*": "9.94",
                        "As at and for\nthe year ended\nMarch 31,\n2023": "13.23",
                        "As at and for\nthe year ended\nMarch 31,\n2022": "(40.60)",
                        "As at and for\nthe year ended\nMarch 31,\n2021": "13.87"
                    },
                    {
                        "Particulars": "Net asset value per Equity Share (in \u20b9)",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2023*": "39.17",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2022*": "48.24",
                        "As at and for\nthe year ended\nMarch 31,\n2023": "50.13",
                        "As at and for\nthe year ended\nMarch 31,\n2022": "43.48",
                        "As at and for\nthe year ended\nMarch 31,\n2021": "61.85"
                    },
                    {
                        "Particulars": "EBITDA",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2023*": "414.31",
                        "As at and for\nthe six months\nperiod ended\nSeptember 30,\n2022*": "1,540.74",
                        "As at and for\nthe year ended\nMarch 31,\n2023": "3,840.55",
                        "As at and for\nthe year ended\nMarch 31,\n2022": "(690.89)",
                        "As at and for\nthe year ended\nMarch 31,\n2021": "2,584.99"
                    }
                ],
                "rows": 5,
                "cols": 6
            },
            {
                "page_number": 330,
                "table_data": [
                    {
                        "Particulars": "(Loss)/ profit before share of (loss)/ profit of an\nassociate, exceptional item and tax (A)",
                        "Six months\nended\nSeptember\n30, 2023": "(445.07)",
                        "Six months\nended\nSeptember\n30, 2022": "836.31",
                        "For the year\nended March\n31, 2023": "2,250.00",
                        "For the year\nended March\n31, 2022": "(1,804.23)",
                        "For the year\nended March\n31, 2021": "1,819.14"
                    },
                    {
                        "Particulars": "Finance costs (B)",
                        "Six months\nended\nSeptember\n30, 2023": "258.00",
                        "Six months\nended\nSeptember\n30, 2022": "179.20",
                        "For the year\nended March\n31, 2023": "462.46",
                        "For the year\nended March\n31, 2022": "166.55",
                        "For the year\nended March\n31, 2021": "67.44"
                    },
                    {
                        "Particulars": "EBIT (C=A+B)",
                        "Six months\nended\nSeptember\n30, 2023": "(187.07)",
                        "Six months\nended\nSeptember\n30, 2022": "1,015.51",
                        "For the year\nended March\n31, 2023": "2,712.46",
                        "For the year\nended March\n31, 2022": "(1,637.68)",
                        "For the year\nended March\n31, 2021": "1,886.58"
                    },
                    {
                        "Particulars": "Depreciation and amortisation expense (D)",
                        "Six months\nended\nSeptember\n30, 2023": "601.38",
                        "Six months\nended\nSeptember\n30, 2022": "525.23",
                        "For the year\nended March\n31, 2023": "1,128.09",
                        "For the year\nended March\n31, 2022": "946.79",
                        "For the year\nended March\n31, 2021": "698.41"
                    },
                    {
                        "Particulars": "EBITDA (E=C+D)",
                        "Six months\nended\nSeptember\n30, 2023": "414.31",
                        "Six months\nended\nSeptember\n30, 2022": "1,540.74",
                        "For the year\nended March\n31, 2023": "3,840.55",
                        "For the year\nended March\n31, 2022": "(690.89)",
                        "For the year\nended March\n31, 2021": "2,584.99"
                    },
                    {
                        "Particulars": "Total Income (F)",
                        "Six months\nended\nSeptember\n30, 2023": "21,660.06",
                        "Six months\nended\nSeptember\n30, 2022": "18,521.36",
                        "For the year\nended March\n31, 2023": "37,009.25",
                        "For the year\nended March\n31, 2022": "36,945.23",
                        "For the year\nended March\n31, 2021": "27,437.85"
                    },
                    {
                        "Particulars": "EBIT Margin (%) (G=C/F)",
                        "Six months\nended\nSeptember\n30, 2023": "-0.86%",
                        "Six months\nended\nSeptember\n30, 2022": "5.48%",
                        "For the year\nended March\n31, 2023": "7.33%",
                        "For the year\nended March\n31, 2022": "-4.43%",
                        "For the year\nended March\n31, 2021": "6.88%"
                    },
                    {
                        "Particulars": "EBITDA Margin (%) (H = E/F)",
                        "Six months\nended\nSeptember\n30, 2023": "1.91%",
                        "Six months\nended\nSeptember\n30, 2022": "8.32%",
                        "For the year\nended March\n31, 2023": "10.38%",
                        "For the year\nended March\n31, 2022": "-1.87%",
                        "For the year\nended March\n31, 2021": "9.42%"
                    },
                    {
                        "Particulars": "Profit after tax for the year (I)",
                        "Six months\nended\nSeptember\n30, 2023": "(1,547.39)",
                        "Six months\nended\nSeptember\n30, 2022": "690.85",
                        "For the year\nended March\n31, 2023": "978.17",
                        "For the year\nended March\n31, 2022": "(2,508.74)",
                        "For the year\nended March\n31, 2021": "1,234.35"
                    },
                    {
                        "Particulars": "PAT Margin (%) (J=I/F)",
                        "Six months\nended\nSeptember\n30, 2023": "-7.14%",
                        "Six months\nended\nSeptember\n30, 2022": "3.73%",
                        "For the year\nended March\n31, 2023": "2.64%",
                        "For the year\nended March\n31, 2022": "-6.79%",
                        "For the year\nended March\n31, 2021": "4.50%"
                    }
                ],
                "rows": 10,
                "cols": 6
            },
            {
                "page_number": 330,
                "table_data": [
                    {
                        "Particulars": "(Loss)/ profit before share of (loss)/ profit of an\nassociate, exceptional item and tax (A)",
                        "Six months\nended\nSeptember\n30, 2023": "(445.07)",
                        "Six months\nended\nSeptember\n30, 2022": "836.31",
                        "For the year\nended March\n31, 2023": "2,250.00",
                        "For the year\nended March\n31, 2022": "(1,804.23)",
                        "For the year\nended March\n31, 2021": "1,819.14"
                    },
                    {
                        "Particulars": "Finance costs (B)",
                        "Six months\nended\nSeptember\n30, 2023": "258.00",
                        "Six months\nended\nSeptember\n30, 2022": "179.20",
                        "For the year\nended March\n31, 2023": "462.46",
                        "For the year\nended March\n31, 2022": "166.55",
                        "For the year\nended March\n31, 2021": "67.44"
                    },
                    {
                        "Particulars": "EBIT (C=A+B)",
                        "Six months\nended\nSeptember\n30, 2023": "(187.07)",
                        "Six months\nended\nSeptember\n30, 2022": "1,015.51",
                        "For the year\nended March\n31, 2023": "2,712.46",
                        "For the year\nended March\n31, 2022": "(1,637.68)",
                        "For the year\nended March\n31, 2021": "1,886.58"
                    },
                    {
                        "Particulars": "Fair value changes to the financial instrument\n(D)",
                        "Six months\nended\nSeptember\n30, 2023": "2,536.46",
                        "Six months\nended\nSeptember\n30, 2022": "(263.27)",
                        "For the year\nended March\n31, 2023": "(439.69)",
                        "For the year\nended March\n31, 2022": "4,941.74",
                        "For the year\nended March\n31, 2021": "538.23"
                    }
                ],
                "rows": 4,
                "cols": 6
            },
            {
                "page_number": 331,
                "table_data": [
                    {
                        "Particulars": "Adjusted EBIT (E=C+D)",
                        "Six months\nended\nSeptember\n30, 2023": "2,349.39",
                        "Six months\nended\nSeptember\n30, 2022": "752.24",
                        "For the year\nended March\n31, 2023": "2,272.77",
                        "For the year\nended March\n31, 2022": "3,304.06",
                        "For the year\nended March\n31, 2021": "2,424.81"
                    },
                    {
                        "Particulars": "Total income (F)",
                        "Six months\nended\nSeptember\n30, 2023": "21,660.06",
                        "Six months\nended\nSeptember\n30, 2022": "18,521.36",
                        "For the year\nended March\n31, 2023": "37,009.25",
                        "For the year\nended March\n31, 2022": "36,945.23",
                        "For the year\nended March\n31, 2021": "27,437.85"
                    },
                    {
                        "Particulars": "Adjusted EBIT Margin (%) (G=E/F)",
                        "Six months\nended\nSeptember\n30, 2023": "10.85%",
                        "Six months\nended\nSeptember\n30, 2022": "4.06%",
                        "For the year\nended March\n31, 2023": "6.14%",
                        "For the year\nended March\n31, 2022": "8.94%",
                        "For the year\nended March\n31, 2021": "8.84%"
                    }
                ],
                "rows": 3,
                "cols": 6
            },
            {
                "page_number": 331,
                "table_data": [
                    {
                        "Particulars": "(Loss)/ profit before share of (loss)/ profit of an\nassociate, exceptional item and tax (A)",
                        "Six months\nended\nSeptember\n30, 2023": "(445.07)",
                        "Six months\nended\nSeptember\n30, 2022": "836.31",
                        "For the year\nended March\n31, 2023": "2,250.00",
                        "For the year\nended March\n31, 2022": "(1,804.23)",
                        "For the year\nended March\n31, 2021": "1,819.14"
                    },
                    {
                        "Particulars": "Finance costs (B)",
                        "Six months\nended\nSeptember\n30, 2023": "258.00",
                        "Six months\nended\nSeptember\n30, 2022": "179.20",
                        "For the year\nended March\n31, 2023": "462.46",
                        "For the year\nended March\n31, 2022": "166.55",
                        "For the year\nended March\n31, 2021": "67.44"
                    },
                    {
                        "Particulars": "EBIT (C=A+B)",
                        "Six months\nended\nSeptember\n30, 2023": "(187.07)",
                        "Six months\nended\nSeptember\n30, 2022": "1,015.51",
                        "For the year\nended March\n31, 2023": "2,712.46",
                        "For the year\nended March\n31, 2022": "(1,637.68)",
                        "For the year\nended March\n31, 2021": "1,886.58"
                    },
                    {
                        "Particulars": "Depreciation and amortisation expense (D)",
                        "Six months\nended\nSeptember\n30, 2023": "601.38",
                        "Six months\nended\nSeptember\n30, 2022": "525.23",
                        "For the year\nended March\n31, 2023": "1,128.09",
                        "For the year\nended March\n31, 2022": "946.79",
                        "For the year\nended March\n31, 2021": "698.41"
                    },
                    {
                        "Particulars": "EBITDA (E=C+D)",
                        "Six months\nended\nSeptember\n30, 2023": "414.31",
                        "Six months\nended\nSeptember\n30, 2022": "1,540.74",
                        "For the year\nended March\n31, 2023": "3,840.55",
                        "For the year\nended March\n31, 2022": "(690.89)",
                        "For the year\nended March\n31, 2021": "2,584.99"
                    },
                    {
                        "Particulars": "Fair value changes to the financial instrument\n(F)",
                        "Six months\nended\nSeptember\n30, 2023": "2,536.46",
                        "Six months\nended\nSeptember\n30, 2022": "(263.27)",
                        "For the year\nended March\n31, 2023": "(439.69)",
                        "For the year\nended March\n31, 2022": "4,941.74",
                        "For the year\nended March\n31, 2021": "538.23"
                    },
                    {
                        "Particulars": "Adjusted EBITDA (G=E+F)",
                        "Six months\nended\nSeptember\n30, 2023": "2,950.77",
                        "Six months\nended\nSeptember\n30, 2022": "1,277.47",
                        "For the year\nended March\n31, 2023": "3,400.86",
                        "For the year\nended March\n31, 2022": "4,250.85",
                        "For the year\nended March\n31, 2021": "3,123.22"
                    },
                    {
                        "Particulars": "Total income (H)",
                        "Six months\nended\nSeptember\n30, 2023": "21,660.06",
                        "Six months\nended\nSeptember\n30, 2022": "18,521.36",
                        "For the year\nended March\n31, 2023": "37,009.25",
                        "For the year\nended March\n31, 2022": "36,945.23",
                        "For the year\nended March\n31, 2021": "27,437.85"
                    },
                    {
                        "Particulars": "Adjusted EBITDA Margin (%) (I=G/H)",
                        "Six months\nended\nSeptember\n30, 2023": "13.62%",
                        "Six months\nended\nSeptember\n30, 2022": "6.90%",
                        "For the year\nended March\n31, 2023": "9.19%",
                        "For the year\nended March\n31, 2022": "11.51%",
                        "For the year\nended March\n31, 2021": "11.38%"
                    }
                ],
                "rows": 9,
                "cols": 6
            },
            {
                "page_number": 331,
                "table_data": [
                    {
                        "Particulars": "Equity share capital (A)",
                        "Six months\nended\nSeptember 30,\n2023": "286.13",
                        "Six months\nended\nSeptember 30,\n2022": "143.07",
                        "For the year\nended March\n31, 2023": "286.13",
                        "For the year\nended March\n31, 2022": "143.07",
                        "For the year\nended March\n31, 2021": "13.01"
                    },
                    {
                        "Particulars": "Other equity (B)",
                        "Six months\nended\nSeptember 30,\n2023": "5,317.72",
                        "Six months\nended\nSeptember 30,\n2022": "6,758.45",
                        "For the year\nended March\n31, 2023": "6,885.76",
                        "For the year\nended March\n31, 2022": "6,076.69",
                        "For the year\nended March\n31, 2021": "8,835.46"
                    },
                    {
                        "Particulars": "Net worth / (Equity attributable to equity\nholders of the Parent) (C = A+B)",
                        "Six months\nended\nSeptember 30,\n2023": "5,603.85",
                        "Six months\nended\nSeptember 30,\n2022": "6,901.52",
                        "For the year\nended March\n31, 2023": "7,171.89",
                        "For the year\nended March\n31, 2022": "6,219.76",
                        "For the year\nended March\n31, 2021": "8,848.47"
                    },
                    {
                        "Particulars": "(Loss)/ profit attributable to equity holders of\nthe parent for the period/ year (D)",
                        "Six months\nended\nSeptember 30,\n2023": "(1,564.17)",
                        "Six months\nended\nSeptember 30,\n2022": "686.08",
                        "For the year\nended March\n31, 2023": "948.55",
                        "For the year\nended March\n31, 2022": "(2,525.36)",
                        "For the year\nended March\n31, 2021": "1,227.05"
                    },
                    {
                        "Particulars": "Return on Net worth (%) (E=D/C)",
                        "Six months\nended\nSeptember 30,\n2023": "-27.91%",
                        "Six months\nended\nSeptember 30,\n2022": "9.94%",
                        "For the year\nended March\n31, 2023": "13.23%",
                        "For the year\nended March\n31, 2022": "-40.60%",
                        "For the year\nended March\n31, 2021": "13.87%"
                    },
                    {
                        "Particulars": "Weighted average number of equity shares\noutstanding during the period/ year (F)",
                        "Six months\nended\nSeptember 30,\n2023": "143,064,350",
                        "Six months\nended\nSeptember 30,\n2022": "143,064,350",
                        "For the year\nended March\n31, 2023": "143,064,350",
                        "For the year\nended March\n31, 2022": "143,064,350",
                        "For the year\nended March\n31, 2021": "143,064,350"
                    },
                    {
                        "Particulars": "Net asset value per equity share (G=C/F)",
                        "Six months\nended\nSeptember 30,\n2023": "39.17",
                        "Six months\nended\nSeptember 30,\n2022": "48.24",
                        "For the year\nended March\n31, 2023": "50.13",
                        "For the year\nended March\n31, 2022": "43.48",
                        "For the year\nended March\n31, 2021": "61.85"
                    }
                ],
                "rows": 7,
                "cols": 6
            },
            {
                "page_number": 331,
                "table_data": [
                    {
                        "Particulars": "(Loss)/ profit for the period/ year (A)",
                        "Six months\nended\nSeptember 30,\n2023": "(1,547.39)",
                        "Six months\nended\nSeptember 30,\n2022": "690.85",
                        "For the year\nended March\n31, 2023": "978.17",
                        "For the year\nended March\n31, 2022": "(2,508.74)",
                        "For the year\nended March\n31, 2021": "1,234.35"
                    },
                    {
                        "Particulars": "Total equity (B)",
                        "Six months\nended\nSeptember 30,\n2023": "5,682.34",
                        "Six months\nended\nSeptember 30,\n2022": "6,938.33",
                        "For the year\nended March\n31, 2023": "7,233.74",
                        "For the year\nended March\n31, 2022": "6,251.71",
                        "For the year\nended March\n31, 2021": "8,871.35"
                    },
                    {
                        "Particulars": "Return on equity (%) (C=A/B)",
                        "Six months\nended\nSeptember 30,\n2023": "-27.23%",
                        "Six months\nended\nSeptember 30,\n2022": "9.96%",
                        "For the year\nended March\n31, 2023": "13.52%",
                        "For the year\nended March\n31, 2022": "-40.13%",
                        "For the year\nended March\n31, 2021": "13.91%"
                    }
                ],
                "rows": 3,
                "cols": 6
            },
            {
                "page_number": 332,
                "table_data": [
                    {
                        "Particulars": "Profit/ (loss) for the period/ year (A)",
                        "Six months\nended\nSeptember 30,\n2023": "(1,547.39)",
                        "Six months\nended\nSeptember 30,\n2022": "690.85",
                        "For the year\nended March\n31, 2023": "978.17",
                        "For the year\nended March\n31, 2022": "(2,508.74)",
                        "For the year\nended March\n31, 2021": "1,234.35"
                    },
                    {
                        "Particulars": "Fair value changes to the financial instrument\n(B)",
                        "Six months\nended\nSeptember 30,\n2023": "2,536.46",
                        "Six months\nended\nSeptember 30,\n2022": "(263.27)",
                        "For the year\nended March\n31, 2023": "(439.69)",
                        "For the year\nended March\n31, 2022": "4,941.74",
                        "For the year\nended March\n31, 2021": "538.23"
                    },
                    {
                        "Particulars": "Adjusted Profit/ (loss) for the period/ year\n(C=A+B)",
                        "Six months\nended\nSeptember 30,\n2023": "989.07",
                        "Six months\nended\nSeptember 30,\n2022": "427.58",
                        "For the year\nended March\n31, 2023": "538.48",
                        "For the year\nended March\n31, 2022": "2,433.00",
                        "For the year\nended March\n31, 2021": "1,772.58"
                    },
                    {
                        "Particulars": "Total equity (D)",
                        "Six months\nended\nSeptember 30,\n2023": "5,682.34",
                        "Six months\nended\nSeptember 30,\n2022": "6,938.33",
                        "For the year\nended March\n31, 2023": "7,233.74",
                        "For the year\nended March\n31, 2022": "6,251.71",
                        "For the year\nended March\n31, 2021": "8,871.35"
                    },
                    {
                        "Particulars": "Put option liability (E)",
                        "Six months\nended\nSeptember 30,\n2023": "12,612.50",
                        "Six months\nended\nSeptember 30,\n2022": "10,252.46",
                        "For the year\nended March\n31, 2023": "10,076.04",
                        "For the year\nended March\n31, 2022": "10,515.74",
                        "For the year\nended March\n31, 2021": "5,574.00"
                    },
                    {
                        "Particulars": "Adjusted total equity (F=D+E)",
                        "Six months\nended\nSeptember 30,\n2023": "18,294.84",
                        "Six months\nended\nSeptember 30,\n2022": "17,190.79",
                        "For the year\nended March\n31, 2023": "17,309.78",
                        "For the year\nended March\n31, 2022": "16,767.45",
                        "For the year\nended March\n31, 2021": "14,445.35"
                    },
                    {
                        "Particulars": "Adjusted Return on equity (%) (G=C/F)",
                        "Six months\nended\nSeptember 30,\n2023": "5.41%",
                        "Six months\nended\nSeptember 30,\n2022": "2.49%",
                        "For the year\nended March\n31, 2023": "3.11%",
                        "For the year\nended March\n31, 2022": "14.51%",
                        "For the year\nended March\n31, 2021": "12.27%"
                    }
                ],
                "rows": 7,
                "cols": 6
            },
            {
                "page_number": 332,
                "table_data": [
                    {
                        "Particulars": "(Loss)/ profit before share of (loss)/ profit of an\nassociate, exceptional item and tax (A)",
                        "Six months\nended\nSeptember 30,\n2023": "(445.07)",
                        "Six months\nended\nSeptember 30,\n2022": "836.31",
                        "For the year\nended March\n31, 2023": "2,250.00",
                        "For the year\nended March\n31, 2022": "(1,804.23)",
                        "For the year\nended March\n31, 2021": "1,819.14"
                    },
                    {
                        "Particulars": "Finance costs (B)",
                        "Six months\nended\nSeptember 30,\n2023": "258.00",
                        "Six months\nended\nSeptember 30,\n2022": "179.20",
                        "For the year\nended March\n31, 2023": "462.46",
                        "For the year\nended March\n31, 2022": "166.55",
                        "For the year\nended March\n31, 2021": "67.44"
                    },
                    {
                        "Particulars": "EBIT (C=A+B)",
                        "Six months\nended\nSeptember 30,\n2023": "(187.07)",
                        "Six months\nended\nSeptember 30,\n2022": "1,015.51",
                        "For the year\nended March\n31, 2023": "2,712.46",
                        "For the year\nended March\n31, 2022": "(1,637.68)",
                        "For the year\nended March\n31, 2021": "1,886.58"
                    },
                    {
                        "Particulars": "",
                        "Six months\nended\nSeptember 30,\n2023": "",
                        "Six months\nended\nSeptember 30,\n2022": "",
                        "For the year\nended March\n31, 2023": "",
                        "For the year\nended March\n31, 2022": "",
                        "For the year\nended March\n31, 2021": ""
                    },
                    {
                        "Particulars": "Non-current borrowings (D)",
                        "Six months\nended\nSeptember 30,\n2023": "1,009.96",
                        "Six months\nended\nSeptember 30,\n2022": "1,369.32",
                        "For the year\nended March\n31, 2023": "1,154.96",
                        "For the year\nended March\n31, 2022": "133.33",
                        "For the year\nended March\n31, 2021": "11.61"
                    },
                    {
                        "Particulars": "Current borrowings (E)",
                        "Six months\nended\nSeptember 30,\n2023": "6,067.55",
                        "Six months\nended\nSeptember 30,\n2022": "5,863.20",
                        "For the year\nended March\n31, 2023": "4,214.77",
                        "For the year\nended March\n31, 2022": "3,446.20",
                        "For the year\nended March\n31, 2021": "959.03"
                    },
                    {
                        "Particulars": "Total equity (F)",
                        "Six months\nended\nSeptember 30,\n2023": "5,682.34",
                        "Six months\nended\nSeptember 30,\n2022": "6,938.33",
                        "For the year\nended March\n31, 2023": "7,233.74",
                        "For the year\nended March\n31, 2022": "6,251.71",
                        "For the year\nended March\n31, 2021": "8,871.35"
                    },
                    {
                        "Particulars": "Cash and Cash equivalents (G)",
                        "Six months\nended\nSeptember 30,\n2023": "1,176.30",
                        "Six months\nended\nSeptember 30,\n2022": "458.67",
                        "For the year\nended March\n31, 2023": "516.08",
                        "For the year\nended March\n31, 2022": "551.39",
                        "For the year\nended March\n31, 2021": "220.67"
                    },
                    {
                        "Particulars": "Bank balances other than cash and cash\nequivalents (H)",
                        "Six months\nended\nSeptember 30,\n2023": "1,288.14",
                        "Six months\nended\nSeptember 30,\n2022": "619.03",
                        "For the year\nended March\n31, 2023": "983.81",
                        "For the year\nended March\n31, 2022": "477.08",
                        "For the year\nended March\n31, 2021": "458.01"
                    },
                    {
                        "Particulars": "Fixed deposits with remaining maturity of\nmore than 12 months (I)",
                        "Six months\nended\nSeptember 30,\n2023": "94.49",
                        "Six months\nended\nSeptember 30,\n2022": "73.47",
                        "For the year\nended March\n31, 2023": "76.33",
                        "For the year\nended March\n31, 2022": "133.13",
                        "For the year\nended March\n31, 2021": "205.71"
                    },
                    {
                        "Particulars": "Capital employed (J=D+E+F-G-H-I)",
                        "Six months\nended\nSeptember 30,\n2023": "10,200.92",
                        "Six months\nended\nSeptember 30,\n2022": "13,019.68",
                        "For the year\nended March\n31, 2023": "11,027.25",
                        "For the year\nended March\n31, 2022": "8,669.64",
                        "For the year\nended March\n31, 2021": "8,957.60"
                    },
                    {
                        "Particulars": "Return on Capital employed (%) (K=C/J)",
                        "Six months\nended\nSeptember 30,\n2023": "-1.83%",
                        "Six months\nended\nSeptember 30,\n2022": "7.80%",
                        "For the year\nended March\n31, 2023": "24.60%",
                        "For the year\nended March\n31, 2022": "-18.89%",
                        "For the year\nended March\n31, 2021": "21.06%"
                    }
                ],
                "rows": 12,
                "cols": 6
            },
            {
                "page_number": 332,
                "table_data": [
                    {
                        "Particulars": "(Loss)/ profit before share of (loss)/ profit of an\nassociate, exceptional item and tax (A)",
                        "Six months\nended\nSeptember 30,\n2023": "(445.07)",
                        "Six months\nended\nSeptember 30,\n2022": "836.31",
                        "For the year\nended March\n31, 2023": "2,250.00",
                        "For the year\nended March\n31, 2022": "(1,804.23)",
                        "For the year\nended March\n31, 2021": "1,819.14"
                    },
                    {
                        "Particulars": "Finance costs (B)",
                        "Six months\nended\nSeptember 30,\n2023": "258.00",
                        "Six months\nended\nSeptember 30,\n2022": "179.20",
                        "For the year\nended March\n31, 2023": "462.46",
                        "For the year\nended March\n31, 2022": "166.55",
                        "For the year\nended March\n31, 2021": "67.44"
                    },
                    {
                        "Particulars": "EBIT (C=A+B)",
                        "Six months\nended\nSeptember 30,\n2023": "(187.07)",
                        "Six months\nended\nSeptember 30,\n2022": "1,015.51",
                        "For the year\nended March\n31, 2023": "2,712.46",
                        "For the year\nended March\n31, 2022": "(1,637.68)",
                        "For the year\nended March\n31, 2021": "1,886.58"
                    },
                    {
                        "Particulars": "Fair value changes to the financial instrument\n(D)",
                        "Six months\nended\nSeptember 30,\n2023": "2,536.46",
                        "Six months\nended\nSeptember 30,\n2022": "(263.27)",
                        "For the year\nended March\n31, 2023": "(439.69)",
                        "For the year\nended March\n31, 2022": "4,941.74",
                        "For the year\nended March\n31, 2021": "538.23"
                    },
                    {
                        "Particulars": "Adjusted EBIT (E=C+D)",
                        "Six months\nended\nSeptember 30,\n2023": "2,349.39",
                        "Six months\nended\nSeptember 30,\n2022": "752.24",
                        "For the year\nended March\n31, 2023": "2,272.77",
                        "For the year\nended March\n31, 2022": "3,304.06",
                        "For the year\nended March\n31, 2021": "2,424.81"
                    },
                    {
                        "Particulars": "",
                        "Six months\nended\nSeptember 30,\n2023": "",
                        "Six months\nended\nSeptember 30,\n2022": "",
                        "For the year\nended March\n31, 2023": "",
                        "For the year\nended March\n31, 2022": "",
                        "For the year\nended March\n31, 2021": ""
                    },
                    {
                        "Particulars": "Non-current borrowings (F)",
                        "Six months\nended\nSeptember 30,\n2023": "1,009.96",
                        "Six months\nended\nSeptember 30,\n2022": "1,369.32",
                        "For the year\nended March\n31, 2023": "1,154.96",
                        "For the year\nended March\n31, 2022": "133.33",
                        "For the year\nended March\n31, 2021": "11.61"
                    },
                    {
                        "Particulars": "Current borrowings (G)",
                        "Six months\nended\nSeptember 30,\n2023": "6,067.55",
                        "Six months\nended\nSeptember 30,\n2022": "5,863.20",
                        "For the year\nended March\n31, 2023": "4,214.77",
                        "For the year\nended March\n31, 2022": "3,446.20",
                        "For the year\nended March\n31, 2021": "959.03"
                    },
                    {
                        "Particulars": "Total equity (H)",
                        "Six months\nended\nSeptember 30,\n2023": "5,682.34",
                        "Six months\nended\nSeptember 30,\n2022": "6,938.33",
                        "For the year\nended March\n31, 2023": "7,233.74",
                        "For the year\nended March\n31, 2022": "6,251.71",
                        "For the year\nended March\n31, 2021": "8,871.35"
                    },
                    {
                        "Particulars": "Cash and Cash equivalents (I)",
                        "Six months\nended\nSeptember 30,\n2023": "1,176.30",
                        "Six months\nended\nSeptember 30,\n2022": "458.67",
                        "For the year\nended March\n31, 2023": "516.08",
                        "For the year\nended March\n31, 2022": "551.39",
                        "For the year\nended March\n31, 2021": "220.67"
                    },
                    {
                        "Particulars": "Bank balances other than cash and cash\nequivalents (J)",
                        "Six months\nended\nSeptember 30,\n2023": "1,288.14",
                        "Six months\nended\nSeptember 30,\n2022": "619.03",
                        "For the year\nended March\n31, 2023": "983.81",
                        "For the year\nended March\n31, 2022": "477.08",
                        "For the year\nended March\n31, 2021": "458.01"
                    },
                    {
                        "Particulars": "Fixed deposits with remaining maturity of\nmore than 12 months (K)",
                        "Six months\nended\nSeptember 30,\n2023": "94.49",
                        "Six months\nended\nSeptember 30,\n2022": "73.47",
                        "For the year\nended March\n31, 2023": "76.33",
                        "For the year\nended March\n31, 2022": "133.13",
                        "For the year\nended March\n31, 2021": "205.71"
                    },
                    {
                        "Particulars": "Capital employed (L=F+G+H-I-J-K)",
                        "Six months\nended\nSeptember 30,\n2023": "10,200.92",
                        "Six months\nended\nSeptember 30,\n2022": "13,019.68",
                        "For the year\nended March\n31, 2023": "11,027.25",
                        "For the year\nended March\n31, 2022": "8,669.64",
                        "For the year\nended March\n31, 2021": "8,957.60"
                    },
                    {
                        "Particulars": "Put option liability (M)",
                        "Six months\nended\nSeptember 30,\n2023": "12,612.50",
                        "Six months\nended\nSeptember 30,\n2022": "10,252.46",
                        "For the year\nended March\n31, 2023": "10,076.04",
                        "For the year\nended March\n31, 2022": "10,515.74",
                        "For the year\nended March\n31, 2021": "5,574.00"
                    }
                ],
                "rows": 14,
                "cols": 6
            },
            {
                "page_number": 333,
                "table_data": [
                    {
                        "Particulars": "Adjusted capital employed (N=L+M)",
                        "Six months\nended\nSeptember 30,\n2023": "22,813.42",
                        "Six months\nended\nSeptember 30,\n2022": "23,272.14",
                        "For the year\nended March\n31, 2023": "21,103.29",
                        "For the year\nended March\n31, 2022": "19,185.38",
                        "For the year\nended March\n31, 2021": "14,531.60"
                    },
                    {
                        "Particulars": "Adjusted return on capital employed (%)\n(O=E/N)",
                        "Six months\nended\nSeptember 30,\n2023": "10.30%",
                        "Six months\nended\nSeptember 30,\n2022": "3.23%",
                        "For the year\nended March\n31, 2023": "10.77%",
                        "For the year\nended March\n31, 2022": "17.22%",
                        "For the year\nended March\n31, 2021": "16.69%"
                    }
                ],
                "rows": 2,
                "cols": 6
            },
            {
                "page_number": 334,
                "table_data": [
                    {
                        "Category of borrowing": "Secured (A)",
                        "Sanctioned amount": null,
                        "Outstanding amount as on December 31,\n2023": null
                    },
                    {
                        "Category of borrowing": "Fund-Based",
                        "Sanctioned amount": "",
                        "Outstanding amount as on December 31,\n2023": ""
                    },
                    {
                        "Category of borrowing": "Term Loans",
                        "Sanctioned amount": "2,162.00",
                        "Outstanding amount as on December 31,\n2023": "1,350.46"
                    },
                    {
                        "Category of borrowing": "Short Term Loans",
                        "Sanctioned amount": "1,000.00",
                        "Outstanding amount as on December 31,\n2023": "1,000.00"
                    },
                    {
                        "Category of borrowing": "Working Capital facilities",
                        "Sanctioned amount": "9,520.00",
                        "Outstanding amount as on December 31,\n2023": "2,776.78"
                    },
                    {
                        "Category of borrowing": "Cash Credit (Non Interchangeable)",
                        "Sanctioned amount": "850.00",
                        "Outstanding amount as on December 31,\n2023": "59.53"
                    },
                    {
                        "Category of borrowing": "Cash Credit (Interchangeable)",
                        "Sanctioned amount": "Interchangeable with Working Capital limit",
                        "Outstanding amount as on December 31,\n2023": "3.21"
                    },
                    {
                        "Category of borrowing": "Overdraft facilities",
                        "Sanctioned amount": "17.25",
                        "Outstanding amount as on December 31,\n2023": "0.00"
                    },
                    {
                        "Category of borrowing": "",
                        "Sanctioned amount": "",
                        "Outstanding amount as on December 31,\n2023": ""
                    },
                    {
                        "Category of borrowing": "Non-Fund Based",
                        "Sanctioned amount": "",
                        "Outstanding amount as on December 31,\n2023": ""
                    },
                    {
                        "Category of borrowing": "Bank Guarantee",
                        "Sanctioned amount": "Non Interchangeable 50.00",
                        "Outstanding amount as on December 31,\n2023": "14.13"
                    },
                    {
                        "Category of borrowing": "Bank Guarantee",
                        "Sanctioned amount": "Interchangeable with Working Capital\nLimits",
                        "Outstanding amount as on December 31,\n2023": "148.31"
                    },
                    {
                        "Category of borrowing": "Letter of Credit",
                        "Sanctioned amount": "Non Interchangeable 50.00",
                        "Outstanding amount as on December 31,\n2023": "0.00"
                    },
                    {
                        "Category of borrowing": "Letter of Credit",
                        "Sanctioned amount": "Interchangeable with Working Capital\nLimits",
                        "Outstanding amount as on December 31,\n2023": "328.90"
                    },
                    {
                        "Category of borrowing": "Total (A)",
                        "Sanctioned amount": "13,649.25",
                        "Outstanding amount as on December 31,\n2023": "5,681.32"
                    },
                    {
                        "Category of borrowing": "Unsecured (B)*",
                        "Sanctioned amount": "",
                        "Outstanding amount as on December 31,\n2023": ""
                    },
                    {
                        "Category of borrowing": "Total (B)",
                        "Sanctioned amount": "0.00",
                        "Outstanding amount as on December 31,\n2023": "0.00"
                    },
                    {
                        "Category of borrowing": "Total (A+B)",
                        "Sanctioned amount": "13,649.25",
                        "Outstanding amount as on December 31,\n2023": "5,681.32"
                    }
                ],
                "rows": 18,
                "cols": 3
            },
            {
                "page_number": 337,
                "table_data": [
                    {
                        "Particulars": "Total borrowings",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "",
                        "Adjusted\nfor the\npropose\nd Offer": "Refer\nnote\nbelow*"
                    },
                    {
                        "Particulars": "Current borrowings$",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "5,611.53",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    },
                    {
                        "Particulars": "Non-current borrowings# (A)",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "1,009.96",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    },
                    {
                        "Particulars": "Current maturities of non-current borrowings (B)",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "456.02",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    },
                    {
                        "Particulars": "Total borrowings (C)",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "7,077.51",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    },
                    {
                        "Particulars": "Total equity",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    },
                    {
                        "Particulars": "Equity share capital#",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "286.13",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    },
                    {
                        "Particulars": "Other equity",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "5,317.72",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    },
                    {
                        "Particulars": "Non \u2013 controlling interests",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "78.49",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    },
                    {
                        "Particulars": "Total equity (D)",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "5,682.34",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    },
                    {
                        "Particulars": "Non-current borrowings (including current maturities of non-current borrowings) (A+B) / Total Equity\n(D)",
                        "Pre-Offer\nas at\nSeptembe\nr 30, 2023": "0.26",
                        "Adjusted\nfor the\npropose\nd Offer": null
                    }
                ],
                "rows": 11,
                "cols": 3
            },
            {
                "page_number": 339,
                "table_data": [
                    {
                        "Particulars": "Client base for CDMO\nbusiness(1)",
                        "Six months ended\nSeptember 30, 2023": "1,345",
                        "Financial Year 2023": "1,543",
                        "Financial Year 2022": "1,386",
                        "Financial Year 2021": "1,161"
                    },
                    {
                        "Particulars": "Revenue contributions\nfrom our ten largest clients\nby revenue in our CDMO\nbusiness (in %)",
                        "Six months ended\nSeptember 30, 2023": "43.35",
                        "Financial Year 2023": "38.92",
                        "Financial Year 2022": "41.27",
                        "Financial Year 2021": "36.16"
                    }
                ],
                "rows": 2,
                "cols": 5
            },
            {
                "page_number": 341,
                "table_data": [
                    {
                        "Particulars": null,
                        "As of/for the six months\nended September 30, 2023": null,
                        "Col2": null,
                        "As of/for the year ended March 31,": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "As of/for the six months\nended September 30, 2023": "Installed\ncapacity\n(production\nvolume in\nmillion)",
                        "Col2": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "As of/for the year ended March 31,": "Installed\ncapacity\n(production\nvolume in\nmillion)",
                        "Col4": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col5": "Installed\ncapacity\n(production\nvolume in\nmillion)",
                        "Col6": "Capacity\nutilization\nas % of\ninstalled\ncapacity",
                        "Col7": "Installed\ncapacity\n(production\nvolume in\nmillion)",
                        "Col8": "Capacity\nutilization\nas % of\ninstalled\ncapacity"
                    },
                    {
                        "Particulars": "Oral solids",
                        "As of/for the six months\nended September 30, 2023": "47,888.78",
                        "Col2": "38.52%",
                        "As of/for the year ended March 31,": "47,878.78",
                        "Col4": "32.16%",
                        "Col5": "44,138.20",
                        "Col6": "41.47%",
                        "Col7": "37,984.20",
                        "Col8": "44.75%"
                    },
                    {
                        "Particulars": "Sterile",
                        "As of/for the six months\nended September 30, 2023": "744.20",
                        "Col2": "50.32%",
                        "As of/for the year ended March 31,": "744.20",
                        "Col4": "46.95%",
                        "Col5": "722.40",
                        "Col6": "52.54%",
                        "Col7": "722.40",
                        "Col8": "40.33%"
                    },
                    {
                        "Particulars": "Liquids",
                        "As of/for the six months\nended September 30, 2023": "417.60",
                        "Col2": "37.88%",
                        "As of/for the year ended March 31,": "417.60",
                        "Col4": "31.05%",
                        "Col5": "283.20",
                        "Col6": "52.51%",
                        "Col7": "279.60",
                        "Col8": "28.43%"
                    },
                    {
                        "Particulars": "External",
                        "As of/for the six months\nended September 30, 2023": "158.40",
                        "Col2": "34.62%",
                        "As of/for the year ended March 31,": "158.40",
                        "Col4": "25.21%",
                        "Col5": "158.40",
                        "Col6": "23.25%",
                        "Col7": "158.40",
                        "Col8": "21.12%"
                    }
                ],
                "rows": 6,
                "cols": 9
            },
            {
                "page_number": 341,
                "table_data": [
                    {
                        "Particulars": "Revenue contributions from our ten largest clients by\nrevenue in our CDMO business (%)",
                        "Six months ended\nSeptember 30, 2023": "43.35",
                        "Financial Year\n2023": "38.92",
                        "Financial Year\n2022": "41.27",
                        "Financial Year\n2021": "36.16"
                    }
                ],
                "rows": 1,
                "cols": 5
            },
            {
                "page_number": 342,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months ended\nSeptember 30, 2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of total\nrevenue from\noperations",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of total\nrevenue from\noperations",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of total\nrevenue from\noperations",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of total\nrevenue from\noperations"
                    },
                    {
                        "Particulars": "Revenue from\noperations \u2013\nwithin India",
                        "For the six months ended\nSeptember 30, 2023": "19,945.62",
                        "Col2": "92.72%",
                        "For the Financial Year": "34,231.47",
                        "Col4": "93.66%",
                        "Col5": "35,726.30",
                        "Col6": "97.30%",
                        "Col7": "26,463.66",
                        "Col8": "97.20%"
                    },
                    {
                        "Particulars": "Revenue from\noperations \u2013\noutside India",
                        "For the six months ended\nSeptember 30, 2023": "1,565.76",
                        "Col2": "7.28%",
                        "For the Financial Year": "2,316.73",
                        "Col4": "6.34%",
                        "Col5": "992.63",
                        "Col6": "2.70%",
                        "Col7": "762.63",
                        "Col8": "2.80%"
                    }
                ],
                "rows": 4,
                "cols": 9
            },
            {
                "page_number": 343,
                "table_data": [
                    {
                        "Segment": null,
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Segment": null,
                        "For the six months\nended September 30,\n2023": "Sales\nReturns\n(\u20b9 in\nmillions)",
                        "Col2": "% of\nsegment\nrevenue\nfrom\noperations",
                        "For the Financial Year": "Sales\nReturns\n(\u20b9 in\nmillions)",
                        "Col4": "% of\nsegment\nrevenue\nfrom\noperations",
                        "Col5": "Sales\nReturns\n(\u20b9 in\nmillions)",
                        "Col6": "% of\nsegment\nrevenue\nfrom\noperations",
                        "Col7": "Sales\nReturns\n(\u20b9 in\nmillions)",
                        "Col8": "% of\nsegment\nrevenue\nfrom\noperations"
                    },
                    {
                        "Segment": "CDMO",
                        "For the six months\nended September 30,\n2023": "109.52",
                        "Col2": "0.65",
                        "For the Financial Year": "153.41",
                        "Col4": "0.56",
                        "Col5": "101.53",
                        "Col6": "0.38",
                        "Col7": "51.41",
                        "Col8": "0.24"
                    },
                    {
                        "Segment": "Branded and generic\nformulations",
                        "For the six months\nended September 30,\n2023": "360.29",
                        "Col2": "9.55",
                        "For the Financial Year": "881.32",
                        "Col4": "11.68",
                        "Col5": "633.02",
                        "Col6": "7.02",
                        "Col7": "398.53",
                        "Col8": "6.82"
                    },
                    {
                        "Segment": "API",
                        "For the six months\nended September 30,\n2023": "20.84",
                        "Col2": "2.23",
                        "For the Financial Year": "145.16",
                        "Col4": "8.19",
                        "Col5": "1.26",
                        "Col6": "0.11",
                        "Col7": "\u2500",
                        "Col8": "\u2500"
                    }
                ],
                "rows": 5,
                "cols": 9
            },
            {
                "page_number": 344,
                "table_data": [
                    {
                        "Particulars": null,
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": "2023",
                        "Col4": null,
                        "Col5": "2022",
                        "Col6": null,
                        "Col7": "2021",
                        "Col8": null
                    },
                    {
                        "Particulars": null,
                        "For the six months\nended September 30,\n2023": "(\u20b9 in\nmillions)",
                        "Col2": "% of total\ncost of raw\nmaterial\npurchased",
                        "For the Financial Year": "(\u20b9 in\nmillions)",
                        "Col4": "% of total\ncost of raw\nmaterial\npurchased",
                        "Col5": "(\u20b9 in\nmillions)",
                        "Col6": "% of total\ncost of raw\nmaterial\npurchased",
                        "Col7": "(\u20b9 in\nmillions)",
                        "Col8": "% of total\ncost of raw\nmaterial\npurchased"
                    },
                    {
                        "Particulars": "CDMO business",
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    },
                    {
                        "Particulars": "Purchases of raw\nmaterials from our ten\nlargest suppliers",
                        "For the six months\nended September 30,\n2023": "2,492.52",
                        "Col2": "29.79",
                        "For the Financial Year": "3,557.73",
                        "Col4": "24.30",
                        "Col5": "3,601.25",
                        "Col6": "21.96",
                        "Col7": "2,624.97",
                        "Col8": "25.32"
                    },
                    {
                        "Particulars": "Purchases of raw\nmaterials from domestic\nsuppliers",
                        "For the six months\nended September 30,\n2023": "7,151.55",
                        "Col2": "85.48",
                        "For the Financial Year": "12,728.44",
                        "Col4": "86.92",
                        "Col5": "14,746.92",
                        "Col6": "89.92",
                        "Col7": "9,287.82",
                        "Col8": "89.60"
                    },
                    {
                        "Particulars": "Direct imports of raw\nmaterials",
                        "For the six months\nended September 30,\n2023": "1,215.26",
                        "Col2": "14.52",
                        "For the Financial Year": "1,914.90",
                        "Col4": "13.08",
                        "Col5": "1,653.31",
                        "Col6": "10.08",
                        "Col7": "1,077.63",
                        "Col8": "10.40"
                    },
                    {
                        "Particulars": "Branded and generic formulations business*",
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    },
                    {
                        "Particulars": "Purchases of raw\nmaterials from our ten\nlargest suppliers",
                        "For the six months\nended September 30,\n2023": "1,504.27",
                        "Col2": "85.95",
                        "For the Financial Year": "3,042.41",
                        "Col4": "75.94",
                        "Col5": "3,768.70",
                        "Col6": "59.92",
                        "Col7": "2,846.07",
                        "Col8": "67.87"
                    },
                    {
                        "Particulars": "Purchases of raw\nmaterials from domestic\nsuppliers",
                        "For the six months\nended September 30,\n2023": "1,750.14",
                        "Col2": "100.00",
                        "For the Financial Year": "3,963.20",
                        "Col4": "98.93",
                        "Col5": "6,079.39",
                        "Col6": "96.65",
                        "Col7": "4,097.91",
                        "Col8": "97.72"
                    },
                    {
                        "Particulars": "Direct imports of raw\nmaterials",
                        "For the six months\nended September 30,\n2023": "-",
                        "Col2": "-",
                        "For the Financial Year": "42.98",
                        "Col4": "1.07",
                        "Col5": "210.46",
                        "Col6": "3.35",
                        "Col7": "95.43",
                        "Col8": "2.28"
                    },
                    {
                        "Particulars": "API business",
                        "For the six months\nended September 30,\n2023": null,
                        "Col2": null,
                        "For the Financial Year": null,
                        "Col4": null,
                        "Col5": null,
                        "Col6": null,
                        "Col7": null,
                        "Col8": null
                    },
                    {
                        "Particulars": "Purchases of raw\nmaterials from our ten\nlargest suppliers",
                        "For the six months\nended September 30,\n2023": "218.18",
                        "Col2": "65.43",
                        "For the Financial Year": "412.17",
                        "Col4": "51.77",
                        "Col5": "978.62",
                        "Col6": "68.45",
                        "Col7": "14.18",
                        "Col8": "94.61"
                    },
                    {
                        "Particulars": "Purchases of raw\nmaterials from domestic\nsuppliers",
                        "For the six months\nended September 30,\n2023": "333.36",
                        "Col2": "99.96",
                        "For the Financial Year": "765.21",
                        "Col4": "96.12",
                        "Col5": "635.39",
                        "Col6": "44.44",
                        "Col7": "14.99",
                        "Col8": "100.00"
                    },
                    {
                        "Particulars": "Direct imports of raw\nmaterials",
                        "For the six months\nended September 30,\n2023": "0.12",
                        "Col2": "0.04",
                        "For the Financial Year": "30.92",
                        "Col4": "3.88",
                        "Col5": "794.27",
                        "Col6": "55.56",
                        "Col7": "-",
                        "Col8": "-"
                    }
                ],
                "rows": 14,
                "cols": 9
            },
            {
                "page_number": 346,
                "table_data": [
                    {
                        "Asset class": "Buildings",
                        "Useful lives": "30 years"
                    },
                    {
                        "Asset class": "Plant and equipment",
                        "Useful lives": "15 years"
                    },
                    {
                        "Asset class": "Furniture and fittings",
                        "Useful lives": "10 years"
                    },
                    {
                        "Asset class": "Vehicles",
                        "Useful lives": "8 to 10 years"
                    },
                    {
                        "Asset class": "Office equipment",
                        "Useful lives": "5 years"
                    },
                    {
                        "Asset class": "Computers",
                        "Useful lives": "3/6 years"
                    },
                    {
                        "Asset class": "Research and development laboratory equipment",
                        "Useful lives": "10 years"
                    },
                    {
                        "Asset class": "Electrical installation",
                        "Useful lives": "10 years"
                    }
                ],
                "rows": 8,
                "cols": 2
            },
            {
                "page_number": 356,
                "table_data": [
                    {
                        "Particulars": null,
                        "Six months ended September 30,": "2023",
                        "Col2": null,
                        "Col3": "2022",
                        "Col4": null
                    },
                    {
                        "Particulars": null,
                        "Six months ended September 30,": "(in \u20b9 millions)",
                        "Col2": "(% of Total Income)",
                        "Col3": "(in \u20b9 millions)",
                        "Col4": "(% of Total Income)"
                    },
                    {
                        "Particulars": "Revenue from operations",
                        "Six months ended September 30,": "21,511.38",
                        "Col2": "99.31%",
                        "Col3": "18,213.63",
                        "Col4": "98.34%"
                    },
                    {
                        "Particulars": "Other income",
                        "Six months ended September 30,": "148.68",
                        "Col2": "0.69%",
                        "Col3": "307.73",
                        "Col4": "1.66%"
                    },
                    {
                        "Particulars": "Total income",
                        "Six months ended September 30,": "21,660.06",
                        "Col2": "100.00%",
                        "Col3": "18,521.36",
                        "Col4": "100.00%"
                    },
                    {
                        "Particulars": "Expenses:",
                        "Six months ended September 30,": "",
                        "Col2": "",
                        "Col3": "",
                        "Col4": ""
                    },
                    {
                        "Particulars": "Cost of materials consumed",
                        "Six months ended September 30,": "11,830.93",
                        "Col2": "54.62%",
                        "Col3": "10,968.77",
                        "Col4": "59.22%"
                    },
                    {
                        "Particulars": "Purchase of stock-in-trade",
                        "Six months ended September 30,": "1,009.37",
                        "Col2": "4.66%",
                        "Col3": "1,545.86",
                        "Col4": "8.35%"
                    },
                    {
                        "Particulars": "Change in inventories of finished goods, stock-in-trade\nand work-in-progress",
                        "Six months ended September 30,": "111.95",
                        "Col2": "0.52%",
                        "Col3": "(779.08)",
                        "Col4": "(4.21)%"
                    },
                    {
                        "Particulars": "Employee benefits expense",
                        "Six months ended September 30,": "3,204.26",
                        "Col2": "14.79%",
                        "Col3": "2,947.18",
                        "Col4": "15.91%"
                    },
                    {
                        "Particulars": "Finance costs",
                        "Six months ended September 30,": "258.00",
                        "Col2": "1.19%",
                        "Col3": "179.20",
                        "Col4": "0.97%"
                    },
                    {
                        "Particulars": "Depreciation and amortisation expense",
                        "Six months ended September 30,": "601.38",
                        "Col2": "2.78%",
                        "Col3": "525.23",
                        "Col4": "2.84%"
                    },
                    {
                        "Particulars": "Fair value changes to financial instruments",
                        "Six months ended September 30,": "2,536.46",
                        "Col2": "11.71%",
                        "Col3": "(263.27)",
                        "Col4": "(1.42)%"
                    },
                    {
                        "Particulars": "Other expenses",
                        "Six months ended September 30,": "2,552.78",
                        "Col2": "11.79%",
                        "Col3": "2,561.16",
                        "Col4": "13.83%"
                    },
                    {
                        "Particulars": "Total expenses",
                        "Six months ended September 30,": "22,105.13",
                        "Col2": "102.05%",
                        "Col3": "17,685.05",
                        "Col4": "95.48%"
                    },
                    {
                        "Particulars": "Profit/ (loss) before share of (loss)/ profit of an\nassociate, exceptional items and tax",
                        "Six months ended September 30,": "(445.07)",
                        "Col2": "(2.05)%",
                        "Col3": "836.31",
                        "Col4": "4.52%"
                    },
                    {
                        "Particulars": "Share of (loss)/ profit of an associate",
                        "Six months ended September 30,": "\u2500",
                        "Col2": "\u2500",
                        "Col3": "(1.70)",
                        "Col4": "(0.01)%"
                    },
                    {
                        "Particulars": "Profit/ (loss) before exceptional items and tax",
                        "Six months ended September 30,": "(445.07)",
                        "Col2": "(2.05)%",
                        "Col3": "834.61",
                        "Col4": "4.51%"
                    },
                    {
                        "Particulars": "Exceptional items",
                        "Six months ended September 30,": "271.66",
                        "Col2": "1.25%",
                        "Col3": "\u2500",
                        "Col4": "\u2500"
                    },
                    {
                        "Particulars": "Profit/ (loss) before tax",
                        "Six months ended September 30,": "(716.73)",
                        "Col2": "(3.31)%",
                        "Col3": "834.61",
                        "Col4": "4.51%"
                    },
                    {
                        "Particulars": "Tax Expense:",
                        "Six months ended September 30,": "",
                        "Col2": "",
                        "Col3": "",
                        "Col4": ""
                    },
                    {
                        "Particulars": "Current tax",
                        "Six months ended September 30,": "598.64",
                        "Col2": "2.76%",
                        "Col3": "204.97",
                        "Col4": "1.11%"
                    },
                    {
                        "Particulars": "Tax for earlier periods",
                        "Six months ended September 30,": "15.53",
                        "Col2": "0.07%",
                        "Col3": "18.69",
                        "Col4": "0.10%"
                    },
                    {
                        "Particulars": "Deferred tax charge/ (reversal)",
                        "Six months ended September 30,": "216.49",
                        "Col2": "1.00%",
                        "Col3": "(79.90)",
                        "Col4": "(0.43)%"
                    },
                    {
                        "Particulars": "Total tax expense",
                        "Six months ended September 30,": "830.66",
                        "Col2": "3.83%",
                        "Col3": "143.76",
                        "Col4": "0.78%"
                    },
                    {
                        "Particulars": "Profit for the period",
                        "Six months ended September 30,": "(1,547.39)",
                        "Col2": "(7.14)%",
                        "Col3": "690.85",
                        "Col4": "3.73%"
                    }
                ],
                "rows": 26,
                "cols": 5
            },
            {
                "page_number": 356,
                "table_data": [
                    {
                        "Particulars": null,
                        "Financial Year": "2023",
                        "Col2": null,
                        "Col3": "2022",
                        "Col4": null,
                        "Col5": "2021",
                        "Col6": null
                    },
                    {
                        "Particulars": null,
                        "Financial Year": "(in \u20b9 millions)",
                        "Col2": "(% of Total Income)",
                        "Col3": "(in \u20b9 millions)",
                        "Col4": "(% of Total Income)",
                        "Col5": "(in \u20b9 millions)",
                        "Col6": "(% of Total Income)"
                    },
                    {
                        "Particulars": "Revenue from\noperations",
                        "Financial Year": "36,548.20",
                        "Col2": "98.75%",
                        "Col3": "36,718.93",
                        "Col4": "99.39%",
                        "Col5": "27,226.29",
                        "Col6": "99.23%"
                    },
                    {
                        "Particulars": "Other income",
                        "Financial Year": "461.05",
                        "Col2": "1.25%",
                        "Col3": "226.30",
                        "Col4": "0.61%",
                        "Col5": "211.56",
                        "Col6": "0.77%"
                    },
                    {
                        "Particulars": "Total income",
                        "Financial Year": "37,009.25",
                        "Col2": "100.00%",
                        "Col3": "36,945.23",
                        "Col4": "100.00%",
                        "Col5": "27,437.85",
                        "Col6": "100.00%"
                    },
                    {
                        "Particulars": "Expenses:",
                        "Financial Year": "",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": "",
                        "Col6": ""
                    },
                    {
                        "Particulars": "Cost of materials\nconsumed",
                        "Financial Year": "20,280.85",
                        "Col2": "54.80%",
                        "Col3": "20,385.94",
                        "Col4": "55.18%",
                        "Col5": "12,837.93",
                        "Col6": "46.79%"
                    },
                    {
                        "Particulars": "Purchase of stock-\nin-trade",
                        "Financial Year": "2,217.88",
                        "Col2": "5.99%",
                        "Col3": "3,942.07",
                        "Col4": "10.67%",
                        "Col5": "4,545.81",
                        "Col6": "16.57%"
                    },
                    {
                        "Particulars": "Change in\ninventories of\nfinished goods,\nstock-in-trade and\nwork-in-progress",
                        "Financial Year": "240.35",
                        "Col2": "0.65%",
                        "Col3": "(877.42)",
                        "Col4": "(2.37)%",
                        "Col5": "(474.63)",
                        "Col6": "(1.73)%"
                    },
                    {
                        "Particulars": "Employee benefits\nexpense",
                        "Financial Year": "5,901.33",
                        "Col2": "15.95%",
                        "Col3": "5,077.58",
                        "Col4": "13.74%",
                        "Col5": "4,245.50",
                        "Col6": "15.47%"
                    },
                    {
                        "Particulars": "Finance costs",
                        "Financial Year": "462.46",
                        "Col2": "1.25%",
                        "Col3": "166.55",
                        "Col4": "0.45%",
                        "Col5": "67.44",
                        "Col6": "0.25%"
                    },
                    {
                        "Particulars": "Depreciation and\namortisation\nexpense",
                        "Financial Year": "1,128.09",
                        "Col2": "3.05%",
                        "Col3": "946.79",
                        "Col4": "2.56%",
                        "Col5": "698.41",
                        "Col6": "2.55%"
                    },
                    {
                        "Particulars": "Fair value changes\nto financial\ninstruments",
                        "Financial Year": "(439.69)",
                        "Col2": "(1.19)%",
                        "Col3": "4,941.74",
                        "Col4": "13.38%",
                        "Col5": "538.23",
                        "Col6": "1.96%"
                    },
                    {
                        "Particulars": "Other expenses",
                        "Financial Year": "4,967.98",
                        "Col2": "13.42%",
                        "Col3": "4,166.21",
                        "Col4": "11.28%",
                        "Col5": "3,160.02",
                        "Col6": "11.52%"
                    },
                    {
                        "Particulars": "Total expenses",
                        "Financial Year": "34,759.25",
                        "Col2": "93.92%",
                        "Col3": "38,749.46",
                        "Col4": "104.88%",
                        "Col5": "25,618.71",
                        "Col6": "93.37%"
                    },
                    {
                        "Particulars": "Profit/ (loss)\nbefore share of\n(loss)/ profit of an\nassociate,\nexceptional items\nand tax",
                        "Financial Year": "2,250.00",
                        "Col2": "6.08%",
                        "Col3": "(1,804.23)",
                        "Col4": "(4.88)%",
                        "Col5": "1,819.14",
                        "Col6": "6.63%"
                    },
                    {
                        "Particulars": "Share of (loss)/\nprofit of an\nassociate",
                        "Financial Year": "(2.03)",
                        "Col2": "(0.01)%",
                        "Col3": "2.03",
                        "Col4": "0.01%",
                        "Col5": "3.47",
                        "Col6": "0.01%"
                    }
                ],
                "rows": 17,
                "cols": 7
            },
            {
                "page_number": 357,
                "table_data": [
                    {
                        "Particulars": null,
                        "Financial Year": "2023",
                        "Col2": null,
                        "Col3": "2022",
                        "Col4": null,
                        "Col5": "2021",
                        "Col6": null
                    },
                    {
                        "Particulars": null,
                        "Financial Year": "(in \u20b9 millions)",
                        "Col2": "(% of Total Income)",
                        "Col3": "(in \u20b9 millions)",
                        "Col4": "(% of Total Income)",
                        "Col5": "(in \u20b9 millions)",
                        "Col6": "(% of Total Income)"
                    },
                    {
                        "Particulars": "Profit/ (loss)\nbefore exceptional\nitems and tax",
                        "Financial Year": "2,247.97",
                        "Col2": "6.07%",
                        "Col3": "(1,802.20)",
                        "Col4": "(4.88)%",
                        "Col5": "1,822.61",
                        "Col6": "6.64%"
                    },
                    {
                        "Particulars": "Exceptional items",
                        "Financial Year": "745.00",
                        "Col2": "2.01%",
                        "Col3": "129.77",
                        "Col4": "0.35%",
                        "Col5": "100.00",
                        "Col6": "0.36%"
                    },
                    {
                        "Particulars": "Profit/ (loss)\nbefore tax",
                        "Financial Year": "1,502.97",
                        "Col2": "4.06%",
                        "Col3": "(1,931.97)",
                        "Col4": "(5.23)%",
                        "Col5": "1,722.61",
                        "Col6": "6.28%"
                    },
                    {
                        "Particulars": "Tax Expense:",
                        "Financial Year": "",
                        "Col2": "",
                        "Col3": "",
                        "Col4": "",
                        "Col5": "",
                        "Col6": ""
                    },
                    {
                        "Particulars": "Current tax",
                        "Financial Year": "781.30",
                        "Col2": "2.11%",
                        "Col3": "690.45",
                        "Col4": "1.87%",
                        "Col5": "552.99",
                        "Col6": "2.02%"
                    },
                    {
                        "Particulars": "Tax for earlier\nyears",
                        "Financial Year": "16.09",
                        "Col2": "0.04%",
                        "Col3": "(53.26)",
                        "Col4": "(0.14)%",
                        "Col5": "\u2500",
                        "Col6": "\u2500"
                    },
                    {
                        "Particulars": "Deferred tax\ncharge/ (reversal)",
                        "Financial Year": "(272.59)",
                        "Col2": "(0.74)%",
                        "Col3": "(60.42)",
                        "Col4": "(0.16)%",
                        "Col5": "(64.73)",
                        "Col6": "(0.24)%"
                    },
                    {
                        "Particulars": "Total tax expense",
                        "Financial Year": "524.80",
                        "Col2": "1.42%",
                        "Col3": "576.77",
                        "Col4": "1.56%",
                        "Col5": "488.26",
                        "Col6": "1.78%"
                    },
                    {
                        "Particulars": "Profit for the year",
                        "Financial Year": "978.17",
                        "Col2": "2.64%",
                        "Col3": "(2,508.74)",
                        "Col4": "(6.79)%",
                        "Col5": "1,234.35",
                        "Col6": "4.50%"
                    }
                ],
                "rows": 11,
                "cols": 7
            },
            {
                "page_number": 362,
                "table_data": [
                    {
                        "Particulars": null,
                        "Six months ended September 30,": "2023",
                        "Col2": "2022",
                        "Financial Year": "2023",
                        "Col4": "2022",
                        "Col5": "2021"
                    },
                    {
                        "Particulars": null,
                        "Six months ended September 30,": "(in \u20b9 millions)",
                        "Col2": null,
                        "Financial Year": null,
                        "Col4": null,
                        "Col5": null
                    },
                    {
                        "Particulars": "Net cash generated from / (used in) operating activities",
                        "Six months ended September 30,": "632.57",
                        "Col2": "(1,348.80)",
                        "Financial Year": "1,766.31",
                        "Col4": "318.54",
                        "Col5": "1,306.14"
                    },
                    {
                        "Particulars": "Net cash (used in) investing activities",
                        "Six months ended September 30,": "(1,333.55)",
                        "Col2": "(2,159.33)",
                        "Financial Year": "(3,047.02)",
                        "Col4": "(2,348.22)",
                        "Col5": "(1,093.85)"
                    },
                    {
                        "Particulars": "Net cash generated from / (used in) financing activities",
                        "Six months ended September 30,": "1,361.20",
                        "Col2": "3,415.41",
                        "Financial Year": "1,245.40",
                        "Col4": "2,360.40",
                        "Col5": "(914.62)"
                    },
                    {
                        "Particulars": "Net increase/ (decrease) in cash and cash equivalents",
                        "Six months ended September 30,": "660.22",
                        "Col2": "(92.72)",
                        "Financial Year": "(35.31)",
                        "Col4": "330.72",
                        "Col5": "(702.33)"
                    }
                ],
                "rows": 6,
                "cols": 6
            },
            {
                "page_number": 364,
                "table_data": [
                    {
                        "Particulars": null,
                        "As of September 30, 2023": "Payment due by period",
                        "Col2": null,
                        "Col3": null,
                        "Col4": "Total"
                    },
                    {
                        "Particulars": null,
                        "As of September 30, 2023": "Less than 1 year",
                        "Col2": "1-5 years",
                        "Col3": "More than 5 years",
                        "Col4": null
                    },
                    {
                        "Particulars": null,
                        "As of September 30, 2023": "(in \u20b9 millions)",
                        "Col2": null,
                        "Col3": null,
                        "Col4": null
                    },
                    {
                        "Particulars": "Borrowings",
                        "As of September 30, 2023": "6,067.55",
                        "Col2": "1,009.96",
                        "Col3": "\u2500",
                        "Col4": "7,077.51"
                    },
                    {
                        "Particulars": "Trade Payables",
                        "As of September 30, 2023": "6,108.69",
                        "Col2": "\u2500",
                        "Col3": "\u2500",
                        "Col4": "6,108.69"
                    },
                    {
                        "Particulars": "Lease Liabilities",
                        "As of September 30, 2023": "56.97",
                        "Col2": "149.32",
                        "Col3": "558.87",
                        "Col4": "765.16"
                    },
                    {
                        "Particulars": "Other Financial Liabilities",
                        "As of September 30, 2023": "659.91",
                        "Col2": "12,903.78",
                        "Col3": "\u2500",
                        "Col4": "13,563.69"
                    },
                    {
                        "Particulars": "Total",
                        "As of September 30, 2023": "12,893.12",
                        "Col2": "14,063.06",
                        "Col3": "558.87",
                        "Col4": "27,515.05"
                    }
                ],
                "rows": 8,
                "cols": 5
            },
            {
                "page_number": 364,
                "table_data": [
                    {
                        "Particulars": null,
                        "As of September 30, 2023": "(in \u20b9 millions)"
                    },
                    {
                        "Particulars": "Income-tax matters",
                        "As of September 30, 2023": "768.80"
                    },
                    {
                        "Particulars": "Product pricing related matters",
                        "As of September 30, 2023": "106.40"
                    },
                    {
                        "Particulars": "Others",
                        "As of September 30, 2023": "3.15"
                    }
                ],
                "rows": 4,
                "cols": 2
            },
            {
                "page_number": 388,
                "table_data": [
                    {
                        "Nature of case": "Our Company",
                        "Number of cases": null,
                        "Amount involved (in \u20b9 million)*": null
                    },
                    {
                        "Nature of case": "Direct Tax",
                        "Number of cases": "8",
                        "Amount involved (in \u20b9 million)*": "72.78"
                    },
                    {
                        "Nature of case": "Indirect Tax",
                        "Number of cases": "6",
                        "Amount involved (in \u20b9 million)*": "7.69"
                    },
                    {
                        "Nature of case": "Our Promoters",
                        "Number of cases": null,
                        "Amount involved (in \u20b9 million)*": null
                    },
                    {
                        "Nature of case": "Direct Tax",
                        "Number of cases": "Nil",
                        "Amount involved (in \u20b9 million)*": "Nil"
                    },
                    {
                        "Nature of case": "Indirect Tax",
                        "Number of cases": "Nil",
                        "Amount involved (in \u20b9 million)*": "Nil"
                    },
                    {
                        "Nature of case": "Our Directors",
                        "Number of cases": null,
                        "Amount involved (in \u20b9 million)*": null
                    },
                    {
                        "Nature of case": "Direct Tax",
                        "Number of cases": "2",
                        "Amount involved (in \u20b9 million)*": "38.33"
                    },
                    {
                        "Nature of case": "Indirect Tax",
                        "Number of cases": "Nil",
                        "Amount involved (in \u20b9 million)*": "Nil"
                    },
                    {
                        "Nature of case": "Our Subsidiaries",
                        "Number of cases": null,
                        "Amount involved (in \u20b9 million)*": null
                    },
                    {
                        "Nature of case": "Direct Tax",
                        "Number of cases": "11",
                        "Amount involved (in \u20b9 million)*": "746.38"
                    },
                    {
                        "Nature of case": "Indirect Tax",
                        "Number of cases": "8",
                        "Amount involved (in \u20b9 million)*": "21.04"
                    }
                ],
                "rows": 12,
                "cols": 3
            },
            {
                "page_number": 389,
                "table_data": [
                    {
                        "Type of creditors": "Micro, Small and Medium Enterprises",
                        "Number of Creditors": "1,330",
                        "Amount\n(in \u20b9 million)": "775.96"
                    },
                    {
                        "Type of creditors": "Material Creditors",
                        "Number of Creditors": "Nil",
                        "Amount\n(in \u20b9 million)": "Nil"
                    },
                    {
                        "Type of creditors": "Other creditors",
                        "Number of Creditors": "2,998",
                        "Amount\n(in \u20b9 million)": "5,332.74"
                    },
                    {
                        "Type of creditors": "Total",
                        "Number of Creditors": "4,328",
                        "Amount\n(in \u20b9 million)": "6,108.70"
                    }
                ],
                "rows": 4,
                "cols": 3
            },
            {
                "page_number": 392,
                "table_data": [
                    {
                        "S.\nNo.": "i.",
                        "Name of the\nmaterial\nsubsidiary": "SPL",
                        "Details of the certificate of incorporation": "Certificate of incorporation dated October 6, 2017, issued by the RoC",
                        "Corporate identity\nnumber": "U51909DL2017PTC324616"
                    },
                    {
                        "S.\nNo.": "ii.",
                        "Name of the\nmaterial\nsubsidiary": "PPL",
                        "Details of the certificate of incorporation": "Certificate of incorporation dated December 11, 2008, issued by the RoC",
                        "Corporate identity\nnumber": "U24232DL2008PLC185686"
                    },
                    {
                        "S.\nNo.": "iii.",
                        "Name of the\nmaterial\nsubsidiary": "MNL",
                        "Details of the certificate of incorporation": "Certificate of incorporation dated February 10, 1994, issued by the RoC",
                        "Corporate identity\nnumber": "U74899DL1994PLC057323"
                    },
                    {
                        "S.\nNo.": "iv.",
                        "Name of the\nmaterial\nsubsidiary": "PCHL",
                        "Details of the certificate of incorporation": "Certificate of incorporation dated September 13, 2005, issued by the RoC",
                        "Corporate identity\nnumber": "U24232DL2005PTC266385"
                    },
                    {
                        "S.\nNo.": "v.",
                        "Name of the\nmaterial\nsubsidiary": "MLPL",
                        "Details of the certificate of incorporation": "Certificate of incorporation dated February 5, 2004, issued by the RoC",
                        "Corporate identity\nnumber": "U63021DL2004PTC299408"
                    },
                    {
                        "S.\nNo.": "vi.",
                        "Name of the\nmaterial\nsubsidiary": "NHL",
                        "Details of the certificate of incorporation": "Certificate of incorporation dated January 20, 2009, issued by the RoC",
                        "Corporate identity\nnumber": "U24232DL2009PLC186841"
                    },
                    {
                        "S.\nNo.": "vii.",
                        "Name of the\nmaterial\nsubsidiary": "AHL",
                        "Details of the certificate of incorporation": "Certificate of incorporation dated July 29, 2010, issued by the RoC",
                        "Corporate identity\nnumber": "U72900DL2010PLC206414"
                    },
                    {
                        "S.\nNo.": "viii.",
                        "Name of the\nmaterial\nsubsidiary": "AHCL",
                        "Details of the certificate of incorporation": "Certificate of incorporation dated December 29, 2020, issued by the RoC",
                        "Corporate identity\nnumber": "U24304DL2020PLC375098"
                    }
                ],
                "rows": 8,
                "cols": 4
            },
            {
                "page_number": 396,
                "table_data": [
                    {
                        "Name of the Selling Shareholder": "Promoter Selling Shareholders",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": null,
                        "Date of corporate authorisation/\nboard resolution": null,
                        "Date of consent\nletter": null
                    },
                    {
                        "Name of the Selling Shareholder": "Sanjeev Jain",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": "2,145,965",
                        "Date of corporate authorisation/\nboard resolution": "N.A.",
                        "Date of consent\nletter": "January 16, 2024"
                    },
                    {
                        "Name of the Selling Shareholder": "Sandeep Jain",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": "2,145,965",
                        "Date of corporate authorisation/\nboard resolution": "N.A.",
                        "Date of consent\nletter": "January 16, 2024"
                    },
                    {
                        "Name of the Selling Shareholder": "Investor Selling Shareholder",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": null,
                        "Date of corporate authorisation/\nboard resolution": null,
                        "Date of consent\nletter": null
                    },
                    {
                        "Name of the Selling Shareholder": "Ruby QC Investment Holdings Pte. Ltd.",
                        "Maximum number of Equity Shares\noffered in the Offer for Sale": "14,306,435",
                        "Date of corporate authorisation/\nboard resolution": "January 16, 2024",
                        "Date of consent\nletter": "January 16, 2024"
                    }
                ],
                "rows": 5,
                "cols": 4
            },
            {
                "page_number": 402,
                "table_data": [
                    {
                        "Sr. No.": "1",
                        "Issue Name": "Fedbank Financial Services Limited^^",
                        "Issue Size\n(Rs. Mn.)": "10,922.64",
                        "Issue\nPrice (Rs.)": "140.00 (1)",
                        "Listing Date": "30-Nov-23",
                        "Opening\nPrice on\nListing\nDate": "138.00",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "-2.75% [+7.94%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    },
                    {
                        "Sr. No.": "2",
                        "Issue Name": "India Shelter Finance Corporation\nLimited^^",
                        "Issue Size\n(Rs. Mn.)": "12,000.00",
                        "Issue\nPrice (Rs.)": "493.00",
                        "Listing Date": "20-Dec-23",
                        "Opening\nPrice on\nListing\nDate": "620.00",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "+17.64% [+1.48%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    },
                    {
                        "Sr. No.": "3",
                        "Issue Name": "DOMS Industries Limited^",
                        "Issue Size\n(Rs. Mn.)": "12,000.00",
                        "Issue\nPrice (Rs.)": "790.00(2)",
                        "Listing Date": "20-Dec-23",
                        "Opening\nPrice on\nListing\nDate": "1,400.00",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "+80.59% [+0.97%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    },
                    {
                        "Sr. No.": "4",
                        "Issue Name": "Inox India Limited^",
                        "Issue Size\n(Rs. Mn.)": "14,593.23",
                        "Issue\nPrice (Rs.)": "660.00",
                        "Listing Date": "21-Dec-23",
                        "Opening\nPrice on\nListing\nDate": "933.15",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "+32.01% [+1.15%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    },
                    {
                        "Sr. No.": "5",
                        "Issue Name": "Muthoot Microfin Limited^",
                        "Issue Size\n(Rs. Mn.)": "9,600.00",
                        "Issue\nPrice (Rs.)": "291.00(3)",
                        "Listing Date": "26-Dec-23",
                        "Opening\nPrice on\nListing\nDate": "278.00",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "-20.77% [-0.39%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    },
                    {
                        "Sr. No.": "6",
                        "Issue Name": "Credo Brands Marketing Limited^",
                        "Issue Size\n(Rs. Mn.)": "5,497.79",
                        "Issue\nPrice (Rs.)": "280.00",
                        "Listing Date": "27-Dec-23",
                        "Opening\nPrice on\nListing\nDate": "282.00",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "-9.89% [-1.86%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    },
                    {
                        "Sr. No.": "7",
                        "Issue Name": "Azad Engineering Limited^",
                        "Issue Size\n(Rs. Mn.)": "7,400.00",
                        "Issue\nPrice (Rs.)": "524.00",
                        "Listing Date": "28-Dec-23",
                        "Opening\nPrice on\nListing\nDate": "710.00",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "+29.06% [-2.36%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    },
                    {
                        "Sr. No.": "8",
                        "Issue Name": "Innova Captab Limited^^",
                        "Issue Size\n(Rs. Mn.)": "5,700.00",
                        "Issue\nPrice (Rs.)": "448.00",
                        "Listing Date": "29-Dec-23",
                        "Opening\nPrice on\nListing\nDate": "452.10",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "+15.16% [-1.74%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    },
                    {
                        "Sr. No.": "9",
                        "Issue Name": "Jyoti CNC Automation Limited^^",
                        "Issue Size\n(Rs. Mn.)": "10,000.00",
                        "Issue\nPrice (Rs.)": "331.00(4)",
                        "Listing Date": "16-Jan-24",
                        "Opening\nPrice on\nListing\nDate": "370.00",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    },
                    {
                        "Sr. No.": "10",
                        "Issue Name": "EPACK Durable Limited^",
                        "Issue Size\n(Rs. Mn.)": "6,400.53",
                        "Issue\nPrice (Rs.)": "230.00",
                        "Listing Date": "30-Jan-24",
                        "Opening\nPrice on\nListing\nDate": "225.00",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 30th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 90th\ncalendar days from\nlisting": "NA*",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]-\n180th calendar days from\nlisting": "NA*"
                    }
                ],
                "rows": 10,
                "cols": 9
            },
            {
                "page_number": 402,
                "table_data": [
                    {
                        "Financi\nal Year": null,
                        "Tot\nal\nno.\nof\nIPO\ns": null,
                        "Total\namount\nof funds\nraised\n(Rs.\nMn.)": null,
                        "No. of IPOs trading at discount - 30th\ncalendar days from listing": "Over\n50%",
                        "Col4": "Between 25-\n50%",
                        "Col5": "Less than\n25%",
                        "No. of IPOs trading at premium - 30th\ncalendar days from listing": "Over\n50%",
                        "Col7": "Between 25-\n50%",
                        "Col8": "Less than\n25%",
                        "No. of IPOs trading at discount - 180th\ncalendar days from listing": "Over\n50%",
                        "Col10": "Between 25-\n50%",
                        "Col11": "Less than\n25%",
                        "No. of IPOs trading at premium - 180th\ncalendar days from listing": "Over\n50%",
                        "Col13": "Between 25-\n50%",
                        "Col14": "Less than\n25%"
                    },
                    {
                        "Financi\nal Year": "2023-\n24*",
                        "Tot\nal\nno.\nof\nIPO\ns": "22",
                        "Total\namount\nof funds\nraised\n(Rs.\nMn.)": "2,09,259.\n46",
                        "No. of IPOs trading at discount - 30th\ncalendar days from listing": "-",
                        "Col4": "-",
                        "Col5": "3",
                        "No. of IPOs trading at premium - 30th\ncalendar days from listing": "4",
                        "Col7": "7",
                        "Col8": "6",
                        "No. of IPOs trading at discount - 180th\ncalendar days from listing": "-",
                        "Col10": "-",
                        "Col11": "-",
                        "No. of IPOs trading at premium - 180th\ncalendar days from listing": "2",
                        "Col13": "-",
                        "Col14": "-"
                    },
                    {
                        "Financi\nal Year": "2022-\n23",
                        "Tot\nal\nno.\nof\nIPO\ns": "9",
                        "Total\namount\nof funds\nraised\n(Rs.\nMn.)": "2,95,341.\n82",
                        "No. of IPOs trading at discount - 30th\ncalendar days from listing": "-",
                        "Col4": "1",
                        "Col5": "3",
                        "No. of IPOs trading at premium - 30th\ncalendar days from listing": "-",
                        "Col7": "3",
                        "Col8": "2",
                        "No. of IPOs trading at discount - 180th\ncalendar days from listing": "-",
                        "Col10": "1",
                        "Col11": "1",
                        "No. of IPOs trading at premium - 180th\ncalendar days from listing": "-",
                        "Col13": "5",
                        "Col14": "2"
                    },
                    {
                        "Financi\nal Year": "2021-\n22",
                        "Tot\nal\nno.\nof\nIPO\ns": "26",
                        "Total\namount\nof funds\nraised\n(Rs.\nMn.)": "7,43,520.\n19",
                        "No. of IPOs trading at discount - 30th\ncalendar days from listing": "-",
                        "Col4": "3",
                        "Col5": "6",
                        "No. of IPOs trading at premium - 30th\ncalendar days from listing": "6",
                        "Col7": "4",
                        "Col8": "7",
                        "No. of IPOs trading at discount - 180th\ncalendar days from listing": "3",
                        "Col10": "4",
                        "Col11": "5",
                        "No. of IPOs trading at premium - 180th\ncalendar days from listing": "5",
                        "Col13": "4",
                        "Col14": "5"
                    }
                ],
                "rows": 4,
                "cols": 15
            },
            {
                "page_number": 403,
                "table_data": [
                    {
                        "Sr.\nNo.": "1",
                        "Issue name": "EPACK Durable Limited(1)",
                        "Issue size\n(\u20b9 millions)": "6,400.53",
                        "Issue\nprice (\u20b9)": "230.00",
                        "Listing date": "30-Jan-24",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "225.00",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "-",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "-",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    },
                    {
                        "Sr.\nNo.": "2",
                        "Issue name": "Medi Assist Healthcare\nServices Limited(1)",
                        "Issue size\n(\u20b9 millions)": "11,715.77",
                        "Issue\nprice (\u20b9)": "418.00",
                        "Listing date": "23-Jan-24",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "465.00",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "-",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "-",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    },
                    {
                        "Sr.\nNo.": "3",
                        "Issue name": "Azad Engineering Limited(1)",
                        "Issue size\n(\u20b9 millions)": "7,400.00",
                        "Issue\nprice (\u20b9)": "524.00",
                        "Listing date": "28-Dec-23",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "710.00",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "+29.06%, [-2.36%]",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "-",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    },
                    {
                        "Sr.\nNo.": "4",
                        "Issue name": "Happy Forgings Limited(2)",
                        "Issue size\n(\u20b9 millions)": "10,085.93",
                        "Issue\nprice (\u20b9)": "850.00",
                        "Listing date": "27-Dec-23",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "1,000.00",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "+14.06%, [-1.40%]",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "-",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    },
                    {
                        "Sr.\nNo.": "5",
                        "Issue name": "Muthoot Microfin Limited*(1)",
                        "Issue size\n(\u20b9 millions)": "9,600.00",
                        "Issue\nprice (\u20b9)": "291.00",
                        "Listing date": "26-Dec-23",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "278.00",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "-20.77%, [-0.39%]",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "-",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    },
                    {
                        "Sr.\nNo.": "6",
                        "Issue name": "Inox India Limited(1)",
                        "Issue size\n(\u20b9 millions)": "14,593.23",
                        "Issue\nprice (\u20b9)": "660.00",
                        "Listing date": "21-Dec-23",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "933.15",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "+32.01%, [+1.15%]",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "-",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    },
                    {
                        "Sr.\nNo.": "7",
                        "Issue name": "Flair Writing Industries\nLimited(2)",
                        "Issue size\n(\u20b9 millions)": "5,930.00",
                        "Issue\nprice (\u20b9)": "304.00",
                        "Listing date": "01-Dec-23",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "501.00",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "+14.69%, [+7.22%]",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "-",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    },
                    {
                        "Sr.\nNo.": "8",
                        "Issue name": "ASK Automotive Limited(2)",
                        "Issue size\n(\u20b9 millions)": "8,339.13",
                        "Issue\nprice (\u20b9)": "282.00",
                        "Listing date": "15-Nov-23",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "303.30",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "+2.73%, [+7.66%]",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "-",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    },
                    {
                        "Sr.\nNo.": "9",
                        "Issue name": "JSW Infrastructure Limited(1)",
                        "Issue size\n(\u20b9 millions)": "28,000.00",
                        "Issue\nprice (\u20b9)": "119.00",
                        "Listing date": "03-Oct-23",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "143.00",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "+41.34%, [-2.93%]",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "+75.04%, [+10.27%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    },
                    {
                        "Sr.\nNo.": "10",
                        "Issue name": "Signature Global (India)\nLimited(2)",
                        "Issue size\n(\u20b9 millions)": "7,300.00",
                        "Issue\nprice (\u20b9)": "385.00",
                        "Listing date": "27-Sep-23",
                        "Opening\nprice on\nlisting date\n(in \u20b9)": "444.00",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 30th\ncalendar days from listing": "+35.79%, [-4.36%]",
                        "+/- % change in closing price,\n[+/- % change in closing\nbenchmark]- 90th\ncalendar days from listing": "+112.43%, [+8.28%]",
                        "+/- % change in closing\nprice, [+/- % change in\nclosing benchmark]- 180th\ncalendar days from listing": "-"
                    }
                ],
                "rows": 10,
                "cols": 9
            },
            {
                "page_number": 403,
                "table_data": [
                    {
                        "Financial\nYear": null,
                        "Total no.\nof\nIPOs": null,
                        "Total funds\nraised\n(\u20b9 in Millions)": null,
                        "Nos. of IPOs trading at discount on\nas on 30th calendar days from\nlisting date": "Over 50%",
                        "Col4": "Between\n25%-50%",
                        "Col5": "Less\nthan",
                        "Nos. of IPOs trading at premium\non as on 30th calendar days from\nlisting date": "Over 50%",
                        "Col7": "Between\n25%-50%",
                        "Col8": "Less\nthan",
                        "Nos. of IPOs trading at discount as\non 180th calendar days from\nlisting date": "Over 50%",
                        "Col10": "Between\n25%-50%",
                        "Col11": "Less\nthan",
                        "Nos. of IPOs trading at premium as\non 180th calendar days from listing\ndate": "Over 50%",
                        "Col13": "Between\n25%-50%",
                        "Col14": "Less\nthan"
                    }
                ],
                "rows": 1,
                "cols": 15
            },
            {
                "page_number": 404,
                "table_data": [
                    {
                        "Col0": "2023-2024*",
                        "Col1": "15",
                        "Col2": "197,238.24",
                        "Col3": "-",
                        "Col4": "-",
                        "5-25%": "1",
                        "Col6": "2",
                        "Col7": "6",
                        "8-25%": "4",
                        "Col9": "-",
                        "Col10": "-",
                        "11-25%": "-",
                        "Col12": "3",
                        "Col13": "-",
                        "14-25%": "-"
                    },
                    {
                        "Col0": "2022-2023",
                        "Col1": "11",
                        "Col2": "279,285.39",
                        "Col3": "-",
                        "Col4": "1",
                        "5-25%": "6",
                        "Col6": "-",
                        "Col7": "2",
                        "8-25%": "2",
                        "Col9": "-",
                        "Col10": "2",
                        "11-25%": "5",
                        "Col12": "-",
                        "Col13": "3",
                        "14-25%": "1"
                    },
                    {
                        "Col0": "2021-2022",
                        "Col1": "25",
                        "Col2": "609,514.77",
                        "Col3": "-",
                        "Col4": "2",
                        "5-25%": "6",
                        "Col6": "6",
                        "Col7": "5",
                        "8-25%": "6",
                        "Col9": "3",
                        "Col10": "4",
                        "11-25%": "3",
                        "Col12": "5",
                        "Col13": "3",
                        "14-25%": "7"
                    }
                ],
                "rows": 3,
                "cols": 15
            },
            {
                "page_number": 404,
                "table_data": [
                    {
                        "Sr.\nNo.": "1.",
                        "Issue Name": "India Shelter Finance Corporation Ltd",
                        "Issue Size (\u20b9\nmillion)": "12,000.00",
                        "Issue Price (\u20b9)": "493.00",
                        "Listing Date": "December 20, 2023",
                        "Opening Price\non listing date\n(in \u20b9)": "620.00",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "+17.74% [+0.97%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "NA",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "NA"
                    },
                    {
                        "Sr.\nNo.": "2.",
                        "Issue Name": "Tata Technologies Limited",
                        "Issue Size (\u20b9\nmillion)": "30,425.14",
                        "Issue Price (\u20b9)": "500.00",
                        "Listing Date": "November 30, 2023",
                        "Opening Price\non listing date\n(in \u20b9)": "1,199.95",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "+136.09% [+7.84%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "NA",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "NA"
                    },
                    {
                        "Sr.\nNo.": "3.",
                        "Issue Name": "Honasa Consumer Limited",
                        "Issue Size (\u20b9\nmillion)": "17,014.40",
                        "Issue Price (\u20b9)": "324.00",
                        "Listing Date": "November 7, 2023",
                        "Opening Price\non listing date\n(in \u20b9)": "330.00",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "+17.58% [+7.89%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "34.61% [+12.61%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "NA"
                    },
                    {
                        "Sr.\nNo.": "4.",
                        "Issue Name": "R R Kabel Limited",
                        "Issue Size (\u20b9\nmillion)": "19,640.10",
                        "Issue Price (\u20b9)": "1,035.00",
                        "Listing Date": "September 20, 2023",
                        "Opening Price\non listing date\n(in \u20b9)": "1,179.00",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "+34.45% [-1.75%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "+64.83% [+6.94%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "NA"
                    },
                    {
                        "Sr.\nNo.": "5.",
                        "Issue Name": "Concord Biotech Limited",
                        "Issue Size (\u20b9\nmillion)": "15,505.21",
                        "Issue Price (\u20b9)": "741.00",
                        "Listing Date": "August 18, 2023",
                        "Opening Price\non listing date\n(in \u20b9)": "900.05",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "+36.82% [+4.57%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "+83.91% [+1.89%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "NA"
                    },
                    {
                        "Sr.\nNo.": "6.",
                        "Issue Name": "Delhivery Limited",
                        "Issue Size (\u20b9\nmillion)": "52,350.0",
                        "Issue Price (\u20b9)": "487.00",
                        "Listing Date": "May 24, 2022",
                        "Opening Price\non listing date\n(in \u20b9)": "495.20",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "+3.49% [-4.41%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "+17.00% [+10.13%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "-27.99% [+13.53%]"
                    },
                    {
                        "Sr.\nNo.": "7.",
                        "Issue Name": "Life Insurance Corporation of India",
                        "Issue Size (\u20b9\nmillion)": "205,572.3",
                        "Issue Price (\u20b9)": "949.00",
                        "Listing Date": "May 17, 2022",
                        "Opening Price\non listing date\n(in \u20b9)": "872.00",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "-27.2% [-3.3%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "-28.1% [+9.5%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "-33.8%[+13.8%]"
                    },
                    {
                        "Sr.\nNo.": "8.",
                        "Issue Name": "Star Health and Allied Insurance\nCompany Limited",
                        "Issue Size (\u20b9\nmillion)": "64,004.39",
                        "Issue Price (\u20b9)": "900.00",
                        "Listing Date": "December 10, 2021",
                        "Opening Price\non listing date\n(in \u20b9)": "845.00",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "-14.78%[+1.96%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "-29.79%[-6.66%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "-22.21%[-6.25%]"
                    },
                    {
                        "Sr.\nNo.": "9.",
                        "Issue Name": "One 97 Communications Limited",
                        "Issue Size (\u20b9\nmillion)": "183,000.00",
                        "Issue Price (\u20b9)": "2,150.00",
                        "Listing Date": "November 18, 2021",
                        "Opening Price\non listing date\n(in \u20b9)": "1,955.00",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "-38.5%[-4.4%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "-60.40%[-2.5%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "-72.5%[-11.2%]"
                    },
                    {
                        "Sr.\nNo.": "10.",
                        "Issue Name": "PB Fintech Limited",
                        "Issue Size (\u20b9\nmillion)": "57,097.15",
                        "Issue Price (\u20b9)": "980.00",
                        "Listing Date": "November 15, 2021",
                        "Opening Price\non listing date\n(in \u20b9)": "1,150.00",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 30th\ncalendar days from\nlisting": "14.86%[-4.17%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 90th\ncalendar days from\nlisting": "-20.52%[-4.06%]",
                        "+/- % change in\nclosing price, [+/- %\nchange in closing\nbenchmark]- 180th\ncalendar days from\nlisting": "-33.86%[-12.85%]"
                    }
                ],
                "rows": 10,
                "cols": 9
            },
            {
                "page_number": 404,
                "table_data": [
                    {
                        "Financial\nYear": null,
                        "Total no.\nof IPOs": null,
                        "Total amount\nof funds\nraised (\u20b9mn.)": null,
                        "No. of IPOs trading at discount \u2013\n30th calendar days from listing": "Over\n50%",
                        "Col4": "Between 25-\n50%",
                        "Col5": "Less\nthan\n25%",
                        "No. of IPOs trading at premium \u2013\n30th calendar days from listing": "Over\n50%",
                        "Col7": "Between 25-\n50%",
                        "Col8": "Less\nthan\n25%",
                        "No. of IPOs trading at discount \u2013\n180th calendar days from listing": "Over\n50%",
                        "Col10": "Between 25-\n50%",
                        "Col11": "Less\nthan\n25%",
                        "No. of IPOs trading at premium \u2013\n180th calendar days from listing": "Over\n50%",
                        "Col13": "Between 25-\n50%",
                        "Col14": "Less\nthan\n25%"
                    },
                    {
                        "Financial\nYear": "2023-24",
                        "Total no.\nof IPOs": "5",
                        "Total amount\nof funds\nraised (\u20b9mn.)": "94,584.85",
                        "No. of IPOs trading at discount \u2013\n30th calendar days from listing": "-",
                        "Col4": "-",
                        "Col5": "-",
                        "No. of IPOs trading at premium \u2013\n30th calendar days from listing": "1",
                        "Col7": "2",
                        "Col8": "2",
                        "No. of IPOs trading at discount \u2013\n180th calendar days from listing": "-",
                        "Col10": "-",
                        "Col11": "-",
                        "No. of IPOs trading at premium \u2013\n180th calendar days from listing": "-",
                        "Col13": "-",
                        "Col14": "-"
                    },
                    {
                        "Financial\nYear": "2022-23",
                        "Total no.\nof IPOs": "2",
                        "Total amount\nof funds\nraised (\u20b9mn.)": "257,922.30",
                        "No. of IPOs trading at discount \u2013\n30th calendar days from listing": "-",
                        "Col4": "1",
                        "Col5": "-",
                        "No. of IPOs trading at premium \u2013\n30th calendar days from listing": "-",
                        "Col7": "-",
                        "Col8": "1",
                        "No. of IPOs trading at discount \u2013\n180th calendar days from listing": "-",
                        "Col10": "2",
                        "Col11": "-",
                        "No. of IPOs trading at premium \u2013\n180th calendar days from listing": "-",
                        "Col13": "-",
                        "Col14": "-"
                    }
                ],
                "rows": 3,
                "cols": 15
            },
            {
                "page_number": 405,
                "table_data": [
                    {
                        "Financial\nYear": null,
                        "Total no.\nof IPOs": null,
                        "Total amount\nof funds\nraised (\u20b9mn.)": null,
                        "No. of IPOs trading at discount \u2013\n30th calendar days from listing": "Over\n50%",
                        "Col4": "Between 25-\n50%",
                        "Col5": "Less\nthan\n25%",
                        "No. of IPOs trading at premium \u2013\n30th calendar days from listing": "Over\n50%",
                        "Col7": "Between 25-\n50%",
                        "Col8": "Less\nthan\n25%",
                        "No. of IPOs trading at discount \u2013\n180th calendar days from listing": "Over\n50%",
                        "Col10": "Between 25-\n50%",
                        "Col11": "Less\nthan\n25%",
                        "No. of IPOs trading at premium \u2013\n180th calendar days from listing": "Over\n50%",
                        "Col13": "Between 25-\n50%",
                        "Col14": "Less\nthan\n25%"
                    },
                    {
                        "Financial\nYear": "2021-22",
                        "Total no.\nof IPOs": "8",
                        "Total amount\nof funds\nraised (\u20b9mn.)": "5,36,816.99",
                        "No. of IPOs trading at discount \u2013\n30th calendar days from listing": "-",
                        "Col4": "1",
                        "Col5": "4",
                        "No. of IPOs trading at premium \u2013\n30th calendar days from listing": "2",
                        "Col7": "-",
                        "Col8": "1",
                        "No. of IPOs trading at discount \u2013\n180th calendar days from listing": "2",
                        "Col10": "2",
                        "Col11": "1",
                        "No. of IPOs trading at premium \u2013\n180th calendar days from listing": "1",
                        "Col13": "1",
                        "Col14": "1"
                    }
                ],
                "rows": 2,
                "cols": 15
            },
            {
                "page_number": 405,
                "table_data": [
                    {
                        "S.N\no": "1",
                        "Issue Name": "India Shelter Finance Corporation\nLimited2",
                        "Issue Size (in INR\nMn)": "12,000.00",
                        "Issue price (INR)": "493",
                        "Listing Date": "20-Dec-23",
                        "Opening price on\nlisting date (INR)": "620.00",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n30th calendar\ndays from listing": "+17.64%,\n[+1.48%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n90th calendar\ndays from listing": "NA",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n180th calendar\ndays from listing": "NA"
                    },
                    {
                        "S.N\no": "2",
                        "Issue Name": "Yatharth Hospital & Trauma Care\nServices Limited1",
                        "Issue Size (in INR\nMn)": "6,865.51",
                        "Issue price (INR)": "300",
                        "Listing Date": "07-Aug-23",
                        "Opening price on\nlisting date (INR)": "304.00",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n30th calendar\ndays from listing": "+23.30, [-0.26%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n90th calendar\ndays from listing": "+20.58%, [-\n2.41%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n180th calendar\ndays from listing": "+26.23%,\n[+9.30%]"
                    },
                    {
                        "S.N\no": "3",
                        "Issue Name": "Senco Gold Limited2",
                        "Issue Size (in INR\nMn)": "4,050.00",
                        "Issue price (INR)": "317",
                        "Listing Date": "14-Jul-23",
                        "Opening price on\nlisting date (INR)": "430.00",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n30th calendar\ndays from listing": "+25.28, [-0.70%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n90th calendar\ndays from listing": "+105.32%,\n[+1.26%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n180th calendar\ndays from listing": "130.13%,\n[+10.12%]"
                    },
                    {
                        "S.N\no": "4",
                        "Issue Name": "Metro Brands1",
                        "Issue Size (in INR\nMn)": "13,675.05",
                        "Issue price (INR)": "500",
                        "Listing Date": "22-Dec-21",
                        "Opening price on\nlisting date (INR)": "436.00",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n30th calendar\ndays from listing": "+21.77%,\n[+4.45%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n90th calendar\ndays from listing": "+14.57%,\n[+0.64%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n180th calendar\ndays from listing": "+7.93%, [-9.78%]"
                    },
                    {
                        "S.N\no": "5",
                        "Issue Name": "Star Health and Allied Insurance\nCompany Limited2",
                        "Issue Size (in INR\nMn)": "60,186.84",
                        "Issue price (INR)": "900",
                        "Listing Date": "10-Dec-21",
                        "Opening price on\nlisting date (INR)": "845.00",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n30th calendar\ndays from listing": "-14.78%,\n[+1.72%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n90th calendar\ndays from listing": "-29.79%, [-6.66%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n180th calendar\ndays from listing": "-22.21%, [-6.25%]"
                    },
                    {
                        "S.N\no": "6",
                        "Issue Name": "Ami Organics Limited1",
                        "Issue Size (in INR\nMn)": "5,696.36",
                        "Issue price (INR)": "610.00",
                        "Listing Date": "14-Sep-21",
                        "Opening price on\nlisting date (INR)": "902.00",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n30th calendar\ndays from listing": "+116.86%,\n[+4.27%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n90th calendar\ndays from listing": "+63.94%,[+0.93%\n]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n180th calendar\ndays from listing": "+47.34%, [-\n4.63%]"
                    },
                    {
                        "S.N\no": "7",
                        "Issue Name": "Chemplast Sanmar Limited2",
                        "Issue Size (in INR\nMn)": "38,500.00",
                        "Issue price (INR)": "541.00",
                        "Listing Date": "24-Aug-21",
                        "Opening price on\nlisting date (INR)": "550.00",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n30th calendar\ndays from listing": "+2.06%, [+5.55%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n90th calendar\ndays from listing": "+12.68%,\n[+6.86%]",
                        "% change in\nclosing price, [+/-\n% change in\nclosing\nbenchmark]-\n180th calendar\ndays from listing": "-3.30%, [+3.92%]"
                    }
                ],
                "rows": 7,
                "cols": 9
            },
            {
                "page_number": 406,
                "table_data": [
                    {
                        "FY": "",
                        "Total no.\nof issues": "",
                        "Total amount of\nfunds raised\n(INR Mn)": "",
                        "No. of IPOs trading at discount -\n30th calendar days from listing": "Over 50%",
                        "Col4": "Between\n25 - 50%",
                        "Col5": "Less than\n25%",
                        "No. of IPOs trading at premium -\n30th calendar days from listing": "Over\n50%",
                        "Col7": "Between\n25 - 50%",
                        "Col8": "Less than\n25%",
                        "No. of IPOs trading at discount -\n180th calendar days from listing": "Over\n50%",
                        "Col10": "Between\n25 - 50%",
                        "Col11": "Less than\n25%",
                        "No. of IPOs trading at premium -\n180th calendar days from listing": "Over\n50%",
                        "Col13": "Between\n25 - 50%",
                        "Col14": "Less\nthan\n25%"
                    },
                    {
                        "FY": "2023-24*",
                        "Total no.\nof issues": "3",
                        "Total amount of\nfunds raised\n(INR Mn)": "22,915.51",
                        "No. of IPOs trading at discount -\n30th calendar days from listing": "-",
                        "Col4": "-",
                        "Col5": "-",
                        "No. of IPOs trading at premium -\n30th calendar days from listing": "-",
                        "Col7": "1",
                        "Col8": "2",
                        "No. of IPOs trading at discount -\n180th calendar days from listing": "-",
                        "Col10": "-",
                        "Col11": "-",
                        "No. of IPOs trading at premium -\n180th calendar days from listing": "1",
                        "Col13": "1",
                        "Col14": "-"
                    },
                    {
                        "FY": "2022-23",
                        "Total no.\nof issues": "-",
                        "Total amount of\nfunds raised\n(INR Mn)": "-",
                        "No. of IPOs trading at discount -\n30th calendar days from listing": "-",
                        "Col4": "-",
                        "Col5": "-",
                        "No. of IPOs trading at premium -\n30th calendar days from listing": "-",
                        "Col7": "-",
                        "Col8": "-",
                        "No. of IPOs trading at discount -\n180th calendar days from listing": "-",
                        "Col10": "-",
                        "Col11": "-",
                        "No. of IPOs trading at premium -\n180th calendar days from listing": "-",
                        "Col13": "-",
                        "Col14": "-"
                    },
                    {
                        "FY": "2021-22",
                        "Total no.\nof issues": "4",
                        "Total amount of\nfunds raised\n(INR Mn)": "1,18,058.25",
                        "No. of IPOs trading at discount -\n30th calendar days from listing": "-",
                        "Col4": "-",
                        "Col5": "1",
                        "No. of IPOs trading at premium -\n30th calendar days from listing": "1",
                        "Col7": "-",
                        "Col8": "2",
                        "No. of IPOs trading at discount -\n180th calendar days from listing": "-",
                        "Col10": "-",
                        "Col11": "2",
                        "No. of IPOs trading at premium -\n180th calendar days from listing": "-",
                        "Col13": "1",
                        "Col14": "1"
                    }
                ],
                "rows": 4,
                "cols": 15
            },
            {
                "page_number": 407,
                "table_data": [
                    {
                        "S. No.": "1.",
                        "Name of the Book Running Lead Manager": "ICICI Securities Limited",
                        "Website": "www.icicisecurities.com"
                    },
                    {
                        "S. No.": "2.",
                        "Name of the Book Running Lead Manager": "Axis Capital Limited",
                        "Website": "www.axiscapital.co.in"
                    },
                    {
                        "S. No.": "3.",
                        "Name of the Book Running Lead Manager": "Citigroup Global Markets India Private Limited",
                        "Website": "www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm"
                    },
                    {
                        "S. No.": "4.",
                        "Name of the Book Running Lead Manager": "Ambit Private Limited",
                        "Website": "www.ambit.co"
                    }
                ],
                "rows": 4,
                "cols": 3
            },
            {
                "page_number": 407,
                "table_data": [
                    {
                        "Scenario": "Delayed unblock for cancelled / withdrawn\n/ deleted applications",
                        "Compensation amount": "\u20b9 100 per day or 15% per annum of the Bid Amount,\nwhichever is higher",
                        "Compensation period": "From the date on which the request for\ncancellation / withdrawal / deletion is\nplaced on the bidding platform of the"
                    }
                ],
                "rows": 1,
                "cols": 3
            },
            {
                "page_number": 408,
                "table_data": [
                    {
                        "Scenario": "",
                        "Compensation amount": "",
                        "Compensation period": "Stock Exchanges till the date of actual\nunblock"
                    },
                    {
                        "Scenario": "Blocking of multiple amounts for the same\nBid made through the UPI Mechanism",
                        "Compensation amount": "1. Instantly revoke the blocked funds other than\nthe original application amount and\n2. \u20b9 100 per day or 15% per annum of the total\ncumulative blocked amount except the original\nBid Amount, whichever is higher",
                        "Compensation period": "From the date on which multiple\namounts were blocked till the date of\nactual unblock"
                    },
                    {
                        "Scenario": "Blocking more amount than the Bid\nAmount",
                        "Compensation amount": "1. Instantly revoke the difference amount, i.e., the\nblocked amount less the Bid Amount and\n2. \u20b9 100 per day or 15% per annum of the\ndifference amount, whichever is higher",
                        "Compensation period": "From the date on which the funds to the\nexcess of the Bid Amount were blocked\ntill the date of actual unblock"
                    },
                    {
                        "Scenario": "Delayed unblock for non \u2013 Allotted /\npartially Allotted applications",
                        "Compensation amount": "\u20b9 100 per day or 15% per annum of the Bid Amount,\nwhichever is higher",
                        "Compensation period": "From the Working Day subsequent to\nthe finalisation of the Basis of Allotment\ntill the date of actual unblock"
                    }
                ],
                "rows": 4,
                "cols": 3
            },
            {
                "page_number": 412,
                "table_data": [
                    {
                        "BID/ OFFER OPENS ON": "BID/ OFFER CLOSES ON",
                        "[\u25cf](1)": "[\u25cf](2)"
                    }
                ],
                "rows": 1,
                "cols": 2
            },
            {
                "page_number": 412,
                "table_data": [
                    {
                        "Event": "Finalisation of Basis of Allotment with the Designated Stock Exchange",
                        "Indicative Date": "On or about [\u25cf]"
                    },
                    {
                        "Event": "Initiation of refunds (if any, for Anchor Investors)/unblocking of funds from ASBA Account*",
                        "Indicative Date": "On or about [\u25cf]"
                    },
                    {
                        "Event": "Credit of Equity Shares to dematerialised accounts of Allottees",
                        "Indicative Date": "On or about [\u25cf]"
                    },
                    {
                        "Event": "Commencement of trading of the Equity Shares on the Stock Exchanges",
                        "Indicative Date": "On or about [\u25cf]"
                    }
                ],
                "rows": 4,
                "cols": 2
            },
            {
                "page_number": 413,
                "table_data": [
                    {
                        "Bid/ Offer Period (except the Bid/ Offer Closing Date)": "Submission and Revision in Bids",
                        "Col1": "Only between 10.00 a.m. and 5.00 p.m. Indian Standard Time (\u201cIST\u201d)"
                    },
                    {
                        "Bid/ Offer Period (except the Bid/ Offer Closing Date)": "Bid/ Offer Closing Date",
                        "Col1": null
                    },
                    {
                        "Bid/ Offer Period (except the Bid/ Offer Closing Date)": "Submission and Revision in Bids",
                        "Col1": "Only between 10.00 a.m. and 3.00 p.m. IST"
                    }
                ],
                "rows": 3,
                "cols": 2
            },
            {
                "page_number": 416,
                "table_data": [
                    {
                        "Particulars": "Number of Equity\nShares available for\nAllotment/\nallocation (2)",
                        "Eligible Employees#": "Up to [\u25cf] Equity\nShares",
                        "QIBs(1)": "Not less than [\u25cf] Equity\nShares",
                        "Non-Institutional Bidders": "Not more than [\u25cf] Equity Shares\navailable for allocation or Offer less\nallocation to QIB Bidders and RIBs",
                        "Retail Individual\nBidders": "Not more than [\u25cf]\nEquity Shares\navailable for allocation\nor Offer less allocation\nto QIB Bidders and\nNon-Institutional\nBidders"
                    },
                    {
                        "Particulars": "Percentage of Offer\nSize available for\nAllotment/\nallocation",
                        "Eligible Employees#": "The Employee\nReservation Portion\nshall constitute up to\n5% of the post-Issue\npaid-up Equity Share\ncapital of our\nCompany.",
                        "QIBs(1)": "Not less than 75% of the Net\nOffer shall be available for\nallocation to QIB Bidders.\nHowever, 5% of the Net QIB\nPortion shall be available for\nallocation on a proportionate\nbasis to Mutual Funds only.\nMutual Funds participating in\nthe Mutual Fund Portion will\nalso be eligible for allocation\nin the remaining QIB Portion.\nThe unsubscribed portion in\nthe Mutual Fund Portion will\nbe added to the Net QIB\nPortion.",
                        "Non-Institutional Bidders": "Not more than 15% of the Net Offer\nor Offer less allocation to QIB\nBidders and RIBs shall be available\nfor allocation out of which (a) one\nthird of such portion shall be\nreserved for applicants with\napplication size of more than\n\u20b9200,000 and up to \u20b91,000,000; and\n(b) two third of such portion shall\nbe reserved for applicants with\napplication size of more than\n\u20b91,000,000, provided that the\nunsubscribed portion in either of\nsuch sub-categories may be\nallocated to applicants in the other\nsub-category of Non-Institutional\nBidders.",
                        "Retail Individual\nBidders": "Not more than 10% of\nthe Net Issue or the Net\nIssue less allocation to\nQIB Bidders and Non-\nInstitutional Bidders"
                    },
                    {
                        "Particulars": "Basis of Allotment/\nallocation if\nrespective category\nis oversubscribed",
                        "Eligible Employees#": "Proportionate#; unless\nthe Employee\nReservation Portion is\nundersubscribed, the\nvalue of allocation to\nan Eligible Employee\nshall not exceed\n\u20b9200,000. In the event\nof undersubscription in\nthe Employee\nReservation Portion,\nthe unsubscribed\nportion may be\nallocated, on a\nproportionate basis, to\nEligible Employees for\na value exceeding\n\u20b9200,000, subject to\ntotal Allotment to an\nEligible Employee not\nexceeding 500,000.",
                        "QIBs(1)": "Proportionate as follows\n(excluding the Anchor\nInvestor Portion):\na) [\u25cf] Equity Shares shall\nbe available for\nallocated on a\nproportionate basis to\nMutual Funds only; and\nb) [\u25cf] Equity Shares shall\nbe allotted on a\nproportionate basis to all\nQIBs, including Mutual\nFunds receiving\nallocation as per (a)\nabove.\nUp to 60% of the QIB Portion\nEquity Shares may be\nallocated on a discretionary\nbasis to Anchor Investors of",
                        "Non-Institutional Bidders": "The Equity Shares available for\nallocation to Bidders in the Non-\nInstitutional Portion shall be\nsubject to the following:\n(a) One-third of the Non-\nInstitutional Portion shall be\navailable for allocation to\nBidders with an application\nsize more than \u20b9200,000 upto\n\u20b91.00 million; and\n(b) Two-thirds of the Non-\nInstitutional Portion shall be\navailable for allocation to\nBidders with an application\nsize of more than \u20b91.00\nmillion.\nProvided that the unsubscribed\nportion in either of these two sub-\ncategories of Non-Institutional",
                        "Retail Individual\nBidders": "Allotment to each\nRetail Individual\nBidder shall not be less\nthan the minimum Bid\nlot, subject to\navailability of Equity\nShares in the Retail\nPortion and the\nremaining available\nEquity Shares if any,\nshall be allotted on a\nproportionate basis.\nFor details see, \u201cOffer\nProcedure\u201d on page\n415."
                    }
                ],
                "rows": 3,
                "cols": 5
            },
            {
                "page_number": 417,
                "table_data": [
                    {
                        "Particulars": "",
                        "Eligible Employees#": "",
                        "QIBs(1)": "which one-third shall be\navailable for allocation to\ndomestic Mutual Funds only,\nsubject to valid Bid received\nfrom domestic Mutual Funds\nat or above the Anchor\nInvestor Allocation Price",
                        "Non-Institutional Bidders": "Portion may be allocated to the\nBidders in the other sub-category of\nNon-Institutional Portion in\naccordance with SEBI ICDR\nRegulations.\nThe allotment to each Non-\nInstitutional Bidder shall not be less\nthan the Minimum NIB Bid Size,\nsubject to availability of Equity\nShares in the Non-Institutional\nPortion and the remaining available\nEquity Shares, if any, shall be\nallotted on a proportionate basis, in\naccordance with SEBI ICDR\nRegulations.",
                        "Retail Individual\nBidders": ""
                    },
                    {
                        "Particulars": "Minimum Bid",
                        "Eligible Employees#": "Such number of Equity\nShares and in multiples\nof [\u25cf] Equity Shares\nthereafter",
                        "QIBs(1)": "Such number of Equity\nShares and in multiples of [\u25cf]\nEquity Shares so that the Bid\nAmount exceeds \u20b9 200,000",
                        "Non-Institutional Bidders": "Such number of Equity Shares and\nin multiples of [\u25cf] Equity Shares so\nthat the Bid Amount exceeds \u20b9\n200,000",
                        "Retail Individual\nBidders": "[\u25cf] Equity Shares."
                    },
                    {
                        "Particulars": "Maximum Bid",
                        "Eligible Employees#": "Such number of Equity\nShares and in multiples\nof [\u25cf] Equity Shares,\nso that the maximum\nBid Amount by each\nEligible Employee in\nEligible Employee\nPortion does not\nexceed \u20b9500,000, if\nany",
                        "QIBs(1)": "Such number of Equity\nShares in multiples of [\u25cf]\nEquity Shares so that the Bid\ndoes not exceed the size of the\nOffer (excluding the Anchor\nInvestor Portion), subject to\napplicable limits, applicable\nto each Bidder",
                        "Non-Institutional Bidders": "Such number of Equity Shares in\nmultiples of [\u25cf] Equity Shares so\nthat the Bid does not exceed the size\nof the Offer, (excluding the QIB\nPortion), subject to applicable\nlimits, applicable to each Bidder",
                        "Retail Individual\nBidders": "Such number of Equity\nShares in multiples of\n[\u25cf] Equity Shares so\nthat the Bid Amount\ndoes not exceed \u20b9\n200,000"
                    },
                    {
                        "Particulars": "Who can apply(3)",
                        "Eligible Employees#": "Eligible Employees\nsuch that the Bid\nAmount does not\nexceed \u20b9500,000",
                        "QIBs(1)": "Public financial institutions\nas specified in Section 2(72)\nof the Companies Act,\nscheduled commercial banks,\nMutual Funds, FPIs (other\nthan individuals, corporate\nbodies and family offices),\nVCFs, AIFs, FVCIs\nregistered with SEBI,\nmultilateral and bilateral\ndevelopment financial\ninstitutions, state industrial\ndevelopment corporation,\ninsurance companies\nregistered with IRDAI,\nprovident funds (subject to\napplicable law) with\nminimum corpus of \u20b9250\nmillion, pension funds with\nminimum corpus of \u20b9250\nmillion, registered with the\nPension Fund Regulatory and\nDevelopment Authority\nestablished under subsection\n(1) of section 3 of the Pension\nFund Regulatory and\nDevelopment Authority Act,\n2013, National Investment\nFund set up by the GoI\nthrough resolution F.\nNo.2/3/2005-DDII dated\nNovember 23, 2005, the\ninsurance funds set up and\nmanaged by army, navy or air\nforce of the Union of India,\ninsurance funds set up and",
                        "Non-Institutional Bidders": "Resident Indian individuals,\nEligible NRIs, HUFs (in the name\nof the karta), companies, corporate\nbodies, scientific institutions\nsocieties and trusts, and FPIs who\nare individuals, corporate bodies\nand family offices and registered\nwith SEBI",
                        "Retail Individual\nBidders": "Resident Indian\nindividuals, Eligible\nNRIs and HUFs (in the\nname of Karta)"
                    }
                ],
                "rows": 4,
                "cols": 5
            },
            {
                "page_number": 418,
                "table_data": [
                    {
                        "Particulars": "",
                        "Eligible Employees#": "",
                        "QIBs(1)": "managed by the Department\nof Posts, India and\nSystemically Important\nNBFCs in accordance with\napplicable laws.",
                        "Non-Institutional Bidders": "",
                        "Retail Individual\nBidders": ""
                    },
                    {
                        "Particulars": "Mode of Bidding",
                        "Eligible Employees#": "Through ASBA process only (except Anchor Investors). In case of UPI Bidders, ASBA process will include the UPI\nMechanism.",
                        "QIBs(1)": null,
                        "Non-Institutional Bidders": null,
                        "Retail Individual\nBidders": null
                    },
                    {
                        "Particulars": "Mode of Allotment",
                        "Eligible Employees#": "Compulsorily in dematerialized form",
                        "QIBs(1)": null,
                        "Non-Institutional Bidders": null,
                        "Retail Individual\nBidders": null
                    },
                    {
                        "Particulars": "Bid Lot",
                        "Eligible Employees#": "[\u25cf] Equity Shares and in multiples of [\u25cf] Equity Shares thereafter",
                        "QIBs(1)": null,
                        "Non-Institutional Bidders": null,
                        "Retail Individual\nBidders": null
                    },
                    {
                        "Particulars": "Allotment Lot",
                        "Eligible Employees#": "A minimum of [\u25cf] Equity Shares and thereafter in multiples of one Equity Share.",
                        "QIBs(1)": null,
                        "Non-Institutional Bidders": null,
                        "Retail Individual\nBidders": null
                    },
                    {
                        "Particulars": "Trading Lot",
                        "Eligible Employees#": "One Equity Share",
                        "QIBs(1)": null,
                        "Non-Institutional Bidders": null,
                        "Retail Individual\nBidders": null
                    },
                    {
                        "Particulars": "Terms of Payment",
                        "Eligible Employees#": "In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission\nof their Bids(4)\nIn case of all other Bidders: Full Bid Amount shall be blocked in the bank account of the ASBA Bidder (other than\nAnchor Investors) or by the Sponsor Bank(s) through the UPI Mechanism (for RIBs or individual investors bidding\nunder the Non \u2013 Institutional Portion for an amount of more than \u20b9 200,000 and up to \u20b9 0.50 million, using the UPI\nMechanism), that is specified in the ASBA Form at the time of submission of the ASBA Form",
                        "QIBs(1)": null,
                        "Non-Institutional Bidders": null,
                        "Retail Individual\nBidders": null
                    }
                ],
                "rows": 7,
                "cols": 5
            },
            {
                "page_number": 423,
                "table_data": [
                    {
                        "Category": "Resident Indians, including resident QIBs, Non-Institutional Bidders, Retail Individual Bidders and\nEligible NRIs applying on a non-repatriation basis(1)",
                        "Colour of Bid cum\nApplication Form*": "[\u25cf]"
                    },
                    {
                        "Category": "Eligible NRIs, FVCIs, FPIs and registered bilateral and multilateral development financial institutions\napplying on a repatriation basis(1)",
                        "Colour of Bid cum\nApplication Form*": "[\u25cf]"
                    },
                    {
                        "Category": "Anchor Investors(2)",
                        "Colour of Bid cum\nApplication Form*": "[\u25cf]"
                    },
                    {
                        "Category": "Eligible Employees Bidding in the Employee Reservation Portion(3)",
                        "Colour of Bid cum\nApplication Form*": "[\u25cf]"
                    }
                ],
                "rows": 4,
                "cols": 2
            }
        ],
        "duration": 233.2054033279419,
        "total_pages": 469,
        "strategy_used": "primary",
        "table_count": 272,
        "total_rows": 2240,
        "error": null
    } }